"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning, my name is Vanessa, and I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions Fourth Quarter 2010 Earnings Call.  [Operator Instructions] I would now like to turn the call over",56,"Good morning, my name is Vanessa, and I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions Fourth Quarter 2010 Earnings Call.  [Operator Instructions] I would now like to turn the call over to Ms. Valerie Hertel, Vice President of Investor Relations. Please go ahead, ma'am."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Vanessa. Good morning, and thank you for joining us on Medco's Fourth Quarter and Full Year 2010 Earnings Conference Call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer.",326,"Thank you, Vanessa. Good morning, and thank you for joining us on Medco's Fourth Quarter and Full Year 2010 Earnings Conference Call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us for our question-and-answer session are: Tom Moriarty, General Counsel, Secretary and Senior Vice President of Pharmaceutical Strategies and Solutions; Tim Wentworth, Group President of the Employer and Key Account; Steve Fitzpatrick, President of Accredo Health Group; Mary Daschner, Group President, Government CBM; Brian Griffin, President of International; and Rob Epstein, Chief Medical Officer and President of the Medco Research Institute.
During the course of this call, we'll make forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in our SEC filings.
Copies of Medco's filings are available from the SEC, the Medco Investor Relations Department or the Medco website. Medco intends to use the Investor Relations section of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. The copyrights for the contents of this discussion and the written materials used on this earning call are owned by MedcoHealth Solutions, Inc. 2011.
Slides to accompany our presentation, which detail our financial and operating results and the guidance discussed on this call, are currently available in the events section of the Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-K after the close of the market today. 
At this time, I would like to turn the call over to Dave Snow. Dave?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valeria, and thanks to all of you for joining us this morning. Medco is pleased to report record fourth quarter and full year 2010 earnings, reflecting strong financial and operating performance at the high end of previously increased guidance.",1527,"Thank you, Valeria, and thanks to all of you for joining us this morning. Medco is pleased to report record fourth quarter and full year 2010 earnings, reflecting strong financial and operating performance at the high end of previously increased guidance. Today, I will focus my remarks on full year 2010 results and 2011 guidance, while Rich will focus on our balance sheet, our fourth quarter results and details surrounding our 2011 guidance. At our analyst in November, we shared with you our expectations for Medco and our business strategy that is designed to continue to delivering strong growth for 2020. We outlined our portfolio of growth drivers that will advance our mission to make medicine smarter for our clients and the more than $65 million members we served. Today we remain confident in our expectations and are pleased to provide you with the details of our performance for 2010 and expectations for 2011. Let's begin with our year-over-year 2010 financial and operational performance.
For the year, we delivered record GAAP diluted earnings per share of $3.15 representing growth of 21.1%. Our diluted earnings per share excluding the amortization of intangibles from the 2003 spin-off grew 20.1% to a record $3.40. Our net revenues reached a record of $66 billion, up 10.3% from 2009 despite the higher volumes of lower-cost generics that reduced our net revenues by nearly $3.7 billion and correspondingly resulted in record client and patient savings. 
Within the revenues, our higher margin generating service revenues grew 28% to a record $1.08 billion fueled by our United BioSource acquisition and service revenue growth across the company. We achieved total gross margin of $4.3 billion, an increase of 7.7% over 2009.
Our EBITDA increased 8.1% to nearly $3 billion and our EBITDA per adjusted script increased 1.6% to a full year record of $3.11. And finally, our net income increased 11.5% to a record $1.4 billion. With respect to the operating metrics that contributed to our strong financial results, overall prescription volumes adjusted for the dates applied between retail and mail grew a strong 6.5% to a record 957 million prescription. 
Mail-order prescriptions for the year grew at a strong 6.5% to 109.8 million, which exceeded the high end of our guidance of 109 million prescriptions and set a new record. Importantly, we experienced continued strength in generic mail-order volumes increasing a substantial 13.4% to 67.6 million prescriptions as patients continue to choose lower-cost generic medications. 
Growth of generic have now for the fourth quarter was even greater at 15.1%. Our overall generic dispensing rate rose 3.5 percentage points to 71% and within that our mail-order generic dispensing rate component increased an even greater amount by 3.7 percentage points to a record 61.5%. For the full year, our Medicare part D PDP revenues achieved a record increasing 33.5% to well over $1.4 billion. We are proud to have been the first and only national PDP to be awarded five stars by CMS and believe these world-class recognition operationally not only validates our investments in our agile enterprise but also enables continued strength in our Medicare business going forward.
Moving on to our Specialty business. Accredo's performance remains strong with revenues increasing 19.1% to a record $11.3 billion and operating income rising 22.7% to a record $438.2 million. Turning to sales and client retention results, Medco delivered another solid year of performance. Our 2010 annualized new-named and net-new sales each remained strong at $5.3 billion and our client retention rate remained over 99%. For 2011 today, our annualized new-named sales stand at $1.7 billion and our net-new sales are currently $1.5 billion, up from the $1.4 billion previously disclosed on our third quarter earnings call. We have now completed over 80% of our 2011 scheduled and early elective client renewals, up from the over 50% we reported on our third quarter call and our 2011 year-to-date client retention rate remains at over 99%.
This past year, we continue to invest in our enterprise by expanding our expertise in genomic and personalized medicines with the acquisition of DNA Direct. We also entered the market for post-approval Phase IV safety economic evaluation and outcomes research through our acquisition of United BioSource. We are very pleased with the results to date for both of these acquisitions. DNA Direct's genomic services are gaining traction in the marketplace. Just a few weeks ago, we announced the addition of four new community hospital clients to DNA Direct genomic medicine hospital networks come extending web-based physicians of core and genetic expertise to their physicians and their which is. We also announced the position addition of four new health plan clients who are implementing DNA Direct policy and benefit support program from molecular diagnostic and genetic tests. This program enables payors to determine coverage for more than 800 molecular diagnostic and genetic tests and provides realtime access to the DNA Direct team of genetic counselors for clinical guidance and counseling on the more than 2,000 genetic tests available today. We are encouraged by the level of market interest in this new service offerings.
We are very pleased with the acquisition of UBC which has been enthusiastically embraced by more than 100 Medco clients representing more than 40 million lives volunteering to be part of the Medco research consortium to participate in UBC research study. This is up from the previously disclosed 89 clients and 33 million lives. As we noted at Analyst Day, both our clients and biotech drug manufacturers have common interests to ensure the safety and efficacy of new drugs coming to market. On top of that, Medco and its clients are fully aligned to pursue better outcomes and lower total healthcare costs, the essence of Making Medicine Smarter.
As we move forward, we anticipate UBC will continue to realize strong growth from its impressive pipeline of opportunities, including safety surveillance for UBC hold to market-leading position globally. Additionally, we expect to leverage UBC as Medco's and Accredo's capabilities to the benefit of our clients and patients as we fundamentally changed the way drugs are introduced to delivered and monitored for both safety and economics. 
Turning to guidance, we are reaffirming our full year 2011 GAAP diluted earnings per share guidance of $3.53 to $3.66 reflecting a growth rate of 12% to 16% over 2010. Diluted earnings per share, excluding all intangible amortization, are new EPS measure is to reaffirm to be in the range of $3.99 to $4.12 reflecting 12% to 16% growth over 2010 earnings per share. Please note that the growth rate change for GAAP and pure cash EPS was 12% to 17% previously, but is narrowed due to the fact that we achieved the high end of our 2010 guidance range.
In closing, we remain confident in our ability to generate strong EPS growth well into the future. In the weeks since we shared our long-range plans with you, I have been asked how we can this be so confidence over such an extended horizon? There are two primary reasons that the first is a detail behind our ten-year strategic financial plan. As we shared on Analyst Day last November, we have a very detailed roadmap for growth that is reasonable and logical based upon the many compelling opportunities we foresee over the next 10 years and a realistic view of the risks we may have encountered along the way. I believe that our growing portfolio of capabilities with leaders who are dedicated and accountable to each one of them will enable us to offer a comprehensive suite of solutions that will likely remain unmatched in the marketplace. 
The second is our people. Our employees are united to a greater good, a noble cause that fuels the passion around Making Medicine Smarter in world-class manner people. While a common vision is important, our people also have proven ability to execute with unparalleled excellence. 
Our CMS five-star rating is a testament to this, further evidence can be found in our January 1 install, which were virtually despite the record number of complex changes required by CMS in the recent healthcare reform mandate. As we continue to make progress in advancing our capabilities through our agile enterprise initiatives, we expect to achieve unprecedented improvements in the way we deliver operational excellence to the benefit of our clients and members.
Yet another example of our operational excellence is the recent final approval we received from the Indiana Board of Pharmacy for our new third-generation automated pharmacy located in Indiana. In the testing phase that ran from September through mid-January, the board found that the pharmacy filled every prescription of the tens of thousands tested with 100% accuracy. I would like to take this opportunity to thank each and every one of our over 24,000 Medco employees now standing the globe with their continued efforts on behalf of clients, patients and shareholders resulting in another great year and strong long-term prospects. They are delivering everyday for our clients, members and shareholders.
With that, I will turn it over to Rich Rubino who will take you through our balance sheet, the fourth quarter 2010 financials and further details on our guidance for 2011. Rich?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. We are pleased to the river another quarter and full year financial operating performance. As Valery mentioned, the slides on our website will prove helpful in following along with my commentary.Starting with our balance s",2359,"Thank you, Dave. Good morning. We are pleased to the river another quarter and full year financial operating performance. As Valery mentioned, the slides on our website will prove helpful in following along with my commentary.
Starting with our balance sheet, we closed the fourth quarter with a cash balance of $853 million, and our cash flow from operations for full year 2010 totaled over $2.34 billion. While our mail-order prescription volumes set record highs in 2010, our inventory balances represent a record year of just over $1 billion at the end of 2010. A $272 million reduction from year end 2009 on top of the $571 million reduction we generated during 2009.
Our capital expenditure at full year 2010 were in line with our guidance at $250 million, reflecting investments in our business to drive agility and enhance efficiencies across the organization, prepare for healthcare reform implementation and to fund future growth. We achieved a full year 2010 return on invested capital of 35%, excluding 2010 acquisitions such as UBC, a meaningful increase over the 2009 return was 27% which was already seven points higher than 2008. 
Our fourth quarter 2010 EPS results were records, with GAAP diluted EPS of $0.88 representing 25.7% growth over fourth quarter 2009 and diluted EPS excluding the amortization of intangibles from the 2003 spin-off of $0.94 representing 23.7% growth over 2009.
Total fourth quarter 2010 net revenues reached a record $16.9 billion, representing growth of 11.1% over fourth quarter 2009. Our product revenue grew 10.4%, reflecting our new business wins as well as higher prices brand name Pharmaceutical manufacturers, partially offset by a higher representation of lower-priced generics in fact a record generic effect of approximately $1.1 billion on fourth quarters revenue a loan.
Service revenue continued to be very meaningful growth driver, increasing 58.7% over fourth quarter 2009. This strong performance reflects a full quarter of service revenue contribution from UBC, which closed on September 16, 2010, as well as the expansion of our overall client base at our Medicare part D services.
Starting with rebates, we earned $1.5 billion for the fourth quarter and $5.8 billion for full year 2010, both records, even though we are dispensing fewer brand-name medications and more generics. These rebate levels represent 7% growth for the quarter and 8.1% growth for the year attributable to new client wins and continues improvements in formulary contracting. Our fourth quarter 2010 rebate retention rate was 13.0% compared to 14.1% in fourth quarter 2009 as we continue to drive significant value to clients in a highly transparent manner. For the full year, our rebate retention rate of 12.5% compared to 13.7% in 2009.
In terms of claims volumes totaled fourth quarter prescription adjusted for the differences in days supply between retail and mail reached a record $244.3 million, an increase of 7.4% over fourth quarter 2009. Retail prescriptions in fourth quarter 2010 grew 7.5% to a record $161.4 million. Mail-order volume remains strong as clients and members continue to choose the lowest cost and most clinically effective channel.
Our mail-order prescriptions reached a record $27.9 million in fourth quarter 2010, a 7.3% increase from fourth quarter 2009. The adjusted mail-order prescription volumes for fourth quarter 2010 comprised 33.9% of the total adjusted prescriptions in line with the 34.0% mail penetration rates in the fourth quarter 2009.
Within the record fourth quarter 2010 mail-order prescription volumes total, generic prescription volumes increased 15.1% to a record $17.5 million, reflecting new generic introductions and continued growth in previous generics, while brand-name prescription volumes decreased 3.7% to 10.4 million prescriptions. The strength in our generic mail-order prescription volumes was an important driver of our fourth quarter gross margin, which increased 13.1% over fourth quarter 2009 to a record of $1.16 billion.
Our consolidated gross margin percentage of 6.9% for the quarter held steady with what we reported a third quarter 2010 and on the year-over-year basis, increased 20 basis points from the 6.7% in fourth quarter 2009, again a result of the strong fourth quarter 2010 mail-order generic prescription volumes and our strong service gross margins. 
Selling, general and administrative expenses of $428.5 million for the fourth quarter increased over fourth quarter 2009 by $53 million or 14.1%, reflecting the addition of UBC as well as higher professional fees and other expenses associated with strategic initiatives. Excluding UBC, SG&A for the fourth quarter was up $32.2 million or 8.6% from fourth quarter 2009. 
The expenses we incurred in 2010 for strategic initiatives are critical to our transformation and to a world-class agile enterprise focused on speed, accuracy, efficiency and providing highest levels of clients and patient care. We invest in ourselves because we are a growth company, with many exciting components of expanding portfolio of businesses. These investments, whether in the form of expense or capital are designed to proactively drive unparalleled levels of client and patient service and top off what we believe is already a world-class service model.
Total EBITDA for fourth quarter 2010 reached a record $786.5 million, representing growth of 13.2%. EBITDA per adjusted prescription for the quarter increased 5.2% to $3.22, a fourth quarter record. Our intangible amortization of $75 million in fourth quarter 2010 decreased slightly from $75.5 million at fourth quarter 2009. The full year amortization of $287.4 million decreased in 2009 by 6.0% or $18.2 million, primarily reflecting lower intangible amortization from Europa and Accredo partially offset by the addition of UBC and DNA Direct intangible assets.
Total net interest and other expense of $50.4 million for the fourth quarter of 2010 increased $10.5 million from the $39.9 million in fourth quarter 2009, reflecting the new debt we added to finance the UBC acquisition last September. For the full year, total net interest and other expense of $163.1 million was slightly higher compared to the $162.6 million for 2009, reflecting this new debt, offset by lower interest rates associated with floating rate debt.
The fourth quarter 2010 effective tax rate was 37.7% compared to 36.3% in 2009 primarily reflecting a 2009 benefit from state-related income tax items. Our effective tax rate for full year was 38.9% in line with the 39.1% in 2009. Net income for the quarter increased 10.8% to a record $378.5 million from the $341.5 million reported for the fourth quarter of 2009. For the full year, net income increased 11.5% to a record of over $1.4 billion from the $1.3 billion reported for 2009.
Moving on to share repurchases. During the fourth quarter of 2010, we repurchased 15.8 million shares for $963.3 million at an average per share cost of $61.05. For Full year 2010, share repurchases totaled 69.9 million at a cost of $4.1 billion with an average per share cost of $58.97. Since share repurchases commenced in 2005, we repurchased a total of 256.2 million shares, with a total cost of $11.1 billion with an average per share cost of $43.18. 
For 2011 to date, we repurchased 7.0 million shares with an average per share cost of $62.06. In January 2011, we completed the remaining $437 million of the $3.0 million authorization that was approved in May 2010. By February 2, 2011, our board authorized a new $3 billion share repurchase plan. We continue to complete approximately $2 billion in share repurchases in 2011, driving meaningful value to our shareholders. We expect the commenced share repurchases under the new authorization later this quarter or.
Turning to our Specialty segment. Accredo achieved record revenues of $3.2 million for fourth quarter of 2010, an increase of 21.3% over the fourth quarter of 2009. Consistent with our guidance, Accredo's gross margin percentage for the quarter amounted to 6.5% compared to the 7.0% in fourth quarter of 2009. This Accredo gross declined reflect product channel and client mix. The 2010 product mix reflects significant growth in our multiple sclerosis, arthritis, oncology and pulmonary arterial hypertension patients with product volumes. Accredo's operating income for fourth quarter 2010 increased 30.7% to $109.9 million. 
Moving on to Medicare. We continue to experience growth in our Medicare PDP. For fourth quarter 2010, Medco's PDP revenues increased 27.7% to $331.7 million. As Dave discussed, we are reaffirming our guidance for 2011. To briefly repeat our reaffirmed 2011 guidance, diluted GAAP EPS is expected to grow 12% to 16% over 2010 in the range of $3.53 to $3.66. As we noted last quarter, the non-GAAP diluted EPS measure change commencing in 2011 to exclude all intangible amortization. Diluted EPS excluding all intangible amortization remains in the guidance range of $3.99 to $4.12, representing growth of 12% to 16% over the 2010 full year equivalent of $3.55.
While this measure will not be used in 2011, diluted EPS, excluding intangible amortization from the 2003 spin-off, would be guided to increase to a range of $3.80 to $3.93 also representing growth of 12% to 16% over 2010. The detailed components of our 2011 guidance are as follows. We currently expect to renew approximately $15 billion of business in 2011, including schedules and early elective renewals, representing less than 1/4 of our business. As Dave mentioned, we have over 80% of our 2011 renewals already completed. As I previously guided, approximately 75% of the renewal pricing is in effect in the first quarter with the majority of the remainder effective in the third quarter of 2011.
Our guidance for mail-order prescription volumes for 2011 remains in the range of $107 million to $109 million, demonstrating solid growth in our base business considering the 3 million script offset I discussed at Analyst day. You may recall the expected reduction of approximately 2 million scripts from the contribution of the Europa Apotheek to the Medco Celesio joint and another 1 million scripts associated with the generic form of Allegra known as fexofenadine to OTC status in early 2011. These expectations remain intact.
As you can see from our slides on the Web, the vast majority of our detailed 2011 guidance components remains consistent with those we provided at our Analyst Day. Including, as examples, the $0.09 incremental contribution from new generics and expectations for stability with probable expansion in gross margin percentage and EBITDA per adjusted script performance in 2011. There is one guidance point that is changing. As I alluded to on our Analyst Day, we are narrowing our guidance for 2011 SG&A expense from a range of $1.7 billion to $1.8 billion to a narrower range of $1.7 billion to $1.75 billion.
Now let's focus specifically on the first quarter of 2011. Our first quarter 2011 pure cash EPS is expected to increase over the first quarter 2010 equivalent of $0.76 by approximately 16% to 17%. This first quarter 2011 guidance includes a planned $0.04 benefit to earnings associated with changes to various employee benefit clients across the company. This item reflects the financial effects associated with the prior service credit from employee, post-employment benefit plan that was in place before our 2003 spin-off. These benefit which equates to approximately 1% full year EPS guidance, was included in our internal operating plan upon where our guidance is based and was ultimately approved by our Board of Directors in January 2011.
For the first quarter of 2011, we expect improvement in gross margin and EBITDA per script compared to first quarter 2010, even when excluding the $0.04 benefit I just mentioned of which 3/4 flows to cost of sales and 1/4 flows to the SG&A expense. Now let me provide some pointers to help you model the remaining quarters of 2011.
You may recall that I indicated on Analyst Day when you look at earnings progression for the year, EPS in 2011 will be even more backend loaded than we experienced in 2010. When excluding the $0.04 first quarter benefited I just mentioned, EPS is expected to be fairly consistent in the first two quarters of 2011 and improve progressively in each of the last two quarters, in part the result of incremental contribution from new generics, with zero, $0.01, $0.02 and $0.06 EPS contributions, respectively for each of the four quarters.
Let me now discuss an item that is not included in guidance at this time, as a matter of fact, it's currently indeterminable. With the contribution of Europa Apotheek Menlo or EAV to the Medco Celesio joint venture is now expected to take place in March 2011. We still expect to record a foreign exchange lost upon contribution, we are awaiting the final fair market valuation of the EAV asset we are contributing. At this point, we believe the exchange loss will likely equate to approximately $20 million. But it remains too early to quantify any gain or loss on the fair market valuation of EAV. This will be onetime transaction we will call out in our first quarter 2011 results that, again, was not and is not included in our quarterly or full year guidance. 
As we reported during the quarter, the Medicare Part D business of Universal American, our Medco client, is planned to be acquired by one of our competitors. As a result, it is expected that their business will no longer be serviced by Medco beginning in 2012. The termination of this business will not impact 2011 financial results and will not have a material impact to 2012 earnings since this account is very heavily weighted toward particularly low margin dual eligible business.
I know many of you in the call are interested in our expected renewals for 2012. At this point, we estimate our 2012 renewals in the range of $16 billion to $17 billion, approximately 25% of our books. One last point, we look forward to look into our scheduled availability late in the fourth quarter of 2011 and the many other blockbuster brand-name drugs that lose their patent protection and become available in generic form in 2012. As we stated at our Analyst Day and on many other occasions, our clients, members and shareholders all stand to benefit from what we expect in 2012. The highest level of generic savings generating in our company's history. 
That concludes my prepared remarks, and now Dave and I would like to open the lines for questions.  Vanessa?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Tom Gallucci from Lazard Capital Markets.",16,"[Operator Instructions] Your first question comes from the line of Tom Gallucci from Lazard Capital Markets."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I guess first question, Rich, there's been obviously a lot of focus on gross margin trends throughout the course of 2010. So maybe could you just highlight for us sort of where you came in relative to your expectations in the quarter and what are some of",53,"I guess first question, Rich, there's been obviously a lot of focus on gross margin trends throughout the course of 2010. So maybe could you just highlight for us sort of where you came in relative to your expectations in the quarter and what are some of the moving parts might have been?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Where we in line with our expectations. As you saw we have stability going from third order to the fourth quarter, which we were of course pleased with. The generic prescription volume mail came in stronger as we expected. UBC also contributed nicely to o",98,"Where we in line with our expectations. As you saw we have stability going from third order to the fourth quarter, which we were of course pleased with. The generic prescription volume mail came in stronger as we expected. UBC also contributed nicely to our service margin expansion. So I'd have to say we're on track to delivering what we expect for 2011 as well. So we're confident again point to the fact that we do expect this momentum to continue with stability and the likelihood of growth, both in gross margins as well as EBITDA per script."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave if I could sort of as a strategic question you mentioned in the oncology therapeutics that resource center open up during the year, can you maybe talk about a little bit more what you are doing there and maybe also to drugs there that are in the drug",74,"Dave if I could sort of as a strategic question you mentioned in the oncology therapeutics that resource center open up during the year, can you maybe talk about a little bit more what you are doing there and maybe also to drugs there that are in the drug benefit versus the medical benefit on the oncology side of the business maybe and how you're getting more of those drugs on the medical side?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure. As you know, at a strategic level many people are talking about oncologic issues moving from catastrophic to chronic in nature tied to the innovations in the drug world. And we've also mentioned to you many times, but we highlighted in the Analyst D",535,"Sure. As you know, at a strategic level many people are talking about oncologic issues moving from catastrophic to chronic in nature tied to the innovations in the drug world. And we've also mentioned to you many times, but we highlighted in the Analyst Day, that when you look at the pipeline of biotech drugs coming to market, 50% of them are oncologic in nature and the vast majority of them have a biomarker associated with the drug, which obviously we've been building around now for years. This state-of-the-art oncologic TRC that opened in Indiana is really gorgeous and it has capacity for 130 pharmacists who do nothing but manage patient care to protocols around various tumor types. We have actually some stratified capabilities tied to evidence-based protocols, working with physicians and patients to drive better outcomes for this what is now becoming chronic disease. So our client clearly loved the concept of therapeutic resource centers. It's highly applicable to the oncology space. Our clients also do want us to bring the medical spend, which is half the specialty spend, that is on the medical side over to the pharmacy side to be better managed. So we're doing many things. One of them we highlighted at Analyst Day, which is many of the drugs on the oncology space are infusible. And one of our nurses got up and demonstrated to all of you the iPad technology that we've developed to manage total patient care in the home that goes well beyond the infusion they're delivering. And we found out that we can actually at the point of care, manage the source of the drug, get that drug sourced at a better price, mail environment for our client. We also can take care of the other drugs needs and the drug gaps in care around the patient, around that home setting and we have well over 1,000 nurses to do nothing but manage patient care in the home around all of these infusibles. And by the way, in the pipeline well over 30% of the drugs in the pipeline are infusible. We are going to see that trend growth the major part of our arsenal at the point-of-care to change how these drugs are managed your. In addition, we are working, especially with our health plan clients, to isolate those specialty drugs that are hidden what people call under the medical coding. J. Coates to me are by definition 100% unmanaged. They are mystery codes that allow payors to the AWP plus dispensing markup, which is grotesquely inefficient and clients are becoming more and more aggressive around pulling that out and managing it properly, levering scale and everything else that we as TDM bring. We do that today and we're actually looking at some more highly scalable model for the future do we can rollout of would one even better job there. but that's literally we could double the size of Accredo simply by taking all of the spend that's burden the medical side of the business and moving into the managed environment we create for specialty jars within Accredo. So we consider that an enormous opportunity and our clients are motivated to work us spirit."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Lipitor, estimates are still good there that you talked about previously for the EPS contribution?",15,"Lipitor, estimates are still good there that you talked about previously for the EPS contribution?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, that's confirmed.",3,"Yes, that's confirmed."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Larry Marsh from Barclays Capital.",13,"Your next question comes from the line of Larry Marsh from Barclays Capital."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave, there's been a lot of discussion, it seems like recently, I noticed around pass-through transparent pricing at SEP and other customers. Obviously one of your competitors just talked about big margin impact with that change you mentioned great custom",78,"Dave, there's been a lot of discussion, it seems like recently, I noticed around pass-through transparent pricing at SEP and other customers. Obviously one of your competitors just talked about big margin impact with that change you mentioned great customer satisfaction we soon to be pricing extension in your guidance. so what's the difference here? Maybe educate us. And then how do we think the pricing in the future for this contract and other's around this pass-through pricing?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Marriott can't really talk about our competitor I can't talk specifically about FTPs renewal rate let me talk more broadly I think you know we've been a leader in transparency. Our definition of transparency has fit very nicely with most of the definition",105,"Marriott can't really talk about our competitor I can't talk specifically about FTPs renewal rate let me talk more broadly I think you know we've been a leader in transparency. Our definition of transparency has fit very nicely with most of the definitions out there of transparency, including government transparency. So we're comfortable with this environment. We also had one-year renewals with FPP and you haven't heard the same sorts of comments from us. So I think you might want to think about that as a unique to a specific DBM and not apply it to the industry. That would be my best advise."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then I guess just a follow with Rich. Just help me we strive got my numbers straight on the two comments about EBITDA and Q2. so you're suggesting EBITDA per adjusted script for Q1 will be above last year's numbers?",41,"And then I guess just a follow with Rich. Just help me we strive got my numbers straight on the two comments about EBITDA and Q2. so you're suggesting EBITDA per adjusted script for Q1 will be above last year's numbers?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's right.",3,"That's right."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I've got it 285, is that right to ballpark for EBITDA per adjusted script for Q1.",17,"I've got it 285, is that right to ballpark for EBITDA per adjusted script for Q1."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think that's about right, yes.",7,"I think that's about right, yes."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And the working about Q2 being about the same as Q1, if I do the math that's mid-80s I guess in cash earnings. And if I compare that to my cash earnings of last year, that would be down year-over-year. Am I thinking of that right or are we talking about e",56,"And the working about Q2 being about the same as Q1, if I do the math that's mid-80s I guess in cash earnings. And if I compare that to my cash earnings of last year, that would be down year-over-year. Am I thinking of that right or are we talking about earnings growth versus actual earnings?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","At this point, I'm just giving you some high-level guidance here. Don't be overly precise with regard to the second quarter in particular. The most important point is, we're going to see a meaningful acceleration of growth in the back half of the year. It",78,"At this point, I'm just giving you some high-level guidance here. Don't be overly precise with regard to the second quarter in particular. The most important point is, we're going to see a meaningful acceleration of growth in the back half of the year. It's difficult for me to be very specific with regard to second quarter performance at this point but more importantly I want you to have the earnings in the right part of the year."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Lisa Gill from JPMorgan.",12,"Your next question comes from the line of Lisa Gill from JPMorgan."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave, maybe we could just talk a little about Accredo in your comments around mix basically right of channel, et cetera. When we look at the gross margins in that business, can you maybe talk about over time, what you expect that to look like? Is the pres",84,"Dave, maybe we could just talk a little about Accredo in your comments around mix basically right of channel, et cetera. When we look at the gross margins in that business, can you maybe talk about over time, what you expect that to look like? Is the pressure on the gross margin aspect a lot of it is still going through retail? And can you maybe talk about specific numbers, but the margin opportunity as you bring that book into Accredo's book of business?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That me kind of give you a way we think about what's going on that in the specialty space. I would tell you that margins generally are quite stable. But what we try to explain in our formal comments is that the mix is something you just need to be aware o",188,"That me kind of give you a way we think about what's going on that in the specialty space. I would tell you that margins generally are quite stable. But what we try to explain in our formal comments is that the mix is something you just need to be aware of. So for example, hemophilia as a category, has been a higher-margin business. But the disease and the growth pattern of that disease among the population is far lower than the growth of many of the other specialty drugs tied to the disease pattern and the population. So Rich and his comments pointed out things like rheumatoid arthritis, things like pulmonary arterial, those are stable margins that we like and when just do the math and they grow dramatically, they change the weightings of margin across the drug products and that simply changes the overall margin perspective. but I wouldn't want investors think about this is declining margins. It's just the relative growth across a product lines. So that's how I would think about. Steve Fitzpatrick is here with us, want to add anything with that?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's a good point. I think the other piece of that is when we talk about channel mix and client mix, it actually drive them. So as we add more Medco client at basically higher volumes of multiple sclerosis, rheumatoid arthritis, oncology. And also withi",97,"That's a good point. I think the other piece of that is when we talk about channel mix and client mix, it actually drive them. So as we add more Medco client at basically higher volumes of multiple sclerosis, rheumatoid arthritis, oncology. And also within those therapy new indications of those drugs coming out and ultimately drive that growth even greater that we have some of our core infused therapies that are very strong on the medical said that's we've always penetrated. Strong medical side it's just as we are growing on the pharmacy side your."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Also the channel though, right? Steve, when you think about this you're going out if using the product my understanding that margin is much better than if you're just adjudicating a claim will you have some aspects in the book you're doing that.",43,"Also the channel though, right? Steve, when you think about this you're going out if using the product my understanding that margin is much better than if you're just adjudicating a claim will you have some aspects in the book you're doing that."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's correct. Our retail volumes has continued to grow pretty steadily into the that's actually a lower margin.",19,"That's correct. Our retail volumes has continued to grow pretty steadily into the that's actually a lower margin."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Are you comfortable giving us some -- I'm looking as the future opportunity. The more that you can bring it to your book the better margins can look over time is that 25% of the book, 40% of the book, can you give us some range of where the opportunities",59,"Are you comfortable giving us some -- I'm looking as the future opportunity. The more that you can bring it to your book the better margins can look over time is that 25% of the book, 40% of the book, can you give us some range of where the opportunities to bring that into the Accredo book of business?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, right now, when you look at the level of penetration of our current clients that currently have Accredo specialty, it's actually between 85% and 90%. So we made great progress over the past few years. You might recall when we started the rubble blee",67,"Well, right now, when you look at the level of penetration of our current clients that currently have Accredo specialty, it's actually between 85% and 90%. So we made great progress over the past few years. You might recall when we started the rubble bleed two years into the acquisition, maybe 60% to 70% range. So we had a very meaningful success for the past few years."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So just one follow-up question, Dave, can you maybe just give us any of your thoughts around kind of the selling season hasn't really started off this year. As we look at the 2012 selling season first of the amount you have for renewal was a little bit le",86,"So just one follow-up question, Dave, can you maybe just give us any of your thoughts around kind of the selling season hasn't really started off this year. As we look at the 2012 selling season first of the amount you have for renewal was a little bit less than we had anticipated, one come have things shifted around at all? And secondly as you look at the RFPs for 2012, are you seeing anything unusual as far as request go in the RFP process?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. The number Rich gave relative to the renewals for '12 is pretty much just how the contracts fall in our selected early renewals. It's just the way I would say that relative to RFPs we're seeing, I can't comment on anything special that we've noticed.",74,"No. The number Rich gave relative to the renewals for '12 is pretty much just how the contracts fall in our selected early renewals. It's just the way I would say that relative to RFPs we're seeing, I can't comment on anything special that we've noticed. But Tim is here in the room. I don't know if Tim, you want to mention relative to RFPs we're seeing and coming to the pipeline right now?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Nothing particularly special. I think a bit more clinical focus, a bit more focused on understanding what we're doing to manage specialty, wellness and workplace health. Those are the things we're getting a bit more focused and certain therapies and we've",66,"Nothing particularly special. I think a bit more clinical focus, a bit more focused on understanding what we're doing to manage specialty, wellness and workplace health. Those are the things we're getting a bit more focused and certain therapies and we've in other years but other than that I would say nothing unusual. We are very pleased with the pipeline right now I've got to say."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Ross Muken from Deutsche Bank.",13,"Your next question comes from the line of Ross Muken from Deutsche Bank."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just off on Lisa's comment on as we think about this upcoming selling season to some of the nice * wins you and look at the high renewal retention rate. As you dug into the some of the specific clients, what were some of the two or three things that you d",98,"Just off on Lisa's comment on as we think about this upcoming selling season to some of the nice * wins you and look at the high renewal retention rate. As you dug into the some of the specific clients, what were some of the two or three things that you don't like in the selling season the sort of stood out to you that finally we've either gotten a lot of traction with XYZ or 123 kind of really pushed the NATO and kind of help us retain business or helped us increase our market share?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","This is an going to be a mob to you Ross. But I would tell you that there is no question that clients when they're buying are looking for overall value prop. I say that and I think sometimes discounted because people thinks it's just about price and it's",230,"This is an going to be a mob to you Ross. But I would tell you that there is no question that clients when they're buying are looking for overall value prop. I say that and I think sometimes discounted because people thinks it's just about price and it's just not the case of. It's overall value prop relative to total healthcare costs and there is no question that clients are looking for the company that can optimize their spend, driving better outcomes of lower costs. The things we're doing around therapeutic resource centers, the things we're doing around pharmacogenomics, even the things we are now introducing tied to post-FDA approval research are all things that clients resonate with clients because they feel as though we're putting their destiny in their hands by creating an ability to drive from shotgun medicine to precision medicine and optimize the value of every dollar they spend. And we're able to do this even in a competitive pricing situations because on top of the fundamental ticket-to-entry which is price, it's about what else you're doing to drive a better outcome and it's really working for us and it just confirmed again in 2010. It was a fantastic year and we're really happy with the way it's run. Glenn, I don't know if you have any thoughts about that question, but feel free to comment."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","David, I'd say there's a couple of other things. The clients are really interested in using technology your. So the iPad example we used earlier is just one of many of the members you can get connect the that's one of the great things it resonated well an",76,"David, I'd say there's a couple of other things. The clients are really interested in using technology your. So the iPad example we used earlier is just one of many of the members you can get connect the that's one of the great things it resonated well and one of the client like the idea that we can connect them or connect them to other providers. That's been a huge positive in the health plans space."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I don't mean to belabor the point, but I'm just getting make sure everyone sort of understanding sort of the EPS progression. If we think about Rich, obviously the progression throughout the year vis--vis when you originally provided relative to the man",117,"I don't mean to belabor the point, but I'm just getting make sure everyone sort of understanding sort of the EPS progression. If we think about Rich, obviously the progression throughout the year vis--vis when you originally provided relative to the management model and what we're seeing today, one is that relatively consistent and then two, as we think about progression throughout the year, isn't the key to deltas the amount of generics obviously coming in per quarter which continues to be backend loaded and then two, the impact of the share repo which typically has more of an impact to earnings growth in the back half, is that the right way to think about it?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, absolutely. Remind you again Ross of the incremental EPS effect of the new generics. It really doesn't do much in the first half at all. It's nothing in the first quarter it runs to $0.01 in the second quarter. So you really are not getting any meani",72,"Yes, absolutely. Remind you again Ross of the incremental EPS effect of the new generics. It really doesn't do much in the first half at all. It's nothing in the first quarter it runs to $0.01 in the second quarter. So you really are not getting any meaningful fuel first to second quarter at all. Of course it's all about the fourth quarter with a $0.06, half of which was from Lipitor."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Randall Stanicky from Goldman Sachs the.",14,"Your next question comes from the line of Randall Stanicky from Goldman Sachs the."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a couple of other, can you give us an update added a few commented on and possible timing or maybe collectively can you let us know when we should expect to hear about an update on both FPP and UNH?",41,"Just a couple of other, can you give us an update added a few commented on and possible timing or maybe collectively can you let us know when we should expect to hear about an update on both FPP and UNH?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","As I said before run the UNH typically history is a predictor of the future. Typically conversations with an account this size start 18 months prior to which means puts us beginning the serious conversations in the summer. So you really shouldn't expect i",141,"As I said before run the UNH typically history is a predictor of the future. Typically conversations with an account this size start 18 months prior to which means puts us beginning the serious conversations in the summer. So you really shouldn't expect information from us really until I'd say in the fall potentially, depending on whether or not history is that accurate predictor As we've said before feel very good about our relationship with United and I am optimistic we will have a fruitful conversation, but serious conversations don't expect until they start in summertime. FPP is in flight now and I really can't say much about a bit processing * process in-flight now. But you should be hearing about that I would assume just given the time frame set out the client, probably by next quarter out the latest."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So it sounds like no change there on either front there. Just one more question we've got to on the farmers side pharma we talked about this before should we expect to see anything in terms of action for Medco or the industry in general to push back on ob",61,"So it sounds like no change there on either front there. Just one more question we've got to on the farmers side pharma we talked about this before should we expect to see anything in terms of action for Medco or the industry in general to push back on obviously what could be a big source of cost savings for clients?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Here's the way to think about this. We are not seeing the copay couponing let's call it influencing our volume. You heard our volumes, they're robust, they're moving to mail, they're moving to generics all the signs are encouraging. Today I can tell you t",210,"Here's the way to think about this. We are not seeing the copay couponing let's call it influencing our volume. You heard our volumes, they're robust, they're moving to mail, they're moving to generics all the signs are encouraging. Today I can tell you that we're not seeing any meaningful influence by coupons. However, let me be clear, to the extent couponing drives the wrong behavior and what I mean by that, if couponing in fact takes a prudent buyer behavior out of the client by eliminating their out-of-pocket responsibility date go to the most expensive drugs which end up going to the payers pocket, we have a series of things that we can easily do to shut that down very quickly. So we monitor, we make sure what's going on is in the client's best interest and we are fully prepared and we work with our clients all the time so that they can see and have visibility to what's going on, to the extent it's not in the payers best interest. We have then if it decides, plan designs and strategies ready to go that can shut couponing down overnight your so we are very comfortable with it and we certainly have plans to help clients respond."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Are clients asking about this or is this in their radar screen yet?",13,"Are clients asking about this or is this in their radar screen yet?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","When you see the article interesting in the same concept recently those articles clients are coming back and revisiting your decisions the preferred drug therapy which really takes the issue pretty much of the table to the extent Travis on formulary the c",91,"When you see the article interesting in the same concept recently those articles clients are coming back and revisiting your decisions the preferred drug therapy which really takes the issue pretty much of the table to the extent Travis on formulary the coupons and member takes because they failed generate is a first step it's in everybody's best interest clearly plans we're looking at this desirability to put those problems in place programs in place the best * best news is builds programs and there will invested in driving it."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Ricky Goldwasser from Morgan Stanley.",13,"Your next question comes from the line of Ricky Goldwasser from Morgan Stanley."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","First on the UBC contribution, so what percent of the growth within services, growth in services came from UBC of the $92 million?",23,"First on the UBC contribution, so what percent of the growth within services, growth in services came from UBC of the $92 million?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","If you look at the change and run rate from say the second quarter, which was the last pure quarter in service without UBC to the fourth quarter, the majority of the dynamic is a contribution from UBC.",38,"If you look at the change and run rate from say the second quarter, which was the last pure quarter in service without UBC to the fourth quarter, the majority of the dynamic is a contribution from UBC."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So if we try to back it out of EBITDA, we get to core growth for the business of about 3% year-over-year, are we in the ballpark there?",28,"So if we try to back it out of EBITDA, we get to core growth for the business of about 3% year-over-year, are we in the ballpark there?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I just don't say take we don't have the EBITDA but I can tell you the pretax contribution in the fourth quarter from UBC was nominal. We're talking about low to single-digit millions.",34,"I just don't say take we don't have the EBITDA but I can tell you the pretax contribution in the fourth quarter from UBC was nominal. We're talking about low to single-digit millions."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","When you talk about EBITDA per script given there was no script associated with the business we assume higher contribution there?",21,"When you talk about EBITDA per script given there was no script associated with the business we assume higher contribution there?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, that's correct.",3,"Yes, that's correct."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Backing into around 3% year-over-year growth is that core business, is that a reasonable estimate?",15,"Backing into around 3% year-over-year growth is that core business, is that a reasonable estimate?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","You're talking about just growth in the EBITDA per adjusted script?",12,"You're talking about just growth in the EBITDA per adjusted script?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Correct.",1,"Correct."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Which is currently in the fourth quarter. Fourth quarter basis 5.2%, you're saying about 3% of is...",17,"Which is currently in the fourth quarter. Fourth quarter basis 5.2%, you're saying about 3% of is..."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Core UBC.",2,"Core UBC."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","The core should be stronger than that.",7,"The core should be stronger than that."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then on the 2012 renewal season of the $16 billion to $17 billion, I don't know if you comment on that. But what percent are early renewals versus scheduled?",30,"And then on the 2012 renewal season of the $16 billion to $17 billion, I don't know if you comment on that. But what percent are early renewals versus scheduled?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I can tell you that the majority of that number is scheduled.",12,"I can tell you that the majority of that number is scheduled."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And does that imply that you had some of the early renewals in 2011 really came from 2012 renewals?",19,"And does that imply that you had some of the early renewals in 2011 really came from 2012 renewals?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. I gave you the 2011 renewal it's $15 billion .",11,"No. I gave you the 2011 renewal it's $15 billion ."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would tell you in any given year vast majority of renewals are scheduled renewals and I would say that consistently, we're very selective about what we early renew and that was true for 2010 it continues to be true for '11 and it will be true for'12.",48,"I would tell you in any given year vast majority of renewals are scheduled renewals and I would say that consistently, we're very selective about what we early renew and that was true for 2010 it continues to be true for '11 and it will be true for'12."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your final question comes from the line of Steven Valiquette from UBS.",12,"Your final question comes from the line of Steven Valiquette from UBS."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I guess first just to clarify, the $16 billion to $17 billion, does that include or exclude UNH?",18,"I guess first just to clarify, the $16 billion to $17 billion, does that include or exclude UNH?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It does not include United. United is not up for renewal in 2012.",13,"It does not include United. United is not up for renewal in 2012."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","You commented about the timing of that drug in 2012 or should at least assume that whatever is going to happen there, will happen sometime in calendar 2011 just trying to get a little more color on there?",38,"You commented about the timing of that drug in 2012 or should at least assume that whatever is going to happen there, will happen sometime in calendar 2011 just trying to get a little more color on there?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It easily drug in 2012.",5,"It easily drug in 2012."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","On SG&A kind more of a general question. I think for the PVM sector, what can we think about startup of expenses for new business wins occurring in the first quarter of each calendar, but just curious with Medicare become a large part of the mix, is it pr",76,"On SG&A kind more of a general question. I think for the PVM sector, what can we think about startup of expenses for new business wins occurring in the first quarter of each calendar, but just curious with Medicare become a large part of the mix, is it probably now more business wins in 4Q just trying to get a general sense of the split between 4Q in 1Q for start of expenses generally speaking?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think the way you should think about is from a software development point of view, to benefit modifications or account setup, that's primarily fourth quarter expense. Service expense is first quarter tied to volumes of calls when you go live. So I would",75,"I think the way you should think about is from a software development point of view, to benefit modifications or account setup, that's primarily fourth quarter expense. Service expense is first quarter tied to volumes of calls when you go live. So I would say historically with us, it's been more expense is more heavily weighted to the fourth quarter relative to the quoting of the benefit and getting the account setup versus first quarter."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","One further point on that Steve, the majority of our startup expenses this year and last year had been in cost of sales to the effect of gross margin, they generally have not been an SG&A expense.",37,"One further point on that Steve, the majority of our startup expenses this year and last year had been in cost of sales to the effect of gross margin, they generally have not been an SG&A expense."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","As far as the lower SG&A expense in 2011, any additional color on that, if you lower the range there by $50 million or so?",26,"As far as the lower SG&A expense in 2011, any additional color on that, if you lower the range there by $50 million or so?"
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","The range was very, very broad. It was almost too wide when you first give guidance which is why an Analyst Day, promised that I would narrow it.",28,"The range was very, very broad. It was almost too wide when you first give guidance which is why an Analyst Day, promised that I would narrow it."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thanks to all of you for joining us today and look forward to speaking with you again in the not-too-distant future.",22,"Thanks to all of you for joining us today and look forward to speaking with you again in the not-too-distant future."
1541811,118622458,104888,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","This concludes today's conference call. Thank you for your participation. You may now disconnect.",15,"This concludes today's conference call. Thank you for your participation. You may now disconnect."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning. My name is Vanessa, and I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions Fourth Quarter 2010 Earnings Call. [Operator Instructions] I would now like to turn the call over t",56,"Good morning. My name is Vanessa, and I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions Fourth Quarter 2010 Earnings Call. [Operator Instructions] I would now like to turn the call over to Ms. Valerie Haertel, Vice President of Investor Relations. Please go ahead, ma'am."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Vanessa. Good morning, and thank you for joining us on Medco's Fourth Quarter and Full Year 2010 Earnings Conference Call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer.",327,"Thank you, Vanessa. Good morning, and thank you for joining us on Medco's Fourth Quarter and Full Year 2010 Earnings Conference Call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us for our question-and-answer session are: Kenny Klepper, President and Chief Operating Officer; Tom Moriarty, General Counsel, Secretary and Senior Vice President of Pharmaceutical Strategies and Solutions; Steve Fitzpatrick, President of Accredo Health Group; Dr. Rob Epstein, President of Advance Chemical Science and Research; Tim Wentworth, Group President of the Employer and Key Accounts; and Glenn Taylor, Group President Health Plans. 
During the course of this call, we will make forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in our SEC filings.
Copies of Medco's filings are available from the SEC, the Medco Investor Relations Department or the Medco website. Medco intends to use the Investor Relations section of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. The copyrights for the contents of this discussion and the written materials used on this earning call are owned by MedcoHealth Solutions, Inc. 2011.
Slides to accompany our presentation, which detail our financial and operating results and the guidance discussed on this call, are currently available in the Events section of the Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-K after the close of the market today. 
At this time, I would like to turn the call over to Dave Snow. Dave?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valerie, and thanks to all of you for joining us this morning. Medco is pleased to report record fourth quarter and full year 2010 earnings, reflecting strong financial and operating performance at the high end of our previously increased guida",1526,"Thank you, Valerie, and thanks to all of you for joining us this morning. Medco is pleased to report record fourth quarter and full year 2010 earnings, reflecting strong financial and operating performance at the high end of our previously increased guidance. Today, I will focus my remarks on full year 2010 results and 2011 guidance, while Rich will focus on our balance sheet, our fourth quarter results and details surrounding our 2011 guidance. At our Analyst Day in November, we shared with you our expectations for Medco and our business strategy that is designed to continue delivering strong growth through 2020. We outlined our portfolio of growth drivers that will advance our mission to make medicine smarter for our clients and the more than $65 million members we serve. Today, we remain confident in our expectations and are pleased to provide you with the details of our performance for 2010 and expectations for 2011. 
Let's begin with our year-over-year 2010 financial and operational performance. For the year, we delivered record GAAP diluted earnings per share of $3.15 representing growth of 21.1%. Our diluted earnings per share excluding the amortization of intangibles from the 2003 spin-off grew 20.1% to a record $3.40. Our net revenues reached a record $66 billion, up 10.3% from 2009 despite the higher volumes of lower-cost generics that reduced our net revenues by nearly $3.7 billion and correspondingly resulted in record client and patient savings. 
Within net revenues, our higher margin-generating service revenues grew 28% to a record $1.08 billion, fueled by our United BioSource acquisition and service revenue growth across the company. We achieved record total gross margin of $4.3 billion, an increase of 7.7% over 2009.
Our EBITDA increased 8.1% to nearly $3 billion and our EBITDA per adjusted script increased 1.6% to a full year record of $3.11. And finally, our net income increased 11.5% to a record $1.4 billion. With respect to the operating metrics that contributed to our strong financial results, overall prescription volumes adjusted for the dates applied between retail and mail grew a strong 6.5% to a record 957 million prescriptions. 
Mail-order prescriptions for the year grew at a strong 6.5% to 109.8 million, which exceeded the high end of our guidance of 109 million prescriptions and set a new record. Importantly, we experienced continued strength in generic mail-order volumes, increasing a substantial 13.4% to 67.6 million prescriptions as patients continued to choose lower-cost generic medications. 
Growth of generics have now for the fourth quarter was even greater at 15.1%. Our overall generic dispensing rate rose 3.5 percentage points to 71% and within that, our mail-order generic dispensing rate component increased an even greater amount by 3.7 percentage points to a record 61.5%. For the full year, our Medicare Part D PDP revenues achieved a record, increasing 33.5% to well over $1.4 billion. We are proud to have been the first and only national PDP to be awarded five stars by CMS and believe this world-class recognition operationally not only validates our investments in our agile enterprise but also enables continued strength in our Medicare business going forward.
Moving on to our Specialty business, Accredo's performance remained strong with revenues increasing 19.1% to a record $11.3 billion and operating income rising 22.7% to a record $438.2 million. Turning to sales and client retention results, Medco delivered another solid year of performance. Our 2010 annualized new-named and net-new sales each remained strong at $5.3 billion, and our client retention rate remained over 99%. For 2011 today, our annualized new-named sales stand at $1.7 billion and our net-new sales are currently $1.5 billion, up from the $1.4 billion previously disclosed on our third quarter earnings call. We have now completed over 80% of our 2011 scheduled and early elective client renewals, up from the over 50% we reported on our third quarter call, and our 2011 year-to-date client retention rate remains at over 99%.
This past year, we continued to invest in our enterprise by expanding our expertise in genomic and personalized medicines with the acquisition of DNA Direct. We also entered the market for post-approval Phase IV safety, economic evaluation and outcomes research through our acquisition of United BioSource. We are very pleased with the results to date for both of these acquisitions. DNA Direct's genomic services are gaining traction in the marketplace. Just a few weeks ago, we announced the addition of four new community hospital clients to DNA Direct genomic medicine hospital network, extending web-based physician support and genetic expertise to their physicians and their patients. 
We also announced the addition of four new health plan clients who are implementing DNA Direct's Policy & Benefit Support Program for molecular diagnostic and genetic tests. This program enables payers to determine coverage for more than 800 molecular diagnostic and genetic tests and provides real-time access to the DNA Direct team of genetic counselors for clinical guidance and counseling on the more than 2,000 genetic tests available today. We are encouraged by the level of market interest in this new service offering.
We are very pleased with the acquisition of UBC, which has been enthusiastically embraced by more than 100 Medco clients, representing more than 40 million lives volunteering to be part of the Medco research consortium to participate in UBC research study. This is up from the previously disclosed 89 clients and 33 million lives. As we noted at Analyst Day, both our clients and biotech drug manufacturers have common interest to ensure the safety and efficacy of new drugs coming to market. On top of that, Medco and its clients are fully aligned to pursue better outcomes and lower total healthcare costs, the essence of Making Medicine Smarter.
As we move forward, we anticipate UBC will continue to realize strong growth from its impressive pipeline of opportunities, including safety surveillance where UBC holds the market-leading position globally. Additionally, we expect to leverage UBC's, Medco's and Accredo's capabilities to the benefit of our clients and patients as we fundamentally change the way drugs are introduced, delivered and monitored for both safety and economics. 
Turning to guidance, we are reaffirming our full year 2011 GAAP diluted earnings per share guidance of $3.53 to $3.66 reflecting a growth rate of 12% to 16% over 2010. Diluted earnings per share excluding all intangible amortization, our new pure cash EPS measure is reaffirmed to be in the range of $3.99 to $4.12, reflecting 12% to 16% growth over 2010 earnings per share. Please note that the growth rate change for GAAP and pure cash EPS was 12% to 17% previously, but is narrowed due to the fact that we achieved the high end of our 2010 guidance range.
In closing, we remain confident in our ability to generate strong EPS growth well into the future. In  the weeks since we shared our long-range plans with you, I have been asked how we can be so confident over such an extended horizon. There are two primary reasons; the first is the rigor and granular detail behind our 10-year strategic financial plan. As we shared on the Analyst Day last November, we have a very detailed roadmap for growth that is reasonable and logical based upon the many compelling opportunities we foresee over the next 10 years and a realistic view of the risk we may have encountered along the way. I believe that our growing portfolio of capabilities with leaders who are dedicated and accountable for each one of them will enable us to offer a comprehensive suite of solutions that will likely remain unmatched in the marketplace. 
The second is our people. Our employees are united to a greater good, a noble cause that fuel the passion around Making Medicine Smarter in a world-class manner. While a common vision is important, our people also have proven ability to execute with unparalleled excellence. Our CMS five-star rating is a testament to this, further evidence can be found in our January 1 install, which were virtually flawless despite the record number of complex changes required by CMS in the recent healthcare reform mandate. 
As we continue to make progress in advancing our capabilities through our agile enterprise initiative, we expect to achieve unprecedented improvements in the way we deliver operational excellence to the benefit of our clients and members. Yet another example of our operational excellence is the recent final approval we received from the Indiana Board of Pharmacy for our new third-generation automated pharmacy located in Whitestown, Indiana. 
In the testing phase that ran from September through mid-January, the board found that the pharmacy filled every prescription of the tens of thousands tested with 100% accuracy. I would like to take this opportunity to thank each and every one of our over 24,000 Medco employees now standing the globe for their continued efforts on behalf of clients, patients and shareholders resulting in another great year and strong long-term prospects. They are delivering everyday for our clients, members and shareholders.
With that, I will turn it over to Rich Rubino, who will take you through our balance sheet, the fourth quarter 2010 financials and further details on our guidance for 2011. Rich?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. We are pleased to deliver another quarter and full year of strong financial and operating performance. As Valerie mentioned, the slides on our website will prove helpful in following along with my commentary.Starting with",2369,"Thank you, Dave. Good morning. We are pleased to deliver another quarter and full year of strong financial and operating performance. As Valerie mentioned, the slides on our website will prove helpful in following along with my commentary.
Starting with our balance sheet, we closed the fourth quarter with a cash balance of $853 million, and our cash flow from operations for full year 2010 totaled over $2.34 billion. While our mail-order prescription volumes set record highs in 2010, our inventory balances represent a record year end low of just over $1 billion at the end of 2010, a $272 million reduction from year-end 2009 on top of the $571 million reduction we generated during 2009.
Our capital expenditures at full year 2010 were in line with our guidance at $250 million, reflecting investments in our business to drive agility and enhance efficiency across the organization, prepare for healthcare reform implementation and to fund the future growth. We achieved the full year 2010 return on invested capital of 35%, excluding 2010 acquisitions such as UBC. A meaningful increase over the 2009 return was 27%, which was already seven points higher than 2008. 
Our fourth quarter 2010 EPS results were record with GAAP diluted EPS of $0.88 representing 25.7% growth over fourth quarter 2009 and diluted EPS excluding the amortization of intangibles from the 2003 spin-off of $0.94 representing 23.7% growth over 2009.
Total fourth quarter 2010 net revenues reached a record $16.9 billion, representing growth of 11.1% over fourth quarter 2009. Our product revenue grew 10.4%, reflecting our new business wins as well as higher prices charged by brand name pharmaceutical manufacturers, partially offset by a higher representation of lower-priced generics, in fact, a record generic effect of approximately $1.1 billion on fourth quarter's revenue alone.
Service revenue continued to be a very meaningful growth driver, increasing 58.7% over fourth quarter 2009. This strong performance reflects a full quarter of service revenue contribution from UBC, which closed on September 16, 2010, as well as the expansion of our overall client base at our Medicare Part D service fees.
Turning to rebates, we earned nearly $1.5 billion for the fourth quarter and $5.8 billion for full year 2010, both records, even though we are dispensing fewer brand name medications and more generics. These earned rebate levels represent 7% growth for the quarter and 8.1% growth for the year attributable to new client wins and continuous improvements in formulary contracting. Our fourth quarter 2010 rebate retention rate was 13.0% compared to 14.1% in fourth quarter 2009 as we continue to drive significant value to clients in a highly transparent manner. For the full year, our rebate retention rate of 12.5% compared to 13.7% in 2009.
In terms of claims volumes, total fourth quarter prescriptions adjusted for the difference in days supply between retail and mail reached a record $244.3 million, an increase of 7.4% over fourth quarter 2009. Retail prescriptions in fourth quarter 2010 grew 7.5% to a record $161.4 million. Mail-order volume remains strong as clients and members continue to choose the lowest cost and most clinically effective channel.
Our mail-order prescriptions reached a record $27.9 million in fourth quarter 2010, a 7.3% increase from fourth quarter 2009. The adjusted mail-order prescription volumes for fourth quarter 2010 comprised 33.9% of the total adjusted prescriptions, in line with the 34.0% mail penetration rate in fourth quarter 2009.
Within the record fourth quarter 2010 mail-order prescription volume total, generic prescription volumes increased 15.1% to a record $17.5 million, reflecting new generic introductions and continued growth in previously released generics, while brand-name prescription volumes decreased 3.7% to 10.4 million prescriptions. The strength in our generic mail-order prescription volumes was an important driver of our fourth quarter gross margin, which increased 13.1% over fourth quarter 2009 to a record of $1.16 billion.
Our consolidated gross margin percentage of 6.9% for the quarter held steady with what we reported at third quarter 2010, and on a year-over-year basis, increased 20 basis points from the 6.7% in fourth quarter 2009, again a result of the strong fourth quarter 2010 mail-order generic prescription volumes and our strong service gross margins. 
Selling, general and administrative expenses of $428.5 million for the fourth quarter increased over fourth quarter 2009 by $53 million or 14.1%, reflecting the addition of UBC as well as higher professional fees and other expenses associated with strategic initiatives. Excluding UBC, SG&A for the fourth quarter was up $32.2 million or 8.6% from fourth quarter 2009. 
The expenses we incurred in 2010 for strategic initiatives are critical to our transformation into a world-class agile enterprise focused on speed, accuracy, efficiency and providing the highest levels of clients and patient care. We invest in ourselves because we are a growth company, with many exciting components of our expanding portfolio of businesses. These investments, whether in the form of expense or capital, are designed to proactively drive unparalleled levels of client and patient service on top of what we believe is already a world-class service model.
Our total EBITDA for fourth quarter 2010 reached a record $786.5 million, representing growth of 13.2%. EBITDA per adjusted prescription for the quarter increased 5.2% to $3.22, a fourth quarter record. Our intangible amortization of $75 million in fourth quarter 2010 decreased slightly from $75.5 million at fourth quarter 2009. The full year amortization of $287.4 million decreased in 2009 by 6.0% or $18.2 million, primarily reflecting lower intangible amortization from PolyMedica and Accredo, partially offset by the addition of UBC and DNA Direct intangible assets.
Total net interest and other expense of $50.4 million for the fourth quarter of 2010 increased $10.5 million from the $39.9 million in fourth quarter 2009, reflecting the new debt we added to finance the UBC acquisition last September. For the full year, total net interest and other expense of $163.1 million was slightly higher compared to the $162.6 million for 2009, reflecting this new debt, offset by lower interest rates associated with floating rate debt.
The fourth quarter 2010 effective tax rate was 37.7% compared to 36.3% in 2009, primarily reflecting a 2009 benefit from state-related income tax items. Our effective tax rate for full year was 38.9%, in line with the 39.1% in 2009. Net income for the quarter increased 10.8% to a record $378.5 million from the $341.5 million reported for the fourth quarter of 2009. For the full year, net income increased 11.5% to a record of over $1.4 billion from the $1.3 billion reported for 2009.
Moving on to share repurchases, during the fourth quarter of 2010, we repurchased 15.8 million shares for $963.3 million at an average per share cost of $61.05. For Full year 2010, share repurchases totaled 69.9 million at a cost of $4.1 billion with an average per share cost of $58.97. Since share repurchases commenced in 2005, we repurchased a total of 256.2 million shares, with a total cost of $11.1 billion, with an average per share cost of $43.18. 
For 2011 to date, we repurchased 7.0 million shares with an average per share cost of $62.06. In January 2011, we completed the remaining $437 million of the $3.0 billion authorization that was approved in May 2010. By February 2, 2011, our Board authorized a new $3 billion share repurchase plan. We continued to complete approximately $2 billion in share repurchases in 2011, driving meaningful value to our shareholders. We expect the commenced share repurchases under the new authorization later this quarter.
Turning to our Specialty segment, Accredo achieved record revenues of $3.0 billion for fourth quarter of 2010, an increase of 21.3% over the fourth quarter of 2009. Consistent with our guidance, Accredo's gross margin percentage for the quarter amounted to 6.5% compared to the 7.0% in fourth quarter 2009. This Accredo gross margin decline reflects product channel and new client mix. The 2010 product mix reflects significant growth in our multiple sclerosis, rheumatoid arthritis, oncology and pulmonary arterial hypertension patients with product volumes. Accredo's operating income for fourth quarter 2010 increased 30.7% to $109.9 million. 
Moving on to Medicare, we continued to experience growth in our Medicare PDP. For fourth quarter 2010, Medco's PDP revenues increased 27.7% to $331.7 million. As Dave discussed, we are reaffirming our guidance for 2011. To briefly repeat our reaffirmed 2011 guidance, diluted GAAP EPS is expected to grow 12% to 16% over 2010 in the range of $3.53 to $3.66. As we noted last quarter, the non-GAAP diluted EPS measure change commencing in 2011 to exclude all intangible amortization. Diluted EPS excluding all intangible amortization remains in the guidance range of $3.99 to $4.12, representing growth of 12% to 16% over the 2010 full year equivalent of $3.55.
While this measure will not be used in 2011, diluted EPS, excluding intangible amortization from the 2003 spin-off would be guided to increase to a range of $3.80 to $3.93, also representing growth of 12% to 16% over 2010. The detailed components of our 2011 guidance are as follows. We currently expect to renew approximately $15 billion of business in 2011, including scheduled and early elective renewals, representing less than 1/4 of our business. As Dave mentioned, we have over 80% of our 2011 renewals already completed. As I've previously guided, approximately 75% of the renewal pricing is in effect in the first quarter with the majority of the remainder effective in the third quarter of 2011.
Our guidance for mail-order prescription volumes for 2011 remains in the range of $107 million to $109 million, demonstrating solid growth in our base business considering the 3 million script offset I discussed at Analyst day. You may recall the expected reduction of approximately 2 million mail-order scripts from the contribution of Europa Apotheek to the Medco Celesio joint venture and another 1 million scripts associated with the conversion of generic Allegra known as fexofenadine to OTC status in early 2011. These expectations remain intact.
As you can see from our slides on the Web, the vast majority of our detailed 2011 guidance components remain consistent with those we provided at our Analyst Day including, as example, the $0.09 incremental contribution from new generics and expectations for stability or probable expansion in gross margin percentage and EBITDA per adjusted script performance in 2011. There is one guidance point that is changing. As I alluded to on Analyst Day, we are narrowing our guidance for 2011 SG&A expense from a range of $1.7 billion to $1.8 billion to a narrower range of $1.7 billion to $1.75 billion.
Now let's focus specifically on the first quarter of 2011. Our first quarter 2011 pure cash EPS is expected to increase over the first quarter 2010 equivalent of $0.76 by approximately 16% to 17%. This first quarter 2011 guidance includes a planned $0.04 benefit to earnings associated with changes to various employee benefit plans across the company. This item reflects the financial effects associated with the prior service credit for our employee post-employment benefit plan that was in place before our 2003 spin-off. This benefit, which equates to approximately 1% full year EPS guidance, was included in our internal operating plan upon which guidance was based and was ultimately approved by our Board of Directors in January 2011.
For the first quarter of 2011, we expect improvement in gross margin and EBITDA per script compared to first quarter 2010, even when excluding the $0.04 benefit I just mentioned of which 3/4 flows to cost of sales and 1/4 flows to SG&A expense. Now let me provide some pointers to help you model the remaining quarters of 2011.
You may recall that I indicated on Analyst Day, when you look at earnings progression for the year, EPS in 2011 will be even more back-end loaded than we experienced in 2010. When excluding the $0.04 first quarter benefit I just mentioned, EPS is expected to be fairly consistent in the first two quarters of 2011 and improve progressively in each of the last two quarters, in part the result of the incremental contribution from new generics, with zero, $0.01, $0.02 and $0.06 EPS contributions, respectively, for each of the four quarters.
Let me now discuss an item that is not included in guidance at this time as the net effect is currently indeterminable. The contribution of Europa Apotheek Venlo or EAV to the Medco Celesio joint venture is now expected to take place in March 2011. We still expect to record a foreign exchange loss upon contribution. We are awaiting the final fair market valuation of the EAV asset we are contributing. At this point, we believe the exchange loss will likely equate to approximately $20 million and it remains too early to quantify any gain or loss on the fair market valuation of EAV. This will be a onetime transaction that we  will call out in our first quarter 2011 results that, again, was not and is not included in our quarterly or full year guidance. 
As we reported during the quarter, the Medicare Part D business of Universal American, a current Medco client, is planned to be acquired by one of our competitors. As a result, it is expected that their business will no longer be serviced by Medco beginning in 2012. The termination of this business will not impact 2011 financial results and will not have a material impact to 2012 earnings since this account is very heavily weighted towards particularly low-margin dual-eligible business.
I know many of you in the call are interested in our expected renewals for 2012. At this point, we estimate our 2012 renewals in the range of $16 billion to $17 billion, approximately 25% of our book. One last point, we look forward to Lipitor's scheduled availability late in the fourth quarter of 2011 and the many other blockbuster brand-name drugs that lose their patent protection and become available in generic form in 2012. As we stated at our Analyst Day and on many other occasions, our clients, members and shareholders all stand to benefit from what we expect in 2012, the highest level of generic savings generating in our company's history. 
That concludes my prepared remarks, and now Dave and I would like to open the lines for questions.  Vanessa?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Tom Gallucci from Lazard Capital Markets.",16,"[Operator Instructions] Your first question comes from the line of Tom Gallucci from Lazard Capital Markets."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I guess first question, Rich, there has been obviously lot of focus on gross margin trends throughout the course of 2010, so maybe could you just highlight for us sort of where you came in relative to your expectations in the quarter and what some of the",52,"I guess first question, Rich, there has been obviously lot of focus on gross margin trends throughout the course of 2010, so maybe could you just highlight for us sort of where you came in relative to your expectations in the quarter and what some of the moving parts might have been?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, we in right in line with our expectations. As you saw, we have stability going from third quarter to the fourth quarter, which we were, of course, pleased with. The generic prescription volume mail came in stronger as we expected. UBC also contribut",102,"Well, we in right in line with our expectations. As you saw, we have stability going from third quarter to the fourth quarter, which we were, of course, pleased with. The generic prescription volume mail came in stronger as we expected. UBC also contributed nicely to our service margin expansion. So I'd have to say that we're on track to delivering what we expect for 2011 as well. So with confidence, I can point to the fact that we do expect this momentum to continue with stability and the likelihood of growth, both in gross margins as well as EBITDA per script."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then Dave, if I could just sort of ask more of a strategic question, you mentioned in the Medco Oncology Therapeutic Research Center that opened up during the year, can you maybe talk a little bit more about what you're doing there, and maybe also wit",81,"And then Dave, if I could just sort of ask more of a strategic question, you mentioned in the Medco Oncology Therapeutic Research Center that opened up during the year, can you maybe talk a little bit more about what you're doing there, and maybe also with respect to drugs there that are in the drug benefit versus the medical benefit on the oncology side of the business maybe and how you're getting more of those drugs on the medical side?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, sure. As you know, at a strategic level, many people are talking about oncologic issues moving from catastrophic to chronic in nature tied to the innovations in the drug world. And we've also mentioned to you many times, but we highlighted in the Ana",549,"Yes, sure. As you know, at a strategic level, many people are talking about oncologic issues moving from catastrophic to chronic in nature tied to the innovations in the drug world. And we've also mentioned to you many times, but we highlighted in the Analyst Day, that when you look at the pipeline of biotech drugs coming to market, 50% of them are oncologic in nature, and the vast majority of them have a biomarker associated with the drug, which obviously we've been building around now for years. This state-of-the-art oncologic TRC that opened up in Whitestown, Indiana is really gorgeous, and it has capacity for 130 pharmacists who do nothing but manage patient care to protocols around various tumor types. We have actually sub-stratified capabilities tied to evidence-based protocols, working with physicians and patients to drive better outcomes for this what is now becoming chronic disease. So our clients clearly love the concept of therapeutic resource centers. It's highly applicable to the oncology space. Our clients also do want us to bring the medical spend, which is half the specialty spend, that is on the medical side over to the pharmacy side to be better managed. So we are doing many things. One of them, we highlighted at Analyst Day, which is many of the drugs on the oncology space are infusible. And one of our nurses got up and demonstrated to all of you the iPad technology that we've developed to manage total patient care in the home that goes well beyond the infusion they're delivering. And we find out, we can actually, at the point of care, manage the source of the drug, get that drug sourced at a better price, mail environment for our client. We also can take care of the other drug needs and the drug gaps in care around that patient in that home setting, and we have well over 1,000 nurses, who do nothing but manage patient care in the home around all of these infusibles. And by the way, in the pipeline, well over 30% of the drugs in the pipeline are infusible. So we're going to see that trend grow as a major part of our arsenal as a point of care to change how these drugs are managed. In addition, we are working, especially with our health plan clients, to isolate those specialty drugs that are hidden under what people call J-Codes under the medical coding. J-Codes to me are, by definition, 100% unmanaged. They are mystery codes that allow payers to pay AWP plus the dispensing fee plus a mark-up, which is just grotesquely inefficient, and clients are becoming more and more aggressive around pulling that out and managing it properly, levering scale and everything else that we as PBM bring. And we do that today, and we're actually looking at some more highly scalable models in the future that we can rollout to do an even better job there but that's -- literally, we could double the size of Accredo simply by taking all of the spend that's buried on the medical side of the business and moving it to the managed environment we create for specialty drugs within Accredo. So we consider that an enormous opportunity and our clients are motivated to work with us."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then just to confirm, Rich, you mentioned Lipitor estimates are still good there that you had talked about previously for the EPS contribution?",24,"And then just to confirm, Rich, you mentioned Lipitor estimates are still good there that you had talked about previously for the EPS contribution?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, that's confirmed.",3,"Yes, that's confirmed."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Larry Marsh from Barclays Capital.",13,"Your next question comes from the line of Larry Marsh from Barclays Capital."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave, there's been a lot of discussion, it seems like recently, as I've noticed it around pass-through transparent pricing at FEP and other customers, obviously, one of your competitors just talked about a big margin impact with that change. Now you have",83,"Dave, there's been a lot of discussion, it seems like recently, as I've noticed it around pass-through transparent pricing at FEP and other customers, obviously, one of your competitors just talked about a big margin impact with that change. Now you have mentioned great customer satisfaction with FEP -- pricing extension already in your guidance. So what's the difference here, maybe educate us and then how do we think of pricing in the future for this contract and others around this pass-through pricing?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Larry, I can't really talk about our competitor. I really can't talk specifically about FEP's renewal, but let me talk more broadly. I think you know we've been a leader in transparency. Our definition of transparency has fit very nicely with most of the",105,"Larry, I can't really talk about our competitor. I really can't talk specifically about FEP's renewal, but let me talk more broadly. I think you know we've been a leader in transparency. Our definition of transparency has fit very nicely with most of the definitions out there of transparency, including government transparency. So we're comfortable with this environment. We also had one-year renewals with FEP. And you haven't heard the same sorts of comments from us. So I think you might want to think about that as unique to a specific PBM and not apply it to the industry. That would be my best advise."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then I guess just a follow with Rich, just help me make sure I've got my numbers straight on the two comments about EBITDA and Q2, so you're suggesting EBITDA per adjusted script for Q1 will be above the last year's numbers?",43,"And then I guess just a follow with Rich, just help me make sure I've got my numbers straight on the two comments about EBITDA and Q2, so you're suggesting EBITDA per adjusted script for Q1 will be above the last year's numbers?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's right.",3,"That's right."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I've got it like 285, is that the right ballpark for EBITDA per adjusted script for last year's Q1?",20,"I've got it like 285, is that the right ballpark for EBITDA per adjusted script for last year's Q1?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I think that's about right, yes.",7,"Yes, I think that's about right, yes."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then just the wording about Q2 being about the same as Q1, if I do the math, that's in the mid-80s, I guess, in cash earnings. And if I compare that to my cash earnings of last year, that would be down year-over-year. Am I thinking of that right, or a",60,"And then just the wording about Q2 being about the same as Q1, if I do the math, that's in the mid-80s, I guess, in cash earnings. And if I compare that to my cash earnings of last year, that would be down year-over-year. Am I thinking of that right, or are we talking about earnings growth versus actual earnings?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","At this point, I'm just giving you some high-level guidance here. Don't be overly precise with regard to the second quarter in particular. But the most important point is, we're going to see a meaningful acceleration of growth in the back half of the year",79,"At this point, I'm just giving you some high-level guidance here. Don't be overly precise with regard to the second quarter in particular. But the most important point is, we're going to see a meaningful acceleration of growth in the back half of the year. It's difficult for me to be very specific with regard to second quarter performance at this point. But more importantly, I want you to have the earnings in the right part of the year."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Lisa Gill from JPMorgan.",12,"Your next question comes from the line of Lisa Gill from JPMorgan."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave, maybe we could just talk a little about Accredo and your comments around mix, basically product channel, et cetera. When we look at the gross margin in that business, can you maybe talk about over time, what you expect that to look like? Is there pr",93,"Dave, maybe we could just talk a little about Accredo and your comments around mix, basically product channel, et cetera. When we look at the gross margin in that business, can you maybe talk about over time, what you expect that to look like? Is there pressure on the gross margin aspect, the fact that a lot of it is still going through retail? And can you maybe talk about -- maybe you want to talk about specific numbers, but the margin opportunity as you bring that book into Accredo's book of business?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Lisa, let me kind of give you a way we think about what's going on in the specialty space. I would tell you that margins, generally, are quite stable. But what we try to explain in our formal comments is that mix is something you just need to be aware of.",199,"Lisa, let me kind of give you a way we think about what's going on in the specialty space. I would tell you that margins, generally, are quite stable. But what we try to explain in our formal comments is that mix is something you just need to be aware of. So for example, hemophilia as a category, has been a higher-margin business. But the disease and the growth pattern of that disease among the population is far slower than the growth of many of the other specialty drugs tied to the disease patterns in the population. So, Rich, in his comments pointed out things like rheumatoid arthritis, things like pulmonary arterial hypertension. Those are stable margins that we like and when you just do the math and they grow dramatically, they change the weightings of margin across the drug products and that simply changes the overall margin perspective. But I wouldn't want investors think about this as declining margins for specialty, that's really not the story. It's just the relative growth across the product lines. So that's how I would think about it. Steve Fitzpatrick is here with us. Steve, do you want to add anything to that?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's a good point. I think the other piece of that is, when we talk about channel mix and client mix, it actually drives us. So as we add more Medco clients at typically higher volumes of the multiple sclerosis, rheumatoid arthritis, oncology in that an",107,"That's a good point. I think the other piece of that is, when we talk about channel mix and client mix, it actually drives us. So as we add more Medco clients at typically higher volumes of the multiple sclerosis, rheumatoid arthritis, oncology in that and also within those therapies, you're also getting new indications of those drugs coming out that ultimately drive that growth even greater that you don't have in some of our core infused therapies that are very strong on the medical said that we've always penetrated and then strong on the medical side, it's just that we're growing in the pharmacy side."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And wouldn't it also be the channel though, right? I mean, Steve, if you think about this, when you're actually have it go through your mail-order facilities or you're going out and infusing a product, my understanding is that, that margin is much better",66,"And wouldn't it also be the channel though, right? I mean, Steve, if you think about this, when you're actually have it go through your mail-order facilities or you're going out and infusing a product, my understanding is that, that margin is much better than if you're just infusicating a claim or you still have some aspect to the book that you're doing that, right?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's correct. Our retail volume has continued to grow fairly steadily into a degree that's actually higher, that is a lower margin.",23,"That's correct. Our retail volume has continued to grow fairly steadily into a degree that's actually higher, that is a lower margin."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Are you comfortable giving us some -- I'm really looking at this as a future opportunity, right? So the more of that, that you can bring into your books, the better the margin's can look over time. Is that 25% of the book, 40% of the book? Can you give us",66,"Are you comfortable giving us some -- I'm really looking at this as a future opportunity, right? So the more of that, that you can bring into your books, the better the margin's can look over time. Is that 25% of the book, 40% of the book? Can you give us some range of where the opportunities to bring that into the Accredo book of business?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, right now, if you look at the level of penetration of our current clients that currently have Accredo specialty, it's actually between 85% and 90%. So we made great progress over the past few years. You might recall, when we started out probably two",68,"Well, right now, if you look at the level of penetration of our current clients that currently have Accredo specialty, it's actually between 85% and 90%. So we made great progress over the past few years. You might recall, when we started out probably two years into the acquisition and then maybe 60% to 70% range. So we had a very meaningful success over the past few years."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then just one follow-up question, Dave, can you maybe just give us any of your thoughts around -- I know that the selling season hasn't really started yet this year, but as we look at the 2012 selling season, first off, the amount that you have up for",91,"And then just one follow-up question, Dave, can you maybe just give us any of your thoughts around -- I know that the selling season hasn't really started yet this year, but as we look at the 2012 selling season, first off, the amount that you have up for renewal was a little bit less than we had anticipated. One, have things shifted around at all? And secondly, as you look at the RFPs for 2012, are you seeing anything unusual as far as request go in the RFP process?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. The number Rich gave relative to the renewals for '12 is pretty much just how the contract fall in our selected early renewals. It's just the way it fell. And I would say that relative to RFPs we're seeing, I can't comment on anything special that we'",81,"No. The number Rich gave relative to the renewals for '12 is pretty much just how the contract fall in our selected early renewals. It's just the way it fell. And I would say that relative to RFPs we're seeing, I can't comment on anything special that we've noticed, but Tim is here in the room. I don't know, Tim, if there's anything special you want to mention relative to the RFPs we're seeing and coming through the pipeline right now?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Nothing particularly special. I think perhaps a bit more general clinical focus, a bit more focused on understanding what we're doing to manage specialty, wellness and workplace health. Those sorts of things are getting a bit more focused in certain RFPs",70,"Nothing particularly special. I think perhaps a bit more general clinical focus, a bit more focused on understanding what we're doing to manage specialty, wellness and workplace health. Those sorts of things are getting a bit more focused in certain RFPs and we've seen in other years. But other than that, I would say nothing is unusual. We are very pleased with the pipeline right now, I've got to say."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Ross Muken from Deutsche Bank.",13,"Your next question comes from the line of Ross Muken from Deutsche Bank."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just off of Lisa's comment on -- as we think about this upcoming selling season, now that you've had some time, is there still some of the nice wins that you had and look at the high renewal retention rate, as you dug into some of the specific clients, wh",116,"Just off of Lisa's comment on -- as we think about this upcoming selling season, now that you've had some time, is there still some of the nice wins that you had and look at the high renewal retention rate, as you dug into some of the specific clients, what were some of the two or three things that you felt like in this last selling season that sort of stood out to you that finally, we've either gotten a lot of traction with X, Y or Z or is one, two or three kind of really push the needle and kind of either helped us retain business or helped us increase our market share?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","This isn't going to be a new ah-ha to you, Ross, but I would tell you that there is no question that clients when they're buying are looking for an overall value prop. I say that and I think sometimes, it's discounted because people think it's just about",233,"This isn't going to be a new ah-ha to you, Ross, but I would tell you that there is no question that clients when they're buying are looking for an overall value prop. I say that and I think sometimes, it's discounted because people think it's just about price, and it's just not the case. It's, overall, value prop relative to total healthcare cost, and there is no question that clients are looking for the company that can optimize their spend driving better outcomes at lower cost. The things we're doing around Therapeutic Resource Centers, the things we are doing around pharmacogenomics, even the things we're now introducing tied to post FDA approval research are all things that resonate with clients because they feel as though we're putting their destiny in their hands by creating an ability to drive from shotgun medicine to precision medicine and optimize the value of every dollar they spend. And we're able to do this even in competitive pricing situations because on top of the fundamental ticket to entry, which is price, it's about what else you're doing to drive a better outcome. And it's really working for us, and it's just confirmed again in 2010. It was a fantastic year, and we're really happy with the way it's run. Glenn, I don't know if you have any thoughts about that question, but feel free to comment."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Dave, I'd say there's a couple of other things. The clients are really interested in using technology, so the iPad example we used earlier is just one of many of how do you get the members more connected mobily or with apps. So I think that's a big thing",89,"Dave, I'd say there's a couple of other things. The clients are really interested in using technology, so the iPad example we used earlier is just one of many of how do you get the members more connected mobily or with apps. So I think that's a big thing that it resonated well and also clients like the idea that we can connect them or connect to other providers with theirs. So we call it extended enterprise. But that has been a huge positive in the health plans space."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I just want to -- and I don't mean to belabor the point, but I'm just getting a lot of questions in my inbox, so I just want to make sure everyone's sort of understanding sort of the EPS progression. If we think about, Rich, obviously, the progression thr",103,"I just want to -- and I don't mean to belabor the point, but I'm just getting a lot of questions in my inbox, so I just want to make sure everyone's sort of understanding sort of the EPS progression. If we think about, Rich, obviously, the progression throughout the year, isn't the key two deltas, the amount of generics obviously coming in for quarter which continues to be back-end weighted and then, two, the impact of the share repo, which typically has more of an impact to earnings growth in the back half, is that the right way to think about it?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, absolutely. And I'll remind you again, Ross, of the incremental EPS effect to new generics. It really doesn't do much in the first half at all. It's nothing in the first quarter. It rounds to $0.01 in the second quarter. So you're really not getting",72,"Yes, absolutely. And I'll remind you again, Ross, of the incremental EPS effect to new generics. It really doesn't do much in the first half at all. It's nothing in the first quarter. It rounds to $0.01 in the second quarter. So you're really not getting any meaningful fuel first to second quarter at all. Of course, it's all about the fourth quarter with a $0.06, half of which is from Lipitor."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Randall Stanicky from Goldman Sachs.",13,"Your next question comes from the line of Randall Stanicky from Goldman Sachs."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a couple other, Dave or Rich, can you just give us an update, I'm not sure if you commented on UNH and possible timing or maybe collectively, can you let us know when we should expect to hear about an update on both FEP and UNH?",47,"Just a couple other, Dave or Rich, can you just give us an update, I'm not sure if you commented on UNH and possible timing or maybe collectively, can you let us know when we should expect to hear about an update on both FEP and UNH?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","As I said before, Randall, UNH, typically, its history is a predictor of the future. Typically, conversations with an account this size start 18 months prior to which means puts us beginning the serious conversations in the summer. So you really shouldn't",146,"As I said before, Randall, UNH, typically, its history is a predictor of the future. Typically, conversations with an account this size start 18 months prior to which means puts us beginning the serious conversations in the summer. So you really shouldn't expect information from us, really - so I'd say in the fall potentially, depending on whether or not history is that accurate predictor. So we, as I've said before, feel very good about our relationship with United, and I'm optimistic we will have a fruitful conversation, but the serious conversations, don't even expect them to really start till summer time. FEP is in flight now, and I really can't say much about a bid process that's flight now. But you should be hearing about that I would assume just given the timeframe set out by the client, probably by next quarter at the latest."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, so it sounds like no change on either front there. It's more a question, we've gotten a lot more so in the specialty pharma side, but can you just -- we've had a lot of question here on co-pay assistant cards. You and I have talked about this before",83,"Okay, so it sounds like no change on either front there. It's more a question, we've gotten a lot more so in the specialty pharma side, but can you just -- we've had a lot of question here on co-pay assistant cards. You and I have talked about this before, should we expect to see anything in terms of action from Medco or the industry in general to push back and obviously, what could be a big source of cost savings for clients?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Here's the way to think about this. We are not seeing the co-pay couponing, let's call it influencing our volume. You heard our volumes, they are robust, they are moving to mail, they're moving to generics, all the things the plan designs are encouraging.",213,"Here's the way to think about this. We are not seeing the co-pay couponing, let's call it influencing our volume. You heard our volumes, they are robust, they are moving to mail, they're moving to generics, all the things the plan designs are encouraging. So today, I can tell you that we're not seeing any meaningful influence by coupons. However, let me be clear, to the extent couponing drives the wrong behavior, so what I mean by that, if couponing, in fact, takes the prudent buyer behavior out of the consumer by eliminating their out-of-pocket responsibility, which means they go to the most expensive drugs, which end up going to the payer's pocket. We have a series of things that we can easily do to shut that down very quickly. So we monitor, we make sure what's going on is in the clients' best interest, and we are fully prepared, and we work with our clients all the time so they can see and have visibility to what's going on. To the extent it's not in the payer's best interest, we have benefit designs, plan designs and strategies ready to go that can shut couponing down overnight. So we're very comfortable with it, and we certainly have plans to help clients respond."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Are clients asking about this or is it on their radar screen yet?",13,"Are clients asking about this or is it on their radar screen yet?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, it is, and what we find the conversation leaning toward and if you saw the Times article, it was interesting because it ended with the same concept. Recently there was a contract go about this phenomenon, is that clients are coming back and revisitin",136,"Yes, it is, and what we find the conversation leaning toward and if you saw the Times article, it was interesting because it ended with the same concept. Recently there was a contract go about this phenomenon, is that clients are coming back and revisiting their decisions around preferred drugs step therapy, which really takes the issue pretty much off the table, because to the extent that a drug is on formulary is couponed and the member takes it because they fail the generic is the first step, and that's actually in everybody's best interest. So clearly, what plans are looking at is our ability to put those programs in place and the great news is those programs create no member noise. We black belts at doing it, and we are well invested in driving it."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Ricky Goldwasser from Morgan Stanley.",13,"Your next question comes from the line of Ricky Goldwasser from Morgan Stanley."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Couple of questions, first on the UBC contribution. So what percent of the growth -- and I assume it was in the services line, what percent of the growth in services came from UBC of the $92 million?",38,"Couple of questions, first on the UBC contribution. So what percent of the growth -- and I assume it was in the services line, what percent of the growth in services came from UBC of the $92 million?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","If you look at the change in run rate from say the second quarter, which was the last pure quarter in service without UBC to the fourth quarter, the majority of the dynamic is a contribution from UBC.",38,"If you look at the change in run rate from say the second quarter, which was the last pure quarter in service without UBC to the fourth quarter, the majority of the dynamic is a contribution from UBC."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So if we try to back it out of EBITDA, we get to core growth for the business of about 3% year-over-year, are we in the ballpark there?",28,"So if we try to back it out of EBITDA, we get to core growth for the business of about 3% year-over-year, are we in the ballpark there?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So I can just tell you, I don't have the EBITDA math in front of me. But I can tell you the pretax contribution in the fourth quarter from UBC was nominal. We're talking about low-single-digit millions.",37,"So I can just tell you, I don't have the EBITDA math in front of me. But I can tell you the pretax contribution in the fourth quarter from UBC was nominal. We're talking about low-single-digit millions."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","No, but when you think about it on an EBITDA per adjusted script, just if we add to the EBITDA and given that there's no script associated with the business, we assume higher contribution there?",35,"No, but when you think about it on an EBITDA per adjusted script, just if we add to the EBITDA and given that there's no script associated with the business, we assume higher contribution there?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, that's correct.",3,"Yes, that's correct."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So, this is going to play -- backing into around 3% year-over-year growth for just the core business, is that a reasonable estimate?",23,"So, this is going to play -- backing into around 3% year-over-year growth for just the core business, is that a reasonable estimate?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","You're talking about just growth in the EBITDA per adjusted script?",12,"You're talking about just growth in the EBITDA per adjusted script?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Correct.",1,"Correct."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Which is currently in the fourth quarter? On a Fourth quarter basis, 5.2%, you're saying about 3% of is...",19,"Which is currently in the fourth quarter? On a Fourth quarter basis, 5.2%, you're saying about 3% of is..."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","IS core, i.e., once we back out UBC?",8,"IS core, i.e., once we back out UBC?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm doing the math in my head. It's probably -- the core should be stronger than that.",18,"I'm doing the math in my head. It's probably -- the core should be stronger than that."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then on the 2012 renewal season of the $16 billion to $17 billion, I don't know if you'd comment on it, but what percent are early renewals versus scheduled?",30,"And then on the 2012 renewal season of the $16 billion to $17 billion, I don't know if you'd comment on it, but what percent are early renewals versus scheduled?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I can tell you that the majority of that number is scheduled.",12,"I can tell you that the majority of that number is scheduled."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And does that imply that you had some of the early renewals in 2011 really came from 2012 renewals?",19,"And does that imply that you had some of the early renewals in 2011 really came from 2012 renewals?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No, I didn't say that. I gave you the 2011 renewal number, it's $15 billion .",16,"No, I didn't say that. I gave you the 2011 renewal number, it's $15 billion ."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Ricky, I would tell you that in any given year, the vast majority of renewals are scheduled renewals, and I would say that consistently, we're very selective about what we early renewed and that was true for 2010. It continues to be true for '11 and it wi",51,"Ricky, I would tell you that in any given year, the vast majority of renewals are scheduled renewals, and I would say that consistently, we're very selective about what we early renewed and that was true for 2010. It continues to be true for '11 and it will be true for'12."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your final question comes from the line of Steven Valiquette from UBS.",12,"Your final question comes from the line of Steven Valiquette from UBS."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I guess first, just to clarify, so the $16 billion to $17 billion, does that include or exclude UNH, just to make that crystal clear. There seems to be some confusion around that.",33,"I guess first, just to clarify, so the $16 billion to $17 billion, does that include or exclude UNH, just to make that crystal clear. There seems to be some confusion around that."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It does not include United. United is not up for renewal in 2012.",13,"It does not include United. United is not up for renewal in 2012."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then you commented on the timing of them. Could UNH drag into 2012 or should at least assume that whatever is going to happen there, will happen some time in calendar 2011? Just trying to get a little more color on that. That's unclear.",45,"And then you commented on the timing of them. Could UNH drag into 2012 or should at least assume that whatever is going to happen there, will happen some time in calendar 2011? Just trying to get a little more color on that. That's unclear."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think it's  easily conceivable in dragging '12.",9,"I think it's  easily conceivable in dragging '12."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just quick final question here on SG&A, kind of more of a general question, I think for the PBM sector, we're all kind of trained to think about start-up expenses for new business wins occurring in the first quarter of each calendar year. But I'm just cur",100,"Just quick final question here on SG&A, kind of more of a general question, I think for the PBM sector, we're all kind of trained to think about start-up expenses for new business wins occurring in the first quarter of each calendar year. But I'm just curious, with Medicare becoming a larger part of the mix, is it more prevalent now to assume more startup costs, renew business wins in 4Q? I mean, we're not getting too granular. I'm just trying to get a general sense that the split between 4Q and 1Q for startup expenses as generally speaking?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think the way you should think about it is that is from a software development point of view, to benefit modifications or account set up, that's primarily fourth quarter expense. Service expense is first quarter tied to volumes of calls when you go live",79,"I think the way you should think about it is that is from a software development point of view, to benefit modifications or account set up, that's primarily fourth quarter expense. Service expense is first quarter tied to volumes of calls when you go live. And I would say, historically, with us the expense has been more heavily weighted to the fourth quarter relative to the coding of the benefits in getting the accounts set up versus first quarter."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","One further point on that, Steve, the majority of our startup expenses this year and last year had been in cost of sales to the effect of gross margin. They generally have not been an SG&A expense.",37,"One further point on that, Steve, the majority of our startup expenses this year and last year had been in cost of sales to the effect of gross margin. They generally have not been an SG&A expense."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","As far as the lower SG&A expense expected for 2011, any additional color on that? I think you lowered the range there by $50 million or so?",28,"As far as the lower SG&A expense expected for 2011, any additional color on that? I think you lowered the range there by $50 million or so?"
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, the range was very, very broad. It was almost too wide when you first give guidance, which is why in Analyst Day, I promised that I would narrow it.",30,"Well, the range was very, very broad. It was almost too wide when you first give guidance, which is why in Analyst Day, I promised that I would narrow it."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thanks to all of you for joining us today, and now look forward to speaking with you again in not-so-distant future.",21,"Thanks to all of you for joining us today, and now look forward to speaking with you again in not-so-distant future."
1541811,118622458,105069,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","This concludes today's conference call. Thank you for your participation. You may now disconnect.",15,"This concludes today's conference call. Thank you for your participation. You may now disconnect."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning. My name is Vanessa. And I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions Fourth-Quarter 2010 Earnings Call. [Operator Instructions] I would now like to turn the call over t",55,"Good morning. My name is Vanessa. And I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions Fourth-Quarter 2010 Earnings Call. [Operator Instructions] I would now like to turn the call over to Ms. Valerie Haertel, Vice President of Investor Relations. Please go ahead, ma'am."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Vanessa. Good morning. And thank you for joining us on Medco's fourth-quarter and full-year 2010 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer.",325,"Thank you, Vanessa. Good morning. And thank you for joining us on Medco's fourth-quarter and full-year 2010 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us for our question-and-answer session are: Kenny Klepper, President and Chief Operating Officer; Tom Moriarty, General Counsel, Secretary and Senior Vice President of Pharmaceutical Strategies and Solutions; Steve Fitzpatrick, President of Accredo Health Group; Dr. Rob Epstein, President of Advance Chemical Science and Research; Tim Wentworth, Group President of the Employer and Key Accounts; and Glenn Taylor, Group President Health Plans. 
During the course of this call, we will make forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in our SEC filings.
Copies of Medco's filings are available from the SEC, the Medco Investor Relations Department or the Medco website. Medco intends to use the Investor Relations section of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. The copyrights for the contents of this discussion and the written materials used on this earning call are owned by MedcoHealth Solutions, Inc. 2011.
Slides to accompany our presentation, which detail our financial and operating results and the guidance discussed on this call, are currently available in the Events section of the Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-K after the close of the market today. 
At this time, I would like to turn the call over to Dave Snow. Dave?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valerie. And thanks to all of you for joining us this morning. Medco is pleased to report record fourth-quarter and full-year 2010 earnings, reflecting strong financial and operating performance at the high end of our previously increased guida",1518,"Thank you, Valerie. And thanks to all of you for joining us this morning. Medco is pleased to report record fourth-quarter and full-year 2010 earnings, reflecting strong financial and operating performance at the high end of our previously increased guidance. Today, I will focus my remarks on full-year 2010 results and 2011 guidance, while Rich will focus on our balance sheet, our fourth-quarter results and details surrounding our 2011 guidance. At our Analyst Day in November, we shared with you our expectations for Medco and our business strategy that is designed to continue delivering strong growth through 2020. We outlined our portfolio of growth drivers that will advance our mission to make medicines smarter for our clients and the more than $65 million members we serve. Today, we remain confident in our expectations and are pleased to provide you with the details of our performance for 2010 and expectations for 2011. 
Let's begin with our year-over-year 2010 financial and operational performance. For the year, we delivered record GAAP diluted earnings per share of $3.15 representing growth of 21.1%. Our diluted earnings per share excluding the amortization of intangibles from the 2003 spin-off grew 20.1% to a record $3.40. Our net revenues reached a record $66 billion, up 10.3% from 2009 despite the higher volumes of lower-cost generics that reduced our net revenues by nearly $3.7 billion and correspondingly resulted in record client and patient savings. 
Within net revenues, our higher margin-generating service revenues grew 28% to a record $1.08 billion, fueled by our United BioSource acquisition and service revenue growth across the company. We achieved record total gross margin of $4.3 billion, an increase of 7.7% over 2009.
Our EBITDA increased 8.1% to nearly $3 billion and our EBITDA per adjusted script increased 1.6% to a full-year record of $3.11. And finally, our net income increased 11.5% to a record $1.4 billion. With respect to the operating metrics that contributed to our strong financial results, overall prescription volumes adjusted for the dates applied between retail and mail grew a strong 6.5% to a record 957 million prescriptions. 
Mail-order prescriptions for the year grew at a strong 6.5% to 109.8 million, which exceeded the high end of our guidance of 109 million prescriptions and set a new record. Importantly, we experienced continued strength in generic mail-order volumes, increasing a substantial 13.4% to 67.6 million prescriptions as patients continued to choose lower-cost generic medications. 
Growth of generics [ph] for the fourth quarter was even greater at 15.1%. Our overall generic dispensing rate rose 3.5 percentage points to 71% and within that, our mail-order generic dispensing rate component increased an even greater amount by 3.7 percentage points to a record 61.5%. For the full year, our Medicare Part D PDP revenues achieved a record, increasing 33.5% to well over $1.4 billion. We are proud to have been the first and only national PDP to be awarded five stars by CMS and believe this world-class recognition operationally not only validates our investments in our agile enterprise but also enables continued strength in our Medicare business going forward.
Moving on to our Specialty business, Accredo's performance remained strong with revenues increasing 19.1% to a record $11.3 billion and operating income rising 22.7% to a record $438.2 million. Turning to sales and client retention results, Medco delivered another solid year of performance. Our 2010 annualized new-named and net-new sales each remained strong at $5.3 billion, and our client retention rate remained over 99%. For 2011 to date, our annualized new-named sales stand at $1.7 billion and our net-new sales are currently $1.5 billion, up from the $1.4 billion previously disclosed on our third-quarter earnings call. We have now completed over 80% of our 2011 scheduled and early elective client renewals, up from the over 50% we reported on our third-quarter call, and our 2011 year-to-date client retention rate remains at over 99%.
This past year, we continued to invest in our enterprise by expanding our expertise in genomic and personalized medicines with the acquisition of DNA Direct. We also entered the market for post-approval Phase IV safety, economic evaluation and outcomes research through our acquisition of United BioSource. We are very pleased with the results to date for both of these acquisitions. DNA Direct's genomic services are gaining traction in the marketplace. Just a few weeks ago, we announced the addition of four new community hospital clients to DNA Direct genomic medicine hospital network, extending web-based physician support and genetic expertise to their physicians and their patients. 
We also announced the addition of four new health plan clients who are implementing DNA Direct's Policy & Benefit Support Program for molecular diagnostic and genetic tests. This program enables payers to determine coverage for more than 800 molecular diagnostic and genetic tests and provides real-time access to the DNA Direct team of genetic counselors for clinical guidance and counseling on the more than 2,000 genetic tests available today. We are encouraged by the level of market interest in these new service offerings.
We are very pleased with the acquisition of UBC, which has been enthusiastically embraced by more than 100 Medco clients, representing more than 40 million lives volunteering to be part of the Medco research consortium to participate in UBC research study. This is up from the previously disclosed 89 clients and 33 million lives. As we noted at Analyst Day, both our clients and biotech drug manufacturers have common interests to ensure the safety and efficacy of new drugs coming to market. On top of that, Medco and its clients are fully aligned to pursue better outcomes and lower total healthcare costs, the essence of Making Medicine Smarter.
As we move forward, we anticipate UBC will continue to realize strong growth from its impressive pipeline of opportunities, including safety surveillance where UBC holds the market-leading position globally. Additionally, we expect to leverage UBC's, Medco's and Accredo's capabilities to the benefit of our clients and patients as we fundamentally change the way drugs are introduced, delivered and monitored for both safety and economics. 
Turning to guidance, we are reaffirming our full year 2011 GAAP diluted earnings per share guidance of $3.53 to $3.66 reflecting a growth rate of 12% to 16% over 2010. Diluted earnings per share excluding all intangible amortization, our new pure cash EPS measure, is reaffirmed to be in the range of $3.99 to $4.12, reflecting 12% to 16% growth over 2010 earnings per share. Please note that the growth rate change for GAAP and pure cash EPS was 12% to 17% previously, but has narrowed due to the fact that we achieved the high end of our 2010 guidance range.
In closing, we remain confident in our ability to generate strong EPS growth well into the future. In the weeks since we shared our long-range plans with you, I have been asked how we can be so confident over such an extended horizon. There are two primary reasons, the first is the rigor and granular detail behind our 10-year strategic financial plan. As we shared on the Analyst Day last November, we have a very detailed roadmap for growth that is reasonable and logical based upon the many compelling opportunities we foresee over the next 10 years and a realistic view of the risks we may have encountered along the way. I believe that our growing portfolio of capabilities with leaders who are dedicated and accountable for each one of them will enable us to offer a comprehensive suite of solutions that will likely remain unmatched in the marketplace. 
The second is our people. Our employees are united to a greater good, a noble cause that fuel the passion around Making Medicine Smarter in a world-class manner. While a common vision is important, our people also have proven ability to execute with unparalleled excellence. Our CMS five-star rating is a testament to this, further evidence can be found in our January 1 install, which were virtually flawless despite the record number of complex changes required by CMS in the recent healthcare reform mandate. 
As we continue to make progress in advancing our capabilities through our agile enterprise initiative, we expect to achieve unprecedented improvements in the way we deliver operational excellence to the benefit of our clients and members. Yet another example of our operational excellence is the recent final approval we received from the Indiana Board of Pharmacy for our new third-generation automated pharmacy located in Whitestown, Indiana. 
In the testing phase that ran from September through mid-January, the board found that the pharmacy filled every prescription of the tens of thousands tested with 100% accuracy. I would like to take this opportunity to thank each and every one of our over 24,000 Medco employees now spanning the globe for their continued efforts on behalf of clients, patients and shareholders resulting in another great year and strong, long-term prospects. They are delivering everyday for our clients, members and shareholders.
With that, I will turn it over to Rich Rubino, who will take you through our balance sheet, the fourth-quarter 2010 financials and further details on our guidance for 2011. Rich?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. We are pleased to deliver another quarter and full year of strong financial and operating performance. As Valerie mentioned, the slides on our website will prove helpful in following along with my commentary.Starting with",2317,"Thank you, Dave. Good morning. We are pleased to deliver another quarter and full year of strong financial and operating performance. As Valerie mentioned, the slides on our website will prove helpful in following along with my commentary.
Starting with our balance sheet, we closed the fourth quarter with a cash balance of $853 million, and our cash flow from operations for full-year 2010 totaled over $2.34 billion. While our mail-order prescription volumes set record highs in 2010, our inventory balances represent a record year-end low of just over $1 billion at the end of 2010, a $272 million reduction from year-end 2009 on top of the $571 million reduction we generated during 2009.
Our capital expenditures at full year 2010 were in line with our guidance at $250 million, reflecting investments in our business to drive agility and enhance efficiency across the organization, prepare for healthcare reform implementation and to fund the future growth. We achieved the full year 2010 return on invested capital of 35%, excluding 2010 acquisitions such as UBC. A meaningful increase over the 2009 return was 27%, which was already seven points higher than 2008. 
Our fourth quarter 2010 EPS results were records, with GAAP diluted EPS of $0.88 representing 25.7% growth over fourth-quarter 2009 and diluted EPS excluding the amortization of intangibles from the 2003 spin-off of $0.94 representing 23.7% growth over 2009.
Total fourth-quarter 2010 net revenues reached a record $16.9 billion, representing growth of 11.1% over fourth-quarter 2009. Our product revenue grew 10.4%, reflecting our new business wins as well as higher prices charged by brand name pharmaceutical manufacturers, partially offset by a higher representation of lower-priced generics, in fact, a record generic effect of approximately $1.1 billion on fourth quarter's revenue alone.
Service revenue continued to be a very meaningful growth driver, increasing 58.7% over fourth quarter-2009. This strong performance reflects a full quarter of service revenue contribution from UBC, which closed on September 16, 2010, as well as the expansion of our overall client base at our Medicare Part D service fees.
Turning to rebates, we earned nearly $1.5 billion for the fourth quarter and $5.8 billion for full-year 2010, both records, even though we are dispensing fewer brand-name medications and more generics. These earned rebate levels represent 7% growth for the quarter and 8.1% growth for the year attributable to new client wins and continuous improvements in formulary contracting. Our fourth-quarter 2010 rebate retention rate was 13.0% compared to 14.1% in fourth-quarter 2009 as we continue to drive significant value to clients in a highly transparent manner. For the full year, our rebate retention rate of 12.5% compared to 13.7% in 2009.
In terms of claims volumes, total fourth-quarter prescriptions adjusted for the difference in days supply between retail and mail reached a record $244.3 million, an increase of 7.4% over fourth-quarter 2009. Retail prescriptions in fourth-quarter 2010 grew 7.5% to a record $161.4 million. Mail-order volume remains strong as clients and members continue to choose the lowest cost and most clinically effective channel.
Our mail-order prescriptions reached a record $27.9 million in fourth-quarter 2010, a 7.3% increase from fourth-quarter 2009. The adjusted mail-order prescription volumes for fourth-quarter 2010 comprised 33.9% of the total adjusted prescriptions, in line with the 34.0% mail penetration rate in fourth-quarter 2009.
Within the record fourth-quarter 2010 mail-order prescription volume total, generic prescription volume increased 15.1% to a record $17.5 million, reflecting new generic introductions and continued growth in previously released generics, while brand-name prescription volumes decreased 3.7% to 10.4 million prescriptions. The strength in our generic mail-order prescription volumes was an important driver of our fourth-quarter gross margin, which increased 13.1% over fourth-quarter 2009 to a record of $1.16 billion.
Our consolidated gross margin percentage of 6.9% for the quarter held steady with what we reported at third-quarter 2010, and on a year-over-year basis, increased 20 basis points from the 6.7% in fourth-quarter 2009, again a result of the strong fourth-quarter 2010 mail-order generic prescription volumes and our strong service gross margins. 
Selling, general and administrative expenses of $428.5 million for the fourth quarter increased over fourth-quarter 2009 by $53 million or 14.1%, reflecting the addition of UBC as well as higher professional fees and other expenses associated with strategic initiatives. Excluding UBC, SG&A for the fourth quarter was up $32.2 million or 8.6% from fourth-quarter 2009. 
The expenses we incurred in 2010 for strategic initiatives are critical to our transformation into a world-class agile enterprise focused on speed, accuracy, efficiency and providing the highest levels of client and patient care. We invest in ourselves because we are a growth company, with many exciting components of our expanding portfolio of businesses. These investments, whether in the form of expense or capital, are designed to proactively drive unparalleled levels of client and patient service on top of what we believe is already a world-class service model.
Our total EBITDA for fourth-quarter 2010 reached a record $786.5 million, representing growth of 13.2%. EBITDA per adjusted prescription for the quarter increased 5.2% to $3.22, a fourth-quarter record. Our intangible amortization of $75 million in fourth-quarter 2010 decreased slightly from $75.5 million at fourth-quarter 2009. The full-year amortization of $287.4 million decreased in 2009 by 6.0% or $18.2 million, primarily reflecting lower intangible amortization from PolyMedica and Accredo, partially offset by the addition of UBC and DNA Direct intangible assets.
Total net interest and other expense of $50.4 million for the fourth quarter of 2010 increased $10.5 million from the $39.9 million in fourth-quarter 2009, reflecting the new debt we added to finance the UBC acquisition last September. For the full year, total net interest and other expense of $163.1 million was slightly higher compared to the $162.6 million for 2009, reflecting this new debt, offset by lower interest rates associated with floating-rate debt.
The fourth-quarter 2010 effective tax rate was 37.7% compared to 36.3% in 2009, primarily reflecting a 2009 benefit from state-related income tax items. Our effective tax rate for full year was 38.9%, in line with the 39.1% in 2009. Net income for the quarter increased 10.8% to a record $378.5 million from the $341.5 million reported for the fourth quarter of 2009. For the full year, net income increased 11.5% to a record of over $1.4 billion from the $1.3 billion reported for 2009.
Moving on to share repurchases. During the fourth quarter of 2010, we repurchased 15.8 million shares for $963.3 million at an average per-share cost of $61.05. For full-year 2010, share repurchases totaled 69.9 million at a cost of $4.1 billion with an average per-share cost of $58.97. Since share repurchases commenced in 2005, we repurchased a total of 256.2 million shares, at a total cost of $11.1 billion, with an average per-share cost of $43.18. 
For 2011 to date, we repurchased 7.0 million shares with an average per-share cost of $62.06. In January 2011, we completed the remaining $437 million of the $3.0 billion authorization that was approved in May 2010. By February 2, 2011, our board authorized a new $3 billion share repurchase plan. We continued to complete approximately $2 billion in share repurchases in 2011, driving meaningful value to our shareholders. We expect to commence share repurchases under the new authorization later this quarter.
Turning to our Specialty segment, Accredo achieved record revenues of $3.0 billion for fourth-quarter 2010, an increase of 21.3% over the fourth quarter of 2009. Consistent with our guidance, Accredo's gross margin percentage for the quarter amounted to 6.5% compared to the 7.0% in fourth-quarter 2009. This Accredo gross margin decline reflects product channel and new client mix. The 2010 product mix reflects significant growth in our multiple sclerosis, rheumatoid arthritis, oncology and pulmonary arterial hypertension patients with product volumes. Accredo's operating income for fourth-quarter 2010 increased 30.7% to $109.9 million. 
Moving on to Medicare, we continued to experience growth in our Medicare PDP. For fourth-quarter 2010, Medco's PDP revenues increased 27.7% to $331.7 million. As Dave discussed, we are reaffirming our guidance for 2011. To briefly repeat our reaffirmed 2011 guidance, diluted GAAP EPS is expected to grow 12% to 16% over 2010 in the range of $3.53 to $3.66. As we noted last quarter, the non-GAAP diluted EPS measure change commencing in 2011 to exclude all intangible amortization. Diluted EPS excluding all intangible amortization remains in the guidance range of $3.99 to $4.12, representing growth of 12% to 16% over the 2010 full-year equivalent of $3.55.
While this measure will not be used in 2011, diluted EPS, excluding intangible amortization from the 2003 spin-off would be guided to increase to a range of $3.80 to $3.93, also representing growth of 12% to 16% over 2010. The detailed components of our 2011 guidance are as follows. We currently expect to renew approximately $15 billion of business in 2011, including scheduled and early elective renewals, representing less than 1/4 of our business. As Dave mentioned, we have over 80% of our 2011 renewals already completed. As I've previously guided, approximately 75% of the renewal pricing is in effect in the first quarter with the majority of the remainder effective in the third quarter of 2011.
Our guidance for mail-order prescription volumes for 2011 remains in the range of $107 million to $109 million, demonstrating solid growth in our base business considering the 3 million script offset I discussed at Analyst day. You may recall the expected reduction of approximately 2 million mail-order scripts from the contribution of Europa Apotheek to the Medco Celesio joint venture and another 1 million scripts associated with the conversion of generic Allegra known as fexofenadine to OTC status in early 2011. These expectations remain intact.
As you can see from our slides on the Web, the vast majority of our detailed 2011 guidance components remain consistent with those we provided at our Analyst Day including, as example, the $0.09 incremental contribution from new generics and expectations for stability or probable expansion in gross margin percentage and EBITDA per adjusted script performance in 2011. There is one guidance point that is changing. As I alluded to on Analyst Day, we are narrowing our guidance for 2011 SG&A expense from a range of $1.7 billion to $1.8 billion to a narrower range of $1.7 billion to $1.75 billion.
Now let's focus specifically on the first quarter of 2011. Our first-quarter 2011 pure cash EPS is expected to increase over the first-quarter 2010 equivalent of $0.76 by approximately 16% to 17%. This first-quarter 2011 guidance includes a planned $0.04 benefit to earnings associated with changes to various employee benefit plans across the company. This item reflects the financial effects associated with the prior service credit for our employee post-employment benefits plan that was in place before our 2003 spin-off. This benefit, which equates to approximately 1% full-year EPS guidance, was included in our internal operating plan upon which guidance was based and was ultimately approved by our Board of Directors in January 2011.
For the first quarter of 2011, we expect improvement in gross margin and EBITDA per script compared to first-quarter 2010, even when excluding the $0.04 benefit I just mentioned of which 3/4 flows to cost of sales and 1/4 flows to SG&A expense. Now let me provide some pointers to help you model the remaining quarters of 2011.
You may recall that I indicated on Analyst Day, when you look at earnings progression for the year, EPS in 2011 will be even more back-end loaded than we experienced in 2010. When excluding the $0.04 first-quarter benefit I just mentioned, EPS is expected to be fairly consistent in the first two quarters of 2011 and improve progressively in each of the last two quarters, in part the result of the incremental contribution from new generics, with zero, $0.01, $0.02 and $0.06 EPS contributions, respectively, for each of the four quarters.
Let me now discuss an item that is not included in guidance at this time as the net effect is currently indeterminable. The contribution of Europa Apotheek Venlo or EAV to the Medco Celesio joint venture is now expected to take place in March 2011. We still expect to record a foreign exchange loss upon contribution. We are awaiting the final fair market valuation of the EAV asset we are contributing. At this point, we believe the exchange loss will likely equate to approximately $20 million and it remains too early to quantify any gain or loss on the fair market valuation of EAV. This will be a onetime transaction that we will call out in our first-quarter 2011 results that, again, was not and is not included in our quarterly or full-year guidance. 
As we reported during the quarter, the Medicare Part D business of Universal American, a current Medco client, is planned to be acquired by one of our competitors. As a result, it is expected that their business will no longer be serviced by Medco beginning in 2012. The termination of this business will not impact 2011 financial results and will not have a material impact to 2012 earnings since this account is very heavily weighted towards particularly low-margin dual-eligible business.
I know many of you on the call are interested in our expected renewals for 2012. At this point, we estimate our 2012 renewals in the range of $16 billion to $17 billion, approximately 25% of our book. One last point, we look forward to Lipitor's scheduled availability late in the fourth quarter of 2011 and the many other blockbuster brand-name drugs that lose their patent protection and become available in generic form in 2012. As we stated at our Analyst Day and on many other occasions, our clients, members and shareholders all stand to benefit from what we expect in 2012, the highest level of generic savings generating in our company's history. 
That concludes my prepared remarks, and now Dave and I would like to open the lines for questions.  Vanessa?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Tom Gallucci from Lazard Capital Markets.",16,"[Operator Instructions] Your first question comes from the line of Tom Gallucci from Lazard Capital Markets."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I guess first question, Rich, there has been obviously lot of focus on gross margin trends throughout the course of 2010, so maybe could you just highlight for us sort of where you came in relative to your expectations in the quarter and what some of the",52,"I guess first question, Rich, there has been obviously lot of focus on gross margin trends throughout the course of 2010, so maybe could you just highlight for us sort of where you came in relative to your expectations in the quarter and what some of the moving parts might have been?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, we came in right in line with our expectations. As you saw, we had stability going from third quarter to the fourth quarter, which we were, of course, pleased with. The generic prescription volume mail came in stronger as we expected. UBC also contr",103,"Well, we came in right in line with our expectations. As you saw, we had stability going from third quarter to the fourth quarter, which we were, of course, pleased with. The generic prescription volume mail came in stronger as we expected. UBC also contributed nicely to our service margin expansion. So I'd have to say that we're on track to delivering what we expect for 2011 as well. So with confidence, I can point to the fact that we do expect this momentum to continue with stability and the likelihood of growth, both in gross margins as well as EBITDA per script."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then Dave, if I could just sort of ask more of a strategic question, you mentioned in the Medco Oncology Therapeutic Research Center that opened up during the year, can you maybe talk a little bit more about what you're doing there, and maybe also wit",81,"And then Dave, if I could just sort of ask more of a strategic question, you mentioned in the Medco Oncology Therapeutic Research Center that opened up during the year, can you maybe talk a little bit more about what you're doing there, and maybe also with respect to drugs there that are in the drug benefit versus the medical benefit on the oncology side of the business maybe and how you're getting more of those drugs on the medical side?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, sure. As you know, at a strategic level, many people are talking about oncologic issues moving from catastrophic to chronic in nature tied to the innovations in the drug world. And we've also mentioned to you many times, but we highlighted in the Ana",550,"Yes, sure. As you know, at a strategic level, many people are talking about oncologic issues moving from catastrophic to chronic in nature tied to the innovations in the drug world. And we've also mentioned to you many times, but we highlighted in the Analyst Day, that when you look at the pipeline of biotech drugs coming to market, 50% of them are oncologic in nature, and the vast majority of them have a biomarker associated with the drug, which obviously we've been building around now for years. This state-of-the-art oncologic TRC that opened up in Whitestown, Indiana is really gorgeous, and it has capacity for 130 pharmacists who do nothing but manage patient care to protocols around various tumor types. We have actually sub-stratified capabilities tied to evidence-based protocols, working with physicians and patients to drive better outcomes for this -- what is now becoming chronic disease. So our clients clearly love the concept of therapeutic resource centers. It's highly applicable to the oncology space. Our clients also do want us to bring the medical spend, which is half the specialty spend, that is on the medical side over to the pharmacy side to be better managed. So we are doing many things. One of them, we highlighted at Analyst Day, which is many of the drugs on the oncology space are infusible. And one of our nurses got up and demonstrated to all of you the iPad technology that we've developed to manage total patient care in the home that goes well beyond the infusion they're delivering. And we find out, we can actually, at the point of care, manage the source of the drug, get that drug sourced at a better price, mail environment for our client. We also can take care of the other drug needs and the drug gaps in care around that patient in that home setting, and we have well over 1,000 nurses, who do nothing but manage patient care in the home around all of these infusibles. And by the way, in the pipeline, well over 30% of the drugs in the pipeline are infusible. So we're going to see that trend grow as a major part of our arsenal at the  point of care to change how these drugs are managed. In addition, we are working, especially with our health plan clients, to isolate those specialty drugs that are hidden under what people call J-Codes under the medical coding. J-Codes to me are, by definition, 100% unmanaged. They are mystery codes that allow payers to pay AWP plus a dispensing fee plus a mark-up, which is just grotesquely inefficient, and clients are becoming more and more aggressive around pulling that out and managing it properly, levering scale and everything else that we as PBM bring. And we do that today, and we're actually looking at some more highly scalable models in the future that we can rollout to do an even better job there but that's -- literally, we could double the size of Accredo simply by taking all of the spend that's buried on the medical side of the business and moving it to the managed environment, we create for specialty drugs within Accredo. So we consider that an enormous opportunity and our clients are motivated to work with us."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then just to confirm, Rich, you mentioned Lipitor estimates are still good there that you had talked about previously for the EPS contribution?",24,"And then just to confirm, Rich, you mentioned Lipitor estimates are still good there that you had talked about previously for the EPS contribution?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, that's confirmed.",3,"Yes, that's confirmed."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Larry Marsh from Barclays Capital.",13,"Your next question comes from the line of Larry Marsh from Barclays Capital."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave, there's been a lot of discussion, it seems like recently, as I've noticed it around pass-through transparent pricing at FEP and other customers, obviously, one of your competitors just talked about a big margin impact with that change. Now you have",83,"Dave, there's been a lot of discussion, it seems like recently, as I've noticed it around pass-through transparent pricing at FEP and other customers, obviously, one of your competitors just talked about a big margin impact with that change. Now you have mentioned great customer satisfaction with FEP -- pricing extension already in your guidance. So what's the difference here, maybe educate us and then how do we think of pricing in the future for this contract and others around this pass-through pricing?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Larry, I can't really talk about our competitor. I really can't talk specifically about FEP's renewal, but let me talk more broadly. I think you know we've been a leader in transparency. Our definition of transparency has fit very nicely with most of the",105,"Larry, I can't really talk about our competitor. I really can't talk specifically about FEP's renewal, but let me talk more broadly. I think you know we've been a leader in transparency. Our definition of transparency has fit very nicely with most of the definitions out there of transparency, including government transparency. So we're comfortable with this environment. We also had one-year renewals with FEP. And you haven't heard the same sorts of comments from us. So I think you might want to think about that as unique to a specific PBM and not apply it to the industry. That would be my best advice."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then I guess just a follow with Rich, just help me make sure I've got my numbers straight on the two comments about EBITDA and Q2. So you're suggesting EBITDA per adjusted script for Q1 will be above last year's number?",42,"And then I guess just a follow with Rich, just help me make sure I've got my numbers straight on the two comments about EBITDA and Q2. So you're suggesting EBITDA per adjusted script for Q1 will be above last year's number?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's right.",3,"That's right."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I've got it like $2.85, is that the right ballpark for EBITDA per adjusted script for last year's Q1?",20,"I've got it like $2.85, is that the right ballpark for EBITDA per adjusted script for last year's Q1?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I think that's about right, yes.",7,"Yes, I think that's about right, yes."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then just the wording about Q2 being about the same as Q1, if I do the math, that's in the mid-80s, I guess, in cash earnings. And if I compare that to my cash earnings of last year, that would be down year-over-year. Am I thinking of that right, or a",60,"And then just the wording about Q2 being about the same as Q1, if I do the math, that's in the mid-80s, I guess, in cash earnings. And if I compare that to my cash earnings of last year, that would be down year-over-year. Am I thinking of that right, or are we talking about earnings growth versus actual earnings?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","At this point, I'm just giving you some high-level guidance here. Don't be overly precise with regard to the second quarter in particular. But the most important point is, we're going to see a meaningful acceleration of growth in the back half of the year",78,"At this point, I'm just giving you some high-level guidance here. Don't be overly precise with regard to the second quarter in particular. But the most important point is, we're going to see a meaningful acceleration of growth in the back half of the year. It's difficult for me to be very specific with regard to second-quarter performance at this point. But more importantly, I want you to have the earnings in the right part of the year."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Lisa Gill from JPMorgan.",12,"Your next question comes from the line of Lisa Gill from JPMorgan."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave, maybe we could just talk a little about Accredo and your comments around mix, basically product channel, et cetera. When we look at the gross margin in that business, can you maybe talk about over time, what you expect that to look like? Is there pr",93,"Dave, maybe we could just talk a little about Accredo and your comments around mix, basically product channel, et cetera. When we look at the gross margin in that business, can you maybe talk about over time, what you expect that to look like? Is there pressure on the gross margin aspect, the fact that a lot of it is still going through retail? And can you maybe talk about -- maybe you want to talk about specific numbers, but the margin opportunity as you bring that book into Accredo's book of business?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Lisa, let me kind of give you the way we think about what's going on in the specialty space. I would tell you that margins, generally, are quite stable. But what we try to explain in our formal comments is that mix is something you just need to be aware o",200,"Lisa, let me kind of give you the way we think about what's going on in the specialty space. I would tell you that margins, generally, are quite stable. But what we try to explain in our formal comments is that mix is something you just need to be aware of. So for example, hemophilia as a category, has been a higher-margin business. But the disease and the growth pattern of that disease among the population is far slower than the growth of many of the other specialty drugs tied to the disease patterns in the population. So, Rich, in his comments pointed out things like rheumatoid arthritis, things like pulmonary arterial hypertension. Those are stable margins, margins that we like, and when you just do the math and they grow dramatically, they change the weightings of margin across the drug products and that simply changes the overall margin perspective. But I wouldn't want investors think about this as declining margins for specialties, that's really not the story. It's just the relative growth across the product lines. So that's how I would think about it. Steve Fitzpatrick is here with us. Steve, do you want to add anything to that?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's a good point. I think the other piece of that is, when we talk about channel mix and client mix, it actually drives us. So as we add more Medco clients at typically higher volumes of the multiple sclerosis, rheumatoid arthritis, oncology [ph] and o",109,"That's a good point. I think the other piece of that is, when we talk about channel mix and client mix, it actually drives us. So as we add more Medco clients at typically higher volumes of the multiple sclerosis, rheumatoid arthritis, oncology [ph] and on to it [ph] those therapies, you're also getting new indications of those drugs coming out that ultimately drive that growth even greater that you don't have in some of our core infused therapies that are very strong on the medical side that we've always penetrated and been strong on the medical side, it's just that weve been growing in the pharmacy side."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And wouldn't it also be the channel though, right? I mean, Steve, if you think about this, when you're actually have it go through your mail-order facilities or you're going out and infusing a product, my understanding is that, that margin is much better",66,"And wouldn't it also be the channel though, right? I mean, Steve, if you think about this, when you're actually have it go through your mail-order facilities or you're going out and infusing a product, my understanding is that, that margin is much better than if you're just adjudicating a claim or you still have some aspect to the book that you're doing that, right?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's correct. Our retail volume has continued to grow fairly steadily and to the degree that's actually higher, that is a lower margin.",24,"That's correct. Our retail volume has continued to grow fairly steadily and to the degree that's actually higher, that is a lower margin."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Are you comfortable giving us some -- I'm really looking at this as a future opportunity, right? So the more of that, that you can bring into your book, the better the margin's can look over time. Is that 25% of the book, 40% of the book? Can you give us",67,"Are you comfortable giving us some -- I'm really looking at this as a future opportunity, right? So the more of that, that you can bring into your book, the better the margin's can look over time. Is that 25% of the book, 40% of the book? Can you give us some range of where the opportunity is to bring that into the Accredo book of business?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, right now, if you look at the level of penetration of our current clients that currently have Accredo specialty, it's actually between 85% and 90%. So we made great progress over the past few years. You might recall, when we started out probably two",68,"Well, right now, if you look at the level of penetration of our current clients that currently have Accredo specialty, it's actually between 85% and 90%. So we made great progress over the past few years. You might recall, when we started out probably two years into the acquisition in the maybe 60% to 70% range. So weve had a very meaningful success over the past few years."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then just one follow-up question, Dave, can you maybe just give us any of your thoughts around -- I know that the selling season hasn't really started yet this year, but as we look at the 2012 selling season, first off, the amount that you have up for",91,"And then just one follow-up question, Dave, can you maybe just give us any of your thoughts around -- I know that the selling season hasn't really started yet this year, but as we look at the 2012 selling season, first off, the amount that you have up for renewal was a little bit less than we had anticipated. One, have things shifted around at all? And secondly, as you look at the RFPs for 2012, are you seeing anything unusual as far as requests go in the RFP process?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. The number Rich gave relative to the renewals for '12 is pretty much just how the contracts fall in our selected early renewals. It's just the way it fell. And I would say that relative to RFPs we're seeing, I can't comment on anything special that we",81,"No. The number Rich gave relative to the renewals for '12 is pretty much just how the contracts fall in our selected early renewals. It's just the way it fell. And I would say that relative to RFPs we're seeing, I can't comment on anything special that we've noticed, but Tim is here in the room. I don't know, Tim, if there's anything special you want to mention relative to the RFPs we're seeing and coming through the pipeline right now?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Nothing particularly special. I think perhaps a bit more general clinical focus, a bit more focused on understanding what we're doing to manage specialty, wellness and workplace health. Those sorts of things are getting a bit more focused in certain RFPs",69,"Nothing particularly special. I think perhaps a bit more general clinical focus, a bit more focused on understanding what we're doing to manage specialty, wellness and workplace health. Those sorts of things are getting a bit more focused in certain RFPs than we've seen in other years. But other than that, I would say nothing unusual. We are very pleased with the pipeline right now, I've got to say."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Ross Muken from Deutsche Bank.",13,"Your next question comes from the line of Ross Muken from Deutsche Bank."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just off of Lisa's comment on -- as we think about this upcoming selling season, now that you've had some time, is there still some of the nice wins that you had and look at the high renewal retention rate, as you dug into some of the specific clients, wh",116,"Just off of Lisa's comment on -- as we think about this upcoming selling season, now that you've had some time, is there still some of the nice wins that you had and look at the high renewal retention rate, as you dug into some of the specific clients, what were some of the two or three things that you felt like in this last selling season that sort of stood out to you that finally, we've either gotten a lot of traction with X, Y or Z or is one, two or three kind of really push the needle and kind of either helped us retain business or helped us increase our market share?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","This isn't going to be a new ah-ha to you, Ross, but I would tell you that there is no question that clients when they're buying are looking for an overall value prop. I say that and I think sometimes, it's discounted because people think it's just about",233,"This isn't going to be a new ah-ha to you, Ross, but I would tell you that there is no question that clients when they're buying are looking for an overall value prop. I say that and I think sometimes, it's discounted because people think it's just about price, and it's just not the case. It's, overall, value prop relative to total healthcare cost, and there is no question that clients are looking for the company that can optimize their spend driving better outcomes at lower cost. The things we're doing around Therapeutic Resource Centers, the things we are doing around pharmacogenomics, even the things we're now introducing tied to post FDA approval research are all things that resonate with clients because they feel as though we're putting their destiny in their hands by creating an ability to drive from shotgun medicine to precision medicine and optimize the value of every dollar they spend. And we're able to do this even in competitive pricing situations because on top of the fundamental ticket to entry, which is price, it's about what else you're doing to drive a better outcome. And it's really working for us, and it's just confirmed again in 2010. It was a fantastic year, and we're really happy with the way it's run. Glenn, I don't know if you have any thoughts about that question, but feel free to comment."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Dave, I'd say there's a couple of other things. The clients are really interested in using technology, so the iPad example we used earlier is just one of many of how do you get the members more connected mobily (sic) or with apps. So I think that's a big",90,"Dave, I'd say there's a couple of other things. The clients are really interested in using technology, so the iPad example we used earlier is just one of many of how do you get the members more connected mobily (sic) or with apps. So I think that's a big thing that it resonated well and also clients like the idea that we can connect them or connect to other providers with theirs. So we call it extended enterprise. But that has been a huge positive in the health plans space."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I just want to -- and I don't mean to belabor the point, but I'm just getting a lot of questions in my inbox, so I just want to make sure everyone's sort of understanding sort of the EPS progression. If we think about, Rich, obviously, the progression thr",136,"I just want to -- and I don't mean to belabor the point, but I'm just getting a lot of questions in my inbox, so I just want to make sure everyone's sort of understanding sort of the EPS progression. If we think about, Rich, obviously, the progression throughout the year, vis--vis when you originally provided guidance relevant to the management model and then what were seeing today, one, is that relatively consistent and then two, as we think about progression throughout the year isn't the key two deltas, the amount of generics obviously coming in per quarter which continues to be back-end weighted and then, two, the impact of the share repo, which typically has more of an impact to earnings growth in the back half? Is that the right way to think about it?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, absolutely. And I'll remind you again, Ross, of the incremental EPS effect of new generics. It really doesn't do much in the first half at all. It's nothing in the first quarter. It rounds to $0.01 in the second quarter. So you're really not getting",70,"Yes, absolutely. And I'll remind you again, Ross, of the incremental EPS effect of new generics. It really doesn't do much in the first half at all. It's nothing in the first quarter. It rounds to $0.01 in the second quarter. So you're really not getting any meaningful fuel first-to-second quarter at all. Of course, it's all about the fourth quarter with a $0.06, half of which is from Lipitor."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Randall Stanicky from Goldman Sachs.",13,"Your next question comes from the line of Randall Stanicky from Goldman Sachs."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a couple other, Dave or Rich, can you just give us an update, I'm not sure if you commented on UNH and possible timing or maybe collectively, can you let us know when we should expect to hear about an update on both FEP and UNH?",47,"Just a couple other, Dave or Rich, can you just give us an update, I'm not sure if you commented on UNH and possible timing or maybe collectively, can you let us know when we should expect to hear about an update on both FEP and UNH?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","As I said before, Randall, UNH, typically, its history is a predictor of the future. Typically, conversations with an account this size start 18 months prior to, which means puts us beginning the serious conversations in the summer. So you really shouldn'",147,"As I said before, Randall, UNH, typically, its history is a predictor of the future. Typically, conversations with an account this size start 18 months prior to, which means puts us beginning the serious conversations in the summer. So you really shouldn't expect information from us, really - so I'd say in the fall potentially, depending on whether or not history is that accurate predictor. So we, as I've said before, feel very good about our relationship with United, and I'm optimistic we will have a fruitful conversation, but the serious conversations, don't even expect them to really start till summer time. FEP is in flight now, and I really can't say much about a bid process that's in flight now. But you should be hearing about that I would assume just given the timeframe set out by the client, probably by next quarter at the latest."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, so it sounds like no change on either front there. Just one more question, we've gotten a lot -- more so in the specialty pharma side, but can you just -- we've had a lot of questions here on co-pay assistant cards. You and I have talked about this",84,"Okay, so it sounds like no change on either front there. Just one more question, we've gotten a lot -- more so in the specialty pharma side, but can you just -- we've had a lot of questions here on co-pay assistant cards. You and I have talked about this before, should we expect to see anything in terms of action from Medco or the industry in general to push back and obviously, what could be a big source of cost savings for clients?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Here's the way to think about this. We are not seeing the co-pay couponing, let's call it influencing our volumes. You heard our volumes, they are robust, they are moving to mail, they're moving to generics, all the things the plan designs are encouraging",213,"Here's the way to think about this. We are not seeing the co-pay couponing, let's call it influencing our volumes. You heard our volumes, they are robust, they are moving to mail, they're moving to generics, all the things the plan designs are encouraging. So today, I can tell you that we're not seeing any meaningful influence by coupons. However, let me be clear, to the extent couponing drives the wrong behavior, so what I mean by that, if couponing, in fact, takes the prudent buyer behavior out of the consumer by eliminating their out-of-pocket responsibility, which means they go to the most expensive drugs, which end up going to the payer's pocket. We have a series of things that we can easily do to shut that down very quickly. So we monitor, we make sure what's going on, is in the clients' best interest, and we are fully prepared, and we work with our clients all the time so they can see and have visibility to what's going on. To the extent it's not in the payer's best interest, we have benefit designs, plan designs and strategies ready to go that can shut couponing down overnight. So we're very comfortable with it, and we certainly have plans to help clients respond."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Are clients asking about this or is it on their radar screen yet?",13,"Are clients asking about this or is it on their radar screen yet?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, it is, and what we find the conversation leaning toward and if you saw the Times article, it was interesting because it ended with the same concept. Recently there was a Times article about this phenomenon, is that clients are coming back and revisit",137,"Yes, it is, and what we find the conversation leaning toward and if you saw the Times article, it was interesting because it ended with the same concept. Recently there was a Times article about this phenomenon, is that clients are coming back and revisiting their decisions around preferred drugs step therapy, which really takes the issue pretty much off the table, because to the extent that a drug is on formulary is couponed and the member takes it because they fail the generic is the first step, and that's actually in everybody's best interest. So clearly, what plans are looking at is our ability to put those programs in place and the great news is those programs create no member noise. We are black belts at doing it, and we are well invested in driving it."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Ricky Goldwasser from Morgan Stanley.",13,"Your next question comes from the line of Ricky Goldwasser from Morgan Stanley."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Couple of questions, first on the UBC contribution. So what percent of the growth -- and I assume it was in the services line, what percent of the growth in services came from UBC of the $92 million?",38,"Couple of questions, first on the UBC contribution. So what percent of the growth -- and I assume it was in the services line, what percent of the growth in services came from UBC of the $92 million?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","If you look at the change in run rate from say the second quarter, which was the last pure quarter in service without UBC to the fourth quarter, the majority of the dynamic is a contribution from UBC.",38,"If you look at the change in run rate from say the second quarter, which was the last pure quarter in service without UBC to the fourth quarter, the majority of the dynamic is a contribution from UBC."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So if we try to back it out of EBITDA, we get to core growth for the business of about 3% year-over-year, are we in the ballpark there?",28,"So if we try to back it out of EBITDA, we get to core growth for the business of about 3% year-over-year, are we in the ballpark there?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So I can just tell you, I don't have the EBITDA math in front of me. But I can tell you the pretax contribution in the fourth quarter from UBC was nominal. We're talking about low-single  well, single-digit millions.",40,"So I can just tell you, I don't have the EBITDA math in front of me. But I can tell you the pretax contribution in the fourth quarter from UBC was nominal. We're talking about low-single  well, single-digit millions."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","No, but when you think about it on an EBITDA per adjusted script, just if we add to the EBITDA and given that there's no script associated with the business, we assume higher contribution there?",35,"No, but when you think about it on an EBITDA per adjusted script, just if we add to the EBITDA and given that there's no script associated with the business, we assume higher contribution there?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, that's correct.",3,"Yes, that's correct."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So, this is kind of like -- backing into around 3% year-over-year growth for just the core business, is that a reasonable estimate?",23,"So, this is kind of like -- backing into around 3% year-over-year growth for just the core business, is that a reasonable estimate?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","You're talking about just growth in the EBITDA per adjusted script?",12,"You're talking about just growth in the EBITDA per adjusted script?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Correct.",1,"Correct."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Which is currently in the fourth quarter? On a fourth-quarter basis, 5.2%, you're saying about 3% of is...",18,"Which is currently in the fourth quarter? On a fourth-quarter basis, 5.2%, you're saying about 3% of is..."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Is core, i.e., once we back out UBC?",8,"Is core, i.e., once we back out UBC?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm doing the math in my head. It's probably -- the core should be stronger than that.",18,"I'm doing the math in my head. It's probably -- the core should be stronger than that."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then on the 2012 renewal season of the $16 billion to $17 billion, I don't know if you'd comment on it, but what percent are early renewals versus scheduled?",30,"And then on the 2012 renewal season of the $16 billion to $17 billion, I don't know if you'd comment on it, but what percent are early renewals versus scheduled?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I can tell you that the majority of that number is scheduled.",12,"I can tell you that the majority of that number is scheduled."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And does that imply that you had some of the early renewals in 2011 really came from 2012 renewals?",19,"And does that imply that you had some of the early renewals in 2011 really came from 2012 renewals?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No, I wouldnt say that. I gave you the 2011 renewal number, it's $15 billion.",15,"No, I wouldnt say that. I gave you the 2011 renewal number, it's $15 billion."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Ricky, I would tell you that in any given year, the vast majority of renewals are scheduled renewals, and I would say that consistently, we're very selective about what we early renew and that was true for 2010. It continues to be true for '11 and it will",51,"Ricky, I would tell you that in any given year, the vast majority of renewals are scheduled renewals, and I would say that consistently, we're very selective about what we early renew and that was true for 2010. It continues to be true for '11 and it will be true for'12."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your final question comes from the line of Steven Valiquette from UBS.",12,"Your final question comes from the line of Steven Valiquette from UBS."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I guess first, just to clarify, so the $16 billion to $17 billion, does that include or exclude UNH, just to make that crystal clear. There seems to be some confusion around that.",33,"I guess first, just to clarify, so the $16 billion to $17 billion, does that include or exclude UNH, just to make that crystal clear. There seems to be some confusion around that."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It does not include United. United is not up for renewal in 2012.",13,"It does not include United. United is not up for renewal in 2012."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then you commented on the timing of that. Could UNH drag into 2012? Or should at least assume that whatever is going to happen there, will happen sometime in calendar 2011? Just trying to get a little more color on that. Unless [ph] unclear.",45,"And then you commented on the timing of that. Could UNH drag into 2012? Or should at least assume that whatever is going to happen there, will happen sometime in calendar 2011? Just trying to get a little more color on that. Unless [ph] unclear."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think it's easily conceivable it can drag into '12 [ph].",12,"I think it's easily conceivable it can drag into '12 [ph]."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just quick final question here on SG&A, kind of more of a general question, I think for the PBM sector, we're all kind of trained to think about start-up expenses for new business wins occurring in the first quarter of each calendar year. But I'm just cur",99,"Just quick final question here on SG&A, kind of more of a general question, I think for the PBM sector, we're all kind of trained to think about start-up expenses for new business wins occurring in the first quarter of each calendar year. But I'm just curious, with Medicare becoming a larger part of the mix, is it more prevalent now to assume more startup costs, renew business wins in 4Q? I mean, without getting too granular. I'm just trying to get a general sense that the split between 4Q and 1Q for startup expenses is generally speaking?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think the way you should think about it is that is from a software development point of view, to benefit modifications or account set up, that's primarily fourth-quarter expense. Service expense is first quarter tied to volumes of calls when you go live",78,"I think the way you should think about it is that is from a software development point of view, to benefit modifications or account set up, that's primarily fourth-quarter expense. Service expense is first quarter tied to volumes of calls when you go live. And I would say, historically, with us the expense has been more heavily weighted to the fourth quarter relative to the coding of the benefits in getting the accounts set up versus first quarter."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","One further point on that, Steve, the majority of our startup expenses this year and last year had been in cost of sales when they effect gross margin. They generally have not been an SG&A expense.",36,"One further point on that, Steve, the majority of our startup expenses this year and last year had been in cost of sales when they effect gross margin. They generally have not been an SG&A expense."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","As far as the lower SG&A expense expected for 2011, any additional color on that? I think you lowered the range there by $50 million or so?",28,"As far as the lower SG&A expense expected for 2011, any additional color on that? I think you lowered the range there by $50 million or so?"
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, the range was very, very broad. It was almost too wide when we first give guidance, which is why on Analyst Day, I promised that I would narrow it.",30,"Well, the range was very, very broad. It was almost too wide when we first give guidance, which is why on Analyst Day, I promised that I would narrow it."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thanks to all of you for joining us today. And look forward to speaking with you again in the not-too-distant future.",21,"Thanks to all of you for joining us today. And look forward to speaking with you again in the not-too-distant future."
1541811,118622458,105132,"MedcoHealth Solutions Inc., Q4 2010 Earnings Call, Feb 22, 2011",2011-02-22,"Earnings Calls","Medco Health Solutions, Inc.","Operator","This concludes today's conference call. Thank you for your participation. You may now disconnect.",15,"This concludes today's conference call. Thank you for your participation. You may now disconnect."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","2008 recently announced his retirement effective July 1, we all think for excellent service and wish him a very happy retirement. We have named Frank Sheehy, a 13 year Medco veteran to proceed as Accredo's President. Frank also joined Medco's executive co",460,"2008 recently announced his retirement effective July 1, we all think for excellent service and wish him a very happy retirement. We have named Frank Sheehy, a 13 year Medco veteran to proceed as Accredo's President. Frank also joined Medco's executive committee. Frank has an outstanding track record of business success and has earned some of the highest client and employee satisfaction ratings ever reported in our company. Frank's deep understanding of our customers and their needs in the specialty drug space make him well-suited to lead the Accredo  business as we continue to obtain Accredo's  capability through new innovation. 
On the 2012 sales front, while it is still too early in the 2012 selling season for the majority of our prospects to have finalized their decisions, we are very pleased with several significant early season wins. We remain confident in our well differentiated services and our strategic positioning in the marketplace. A good example of our differentiated service offering is our Medicare business. For the quarter, our Medicare PDP grew 16% over first quarter 2010, driven by the national five-star rating excellence awarded to Medco. This five-star rating was the first and only 1 awarded to any national PDP by CMS. 
For 2011 year-to-date, our annualized  new-named sales remained at approximately $1.7 billion and our net sales remained approximately $1.5 billion. We have now completed over 90% of our 2011 schedule and early elected client renewal, up from the over 80% we reported on our fourth quarter call and our 2011 year-to-date client retention rate remains at over 99%.
Turning to guidance, it is with confidence that we raised the midpoint of what our GAAP diluted EPS and our diluted EPS excluding all intangible amortization, reflecting the strength we are seeing thus far in our 2011 results. In addition, we are raising our GAAP diluted EPS range by $0.03 due to a lower-than-expected intangible amortization expense associated with our UBC asset, which Rich will discuss further. Our full year 2011 GAAP diluted guidance increased total range of $3.59 to $3.69 up from the previous range of $3.53 to $3.56, now reflecting a growth rate of 14% to 17% over 2010. Diluted earnings per share, excluding all intangible amortization is now expected to be the range of $4.2 to $4.12, up from $3.99 to $4.12, now reflecting 13% to 16% growth over 2010 earnings per share. 
In summary, we remain focused on the fundamentals of our business, and are enthusiastic about our prospects for continued strong growth. Our ability to narrow guidance this early in the year serves to further fuel back enthusiasm. With that, I'll turn the call over to Rick Rubino, who will take you through the details of our first quarter 2011 financial and 2011 guidance. Rich?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. As Dave mentioned come first quarter diluted results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representin",1575,"Thank you, Dave. Good morning. As Dave mentioned come first quarter diluted results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representing 19.7% growth over the first quarter equivalent of $0.76. 
As we previously guided, first quarter 2011 EPS results include a plan of $0.04, associated with changes to the employee postretirement Health Care benefit plan. Approximately 3/4 of roots sales and 1/4 to SG&A expense. 
Even when excluding net benefit, the GAAP EPS growth rate was 13.4% and the pure cash EPS growth rate was 14.5%. Our gross margin and EBITDA per adjusted script both grew with this 1 time benefit is excluded. Total first quarter 2011 net revenues reached a record $17 billion, representing growth of 4.3% over first quarter 2010. Our product revenue grew 3.6%, reflecting our new business wins, as well as higher prices charged by brand name, pharmaceutical manufacturers, partially offset by a higher representation of lower-priced generics. 
Service revenue continue to be a very meaningful growth driver, increasing 57.5% over first quarter 2010. This strong performance reflects the service revenue contribution from UBC, which closed on September 16, 2010, as well as the expansion of our overall client base and our Medicare Part D service fees.
Turning to rebates, we earned a record $1.5 billion for the first quarter, an increase of 3.4% over the same period last year, even though we are dispensing fewer brand-name medication and more generics. This year-over-year growth is attributable from new client wins and continuous improvements with formulary contracts. Our first quarter 2011 rebate retention rate was 11.6% compared to 12.1% in the first quarter of 2010 as we continue to drive significant value to clients in a highly transparent manner. 
As Dave mentioned, mail-order volume remained strong as client and members continue to choose this lower cost and clinically effective service. In the first quarters 2011, our total mail-order prescription volume was $23.7 million. Within this, generic increased 9.3% to a record $17.7 million, while brand-name prescription volume decreased 9.1% to $10 million prescriptions. Our generic this patiently very substantial 250 basis points since first quarter 2010 to a record of 63.8%. Based upon our current forecast, we are raising our 2011 mail-order volume guidance range to $108 million to $110 million, up from the previous $107 million to $109 million scripts. 
Our strong generic mail-order volumes and our fee service gross margin meaningful drove our first quarter consolidated gross margin, which increased 7.8% over first quarter 2010 to $1.07 billion. Our consolidated gross margin percentage of 6.3% for the quarter increased 20 basis points from the 6.1% in the first quarter 2010, including a strong first quarter 2011, generic mail-order prescription volume and growth in service margin. 
Selling, general and administrative expenses of $387.1 million for the first quarter increased over first quarter of 2010 by $36.5 million or 10.4%, including increased expenses associated with the addition of UBC, as well as higher professional fees and other expenses associated with the strategic initiatives. Our total EBITDA for first quarter of 2011 reached $734.2 million, representing growth of 6.9%. EBITDA for adjusted prescription for the quarter increased 4.9% to $3.1. Our intangible amortization of $73.2 million in the first quarter 2011 increased 3.8% from $70.5 million in first quarter 2010, primarily reflecting the UBC intangible assets. The final purchase accounting valuation for the UBC acquisition resulted in a lower identified intangible asset value that we included in our previous GAAP EPS guidance. And therefore, overall intangible amortization expense for full-year 2011 will be lower than originally guided by approximately $20 million.
Total amortization of intangibles for 2011 is now expected to be in the range of $280 million to $300 million compared to the previous guidance of $300 million to $320 million. The $20 million reduction in the range equates to the $0.03 improvement in our revised full-year 2011 GAAP diluted EPS guidance.
Total net interest and other expense of $54.2 million for the first quarter of 2011 increased $14.9 million from the $39.3 million in first quarter 2010, primarily reflecting the new GAAP reedited finance the UBC acquisition last September. 
First quarter 2011 effective tax rate was 40.1% compared to 39.8% in the first quarter 2010. We still expect the full-year 2011 effective tax rate to be approximately 39%. Net income for the quarter increased 3.9% to $333.1 million from the $320.5 million reported for the first quarter of 2010.
Moving on to share repurchases, during the first quarter of 2011, we repurchased 13.5 million shares for $836.6 million at an average per share cost of $62.23 through our preauthorized trading plan. Of these repurchases a total 6.4 million shares cost of $400 million have been repurchased under the new $3 billion plan authorized by Medco's Board of Directors on February 2. We expect to begin repurchasing shares again next week and anticipate represent approximately $2 billion of shares during 2011, consistent with the detailed guidance we provided last November. 
As a result of our share repurchases and normal climate component, we close the first quarter  with the cash balance of $127 million. We expect our quarterly cash balances to increase over the course of this year. Our total debt for the first quarter remained consistent with fourth quarter 2010 of $5.0 billion.
Turning to our specialty segment, as Dave already mentioned, Accredo achieved revenue $3.1 million and record operating income of $120.6 million for first quarter 2011. Accredo's gross margin percentage for the quarter was 6.6% compared to 7.1% first quarter 2010, reflecting the product, channel and new client mix effects to be experienced as 2010 progressed, which includes meaningful growth across the vast majority of Accredo's products. Sequentially, Accredo's gross margin percentage increased 10 basis points from the 6.5% reported in the fourth quarter 2010.
Moving on to Medicare, we continue to experience growth in our highly-rated Medicare PDP.  First quarter 2011, Medco's PDP revenues increased over 16% to nearly $440 million. As Dave explained, we are raised the midpoint of our 2011 EPS guidance for both GAAP or pure cash EPS measures, narrowing the range for the high-end to a $0.10 to the previous $0.13 range. And additionally, increasing the full-year GAAP diluted EPS by $0.03. The raising of the midpoint reflects strengthened fundamental or earnings for the year, while the $0.03 range of the full year GAAP diluted EPS of the function of the lower intangible expense I mentioned earlier. 
Table 9 of our earnings release place out the map very clearly. To briefly repeat our improved 2011 guidance, diluted GAAP EPS is now expected to grow 14% to 17% over 2010 in the range of $3.59 to $3.69. Pure cash EPS is now expected in the guidance range of $4.02 to $4.12, representing a growth of 13% to 16% over 2010 full year equivalent of $3.55.
Now, I would like to take you through the detailed component of our 2011 guidance beginning with renewals. We continue to expect to renew approximately $15 billion of business in 2011, including schedule and early elective renewals, representing less than 1/4 of our business. As Dave mentioned, we now have over 90% of our 2011 renewals completed, up from the over 80% we recorded last quarter. As previously disclosed, approximately 75% of the 2011 renewal pricing already took effect in the first quarter 2011, which we remain to expect primarily in the third quarter. At this point, we continue to expect that 2012 renewals to be in the range of $16 billion to $17 billion. Approximately 25% of our book. 
As you can see from our slides on the web, the majority of our detailed 2011 guidance component remained consistent with those we provided on our fourth quarter call. 2011, we continuing to expect a $0.09 incremental contribution from new generics, $0.01 expected in the second quarter, $0.02 expected in the third quarter and $0.06 expected in the fourth quarter. $0.03 of which relates to Lipitor for the five-week month of December.  We continue to expect stability or year-over-year expansion in our gross margin percentage and EBITDA for adjusted script performance for 2011. 
Now I would like to walk you through some of the changes to our 2011 guidance components. As I've briefly mentioned earlier, our mail-order prescription volumes for 2011 are now expected to be in the range of $108 million to $110 million, up from the previous range of $107 million to $109 million. SG&A expenses for 2011 are now expected to be approximately $1.7 billion, an improvement of the previously narrowed range of $1.7 billion to $1.75 billion. 
Now to give you some insights into the quarterly flow of earnings for 2011, we now expect EPS to improve progressively quarter-to-quarter, with the largest sequential improvement from third quarter to fourth quarter 2011. The  second quarter 2011, pure cash EPS is now expected to increase slightly over the first quarter 2011 EPS amount of $0.91. The percentage split in EPS between the first half and the second half of 2011 is now expected to be consistent with that experienced in 2010. 
In conclusion, we delivered a strong quarter of operating results and EPS, representing a solid start to 2011. We remain confident in our prospects for the quarters ahead and for our continued growth relative to the future. Now Dave and I would like to open the lines for questions. Andrea?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Lisa Gill with J.P. Morgan",15,"[Operator Instructions] Your first question comes from the line of Lisa Gill with J.P. Morgan"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter which includes the one-time benefit, is that correct?",37,"Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter which includes the one-time benefit, is that correct?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That is correct. We expect it to be higher than the $0.91 we reported this quarter.",16,"That is correct. We expect it to be higher than the $0.91 we reported this quarter."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offerings, can you talk it all what happened recently with Calpers. Does that come up with the conversation? A",90,"And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offerings, can you talk it all what happened recently with Calpers. Does that come up with the conversation? Are people just looking beyond that and saying, Medco's go has got a great offering and it's not having an impact on your selling season for 2012? Any comments would be helpful. And then just lastly, if you could just help us understand the timing of the SEP?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure. I'll answer a couple of pieces, and then I'll ask the guys with the client with another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty side of the business, and they're",257,"Sure. I'll answer a couple of pieces, and then I'll ask the guys with the client with another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty side of the business, and they're looking for new innovation and solutions there because it's the small molecule goes from brand generic. They're getting great relief. But they see where specialty is heading. That's where the new brand innovation is occurring, and we're working with them on some, I think, exciting solutions for the future. And that's where a lot of the conversation goes when you talk about renewals and retention. When you look at FDPO, I would just tell you that we actually went back and look at what the timing was for announcement last time they went out the full RFB. And they're on schedule actually. And we looked at it last time, which is I think 5 years ago now. They didn't actually announced till late in the second quarter. We didn't have -- we weren't able to tell investors where that went until our second quarter call. So they may or may not be ahead of that schedule, but relative to some previous years, they're on-schedule and we still feel as though we have a very competitive offering there. Relative to your final question, Lisa, I'm going to ask Tim Wentworth and then Glenn Taylor to reflect their markets and the Calpers situation. So guys, why don't you go ahead."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","In a nutshell, it's not been a significant topic of conversation. Once we got passed the next week and we file the 8-K. It's not a significant distraction. I don't think it's an issue to putting together a fabulous  sales and retention year for us. When y",151,"In a nutshell, it's not been a significant topic of conversation. Once we got passed the next week and we file the 8-K. It's not a significant distraction. I don't think it's an issue to putting together a fabulous  sales and retention year for us. When you look in the marketplace which include the states, where we maybe expected some sensitivity, plans and their consolidations have significant challenges they recognize the quality of our programs, they recognize the long standing integrity of our company, and most importantly, we've consistently delivered. When you take a look at the most recent awards that we're very pleased to get and the information of the publicly, there except [ph] they believe Medco provide high value cross management programs and they have a strong critical underpinning that sits under that. So we have had no issue. And in fact, extraordinarily excited about what they this year."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Glenn Taylor. Says the 8-K we were able to get more explanation. We have a 10 day news cycle if you will from the middle to the end of March. And that was I have single conversation March 31. In that time, we've had 2 significant renewals, which we don't",87,"Glenn Taylor. Says the 8-K we were able to get more explanation. We have a 10 day news cycle if you will from the middle to the end of March. And that was I have single conversation March 31. In that time, we've had 2 significant renewals, which we don't talk about and disclosed individual contracts. We've had 2 fairly significant wins. So we're thinking we're in a very good shape and have a very good selling this year, and this issue is just not an issue."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Larry Marshall, Mary marsh, Barclays Capital",14,"Your next question comes from the line of Larry Marshall, Mary marsh, Barclays Capital"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a follow up to Lisa's question may be another add-on, which is around timing. Dave, obviously, when you're at Health Care conference, you stepped over which is I think inflammatory, and you did disclosed in the 8-K that clearly there's nothing to do",88,"Just a follow up to Lisa's question may be another add-on, which is around timing. Dave, obviously, when you're at Health Care conference, you stepped over which is I think inflammatory, and you did disclosed in the 8-K that clearly there's nothing to do anything wrong. But there's still a little bit of unnecessary uncertainty. Are you in a position at all to talk about when you like to be able to be clear about the positioning you have in the marketplace and the resolution of this?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll ask Tom Moriarty. This is a legal matter and [indiscernible] some thoughts.",14,"I'll ask Tom Moriarty. This is a legal matter and [indiscernible] some thoughts."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure, Larry. I mean, as we said before, we're working with the SEC and the California . We have been and will continue to voluntarily provide information the very clearly, but I cannot predict with any real certainty of the timing of that and the outcome.",82,"Sure, Larry. I mean, as we said before, we're working with the SEC and the California . We have been and will continue to voluntarily provide information the very clearly, but I cannot predict with any real certainty of the timing of that and the outcome. But as we've seen this quarter as we go forward, we're going to remain very focused on our business and continue to   drive value for our clients, and continue to work to put this behind us."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your for next question comes from the line of Ross Muken with Deutsche Bank.",14,"Your for next question comes from the line of Ross Muken with Deutsche Bank."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So in talking to the consultants, 1 of the things that consistently comes up this season, and it's come up in prior seasons is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of the regul",114,"So in talking to the consultants, 1 of the things that consistently comes up this season, and it's come up in prior seasons is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of the regular basis. As you think about sort of the key messaging in the upcoming season and where you really feel like you're kind of driving the biggest delta versus your peers, what for you is kind of the key focal points that's new and different versus the prior year? And what do you have kind of that you sort of talked about more recently on the pharmacodynamic genomic front?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Let me talk about the things that I'm excited about and the things that have resonated with my conversations with clients, and then again I'll as the group's president to add anything that I don't cover. But for me, continuing to expand the Consumer-drive",407,"Let me talk about the things that I'm excited about and the things that have resonated with my conversations with clients, and then again I'll as the group's president to add anything that I don't cover. But for me, continuing to expand the Consumer-driven capabilities down to the individual consumers. So, for example, expressing gaps in care and evidence-based protocols through our website in the layperson language so the consumer can understand how to manage their care better and where their gap exists and how they're following their treatment protocol has been hugely powerful. And in fact, the gap and care closure we're getting on the self-help basis has been dramatic and on-going and I'm excited about that, both because it improves outcomes at lower cost, but also it's the least expensive way to close gaps in care, because I don't need to do the labor intensive pharmacist coaching each and every time. I'm also thrilled that we just recently launched the Medco smart phone app with Verizon, available both Android and BlackBerry version. These are really exciting apps and again gets to the next level of influencing consumers a powerful way that are clinically oriented, but also give them enormous financial information at the point of care with their doctor. And I think that that's something that is going to continue to propel better outcomes at lower costs through real clinical care and in complete communication among the parties involved for that care, and I like that. The other thing that isn't getting a lot of air time, and we've talked to all of you 2 times at 2 Analyst Day's, and I don't think people fully appreciate the power of it yet, but I guarantee you they will if our investments and our efforts around what we call Medco 2.0 and the Agile Enterprise. The benefit that will bring to the competitive marketplace in go forward years is incredible for me. It will unleash our ability to innovate in a quantum way. And I think we're going to take another attempt next Analyst Day to further explain how powerful this is, but that to me is what is really going to make a difference in how we take care our patients and how we service our customers in a way no one else can. And I'm going to leave it there. I'll ask you guys, Tim and Glen, if you have anything to add."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think the only thing that I would really be going to since we launched and we are in concert with group and we launch recently to them and everyone of them is going to heavily promote the app to their members, particularly once we get an iPhone applicat",268,"I think the only thing that I would really be going to since we launched and we are in concert with group and we launch recently to them and everyone of them is going to heavily promote the app to their members, particularly once we get an iPhone application as well which will be deployed at the second quarter. Huge in terms of the response to them what's the enable in terms of the way we engage with our patients. But beyond that, I think the big thing, Dave are the 2 things. 1 is our extended enterprise. We are continually being the leader at vendor summit to sit down with multiple points of care inside of their constellation and being able to enable a greater level of connectivity than they can get by virtue of the way it goes in an unmanaged setting. So that's very powerful and the fact that we can enabled that and bring to our table are open architecture, our patient health action plan and we can work that by directionally with these other caregivers is compelling. The third piece I would say is our strategy has been hugely successful. We have modeled over 50 clients in terms of looking at the value. We are installing a whole lot of them for '12, or '13 we think we have brought a level of value that is unparalleled in terms of both the member care for these clients want to continue to care for members and at the same time bring a significant financial changed to what it looks likes in terms of the."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree and say that every health plan and selling a 360 view of patient through research and review. While we can that on pharmacy side we need to integrate that with medical the lab et cetera. And that with the enterprise that we mentioned really",54,"I would agree and say that every health plan and selling a 360 view of patient through research and review. While we can that on pharmacy side we need to integrate that with medical the lab et cetera. And that with the enterprise that we mentioned really came of the dividends of our conversation."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So obviously, Ross, we lost that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going to have Dr. Epstein to talk about his world, both research, UBC and the things we'",132,"So obviously, Ross, we lost that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going to have Dr. Epstein to talk about his world, both research, UBC and the things we're doing that are resonating with clients there. I'm also going to ask Kenny if you can or have to talk about some of the innovations we're working on relative to physicians which we prepare for a comfortable care. Because I think that Health Care reform initiative is important. I think it again drives better outcomes and we think we can be a major enabler in that space. And maybe a brief comment on that related to that 2.0 might be helpful. So Rob?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","On the pharmacogenemics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer and they are selling very briefly, we have over 300 clients enrolled in multiple pharmacogenemics programs, representing about 12 millio",427,"On the pharmacogenemics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer and they are selling very briefly, we have over 300 clients enrolled in multiple pharmacogenemics programs, representing about 12 million of our lives. So it's really exciting, and they're really excited to take on new pharmacogenemics test which is new. These are trickier to do than the ones [indiscernible] so it's a real positive for us to be able to figure out how that gets on. Also, we've launched our new service which is kind of like a 1-800 number to call certified generic Health Care to get advice when you're newly diagnosed with any sort of  problem like cancer and that's actually traction event even when describing that new service. We've added a number of hospitals medical institute network including 1 in Canada, which is pretty exciting where we are arming hospitals around the country genomic information to make them certified Javon at the center. And in another area in genomic which is new for us it takes the intelligence around the with DNA Direct has and off of those as the policy health plan. You don't have their own technology assessment and we actually had a number of sales in that area because they're a real uplift for us. So all areas are inspiring. They're all new. On the research front, we have a dozen large multi patient going studies of which we'll complete this year. But you'll be hearing at the back half of the year some of the results of our very large prospective studies that have taken us into new areas including psychiatry that is not there before. So it's pretty exciting and the has been really excited about the work we're doing since no one else is doing it.On the UBC front, the synergy has been simply awesome. Since we announced the acquisition in September, we also launched the Medco Research Consortium, which any client interested in participating in the research, including BBC, we now have well over 100 clients representing 40 million of our lives in the consortium. And we now actually have clients participating in Pfizer competitive effect on these studies or safety studies are both and are the feedback has been really exciting. People love it The member love it. They like to be having the added protection of the safety in the particular type study. And so everything has been really excited for quarter for us and we're just really looking forward to ongoing events this year."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","To end what has been said, we view the area of health Information Technology is a really exciting space for us. 1 of the things that we're very excited when you think about in terms of extended enterprise and the broad portfolio of clinical capability is",199,"To end what has been said, we view the area of health Information Technology is a really exciting space for us. 1 of the things that we're very excited when you think about in terms of extended enterprise and the broad portfolio of clinical capability is the real game changer is to help get the Health Care system wire in the country, and 1 of the most powerful features of that is being able to help support the point of care where the patient and the physician interaction is at its most important. to be able to provide 360 degree insights to that point of care. We believe it improves the ability of the physician to make decisions and prescribing treatment, and also allows us to play the evidence based protocol that allows a sort of benchmark capital the activities that are happening. So I think you will see over the not too distant future an expanding portfolio of cloud computing based solutions to point of care, and it's also the mechanism we're going to be using to enable both the medical home care organization as well. So the wiring aspect that we think has a lot of potential."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of your shoe from Citigroup.",12,"Your next question comes from the line of your shoe from Citigroup."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","The increase in generic volumes in mail is pretty impressive this quarter. Given the lack in generic introductions, can you talk about what drove that?",25,"The increase in generic volumes in mail is pretty impressive this quarter. Given the lack in generic introductions, can you talk about what drove that?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes I'll mention a few things, and then Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an to effectively cost effective channel, and that mail is outstanding at driving generi",214,"Yes I'll mention a few things, and then Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an to effectively cost effective channel, and that mail is outstanding at driving generic expensing rates. So we have great benefit design support on part of our clients to drive this outcome, and I would also tell that the economy continues to aid the choice of generic. Because clearly when people are financially strapped, they say, ""Hey, I'd rather have less out of pocket expense,"" and then moving from brand to generic. And the interchange going on between brand and generic voluntary on the part of consumer to simply that they simply have to save some money has been incredibly strong. The final thing I've mention is that we have a team that's always working with clients to drive better generic results across the channel both mail and retail and we've come up with few new innovations that I don't choose to describe in great detail, but they've been very effective in improving mail choice and generic choices at mail. So we're actually feeling this as though this is a momentum thing that we can sustain for a while."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Understand to that, when you look into the significant products that like generic last year Flomax, Cozaar, Hyzaar, Effexor XR, those all have very high mail-order penetration rates in our book of business. You might recall that at Analyst Day, I pointed",135,"Understand to that, when you look into the significant products that like generic last year Flomax, Cozaar, Hyzaar, Effexor XR, those all have very high mail-order penetration rates in our book of business. You might recall that at Analyst Day, I pointed to them on average thing about 45% mail-order penetration, which is over 10 points higher book of business average. In addition, we continue to see significant share gains as volume increases for simvastatin. That continues to be the case. Of course, we pointed to that in the past as well. Lastly, I'll say that plan designs have been established recently perhaps more than ever before in support of step therapy programs. We're ultimately -- we are driving a very material savings for client and patients by starting them on the lower cost alternatives."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard",14,"[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess you confuse some people with sort of sequential ramp earlier this year, and know it seems it's a bit more than we might've expected some progress from Q1 into",95,"My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess you confuse some people with sort of sequential ramp earlier this year, and know it seems it's a bit more than we might've expected some progress from Q1 into Q2. And you're sort of flattening I guess, a little bit the steepness of the ramp throughout the year. So can you tell us what changed in the last couple that gives you a little bit more weight towards the first half as opposed to the second half?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter and obviously as we get deeper into the yearly you have a clear line of sight, and now obviously the second quarter is a up and I'm con",151,"Probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter and obviously as we get deeper into the yearly you have a clear line of sight, and now obviously the second quarter is a up and I'm confident at that this point with my current line of sight that it will be stronger than the first quarter. So the way I look at my -- really have to take advantage of the most current information and projecting the year on this company because it's not that easy to look out for 2, 3, 4 full quarters. So I'm very confident in the second quarter. What I'm saying is a continuation of what we've seen in the first. Strong mail, strong generic, continued competitiveness we've been going to our ability to achieve competitive purchasing discounts, significant level of efficiency across the board."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to add secondary players. Rich is right in terms of 1 of the big player. But I'm going to also add that we're very pleased with incrementally grow with enrollment fee we got with our Medicare PDP and I think that's heavily related to the 5 star",166,"I'm going to add secondary players. Rich is right in terms of 1 of the big player. But I'm going to also add that we're very pleased with incrementally grow with enrollment fee we got with our Medicare PDP and I think that's heavily related to the 5 star rating we got as a national PDP because many of the patients who are 65 plus and 50 PDPs go to the government's website and make their choice, and they look at the star rating as an important metric for making choice. So we had a nice surprise there relative to enrollment, which will present itself the members will stay members through the year. I would also say I'm extremely pleased in the rate of growth we're seeing at UBC. And at this point, out performing my original expectations, and I think it's sustainable. So there's some other players out there that are actually at an operating level contributing to our growing optimism for the year."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And may be just a follow there. You're talking about, Rich, mail generic being one of the bigger drivers. I guess, can you tell us where you sort of get factored in as you look at the second of the year relative to what we've seen in the first quarter? Is",97,"And may be just a follow there. You're talking about, Rich, mail generic being one of the bigger drivers. I guess, can you tell us where you sort of get factored in as you look at the second of the year relative to what we've seen in the first quarter? Is there is a chance that if these trends sustain themselves and your line of sight continues to improve with times that you could do a little bit more better or have your sort of got to higher expectations of what you factored into the second have?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see as the year progresses as we get closer to the middle of the year. So obviously, I'll give you further in our next quarter call.",78,"Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see as the year progresses as we get closer to the middle of the year. So obviously, I'll give you further in our next quarter call. But right now, we're delighted with where we are. Obviously, we're pleased to lap off the $0.03 in the bottom end of guidance. And just stay tuned."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of from Goldman Sachs.",11,"Your next question comes from the line of from Goldman Sachs."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","On the Lipitor, Dave, in pressing little hard on the litigation perspective to get a generic in earlier, we're going to get an update on that today. Question is, if that was the case and we saw a generic come earlier, should we be thinking about your $0.0",55,"On the Lipitor, Dave, in pressing little hard on the litigation perspective to get a generic in earlier, we're going to get an update on that today. Question is, if that was the case and we saw a generic come earlier, should we be thinking about your $0.03 per month contribution in any different way?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll ask Rich to take that, and then Tom, who's obviously the 1 who put together all our pharma  deals, if you have anything to add please feel free to...",31,"I'll ask Rich to take that, and then Tom, who's obviously the 1 who put together all our pharma  deals, if you have anything to add please feel free to..."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","As would just like to say that at this point, the probably the level there is probably quite low. Would you agree with that?",24,"As would just like to say that at this point, the probably the level there is probably quite low. Would you agree with that?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree with that.",5,"I would agree with that."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So ultimately from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before them but Tom...",36,"So ultimately from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before them but Tom..."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree more likely the day [indiscernible].",8,"I would agree more likely the day [indiscernible]."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?",27,"The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","As a matter of policy, we don't get into different sources. And get pushed at the profitability there with. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you.",48,"As a matter of policy, we don't get into different sources. And get pushed at the profitability there with. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Amanda Murphy with William Blair.",13,"Your next question comes from the line of Amanda Murphy with William Blair."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I had a question on Accredo . The revenue growth there seems to be inline with sort of what you've guided to. But has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind o",75,"I had a question on Accredo . The revenue growth there seems to be inline with sort of what you've guided to. But has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind of longer term and have you seen the gross margin line kind of normalize? Was there a little bit of an improvement over last quarter?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll give you ask Steve Fitzpatrick to give you some help on that question.",15,"I'll give you ask Steve Fitzpatrick to give you some help on that question."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's may be come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lots of opportunity as this proportion of the specialties on the medical side of t",112,"It's may be come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lots of opportunity as this proportion of the specialties on the medical side of the business, which we had historically been fairly effective in pulling over and we'll continue to drive that. Particularly as we package our capabilities, which are really unmatched in the market, and move forward to be a little more aggressive in the packaging [indiscernible]. We should continue to drive, not only our core specialty, which has driven a lot of our growth recently, but in the future [indiscernible]"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll add to just what Steve said. I think the infusion capabilities are real. Competitive assets that Medco uniquely have. But I would also say more broadly in the specialty space there's an enormous opportunity on the medical side of the specialty spend",145,"I'll add to just what Steve said. I think the infusion capabilities are real. Competitive assets that Medco uniquely have. But I would also say more broadly in the specialty space there's an enormous opportunity on the medical side of the specialty spend benefit and we're making great inroads there. I expect that to grow over time as we continue to build products that make that whole over from medical to drug management on the PBM side. More scalable so you know we technically double the size of Accredo  if we could get the biotech spend on the medical side of the business over the PMB side of the business. On top of that, there are 611 drugs in the pipeline of clinical Phase II and 3 on their way to FDA approval, which will create its own source of growth for our business."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would add From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but a Passive variability?",41,"I would add From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but a Passive variability?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then just one more on. Some other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that the sort of underlying prescription consumption standpoint?",38,"And then just one more on. Some other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that the sort of underlying prescription consumption standpoint?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I would say that we'll be issuing our joint term report soon and for last year, certainly with utilization increase call us about 2-plus percent. That trend is not changing so we are starting to see some since of that this year early. But we certainl",53,"Yes, I would say that we'll be issuing our joint term report soon and for last year, certainly with utilization increase call us about 2-plus percent. That trend is not changing so we are starting to see some since of that this year early. But we certainly aren't seeing any declines in utilization."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Helene Wolk with Stanford Bernstein.",13,"Your next question comes from the line of Helene Wolk with Stanford Bernstein."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a question around cost trends and understanding what you're seeing from a generic sourcing and Retail network fee perspective, both currency what you expected for the year.",29,"Just a question around cost trends and understanding what you're seeing from a generic sourcing and Retail network fee perspective, both currency what you expected for the year."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think as we've commented, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]",25,"I think as we've commented, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Saying from our Retail contracting perspective as well, we have the line of sight is the continued improvement on the broader procurement front across the channel.",26,"Saying from our Retail contracting perspective as well, we have the line of sight is the continued improvement on the broader procurement front across the channel."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And any sense of or help that you can provide in terms of the timing of the share, how should we think about the rest of the year unfolding?",29,"And any sense of or help that you can provide in terms of the timing of the share, how should we think about the rest of the year unfolding?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Obviously we're still at the $2 million level. The strongest quarter for repurchases is the first quarter  are expected to come down a little bit in the second quarter from the dollar value perspective. And that should flattened off in the back half of th",83,"Obviously we're still at the $2 million level. The strongest quarter for repurchases is the first quarter  are expected to come down a little bit in the second quarter from the dollar value perspective. And that should flattened off in the back half of the year. So you'll see us going do when from the $836 million the first quarter to some level probably north of $500 million in the second quarter and then even in the back half of the year."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your final question comes from of Ricky Goldwasser with Morgan Stanley.",12,"And your final question comes from of Ricky Goldwasser with Morgan Stanley."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3  manufactured in December?",33,"I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3  manufactured in December?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in $0.03 as we were when we brought up $0.03 several months ago.",44,"Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in $0.03 as we were when we brought up $0.03 several months ago."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then Dave, any update on the timing of United? Do still expect to hear any resolution at the around the full-time?",22,"And then Dave, any update on the timing of United? Do still expect to hear any resolution at the around the full-time?"
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to echo the comment of Steve Ansley he made on his earnings call. That this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I can't speculate a",95,"I'm going to echo the comment of Steve Ansley he made on his earnings call. That this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I can't speculate about what the outcome will be, but we are anticipating a process just as we've talked about before. There's nothing really new to add at this point. But my view is, there's always a strong possibility of future relationships when your current relationship is so fundamentally strong."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And I would know turn it over to our presentors for closing remarks.",13,"And I would know turn it over to our presentors for closing remarks."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day.",31,"Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day."
1541811,129808770,118803,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect.",14,"Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning. My name is Andrea and I will bear conference operator today. At this time, I would like to welcome everyone to the Medco Health Solutions First Quarter 2011 Earnings Call. [Operator Instructions] I would like to now turn the call over to Ms.",55,"Good morning. My name is Andrea and I will bear conference operator today. At this time, I would like to welcome everyone to the Medco Health Solutions First Quarter 2011 Earnings Call. [Operator Instructions] I would like to now turn the call over to Ms. Valerie Haertel. Ms. Haertel, you may begin your conference. ."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Andrea.Good morning, and thank you for joining us on Medco's first quarter 2011 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us f",323,"Thank you, Andrea.Good morning, and thank you for joining us on Medco's first quarter 2011 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us for our question-and-answer session are: Kenny Klepper, President and Chief Operating Officer; Tom Moriarty, General Counsel, Secretary and President of Global Pharmaceutical Strategies; Steve Fitzpatrick, President of Accredo Health Group; Dr. Rob Epstein, President of Advanced Clinical Science and Research; Tim Wentworth, Group President of the Employer and Key Accounts; Glenn Taylor, Group President of Health Plans; and Mary Daschner, Group President of Government PBM.
During the course of this call, we will make forward-looking statements Private Securities Litigation Reform Act of 1995. No forward-looking statements have can be guaranteed and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in hour SEC filings. Copies of Medco's filings are available from the SEC and the Medco Investor Relations department or the Medco website. Medco intends to use the Investor Relations section of its website as a means for disclosing material forward looking information and for complying with disclosure obligations under Regulation FD. The copyright for the contents of the discussion and the written material used on this conference call are owned by Medco Health Solutions Inc. 2011. 
Slide to accompany our presentation, which detail our financial and operating results and the guidance discussed on this call are currently available in the investor section of Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-Q after the close of the market today. 
At this time, I would like to turn the call over to David Snow. Dave?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valerie, and thanks to all of you for joining us this morning. Today, we're reporting strong first quarter 2011 earnings reflecting continued success across our strategic growth targets. Additionally, we are raising the midpoint of our full-yea",809,"Thank you, Valerie, and thanks to all of you for joining us this morning. Today, we're reporting strong first quarter 2011 earnings reflecting continued success across our strategic growth targets. Additionally, we are raising the midpoint of our full-year 2011 EPS guidance range. 
For the first quarter, GAAP diluted earnings per share reached $0.80, representing 19.4% growth over first quarter 2010. Diluted earnings per share, excluding all intangible amortization, our new pure cash EPS measures reached $0.91 to 19.7% increase over  first quarter  2010 equivalent. Even with ever-growing volumes of the lower priced generic drugs in our genetic makes this quarter 2011 that revenues increased to a record of more than $17 billion, representing 4.3% growth over the same period last year. Within our net revenues, service revenues grew 57.5% to a record $357.8 million, fueled by our United Biosource acquisition and service revenue growth across the company.
With respect to the operating metrics that contributed to our strong financial results, total prescription volumes for first quarter 2011 adjusted for the difference in days applied between retail and mail grew 2.1% to $244.3 million prescriptions. Importantly, mail-order prescriptions totaled $27.7 million, with generic mail-order volumes increasing a substantial 9.3% to a record $17.7 million prescription , even in the quarter where there were no contributions from a generic. Our first quarter 2011 overall generic suspending rate rose 3.4 percentage point to a record 73.1%. And within that, our mail-order generic dispensing rate component increased 4.5 percentage points to a record 53.8%.
The year-over-year improvement in our overall generic dispensing rate grow record incremental savings to our clients and members of $1.1 billion for the quarter, as the growing number of members took advantage of this high-quality more affordable alternative.
Moving on to our specialty business, Accredo's performance remain strong, with record first quarter 2011 revenues of $3.1 billion, up 14.9%. Accredo's operating income rose 13.2% to a record $120.6 million. 
As in aside, Keith Fitzpatrick who has served as President of Accredo since 2008 recently announced his retirement effective July 1. We all thank Steve for his years of excellent service and wish him a very happy retirement. We have named Frank Sheehy, a 13-year Medco veteran, to succeed Steve on July 1 as Accredo's President. Frank also joins Medco's Executive Committee. Frank has an outstanding track record of business success and has earned some of the highest client and employee satisfaction ratings ever recorded in our company. Frank's deep understanding of our customers and their needs in the specialty drug space make him well suited to lead the Accredo  business as we continue to expand Accredo's capabilities through new innovations. 
On the 2012 sales front, while it is still too early in the 2012 selling season for the majority of our prospects who have finalized their decisions, we are very pleased with several significant early season wins. We remain confident in our well differentiated services and our strategic positioning in the marketplace. A good example of our differentiated service offerings is our Medicare business. For the quarter, our Medicare PDP grew 16% over first quarter 2010, driven by the national 5-star rating of excellence that was awarded to Medco. This 5-star rating was the first and only one to be awarded to any national PDP by CMS. 
For 2011 year-to-date, our annualized new-named sales remain at approximately $1.7 billion, and our net-new sales remain approximately $1.5 billion. We have now completed over 90% of our 2011 scheduled and early elective client renewals, up from the over 80% we reported on our fourth quarter call, and our 2011 year-to-date client retention rate remains at over 99%.
Turning to guidance. It is with confidence that we raise the midpoint of both our GAAP diluted EPS and our diluted EPS excluding all intangible amortization, reflecting the strength we are seeing, thus far, in our 2011 results. In addition, we are raising our GAAP diluted EPS range by $0.03 due to a lower-than-expected intangible amortization expense associated with our UBC asset, which Rich will discuss further. Our full year 2011 GAAP diluted EPS guidance increased to a range of $3.59 to $3.69, up from the previous range of $3.53 to $3.56, now reflecting a growth rate of 14% to 17% over 2010. Diluted earnings per share, excluding all intangible amortization is now expected to be in the range of $4.2 to $4.12, up from $3.99 to $4.12, now reflecting 13% to 16% growth over 2010 earnings per share. 
In summary, we remain focused on the fundamentals of our business, and are enthusiastic about our prospects for continued strong growth. Our ability to narrow guidance this early in the year serves to further fuel back enthusiasm. With that, I'll turn the call over to Rich Rubino, who will take you through the details of our first quarter 2011 financial and 2011 guidance. Rich?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. As Dave mentioned come first quarter EPS results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representing 19",1593,"Thank you, Dave. Good morning. As Dave mentioned come first quarter EPS results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representing 19.7% growth over the first quarter equivalent of $0.76. 
As we previously guided, first quarter 2011 EPS results include a planned $0.04 benefit associated with changes to the employee post-retirement health care benefit plan. Approximately 3/4 of which flowed to cost of sales and 1/4 to SG&A expense. 
Even when excluding net benefit, the GAAP EPS growth rate was 13.4% and the pure cash EPS growth rate was 14.5%. Our gross margin and EBITDA per adjusted script both grew with this onetime benefit is excluded. Total first quarter 2011 net revenues reached a record $17 billion, representing growth of 4.3% over first quarter 2010. Our product revenue grew 3.6%, reflecting our new business wins, as well as higher prices charged by brand name, pharmaceutical manufacturers, partially offset by a higher representation of lower-priced generics. 
Service revenue continues to be a very meaningful growth driver, increasing 57.5% over first quarter 2010. This strong performance reflects the service revenue contribution from UBC, which closed on September 16, 2010, as well as the expansion of our overall client base and our Medicare Part D service fees.
Turning to rebates, we earned a record $1.5 billion for the first quarter, an increase of 3.4% over the same period last year, even though we are dispensing fewer brand-name medication and more generics. This year-over-year growth is attributable to new client wins and continuous improvements with formulary contracting. Our first quarter 2011 rebate retention rate was 11.6% compared to 12.1% in the first quarter of 2010 as we continue to drive significant value to clients in a highly transparent manner. 
As Dave mentioned, mail-order volume remains strong as client and members continue to choose this lower cost and clinically effective service. In the first quarters 2011, our total mail-order prescription volume was $27.7 million. Within this, generic increased 9.3% to a record $17.7 million, while brand-name prescription volume decreased 9.1% to $10 million prescriptions. Our generic dispensing rate now increased a very substantial 450 basis points since first quarter 2010 to a new record of 63.8%. Based upon our current forecast, we are raising our 2011 mail-order volume guidance range to 108 million to 110 million, up from the previous 107 million to 109 million scripts. 
Our strong generic mail-order prescription volumes and our fee service gross margin meaningfully drove our first quarter consolidated gross margin, which increased 7.8% over first quarter 2010 to $1.07 billion. Our consolidated gross margin percentage of 6.3% for the quarter increased 20 basis points from the 6.1% in the first quarter 2010, including the strong first quarter 2011 generic mail-order prescription volume and growth in service margin. 
Selling, general and administrative expenses of $387.1 million for the first quarter increased over first quarter of 2010 by $36.5 million or 10.4%, including increased expenses associated with the addition of UBC, as well as higher professional fees and other expenses associated with strategic initiatives. Our total EBITDA for first quarter of 2011 reached $734.2 million, representing growth of 6.9%. EBITDA for adjusted prescription for the quarter increased 4.9% to $3.01. Our intangible amortization of $73.2 million in the first quarter 2011 increased 3.8% from $70.5 million in first quarter 2010, primarily reflecting the UBC intangible assets. The final purchase accounting valuation for the UBC acquisition resulted in a lower identified intangible asset value that we included in our previous GAAP EPS guidance. And therefore, overall intangible amortization expense for full year 2011 will be lower than originally guided by approximately $20 million.
Total amortization of intangibles for 2011 is now expected to be in the range of $280 million to $300 million compared to the previous guidance of $300 million to $320 million. The $20 million reduction in the range equates to the $0.03 improvement in our revised full year 2011 GAAP diluted EPS guidance.
Total net interest and other expense of $54.2 million for the first quarter of 2011 increased $14.9 million from the $39.3 million in first quarter 2010, primarily reflecting the new debt we added to finance the UBC acquisition last September. 
First quarter of 2011 effective tax rate was 40.1% compared to 39.8% in the first quarter 2010. We still expect the full year of 2011 effective tax rate to be approximately 39%. Net income for the quarter increased 3.9% to $333.1 million from the $320.5 million reported for the first quarter of 2010.
Moving on to share repurchases, during the first quarter of 2011, we repurchased 13.5 million shares for $836.6 million at an average per share cost of $62.23 through our pre-authorized trading plan. Of these repurchases, a total 6.4 million shares cost of $400 million have been repurchased under the new $3 billion plan authorized by Medco's Board of Directors on February 2. We expect to begin repurchasing shares again next week and anticipate repurchasing approximately $2 billion of shares during 2011, consistent with the detailed guidance we provided last November. 
As a result of our share repurchases and normal climate component, we closed the first quarter with a cash balance of $127 million. We expect our quarterly cash balances to increase over the course of this year. Our total debt for the first quarter remained consistent with fourth quarter 2010 of $5.0 billion.
Turning to our Specialty segment, as Dave already mentioned, Accredo achieved revenues of $3.1 billion and record operating income of $120.6 million for first quarter 2011. Accredo's gross margin percentage for the quarter was 6.6% compared to 7.1% first quarter 2010, reflecting the product, channel and new client mix effects to be experienced as 2010 progressed, which includes meaningful growth across the vast majority of Accredo's products. Sequentially, Accredo's gross margin percentage increased 10 basis points from the 6.5% reported in the fourth quarter 2010.
Moving on to Medicare, we continue to experience growth in our highly rated Medicare PDP. First quarter 2011, Medco's PDP revenues increased over 16% to nearly $440 million. As Dave explained, we are raising the midpoint of our 2011 EPS guidance for both GAAP and pure cash EPS measures, narrowing the range for the high-end to a $0.10 range from the previous $0.13 range, and additionally, increasing our full year GAAP diluted EPS by $0.03. The raising of the midpoint reflects strengthened fundamental operating earnings expectations for the year, while the $0.03 raise to full year GAAP diluted EPS is the function of the lower intangible amortization expense I mentioned earlier. 
Table 9 of our earnings release lays out the map very clearly. To briefly repeat our improved 2011 guidance, diluted GAAP EPS is now expected to grow 14% to 17% over 2010 in the range of $3.59 to $3.69. Pure cash EPS is now expected in the guidance range of $4.02 to $4.12, representing growth of 13% to 16% over the 2010 full year equivalent of $3.55.
Now I would like to take you through the detailed component of our 2011 guidance beginning with renewals. We continue to expect to renew approximately $15 billion of business in 2011, including schedule and early elective renewals, representing less than 1/4 of our business. As Dave mentioned, we now have over 90% of our 2011 renewals completed, up from the over 80% we recorded last quarter. As previously disclosed, approximately 75% of the 2011 renewal pricing already took effect in the first quarter of 2011, with the remainder expected primarily in the third quarter. At this point, we continue to expect 2012 renewals to be in the range of $16 billion to $17 billion, approximately 25% of our book. 
As you can see from our slides on the web, the majority of our detailed 2011 guidance component remain consistent with those we provided on our fourth quarter call. 2011, we continue to expect a $0.09 incremental contribution from new generics, $0.01 expected in the second quarter, $0.02 expected in the third quarter and $0.06 expected in the fourth quarter, $0.03 of which relates to Lipitor for the five-week month of December.  We continue to expect stability or year-over-year expansion in our gross margin percentage and EBITDA for adjusted script performance in 2011. 
Now I would like to walk you through some of the changes to our 2011 guidance components. As I briefly mentioned earlier, our mail-order prescription volumes for 2011 are now expected to be in the range of $108 million to $110 million, up from the previous range of $107 million to $109 million. SG&A expenses for 2011 are now expected to be approximately $1.7 billion, an improvement from the previously narrowed range of $1.7 billion to $1.75 billion. 
Now to give you some insights into the quarterly flow of earnings for 2011, we now expect EPS to improve progressively quarter-to-quarter, with the largest sequential improvement from third quarter to fourth quarter 2011. Our second quarter 2011 pure cash EPS is now expected to increase slightly over the first quarter 2011 EPS amount of $0.91. The percentage split in EPS between the first half and the second half of 2011 is now expected to be consistent with that experienced in 2010. 
In conclusion, we delivered a strong quarter of operating results and EPS, representing a solid start to 2011. We remain confident in our prospects for the quarters ahead and for our continued growth well into the future. Now Dave and I would like to open the lines for questions. Andrea?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Lisa Gill with JPMorgan",14,"[Operator Instructions] Your first question comes from the line of Lisa Gill with JPMorgan"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter, which includes the onetime benefit, is that correct?",37,"Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter, which includes the onetime benefit, is that correct?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That is correct. We expect it to be higher than the $0.91 we reported this quarter.",16,"That is correct. We expect it to be higher than the $0.91 we reported this quarter."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, great. And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offering, can you talk at all if -- what happened recently with CalPERS? Does that come up in the",91,"Okay, great. And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offering, can you talk at all if -- what happened recently with CalPERS? Does that come up in the conversation? Are people just looking beyond that and saying, ""Medco's got a great offering, and it's not having any impact on your selling season for 2012""? Any comments would be helpful. And then just lastly, if you can help us to understand the timing of FEP?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure. I'll answer a couple of pieces, and then I'll ask the guys who are out there everyday with the clients to answer another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty",271,"Sure. I'll answer a couple of pieces, and then I'll ask the guys who are out there everyday with the clients to answer another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty side of the business. And they're looking for new innovation and solutions there because it's -- the small molecule goes from brand -- generic, they're getting great relief. But they see where specialty is heading. That's where all the new brand innovation is occurring, and we're working with them on some, I think, exciting solutions for the future. And that's where a lot of the conversation goes when you talk about renewals and retention. When you look at FEPO, I will just tell you that we actually went back and look at what this timing was for announcement last time they went out the full RFP. And they're on schedule actually. When we looked at it last time, which is I think 5 years ago now, they didn't actually announced till late in the second quarter. And we didn't have invest -- we weren't able to tell investors where we - where that went until our second quarter call. So they may or may not be ahead of that schedule, but relative to previous years, they're on schedule and we still feel as though we have a very competitive offering there. Relative to your final question, Lisa, I'm going to ask Tim Wentworth and then Glenn Taylor to reflect their markets and the CalPERS situation. So, guys, why don't you go ahead."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We feel, in a nutshell, it's not been a significant topic of conversation. Once we got passed the first week and were able to file the points of the 8-K. It's not been a significant distraction. I don't think it's an issue to putting together a fabulous",162,"We feel, in a nutshell, it's not been a significant topic of conversation. Once we got passed the first week and were able to file the points of the 8-K. It's not been a significant distraction. I don't think it's an issue to putting together a fabulous  sales and retention year for us. When you look in the marketplace which include the states, where we you may have expected some sensitivity, plans their consolidations have significant challenges. They recognize the quality of our programs. They recognize the long standing integrity of our company. And most importantly, we've consistently delivered. When you take a look at the most recent awards that we're very pleased to get and the information of that publicly, there exact quote was they believe Medco provides high value cost-management programs, and they have a strong critical underpinning that sits under that. So we have had no issue. And in fact, I'm extraordinarily excited about what I see this year."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Lisa, this is Glenn Taylor. Says the 8-K and we were able to give a little more explanation. We've had about a 10-day news cycle, if you will, from the middle to the end of March. And that was that I haven't had a single conversation since March 31. In th",97,"Lisa, this is Glenn Taylor. Says the 8-K and we were able to give a little more explanation. We've had about a 10-day news cycle, if you will, from the middle to the end of March. And that was that I haven't had a single conversation since March 31. In that time, we've had 2 significant renewals, which we don't talk about and disclose individual contracts. We've had 2 fairly significant wins. So we're thinking we're in very good shape to have a very good selling season this year, and this issue is just not an issue."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Larry Marshall from Barclays Capital",13,"Your next question comes from the line of Larry Marshall from Barclays Capital"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a follow up to Lisa's question, maybe another add-on, which is around timing. Dave, obviously, when you're at healthcare conference, the report came out which, I thought, was very inflammatory, and you did disclose in the 8-K that clearly there's not",96,"Just a follow up to Lisa's question, maybe another add-on, which is around timing. Dave, obviously, when you're at healthcare conference, the report came out which, I thought, was very inflammatory, and you did disclose in the 8-K that clearly there's nothing that she's done wrong, [indiscernible] to do anything. But as you talked about, there's still a little bit of unnecessary uncertainty. Are you in a position at all to talk about when you like to be able to be clear about the position you have in the marketplace and the resolution of this?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I'm going to ask Tom Moriarty, our General Counsel. This is a legal matter and I'm going to have to [Iindiscernible] some thoughts, okay, Larry?",26,"Well, I'm going to ask Tom Moriarty, our General Counsel. This is a legal matter and I'm going to have to [Iindiscernible] some thoughts, okay, Larry?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure, Larry. I mean, as we said before, we're working with both the SEC and the California AG. We have been and will continue to voluntarily provide information. We very clearly are working to put this behind us, but I cannot predict with any real certain",91,"Sure, Larry. I mean, as we said before, we're working with both the SEC and the California AG. We have been and will continue to voluntarily provide information. We very clearly are working to put this behind us, but I cannot predict with any real certainty of the timing of that or the outcome. But as we've seen this quarter and as we go forward, we're going to remain very focused on our business and continue to drive value for our clients, and continue to work to put this behind us."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your for next question comes from the line of Ross Muken with Deutsche Bank.",14,"Your for next question comes from the line of Ross Muken with Deutsche Bank."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So in talking to the consultants, one of the things that consistently comes up this season, and it's come up in prior seasons, is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of a regu",113,"So in talking to the consultants, one of the things that consistently comes up this season, and it's come up in prior seasons, is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of a regular basis. As you think about sort of the key messaging in the upcoming season and where you really feel like you're kind of driving the biggest delta versus your peers, what for you is kind of the key focal points that's new and different versus the prior year? And what do you have, kind of, that you sort of talked about more recently on the pharmacogenomic front?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Let me talk about the things that I'm excited about and the things that have resonated in my conversations with clients. And then again I'll ask the Group Presidents to add anything that I don't cover. But for me, continuing to extend the consumer-driven",411,"Let me talk about the things that I'm excited about and the things that have resonated in my conversations with clients. And then again I'll ask the Group Presidents to add anything that I don't cover. But for me, continuing to extend the consumer-driven capabilities down to the individual consumers -- so, for example, expressing gaps in care and evidence-based protocols through our website in the layperson language, so the consumer can understand how to manage their care better and where their gap exists and how they're following their treatment protocol has been hugely powerful. And in fact, the gap in care closures we're getting on the self-help basis has been dramatic and growing, and I'm excited about that, both because it improves outcomes at lower cost, but also it's the least expensive way to close gaps in care because I don't need to do the labor-intensive pharmacist coaching each and every time. I'm also thrilled that we just recently launched the Medco's smart phone app with Verizon, available both in Android and BlackBerry version. These are really exciting apps and again get us to the next levels of influencing consumers in powerful ways that are clinically oriented, but also give them enormous financial information at the point of care with their doctor. And I think that that's something that is going to continue to propel better outcomes at lower costs through real clinical care and in complete communication among the parties involved for that care. And I like that. The other thing that isn't getting a lot of air time, and we've talked to all of you 2 times at 2 Analyst Day's, and I don't think people fully appreciate the power of it yet, but I guarantee you they will, if our investments and our efforts around what we call Medco 2.0 and the agile enterprise. The benefit that will bring to the competitive marketplace in go-forward years is incredible for me. It will unleash our ability to innovate in a quantum way. And I think we're going to take another attempt next Analyst Day to further explain how powerful this is, but that to me is what is really going to make a difference in how we take care of patients in a way and how we service our customers in a way no one else can. And I'm going to leave it there. I'll ask you guys, Tim and Glen, if you have anything to add."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think the only thing that I would really be going -- the application which we launched and we develop in concert with our client advisory group, and we launched it recently to them. And everyone of them is going to heavily promote the app to their membe",280,"I think the only thing that I would really be going -- the application which we launched and we develop in concert with our client advisory group, and we launched it recently to them. And everyone of them is going to heavily promote the app to their members, particularly once we get an iPhone application as well, which will be before the end of the second quarter. Huge in terms of the response to them, what that's going to enable in terms of the way we engage with our patients. But beyond that, I think the other big thing, Dave, are 2 things. One is our extended enterprise. We are continually being the leader at vendor summits that clients have to sit down with multiple points of care inside of their constellation, and being able to enable a greater level of connectivity than they can get by virtue of the way it goes in an unmanaged setting. So that's very powerful. And the fact that we can enabled that and bring to the table our open architecture, our patient health action plan and we can work that bidirectionally with these other caregivers is compelling. The third piece I would say is our strategy has been hugely successful. We have modeled over 50 clients in terms of looking at the value. We are installing a whole lot of them for '12, or '13 we think we have brought a level of value that is unparalleled in terms of both the member care for these clients want to continue to care for members and at the same time bring a significant financial changed to what it looks likes in terms of the."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree and say that every health plan and selling a 360 view of patient through research and review. While we can that on pharmacy side we need to integrate that with medical the lab et cetera. And that with the enterprise that we mentioned really",54,"I would agree and say that every health plan and selling a 360 view of patient through research and review. While we can that on pharmacy side we need to integrate that with medical the lab et cetera. And that with the enterprise that we mentioned really came of the dividends of our conversation."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So obviously, Ross, we lost that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going to have Dr. Epstein to talk about his world, both research, UBC and the things we'",132,"So obviously, Ross, we lost that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going to have Dr. Epstein to talk about his world, both research, UBC and the things we're doing that are resonating with clients there. I'm also going to ask Kenny if you can or have to talk about some of the innovations we're working on relative to physicians which we prepare for a comfortable care. Because I think that Health Care reform initiative is important. I think it again drives better outcomes and we think we can be a major enabler in that space. And maybe a brief comment on that related to that 2.0 might be helpful. So Rob?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","On the pharmacogenemics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer and they are selling very briefly, we have over 300 clients enrolled in multiple pharmacogenemics programs, representing about 12 millio",427,"On the pharmacogenemics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer and they are selling very briefly, we have over 300 clients enrolled in multiple pharmacogenemics programs, representing about 12 million of our lives. So it's really exciting, and they're really excited to take on new pharmacogenemics test which is new. These are trickier to do than the ones [indiscernible] so it's a real positive for us to be able to figure out how that gets on. Also, we've launched our new service which is kind of like a 1-800 number to call certified generic Health Care to get advice when you're newly diagnosed with any sort of  problem like cancer and that's actually traction event even when describing that new service. We've added a number of hospitals medical institute network including 1 in Canada, which is pretty exciting where we are arming hospitals around the country genomic information to make them certified Javon at the center. And in another area in genomic which is new for us it takes the intelligence around the with DNA Direct has and off of those as the policy health plan. You don't have their own technology assessment and we actually had a number of sales in that area because they're a real uplift for us. So all areas are inspiring. They're all new. On the research front, we have a dozen large multi patient going studies of which we'll complete this year. But you'll be hearing at the back half of the year some of the results of our very large prospective studies that have taken us into new areas including psychiatry that is not there before. So it's pretty exciting and the has been really excited about the work we're doing since no one else is doing it.On the UBC front, the synergy has been simply awesome. Since we announced the acquisition in September, we also launched the Medco Research Consortium, which any client interested in participating in the research, including BBC, we now have well over 100 clients representing 40 million of our lives in the consortium. And we now actually have clients participating in Pfizer competitive effect on these studies or safety studies are both and are the feedback has been really exciting. People love it The member love it. They like to be having the added protection of the safety in the particular type study. And so everything has been really excited for quarter for us and we're just really looking forward to ongoing events this year."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","To end what has been said, we view the area of health Information Technology is a really exciting space for us. 1 of the things that we're very excited when you think about in terms of extended enterprise and the broad portfolio of clinical capability is",199,"To end what has been said, we view the area of health Information Technology is a really exciting space for us. 1 of the things that we're very excited when you think about in terms of extended enterprise and the broad portfolio of clinical capability is the real game changer is to help get the Health Care system wire in the country, and 1 of the most powerful features of that is being able to help support the point of care where the patient and the physician interaction is at its most important. to be able to provide 360 degree insights to that point of care. We believe it improves the ability of the physician to make decisions and prescribing treatment, and also allows us to play the evidence based protocol that allows a sort of benchmark capital the activities that are happening. So I think you will see over the not too distant future an expanding portfolio of cloud computing based solutions to point of care, and it's also the mechanism we're going to be using to enable both the medical home care organization as well. So the wiring aspect that we think has a lot of potential."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of your shoe from Citigroup.",12,"Your next question comes from the line of your shoe from Citigroup."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","The increase in generic volumes in mail is pretty impressive this quarter. Given the lack in generic introductions, can you talk about what drove that?",25,"The increase in generic volumes in mail is pretty impressive this quarter. Given the lack in generic introductions, can you talk about what drove that?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes I'll mention a few things, and then Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an to effectively cost effective channel, and that mail is outstanding at driving generi",214,"Yes I'll mention a few things, and then Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an to effectively cost effective channel, and that mail is outstanding at driving generic expensing rates. So we have great benefit design support on part of our clients to drive this outcome, and I would also tell that the economy continues to aid the choice of generic. Because clearly when people are financially strapped, they say, ""Hey, I'd rather have less out of pocket expense,"" and then moving from brand to generic. And the interchange going on between brand and generic voluntary on the part of consumer to simply that they simply have to save some money has been incredibly strong. The final thing I've mention is that we have a team that's always working with clients to drive better generic results across the channel both mail and retail and we've come up with few new innovations that I don't choose to describe in great detail, but they've been very effective in improving mail choice and generic choices at mail. So we're actually feeling this as though this is a momentum thing that we can sustain for a while."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Understand to that, when you look into the significant products that like generic last year Flomax, Cozaar, Hyzaar, Effexor XR, those all have very high mail-order penetration rates in our book of business. You might recall that at Analyst Day, I pointed",135,"Understand to that, when you look into the significant products that like generic last year Flomax, Cozaar, Hyzaar, Effexor XR, those all have very high mail-order penetration rates in our book of business. You might recall that at Analyst Day, I pointed to them on average thing about 45% mail-order penetration, which is over 10 points higher book of business average. In addition, we continue to see significant share gains as volume increases for simvastatin. That continues to be the case. Of course, we pointed to that in the past as well. Lastly, I'll say that plan designs have been established recently perhaps more than ever before in support of step therapy programs. We're ultimately -- we are driving a very material savings for client and patients by starting them on the lower cost alternatives."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard",14,"[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess you confuse some people with sort of sequential ramp earlier this year, and know it seems it's a bit more than we might've expected some progress from Q1 into",95,"My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess you confuse some people with sort of sequential ramp earlier this year, and know it seems it's a bit more than we might've expected some progress from Q1 into Q2. And you're sort of flattening I guess, a little bit the steepness of the ramp throughout the year. So can you tell us what changed in the last couple that gives you a little bit more weight towards the first half as opposed to the second half?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter and obviously as we get deeper into the yearly you have a clear line of sight, and now obviously the second quarter is a up and I'm con",151,"Probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter and obviously as we get deeper into the yearly you have a clear line of sight, and now obviously the second quarter is a up and I'm confident at that this point with my current line of sight that it will be stronger than the first quarter. So the way I look at my -- really have to take advantage of the most current information and projecting the year on this company because it's not that easy to look out for 2, 3, 4 full quarters. So I'm very confident in the second quarter. What I'm saying is a continuation of what we've seen in the first. Strong mail, strong generic, continued competitiveness we've been going to our ability to achieve competitive purchasing discounts, significant level of efficiency across the board."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to add secondary players. Rich is right in terms of 1 of the big player. But I'm going to also add that we're very pleased with incrementally grow with enrollment fee we got with our Medicare PDP and I think that's heavily related to the 5 star",166,"I'm going to add secondary players. Rich is right in terms of 1 of the big player. But I'm going to also add that we're very pleased with incrementally grow with enrollment fee we got with our Medicare PDP and I think that's heavily related to the 5 star rating we got as a national PDP because many of the patients who are 65 plus and 50 PDPs go to the government's website and make their choice, and they look at the star rating as an important metric for making choice. So we had a nice surprise there relative to enrollment, which will present itself the members will stay members through the year. I would also say I'm extremely pleased in the rate of growth we're seeing at UBC. And at this point, out performing my original expectations, and I think it's sustainable. So there's some other players out there that are actually at an operating level contributing to our growing optimism for the year."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And may be just a follow there. You're talking about, Rich, mail generic being one of the bigger drivers. I guess, can you tell us where you sort of get factored in as you look at the second of the year relative to what we've seen in the first quarter? Is",97,"And may be just a follow there. You're talking about, Rich, mail generic being one of the bigger drivers. I guess, can you tell us where you sort of get factored in as you look at the second of the year relative to what we've seen in the first quarter? Is there is a chance that if these trends sustain themselves and your line of sight continues to improve with times that you could do a little bit more better or have your sort of got to higher expectations of what you factored into the second have?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see as the year progresses as we get closer to the middle of the year. So obviously, I'll give you further in our next quarter call.",78,"Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see as the year progresses as we get closer to the middle of the year. So obviously, I'll give you further in our next quarter call. But right now, we're delighted with where we are. Obviously, we're pleased to lap off the $0.03 in the bottom end of guidance. And just stay tuned."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of from Goldman Sachs.",11,"Your next question comes from the line of from Goldman Sachs."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","On the Lipitor, Dave, in pressing little hard on the litigation perspective to get a generic in earlier, we're going to get an update on that today. Question is, if that was the case and we saw a generic come earlier, should we be thinking about your $0.0",55,"On the Lipitor, Dave, in pressing little hard on the litigation perspective to get a generic in earlier, we're going to get an update on that today. Question is, if that was the case and we saw a generic come earlier, should we be thinking about your $0.03 per month contribution in any different way?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll ask Rich to take that, and then Tom, who's obviously the 1 who put together all our pharma  deals, if you have anything to add please feel free to...",31,"I'll ask Rich to take that, and then Tom, who's obviously the 1 who put together all our pharma  deals, if you have anything to add please feel free to..."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","As would just like to say that at this point, the probably the level there is probably quite low. Would you agree with that?",24,"As would just like to say that at this point, the probably the level there is probably quite low. Would you agree with that?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree with that.",5,"I would agree with that."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So ultimately from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before them but Tom...",36,"So ultimately from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before them but Tom..."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree more likely the day [indiscernible].",8,"I would agree more likely the day [indiscernible]."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?",27,"The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","As a matter of policy, we don't get into different sources. And get pushed at the profitability there with. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you.",48,"As a matter of policy, we don't get into different sources. And get pushed at the profitability there with. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Amanda Murphy with William Blair.",13,"Your next question comes from the line of Amanda Murphy with William Blair."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I had a question on Accredo . The revenue growth there seems to be inline with sort of what you've guided to. But has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind o",75,"I had a question on Accredo . The revenue growth there seems to be inline with sort of what you've guided to. But has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind of longer term and have you seen the gross margin line kind of normalize? Was there a little bit of an improvement over last quarter?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll give you ask Steve Fitzpatrick to give you some help on that question.",15,"I'll give you ask Steve Fitzpatrick to give you some help on that question."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's may be come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lots of opportunity as this proportion of the specialties on the medical side of t",112,"It's may be come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lots of opportunity as this proportion of the specialties on the medical side of the business, which we had historically been fairly effective in pulling over and we'll continue to drive that. Particularly as we package our capabilities, which are really unmatched in the market, and move forward to be a little more aggressive in the packaging [indiscernible]. We should continue to drive, not only our core specialty, which has driven a lot of our growth recently, but in the future [indiscernible]"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll add to just what Steve said. I think the infusion capabilities are real. Competitive assets that Medco uniquely have. But I would also say more broadly in the specialty space there's an enormous opportunity on the medical side of the specialty spend",145,"I'll add to just what Steve said. I think the infusion capabilities are real. Competitive assets that Medco uniquely have. But I would also say more broadly in the specialty space there's an enormous opportunity on the medical side of the specialty spend benefit and we're making great inroads there. I expect that to grow over time as we continue to build products that make that whole over from medical to drug management on the PBM side. More scalable so you know we technically double the size of Accredo  if we could get the biotech spend on the medical side of the business over the PMB side of the business. On top of that, there are 611 drugs in the pipeline of clinical Phase II and 3 on their way to FDA approval, which will create its own source of growth for our business."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would add From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but a Passive variability?",41,"I would add From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but a Passive variability?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then just one more on. Some other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that the sort of underlying prescription consumption standpoint?",38,"And then just one more on. Some other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that the sort of underlying prescription consumption standpoint?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I would say that we'll be issuing our joint term report soon and for last year, certainly with utilization increase call us about 2-plus percent. That trend is not changing so we are starting to see some since of that this year early. But we certainl",53,"Yes, I would say that we'll be issuing our joint term report soon and for last year, certainly with utilization increase call us about 2-plus percent. That trend is not changing so we are starting to see some since of that this year early. But we certainly aren't seeing any declines in utilization."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Helene Wolk with Stanford Bernstein.",13,"Your next question comes from the line of Helene Wolk with Stanford Bernstein."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a question around cost trends and understanding what you're seeing from a generic sourcing and Retail network fee perspective, both currency what you expected for the year.",29,"Just a question around cost trends and understanding what you're seeing from a generic sourcing and Retail network fee perspective, both currency what you expected for the year."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think as we've commented, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]",25,"I think as we've commented, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Saying from our Retail contracting perspective as well, we have the line of sight is the continued improvement on the broader procurement front across the channel.",26,"Saying from our Retail contracting perspective as well, we have the line of sight is the continued improvement on the broader procurement front across the channel."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And any sense of or help that you can provide in terms of the timing of the share, how should we think about the rest of the year unfolding?",29,"And any sense of or help that you can provide in terms of the timing of the share, how should we think about the rest of the year unfolding?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Obviously we're still at the $2 million level. The strongest quarter for repurchases is the first quarter  are expected to come down a little bit in the second quarter from the dollar value perspective. And that should flattened off in the back half of th",83,"Obviously we're still at the $2 million level. The strongest quarter for repurchases is the first quarter  are expected to come down a little bit in the second quarter from the dollar value perspective. And that should flattened off in the back half of the year. So you'll see us going do when from the $836 million the first quarter to some level probably north of $500 million in the second quarter and then even in the back half of the year."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your final question comes from of Ricky Goldwasser with Morgan Stanley.",12,"And your final question comes from of Ricky Goldwasser with Morgan Stanley."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3  manufactured in December?",33,"I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3  manufactured in December?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in $0.03 as we were when we brought up $0.03 several months ago.",44,"Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in $0.03 as we were when we brought up $0.03 several months ago."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then Dave, any update on the timing of United? Do still expect to hear any resolution at the around the full-time?",22,"And then Dave, any update on the timing of United? Do still expect to hear any resolution at the around the full-time?"
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to echo the comment of Steve Ansley he made on his earnings call. That this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I can't speculate a",95,"I'm going to echo the comment of Steve Ansley he made on his earnings call. That this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I can't speculate about what the outcome will be, but we are anticipating a process just as we've talked about before. There's nothing really new to add at this point. But my view is, there's always a strong possibility of future relationships when your current relationship is so fundamentally strong."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And I would know turn it over to our presentors for closing remarks.",13,"And I would know turn it over to our presentors for closing remarks."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day.",31,"Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day."
1541811,129808770,118992,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect.",14,"Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning. My name is Andrea, And I will be your conference operator today. At this time, I would like to Welcome everyone to the MedcoHealth Solutions First Quarter 2011 Earnings Call. [Operator Instructions] I would like to now turn the call over to",54,"Good morning. My name is Andrea, And I will be your conference operator today. At this time, I would like to Welcome everyone to the MedcoHealth Solutions First Quarter 2011 Earnings Call. [Operator Instructions] I would like to now turn the call over to Ms. Valerie Haertel. Ms. Haertel, you may begin your conference."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Andrea. Good morning, and thank you for joining us on Medco's first quarter 2011 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us",329,"Thank you, Andrea. Good morning, and thank you for joining us on Medco's first quarter 2011 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us for our question-and-answer session are: Kenny Klepper, President and Chief Operating Officer; Tom Moriarty, General Counsel, Secretary and President of Global Pharmaceutical Strategies; Steve Fitzpatrick, President of Accredo Health Group; Dr. Rob Epstein, President of Advanced Clinical Science and Research; Tim Wentworth, Group President of the Employer and Key Accounts; Glenn Taylor, Group President of Health Plans; and Mary Daschner, Group President of Government PBM. 
During the course of this call, we will make forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in our SEC filings. 
Copies of Medco's filings are available from the SEC, the Medco Investor Relations Department or the Medco website. Medco intends to use the Investor Relations section of its website as a means for disclosing material non-public information and for complying with these disclosure obligations under Regulation FD. The copyrights for the contents of this discussion and the written materials used on this earning call are owned by MedcoHealth Solutions, Inc. 2011. 
Slides to accompany our presentation, which detail our financial and operating results and the guidance discussed on this call, are currently available in the Events section of the Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-Q after the close of the market today. 
At this time, I would like to turn the call over to Dave Snow. Dave?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valerie, and thanks to all of you for joining us this morning. Today we're reporting strong first quarter 2011 earnings reflecting continuous success across our strategic growth drivers. Additionally, we are raising the midpoint of our full yea",812,"Thank you, Valerie, and thanks to all of you for joining us this morning. Today we're reporting strong first quarter 2011 earnings reflecting continuous success across our strategic growth drivers. Additionally, we are raising the midpoint of our full year 2011 EPS guidance range of -- for the first quarter, GAAP diluted earnings per share reached $0.80 representing 19.4% growth over first quarter 2010. Diluted earnings split per share, excluding all intangible amortization, our new pure cash EPS measure, reached $0.91, a 19.7% increase over first quarter 2010 equivalent. 
Even with ever growing volumes at the lower-priced generic drugs in our revenue mix, first quarter 2011 net revenues increased to a record of more than $17 billion representing 4.3% growth over the same period last year. Within our net revenues, service revenues grew 57.5% to a record $357.8 million fueled by our United BioSource acquisition and service revenue growth across the company. With respect to the operating metrics that contributed to our strong financial results. Total prescription volumes for first quarter 2011 adjusted to the difference in dates applied between retail and mail grew 2.1% to 244.3 million prescription. Importantly, mail-order prescriptions totaled 27.7 million, with generic mail-order volumes increasing a substantial 9.3% to a record $17.7 million prescription, even in a quarter where there were no contributions from new generics. Our first quarter 2011 overall generic dispensing rate rose 3.4 percentage point to a record 73.1%. And within that, our mail-order generic dispensing rate component increased 4.5 percentage points to a record 53.8%.
The year-over-year improvement in our overall generic dispensing rate drove record incremental savings to our clients and members of $1.1 billion for the quarter, as a growing number of members took advantage of this high-quality, more affordable alternative.
Moving on to our Specialty business, Accredo's performance remains strong, with record first quarter 2011 revenues of $3.1 billion, up 14.9%. Accredo's operating income rose 13.2% to a record $120.6 million. 
As an aside, Keith Fitzpatrick, who has served as President of Accredo since 2008, recently announced his retirement effective July 1.
We all thank Steve for his years of excellent service and wish him a very happy retirement. We have named Frank Sheehy, a 13-year Medco veteran, to succeed Steve on July 1 as Accredo's President. Frank also joins Medco's Executive Committee. Frank has an outstanding track record of business success and has earned some of the highest client and employee satisfaction ratings ever recorded in our company. Frank's deep understanding of our customers and their needs in the specialty drug space make him well suited to lead the Accredo  business as we continue to expand Accredo's capabilities through new innovations. 
On the 2012 sales front, while it is still too early in the 2012 selling season for the majority of our prospects who have finalized their decisions, we are very pleased with several significant early season wins. We remain confident in our well differentiated services and our strategic positioning in the marketplace. A good example of our differentiated service offerings is our Medicare business. For the quarter, our Medicare PDP grew 16% over first quarter 2010, driven by the national 5-star rating of excellence that was awarded to Medco. This 5-star rating was the first and only one to be awarded to any national PDP by CMS. 
For 2011 year-to-date, our annualized new-named sales remain at approximately $1.7 billion, and our net-new sales remain approximately $1.5 billion. We have now completed over 90% of our 2011 scheduled and early elective client renewals, up from the over 80% we reported on our fourth quarter call, and our 2011 year-to-date client retention rate remains at over 99%.
Turning to guidance. It is with confidence that we raise the midpoint of both our GAAP diluted EPS and our diluted EPS excluding all intangible amortization, reflecting the strength we are seeing, thus far, in our 2011 results. In addition, we are raising our GAAP diluted EPS range by $0.03 due to a lower-than-expected intangible amortization expense associated with our UBC asset, which Rich will discuss further. Our full year 2011 GAAP diluted EPS guidance increased to a range of $3.59 to $3.69, up from the previous range of $3.53 to $3.56, now reflecting a growth rate of 14% to 17% over 2010. Diluted earnings per share, excluding all intangible amortization is now expected to be in the range of $4.2 to $4.12, up from $3.99 to $4.12, now reflecting 13% to 16% growth over 2010 earnings per share. 
In summary, we remain focused on the fundamentals of our business, and are enthusiastic about our prospects for continued strong growth. Our ability to narrow guidance this early in the year serves to further fuel back enthusiasm. With that, I'll turn the call over to Rich Rubino, who will take you through the details of our first quarter 2011 financial and 2011 guidance. Rich?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. As Dave mentioned come first quarter EPS results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representing 19",1593,"Thank you, Dave. Good morning. As Dave mentioned come first quarter EPS results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representing 19.7% growth over the first quarter equivalent of $0.76. 
As we previously guided, first quarter 2011 EPS results include a planned $0.04 benefit associated with changes to the employee post-retirement health care benefit plan. Approximately 3/4 of which flowed to cost of sales and 1/4 to SG&A expense. 
Even when excluding net benefit, the GAAP EPS growth rate was 13.4% and the pure cash EPS growth rate was 14.5%. Our gross margin and EBITDA per adjusted script both grew with this onetime benefit is excluded. Total first quarter 2011 net revenues reached a record $17 billion, representing growth of 4.3% over first quarter 2010. Our product revenue grew 3.6%, reflecting our new business wins, as well as higher prices charged by brand name, pharmaceutical manufacturers, partially offset by a higher representation of lower-priced generics. 
Service revenue continues to be a very meaningful growth driver, increasing 57.5% over first quarter 2010. This strong performance reflects the service revenue contribution from UBC, which closed on September 16, 2010, as well as the expansion of our overall client base and our Medicare Part D service fees.
Turning to rebates, we earned a record $1.5 billion for the first quarter, an increase of 3.4% over the same period last year, even though we are dispensing fewer brand-name medication and more generics. This year-over-year growth is attributable to new client wins and continuous improvements with formulary contracting. Our first quarter 2011 rebate retention rate was 11.6% compared to 12.1% in the first quarter of 2010 as we continue to drive significant value to clients in a highly transparent manner. 
As Dave mentioned, mail-order volume remains strong as client and members continue to choose this lower cost and clinically effective service. In the first quarters 2011, our total mail-order prescription volume was $27.7 million. Within this, generic increased 9.3% to a record $17.7 million, while brand-name prescription volume decreased 9.1% to $10 million prescriptions. Our generic dispensing rate now increased a very substantial 450 basis points since first quarter 2010 to a new record of 63.8%. Based upon our current forecast, we are raising our 2011 mail-order volume guidance range to 108 million to 110 million, up from the previous 107 million to 109 million scripts. 
Our strong generic mail-order prescription volumes and our fee service gross margin meaningfully drove our first quarter consolidated gross margin, which increased 7.8% over first quarter 2010 to $1.07 billion. Our consolidated gross margin percentage of 6.3% for the quarter increased 20 basis points from the 6.1% in the first quarter 2010, including the strong first quarter 2011 generic mail-order prescription volume and growth in service margin. 
Selling, general and administrative expenses of $387.1 million for the first quarter increased over first quarter of 2010 by $36.5 million or 10.4%, including increased expenses associated with the addition of UBC, as well as higher professional fees and other expenses associated with strategic initiatives. Our total EBITDA for first quarter of 2011 reached $734.2 million, representing growth of 6.9%. EBITDA for adjusted prescription for the quarter increased 4.9% to $3.01. Our intangible amortization of $73.2 million in the first quarter 2011 increased 3.8% from $70.5 million in first quarter 2010, primarily reflecting the UBC intangible assets. The final purchase accounting valuation for the UBC acquisition resulted in a lower identified intangible asset value that we included in our previous GAAP EPS guidance. And therefore, overall intangible amortization expense for full year 2011 will be lower than originally guided by approximately $20 million.
Total amortization of intangibles for 2011 is now expected to be in the range of $280 million to $300 million compared to the previous guidance of $300 million to $320 million. The $20 million reduction in the range equates to the $0.03 improvement in our revised full year 2011 GAAP diluted EPS guidance.
Total net interest and other expense of $54.2 million for the first quarter of 2011 increased $14.9 million from the $39.3 million in first quarter 2010, primarily reflecting the new debt we added to finance the UBC acquisition last September. 
First quarter of 2011 effective tax rate was 40.1% compared to 39.8% in the first quarter 2010. We still expect the full year of 2011 effective tax rate to be approximately 39%. Net income for the quarter increased 3.9% to $333.1 million from the $320.5 million reported for the first quarter of 2010.
Moving on to share repurchases, during the first quarter of 2011, we repurchased 13.5 million shares for $836.6 million at an average per share cost of $62.23 through our pre-authorized trading plan. Of these repurchases, a total 6.4 million shares cost of $400 million have been repurchased under the new $3 billion plan authorized by Medco's Board of Directors on February 2. We expect to begin repurchasing shares again next week and anticipate repurchasing approximately $2 billion of shares during 2011, consistent with the detailed guidance we provided last November. 
As a result of our share repurchases and normal climate component, we closed the first quarter with a cash balance of $127 million. We expect our quarterly cash balances to increase over the course of this year. Our total debt for the first quarter remained consistent with fourth quarter 2010 of $5.0 billion.
Turning to our Specialty segment, as Dave already mentioned, Accredo achieved revenues of $3.1 billion and record operating income of $120.6 million for first quarter 2011. Accredo's gross margin percentage for the quarter was 6.6% compared to 7.1% first quarter 2010, reflecting the product, channel and new client mix effects to be experienced as 2010 progressed, which includes meaningful growth across the vast majority of Accredo's products. Sequentially, Accredo's gross margin percentage increased 10 basis points from the 6.5% reported in the fourth quarter 2010.
Moving on to Medicare, we continue to experience growth in our highly rated Medicare PDP. First quarter 2011, Medco's PDP revenues increased over 16% to nearly $440 million. As Dave explained, we are raising the midpoint of our 2011 EPS guidance for both GAAP and pure cash EPS measures, narrowing the range for the high-end to a $0.10 range from the previous $0.13 range, and additionally, increasing our full year GAAP diluted EPS by $0.03. The raising of the midpoint reflects strengthened fundamental operating earnings expectations for the year, while the $0.03 raise to full year GAAP diluted EPS is the function of the lower intangible amortization expense I mentioned earlier. 
Table 9 of our earnings release lays out the map very clearly. To briefly repeat our improved 2011 guidance, diluted GAAP EPS is now expected to grow 14% to 17% over 2010 in the range of $3.59 to $3.69. Pure cash EPS is now expected in the guidance range of $4.02 to $4.12, representing growth of 13% to 16% over the 2010 full year equivalent of $3.55.
Now I would like to take you through the detailed component of our 2011 guidance beginning with renewals. We continue to expect to renew approximately $15 billion of business in 2011, including schedule and early elective renewals, representing less than 1/4 of our business. As Dave mentioned, we now have over 90% of our 2011 renewals completed, up from the over 80% we recorded last quarter. As previously disclosed, approximately 75% of the 2011 renewal pricing already took effect in the first quarter of 2011, with the remainder expected primarily in the third quarter. At this point, we continue to expect 2012 renewals to be in the range of $16 billion to $17 billion, approximately 25% of our book. 
As you can see from our slides on the web, the majority of our detailed 2011 guidance component remain consistent with those we provided on our fourth quarter call. 2011, we continue to expect a $0.09 incremental contribution from new generics, $0.01 expected in the second quarter, $0.02 expected in the third quarter and $0.06 expected in the fourth quarter, $0.03 of which relates to Lipitor for the five-week month of December.  We continue to expect stability or year-over-year expansion in our gross margin percentage and EBITDA for adjusted script performance in 2011. 
Now I would like to walk you through some of the changes to our 2011 guidance components. As I briefly mentioned earlier, our mail-order prescription volumes for 2011 are now expected to be in the range of $108 million to $110 million, up from the previous range of $107 million to $109 million. SG&A expenses for 2011 are now expected to be approximately $1.7 billion, an improvement from the previously narrowed range of $1.7 billion to $1.75 billion. 
Now to give you some insights into the quarterly flow of earnings for 2011, we now expect EPS to improve progressively quarter-to-quarter, with the largest sequential improvement from third quarter to fourth quarter 2011. Our second quarter 2011 pure cash EPS is now expected to increase slightly over the first quarter 2011 EPS amount of $0.91. The percentage split in EPS between the first half and the second half of 2011 is now expected to be consistent with that experienced in 2010. 
In conclusion, we delivered a strong quarter of operating results and EPS, representing a solid start to 2011. We remain confident in our prospects for the quarters ahead and for our continued growth well into the future. Now Dave and I would like to open the lines for questions. Andrea?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Lisa Gill with JPMorgan",14,"[Operator Instructions] Your first question comes from the line of Lisa Gill with JPMorgan"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter, which includes the onetime benefit, is that correct?",37,"Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter, which includes the onetime benefit, is that correct?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That is correct. We expect it to be higher than the $0.91 we reported this quarter.",16,"That is correct. We expect it to be higher than the $0.91 we reported this quarter."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, great. And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offering, can you talk at all if -- what happened recently with CalPERS? Does that come up in the",91,"Okay, great. And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offering, can you talk at all if -- what happened recently with CalPERS? Does that come up in the conversation? Are people just looking beyond that and saying, ""Medco's got a great offering, and it's not having any impact on your selling season for 2012""? Any comments would be helpful. And then just lastly, if you can help us to understand the timing of FEP?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure. I'll answer a couple of pieces, and then I'll ask the guys who are out there everyday with the clients to answer another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty",271,"Sure. I'll answer a couple of pieces, and then I'll ask the guys who are out there everyday with the clients to answer another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty side of the business. And they're looking for new innovation and solutions there because it's -- the small molecule goes from brand -- generic, they're getting great relief. But they see where specialty is heading. That's where all the new brand innovation is occurring, and we're working with them on some, I think, exciting solutions for the future. And that's where a lot of the conversation goes when you talk about renewals and retention. When you look at FEPO, I will just tell you that we actually went back and look at what this timing was for announcement last time they went out the full RFP. And they're on schedule actually. When we looked at it last time, which is I think 5 years ago now, they didn't actually announced till late in the second quarter. And we didn't have invest -- we weren't able to tell investors where we - where that went until our second quarter call. So they may or may not be ahead of that schedule, but relative to previous years, they're on schedule and we still feel as though we have a very competitive offering there. Relative to your final question, Lisa, I'm going to ask Tim Wentworth and then Glenn Taylor to reflect their markets and the CalPERS situation. So, guys, why don't you go ahead."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We feel, in a nutshell, it's not been a significant topic of conversation. Once we got passed the first week and were able to file the points of the 8-K. It's not been a significant distraction. I don't think it's an issue to putting together a fabulous",162,"We feel, in a nutshell, it's not been a significant topic of conversation. Once we got passed the first week and were able to file the points of the 8-K. It's not been a significant distraction. I don't think it's an issue to putting together a fabulous  sales and retention year for us. When you look in the marketplace which include the states, where we you may have expected some sensitivity, plans their consolidations have significant challenges. They recognize the quality of our programs. They recognize the long standing integrity of our company. And most importantly, we've consistently delivered. When you take a look at the most recent awards that we're very pleased to get and the information of that publicly, there exact quote was they believe Medco provides high value cost-management programs, and they have a strong critical underpinning that sits under that. So we have had no issue. And in fact, I'm extraordinarily excited about what I see this year."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Lisa, this is Glenn Taylor. Tim's right since the 8-K and we were able to give a little bit more explanation. We've had about a 10-day news cycle, if you will, from the middle to the end of March. And that was that I haven't had a single conversation sinc",100,"Lisa, this is Glenn Taylor. Tim's right since the 8-K and we were able to give a little bit more explanation. We've had about a 10-day news cycle, if you will, from the middle to the end of March. And that was that I haven't had a single conversation since March 31. In that time, we've had 2 significant renewals, which we don't talk about and disclose individual contracts. We've had 2 fairly significant wins. So we're thinking we're in very good shape to have a very good selling season this year, and this issue is just not an issue."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Larry Marsh from Barclays Capital",13,"Your next question comes from the line of Larry Marsh from Barclays Capital"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a follow up to Lisa's question, maybe another add-on, which is around timing. Dave, obviously, when you're at healthcare conference, the report came out which, I thought, was very inflammatory, and you did disclose in the 8-K that clearly you see the",101,"Just a follow up to Lisa's question, maybe another add-on, which is around timing. Dave, obviously, when you're at healthcare conference, the report came out which, I thought, was very inflammatory, and you did disclose in the 8-K that clearly you see there's nothing that you've done wrong. You're not alleged to do anything wrong. But as you talked about, there's still a little bit of unnecessary uncertainty. Are you in a position at all to talk about when you like to be able to be clear about the position you have in the marketplace and the resolution of this?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I'm going to ask Tom Moriarty, our General Counsel. This is a legal matter and I'm going to have to [indiscernible] some thoughts, okay, Larry?",26,"Well, I'm going to ask Tom Moriarty, our General Counsel. This is a legal matter and I'm going to have to [indiscernible] some thoughts, okay, Larry?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure, Larry. I mean, as we said before, we're working with both the SEC and the California AG. We have been and will continue to voluntarily provide information. We very clearly are working to put this behind us, but I cannot predict with any real certain",91,"Sure, Larry. I mean, as we said before, we're working with both the SEC and the California AG. We have been and will continue to voluntarily provide information. We very clearly are working to put this behind us, but I cannot predict with any real certainty of the timing of that or the outcome. But as we've seen this quarter and as we go forward, we're going to remain very focused on our business and continue to drive value for our clients, and continue to work to put this behind us."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your for next question comes from the line of Ross Muken with Deutsche Bank.",14,"Your for next question comes from the line of Ross Muken with Deutsche Bank."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So in talking to the consultants, one of the things that consistently comes up this season, and it's come up in prior seasons, is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of a regu",113,"So in talking to the consultants, one of the things that consistently comes up this season, and it's come up in prior seasons, is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of a regular basis. As you think about sort of the key messaging in the upcoming season and where you really feel like you're kind of driving the biggest delta versus your peers, what for you is kind of the key focal points that's new and different versus the prior year? And what do you have, kind of, that you sort of talked about more recently on the pharmacogenomic front?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Let me talk about the things that I'm excited about and the things that have resonated in my conversations with clients. And then again I'll ask the Group Presidents to add anything that I don't cover. But for me, continuing to extend the consumer-driven",411,"Let me talk about the things that I'm excited about and the things that have resonated in my conversations with clients. And then again I'll ask the Group Presidents to add anything that I don't cover. But for me, continuing to extend the consumer-driven capabilities down to the individual consumers -- so, for example, expressing gaps in care and evidence-based protocols through our website in the layperson language, so the consumer can understand how to manage their care better and where their gap exists and how they're following their treatment protocol has been hugely powerful. And in fact, the gap in care closures we're getting on the self-help basis has been dramatic and growing, and I'm excited about that, both because it improves outcomes at lower cost, but also it's the least expensive way to close gaps in care because I don't need to do the labor-intensive pharmacist coaching each and every time. I'm also thrilled that we just recently launched the Medco's smart phone app with Verizon, available both in Android and BlackBerry version. These are really exciting apps and again get us to the next levels of influencing consumers in powerful ways that are clinically oriented, but also give them enormous financial information at the point of care with their doctor. And I think that that's something that is going to continue to propel better outcomes at lower costs through real clinical care and in complete communication among the parties involved for that care. And I like that. The other thing that isn't getting a lot of air time, and we've talked to all of you 2 times at 2 Analyst Day's, and I don't think people fully appreciate the power of it yet, but I guarantee you they will, if our investments and our efforts around what we call Medco 2.0 and the agile enterprise. The benefit that will bring to the competitive marketplace in go-forward years is incredible for me. It will unleash our ability to innovate in a quantum way. And I think we're going to take another attempt next Analyst Day to further explain how powerful this is, but that to me is what is really going to make a difference in how we take care of patients in a way and how we service our customers in a way no one else can. And I'm going to leave it there. I'll ask you guys, Tim and Glen, if you have anything to add."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think the only thing that I would really be going -- the application which we launched and we develop in concert with our client advisory group, and we launched it recently to them. And everyone of them is going to heavily promote the app to their membe",286,"I think the only thing that I would really be going -- the application which we launched and we develop in concert with our client advisory group, and we launched it recently to them. And everyone of them is going to heavily promote the app to their members, particularly once we get an iPhone application as well, which will be before the end of the second quarter. Huge in terms of the response to them, what that's going to enable in terms of the way we engage with our patients. But beyond that, I think the other big thing, Dave, are 2 things. One is our extended enterprise. We are continually being the leader at vendor summits that clients have to sit down with multiple points of care inside of their constellation, and being able to enable a greater level of connectivity than they can get by virtue of the way it goes in an unmanaged setting. So that's very powerful. And the fact that we can enabled that and bring to the table our open architecture, our patient health action plan and we can work that bidirectionally with these other caregivers is compelling. The third piece I would say is our EGWP strategy has been hugely successful. We have modeled over 50 clients in terms of looking at the value list. We are installing a whole lot of them for '12 or '13. And we think that we brought a level of value there that is unparalleled in terms of both the number care that these clients want to continue to care for the members and at the same time bringing it significant financial change to what it looks like in terms of providing that."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I would agree and say that every plan, health plan that I'm selling for a 360 view of patient through research and review. While we can provide that that on the pharmacy side, we need to integrate that in with what they're doing in the medical, the l",69,"Yes, I would agree and say that every plan, health plan that I'm selling for a 360 view of patient through research and review. While we can provide that that on the pharmacy side, we need to integrate that in with what they're doing in the medical, the lab et cetera. And that's what the extended enterprise that we mentioned is really paying off, big dividends in our conversation."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So obviously, Ross, we love that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going ask Dr. Epstein to talk about his world, both research, UBC and the things we're d",129,"So obviously, Ross, we love that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going ask Dr. Epstein to talk about his world, both research, UBC and the things we're doing that are resonating with clients there. I'm also going to ask Kenny if you can perhaps talk about some of the innovations we're working on relative to physicians stakeholders as we prepare for accountable comfortable care because I think that healthcare reform initiative is important. I think it again drives better clinical outcomes, and we think we can be a major enabler in that space. And maybe a brief comment on that related to 2.0 might be helpful. So, Rob?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","On the pharmacogenomics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer, and they are selling very briskly. We now have over 300 clients enrolled in multiple pharmacogenomics programs, representing about 12 m",448,"On the pharmacogenomics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer, and they are selling very briskly. We now have over 300 clients enrolled in multiple pharmacogenomics programs, representing about 12 million of our lives. So it's really exciting, and they're really excited to take on new pharmacogenomics tests which are new. These are trickier to do than -- the ones, they're not cheap [indiscernible] So it's a real positive for us to be able to figure out how to get that done. Also, we've launched our new service which is kind of like a 1-800 number to call certified genetic and get advice when you're newly diagnosed with any sort of  problem like cancer. And that's actually gotten a little traction even when we just started driving that new service. We've added a number of hospitals to our genomic medical institute network, including one in Canada, which is pretty exciting, where we are arming hospitals around the country with genomic information to make them certified genomic centers. And in another area in genomic which is new for us is to take the intelligence around  [ph] that DNA Direct has and offer those as the policy service health plan, who don't have their own technology equipment. And we've actually had a number of sales in that area since the beginning which has been a real uplift for us. So all areas are inspiring. They're all new. On the research front, we have a dozen large multi  [indiscernible] patient ongoing studies, several of which we'll complete this year. But you'll be hearing in the back half of the year some of the results that are very large prospective studies that has taken us into new areas including neuropsychiatry, where we have not been before. So it's pretty exciting. Actually, the scientific community has been really excited about the work we're doing since no one else is doing it.On the UBC front, the synergy has been simply awesome. Since we announced the acquisition at the end of September, we also launched the Medco Research Consortium, which is any client interested in participating in the research, including UBC. We now have well over 100 clients representing 40 million of our lives in the consortium. And we now actually have clients participating in  [indiscernible] studies or safety studies or both. And the early feedback has been really exciting. People love it. The members love it. They like the having the added protection of the safety in the particular type study. And so everything has been a real exciting first quarter for us, and we're just really looking forward to ongoing events this year."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Just to add to what's been said is we view the area of health Information Technology as a really exciting space for us. One of the things that we're very excited when you think in terms of extended enterprise and the broad portfolio of clinical capability",210,"Just to add to what's been said is we view the area of health Information Technology as a really exciting space for us. One of the things that we're very excited when you think in terms of extended enterprise and the broad portfolio of clinical capability is -- the real game changer is to help get the healthcare system wired in the country. And 1 of the most powerful features of that is being able to help support the point of care where the patient and the physician interaction is at its most important. To be able to provide this 360 degree insights to that point of care. We believe it improves the ability of the physician to make decisions and prescribing course of treatment and also allows us to place a set of evidence-based protocol that allows us to put a benchmark to the type of activities that are happening. So I think you will see over the not too distant future an expanding portfolio of cloud computing based solutions to point of care, and it's also the mechanism we're going to be using to enable both the medical home and Campbell Care Organization  [ph as well. So the wiring aspect, we think, has a lot of potential."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of George Hill with Citigroup.",12,"Your next question comes from the line of George Hill with Citigroup."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave and Rich, the increase in generic volumes in mail is pretty impressive this quarter given the lack of generic introductions. Can you talk about what drove that?",28,"Dave and Rich, the increase in generic volumes in mail is pretty impressive this quarter given the lack of generic introductions. Can you talk about what drove that?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes I'll mention a few things, and then, Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an incredible cost-effective channel, and that mail is outstanding at driving generic e",215,"Yes I'll mention a few things, and then, Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an incredible cost-effective channel, and that mail is outstanding at driving generic expensing rates. So we've had great benefit design support on the part of our clients to drive this outcome. And I would also tell you the economy continues to aid the choice of generics because clearly when people are financially strapped, they say, ""Hey, I'd rather have less out of pocket expense,"" and then moving from brands to generic. And the interchange that's going on between brand and generic voluntarily on the part of consumers is simply that I need to save some money has been incredibly strong. The final thing I've mentioned is that we have a team that always is working with clients to drive better generic expensing results across the channel, both mail and retail, and we've come up with a few new innovations that I don't choose to describe in great detail, but they've been very effective in improving mail choice and generic choices at mail. So we're actually feeling as though this is a momentum thing that we can sustain for a while."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll just add to that. Understand to that, when you look into the significant products that, like generic last year, Flomax, Cozaar, Hyzaar, Effexor XR, those all had very high mail-order penetration rates in our book of business. You might recall that at",140,"I'll just add to that. Understand to that, when you look into the significant products that, like generic last year, Flomax, Cozaar, Hyzaar, Effexor XR, those all had very high mail-order penetration rates in our book of business. You might recall that at Analyst Day, I pointed to them on average being about 45% mail-order penetration, which is probably 10 points higher book of business average. In addition, we continue to see significant share gains as volume increases for simvastatin. That continues to be the case. Of course, we pointed to that in the past as well. Lastly, I'll say that plan designs have been established recently perhaps more than ever before in support of step therapy programs. We're ultimately -- we are driving very material savings for clients and patients by starting them on the lower cost alternatives."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard",14,"[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess, you confuse some people with sort of sequential ramp earlier this year. And now it seems it's a little bit more than we might have expected with some progres",98,"My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess, you confuse some people with sort of sequential ramp earlier this year. And now it seems it's a little bit more than we might have expected with some progress from Q1 into Q2. And you're sort of flattening, I guess, a little bit the steepness of the ramp throughout the year. So can you tell us what changed in the last couple that gives you a little bit more weight towards the first half as opposed to the second half?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I can tell you probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter. And obviously as we get deeper into the year, we have a clearer line of sight. And now obviously the second quart",155,"Well, I can tell you probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter. And obviously as we get deeper into the year, we have a clearer line of sight. And now obviously the second quarter is upon us, and I'm confident, at that this point, with my current line of sight, that it will be stronger than the first quarter. So the way I look at my -- you really have to take advantage of the most current information in projecting the year on this company because it's not that easy to look out for 2, 3, 4 quarters. I'm very confident in the second quarter. What I'm seeing is a continuation of what we've seen in the first. Strong mail, strong generic, continued competitiveness with regards to our ability to achieve competitive purchasing discounts, significant level of business efficiency across the board."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to add a couple of secondary players. Rich is right in terms of one of the big player. But I would also add that we were very pleased with incrementally enrollment we got in our Medicare PDP. And I think that's heavily related to the 5-star rati",167,"I'm going to add a couple of secondary players. Rich is right in terms of one of the big player. But I would also add that we were very pleased with incrementally enrollment we got in our Medicare PDP. And I think that's heavily related to the 5-star rating we got as a national PDP because many of the patients who are 65 plus who picked these PDPs go to the government website to make their choice, and they look at the star rating as an important metric for making choice. So we had a nice surprise there relative to enrollment, which will sustain itself. The key members will stay members through the year. I would also say I'm extremely pleased in the rate of growth we're seeing at UBC. It's, and at this point, outperforming my original expectations, and I think it's sustainable. So there's some other players out there that are actually at an operating level contributing to our growing optimism for the year."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, great. And maybe just as a follow there. You're talking about, Rich, mail generics being one of the bigger drivers. I guess, can you tell us what you sort of get factored in as you look at the second of the year relative to what we've seen in the fi",99,"Okay, great. And maybe just as a follow there. You're talking about, Rich, mail generics being one of the bigger drivers. I guess, can you tell us what you sort of get factored in as you look at the second of the year relative to what we've seen in the first quarter? Is there a chance that if these trends sustain themselves and your line of sight continues to improve with times that you could do a little bit better or have you, sort of, got a little higher expectations than what you factored in in the second half?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see how the year progresses as we get closer to the middle of the year. So obviously, I'll give you further insight in our next quar",79,"Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see how the year progresses as we get closer to the middle of the year. So obviously, I'll give you further insight in our next quarter call, but right now, we're delighted with where we are. Obviously, we're pleased to lap off the $0.03 in the bottom end of guidance. And just stay tuned."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line Randall Stanicky with Goldman Sachs.",12,"Your next question comes from the line Randall Stanicky with Goldman Sachs."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","On the Lipitor, Dave, I'm sure you're aware of  [ph] pressing pretty hard from the litigation perspective to get a generic in earlier. And we're going to get an update on that today. Question is, if that was the case and we saw generics come earlier, shou",66,"On the Lipitor, Dave, I'm sure you're aware of  [ph] pressing pretty hard from the litigation perspective to get a generic in earlier. And we're going to get an update on that today. Question is, if that was the case and we saw generics come earlier, should we be thinking about your $0.03 per month contribution in any different way? And then I have one follow-up."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay,Randall, I'll ask Rich to take that, and then Tom, who's obviously the one who put together all our pharma deals. If you have anything to add, Tom, please feel free to...",33,"Okay,Randall, I'll ask Rich to take that, and then Tom, who's obviously the one who put together all our pharma deals. If you have anything to add, Tom, please feel free to..."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would just say that at this point, the probability level there is probably, I would think, quite low. Tom, would you agree with that?",25,"I would just say that at this point, the probability level there is probably, I would think, quite low. Tom, would you agree with that?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree with that.",5,"I would agree with that."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So ultimately, from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before then, but, Tom, why don't you try to...",41,"So ultimately, from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before then, but, Tom, why don't you try to..."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree with that. I think if you look at the scenario, it's looking more likely towards November date as a  [indiscernible] day.",24,"I would agree with that. I think if you look at the scenario, it's looking more likely towards November date as a  [indiscernible] day."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?",27,"The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Randall, as a matter of policy, we don't get into different sources and get pushed into probability therewith. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you",47,"Randall, as a matter of policy, we don't get into different sources and get pushed into probability therewith. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Amanda Murphy with William Blair.",13,"Your next question comes from the line of Amanda Murphy with William Blair."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I had a question on Accredo. The revenue growth there seems to be inline with sort of what you've guided to but it has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind",76,"I had a question on Accredo. The revenue growth there seems to be inline with sort of what you've guided to but it has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind of longer term? And have we seen the gross margin line kind of normalize? It was a little but of an improvement over last quarter."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay, I'll ask Steve Fitzpatrick to give you some help on that question.",13,"Okay, I'll ask Steve Fitzpatrick to give you some help on that question."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's maybe come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lots of opportunity as this proportion of the specialties spin is on the medical si",124,"It's maybe come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lots of opportunity as this proportion of the specialties spin is on the medical side of the business, which we had historically been fairly effective in pulling over, and we'll continue to drive that. Particularly as we package our infusion capabilities, which are really unmatched in the market, and move forward to be a little more aggressive in the packaging [indiscernible]. We should continue to drive, not only our core specialty, which has driven a lot of our growth recently, but in the future the infusion capability which is some of the higher margin benefits."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I'd add to what Steve has said. I think the infusion capabilities are real competitive assets that Medco uniquely has. But I would also say more broadly in the specialty space, there's an enormous opportunity on the medical side of the specialty spen",147,"Yes, I'd add to what Steve has said. I think the infusion capabilities are real competitive assets that Medco uniquely has. But I would also say more broadly in the specialty space, there's an enormous opportunity on the medical side of the specialty spend benefit. And we're making great inroads there. I expect that to grow over time as we continue to build the products that make that whole over from medical to drug management on the PBM side more scalable. So we technically could double the size of Accredo if we could get the biotech spend on some of the medical side of the business over to the PBM side of the business. On top of that, there are 611 drugs in the pipeline clinical Phase II and III on their way to FDA approval, which will create its own source of growth for our business."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would just add. From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but not massive variability.",42,"I would just add. From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but not massive variability."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, thanks. And then just one more on utilization. Some of the other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that just from an underlying prescri",43,"Okay, thanks. And then just one more on utilization. Some of the other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that just from an underlying prescription consumption standpoint?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I would say that we'll be issuing our drug term report soon. And for last year, certainly, we did see utilization increases, as I recall, of about 2-plus percent. That trend is not changing, so we are starting to see signs of that carrying into this",61,"Yes, I would say that we'll be issuing our drug term report soon. And for last year, certainly, we did see utilization increases, as I recall, of about 2-plus percent. That trend is not changing, so we are starting to see signs of that carrying into this as well a little early. But we certainly aren't seeing any declines in utilization."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Helene Wolk with Stanford Bernstein.",13,"Your next question comes from the line of Helene Wolk with Stanford Bernstein."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a question around cost trends and understanding what you're seeing from a generic sourcing and retail network fee perspective, both currently and what you expect for the year.",30,"Just a question around cost trends and understanding what you're seeing from a generic sourcing and retail network fee perspective, both currently and what you expect for the year."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay, Tom, you want to take that?",7,"Okay, Tom, you want to take that?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I think, as we've commented before, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]",26,"Well, I think, as we've commented before, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's the same from a retail contracting perspective as well. We have a line of sight into the continued improvement on the broader procurement front across channel.",28,"It's the same from a retail contracting perspective as well. We have a line of sight into the continued improvement on the broader procurement front across channel."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And any sense of or help that you can provide in terms of the timing of the share repurchases? How we should think about the rest of the year unfolding?",30,"And any sense of or help that you can provide in terms of the timing of the share repurchases? How we should think about the rest of the year unfolding?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Obviously, we're still at the $2 billion level. So the strongest quarter for repurchases is first quarter, but we expect it to come down a little bit in the second quarter from a dollar-value perspective. And then it should flatten off in the back half of",84,"Obviously, we're still at the $2 billion level. So the strongest quarter for repurchases is first quarter, but we expect it to come down a little bit in the second quarter from a dollar-value perspective. And then it should flatten off in the back half of the year. So you'll see us going down from the $836 million the first quarter to some level probably north of $500 million in the second quarter and then evens off in the back half of the year."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your final question comes from the line of Ricky Goldwasser with Morgan Stanley.",14,"And your final question comes from the line of Ricky Goldwasser with Morgan Stanley."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3 manufacturers in December?",33,"I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3 manufacturers in December?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in the $0.03 as we were when we brought up the $0.03 several months ago.",46,"Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in the $0.03 as we were when we brought up the $0.03 several months ago."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then, Dave, any update on the timing of United? Do still expect to hear any resolution at the around the fall time?",23,"And then, Dave, any update on the timing of United? Do still expect to hear any resolution at the around the fall time?"
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to echo the comment of Steve Hensley  [ph] that he made on his earnings call. And that this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I c",98,"I'm going to echo the comment of Steve Hensley  [ph] that he made on his earnings call. And that this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I can't speculate about what the outcome will be, but we are anticipating a process just as we've talked about before. There's nothing really new to add at this point. But my view is, there's always a strong possibility of future relationships when your current relationship is so fundamentally strong."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And I would now turn it back over to our presentors for closing remarks.",14,"And I would now turn it back over to our presentors for closing remarks."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day.",31,"Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day."
1541811,129808770,119062,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect.",14,"Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning. My name is Andrea, And I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions First Quarter 2011 Earnings Call. [Operator Instructions] I would like to now turn the call over to",54,"Good morning. My name is Andrea, And I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions First Quarter 2011 Earnings Call. [Operator Instructions] I would like to now turn the call over to Ms. Valerie Haertel. Ms. Haertel, you may begin your conference."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Andrea. Good morning, and thank you for joining us on Medco's first quarter 2011 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us",329,"Thank you, Andrea. Good morning, and thank you for joining us on Medco's first quarter 2011 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us for our question-and-answer session are: Kenny Klepper, President and Chief Operating Officer; Tom Moriarty, General Counsel, Secretary and President of Global Pharmaceutical Strategies; Steve Fitzpatrick, President of Accredo Health Group; Dr. Rob Epstein, President of Advanced Clinical Science and Research; Tim Wentworth, Group President of the Employer and Key Accounts; Glenn Taylor, Group President of Health Plans; and Mary Daschner, Group President of Government PBM. 
During the course of this call, we will make forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in our SEC filings. 
Copies of Medco's filings are available from the SEC, the Medco Investor Relations Department or the Medco website. Medco intends to use the Investor Relations section of its website as a means for disclosing material non-public information and for complying with these disclosure obligations under Regulation FC. The copyrights for the contents of this discussion and the written materials used on this earning call are owned by MedcoHealth Solutions, Inc. 2011. 
Slides to accompany our presentation, which detail our financial and operating results and the guidance discussed on this call, are currently available in the Events section of the Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-Q after the close of the market today. 
At this time, I would like to turn the call over to Dave Snow. Dave?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valerie, and thanks to all of you for joining us this morning. Today we're reporting strong first quarter 2011 earnings reflecting continuous success across our strategic growth drivers. Additionally, we are raising the midpoint of our full yea",821,"Thank you, Valerie, and thanks to all of you for joining us this morning. Today we're reporting strong first quarter 2011 earnings reflecting continuous success across our strategic growth drivers. Additionally, we are raising the midpoint of our full year 2011 EPS guidance range of -- for the first quarter, GAAP diluted earnings per share reached $0.80 representing 19.4% growth over first quarter 2010. Diluted earnings split per share, excluding all intangible amortization, our new pure cash EPS measure, reached $0.91, a 19.7% increase over first quarter 2010 equivalent. 
Even with ever growing volumes at the lower-priced generic drugs in our revenue mix, first quarter 2011 net revenues increased to a record of more than $17 billion representing 4.3% growth over the same period last year. Within our net revenues, service revenues grew 57.5% to a record $357.8 million fueled by our United BioSource acquisition and service revenue growth across the company. With the respect to the operating metrics that contributed to our strong financial results. Total prescription volumes for first quarter 2011 adjusted to the difference in dates applied between retail and mail grew 2.1% to 244.3 million prescription. Importantly, mail-order prescriptions totaled 27.7 million, with generic mail-order volumes increasing a substantial 9.3% to a record 17.7 million prescription, even in a quarter where there were no contributions from new generics. Our first quarter 2011 overall generic dispensing rate rose 3.4 percentage point to a record 73.1%. And within that, our mail-order generic dispensing rate component increased 4.5 percentage points to a record 53.8%.
The year-over-year improvement in our overall generic dispensing rate drove record incremental savings to our clients and members of $1.1 billion for the quarter, as a growing number of members took advantage of this high-quality, more affordable alternative.
Moving on to our Specialty business, Accredo's performance remains strong, with record first quarter 2011 revenues of $3.1 billion, up 14.9%. Accredo's operating income rose 13.2% to a record $120.6 million. 
As an aside, Keith Fitzpatrick, who has served as President of Accredo since 2008, recently announced his retirement effective July 1.
2008 recently announced his retirement effective July 1. We all thank Steve for his years of excellent service and wish him a very happy retirement. We have named Frank Sheehy, a 13-year Medco veteran, to succeed Steve on July 1 as Accredo's President. Frank also joins Medco's Executive Committee. Frank has an outstanding track record of business success and has earned some of the highest client and employee satisfaction ratings ever recorded in our company. Frank's deep understanding of our customers and their needs in the specialty drug space make him well suited to lead the Accredo  business as we continue to expand Accredo's capabilities through new innovations. 
On the 2012 sales front, while it is still too early in the 2012 selling season for the majority of our prospects who have finalized their decisions, we are very pleased with several significant early season wins. We remain confident in our well differentiated services and our strategic positioning in the marketplace. A good example of our differentiated service offerings is our Medicare business. For the quarter, our Medicare PDP grew 16% over first quarter 2010, driven by the national 5-star rating of excellence that was awarded to Medco. This 5-star rating was the first and only one to be awarded to any national PDP by CMS. 
For 2011 year-to-date, our annualized new-named sales remain at approximately $1.7 billion, and our net-new sales remain approximately $1.5 billion. We have now completed over 90% of our 2011 scheduled and early elective client renewals, up from the over 80% we reported on our fourth quarter call, and our 2011 year-to-date client retention rate remains at over 99%.
Turning to guidance. It is with confidence that we raise the midpoint of both our GAAP diluted EPS and our diluted EPS excluding all intangible amortization, reflecting the strength we are seeing, thus far, in our 2011 results. In addition, we are raising our GAAP diluted EPS range by $0.03 due to a lower-than-expected intangible amortization expense associated with our UBC asset, which Rich will discuss further. Our full year 2011 GAAP diluted EPS guidance increased to a range of $3.59 to $3.69, up from the previous range of $3.53 to $3.56, now reflecting a growth rate of 14% to 17% over 2010. Diluted earnings per share, excluding all intangible amortization is now expected to be in the range of $4.02
 to $4.12, up from $3.99 to $4.12, now reflecting 13% to 16% growth over 2010 earnings per share. 
In summary, we remain focused on the fundamentals of our business, and are enthusiastic about our prospects for continued strong growth. Our ability to narrow guidance this early in the year serves to further fuel that enthusiasm. With that, I'll turn the call over to Rich Rubino, who will take you through the details of our first quarter 2011 financial and 2011 guidance. Rich?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. As Dave mentioned come first quarter EPS results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representing 19",1595,"Thank you, Dave. Good morning. As Dave mentioned come first quarter EPS results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representing 19.7% growth over the first quarter equivalent of $0.76. 
As we previously guided, first quarter 2011 EPS results include a planned $0.04 benefit associated with changes to the employee post-retirement health care benefit plan. Approximately 3/4 of which flowed to cost of sales and 1/4 to SG&A expense. 
Even when excluding net benefit, the GAAP EPS growth rate was 13.4% and the pure cash EPS growth rate was 14.5%. Our gross margin and EBITDA per adjusted script both grew with this onetime benefit is excluded. Total first quarter 2011 net revenues reached a record $17 billion, representing growth of 4.3% over first quarter 2010. Our product revenue grew 3.6%, reflecting our new business wins, as well as higher prices charged by brand name, pharmaceutical manufacturers, partially offset by a higher representation of lower-priced generics. 
Service revenue continues to be a very meaningful growth driver, increasing 57.5% over first quarter 2010. This strong performance reflects the service revenue contribution from UBC, which closed on September 16, 2010, as well as the expansion of our overall client base and our Medicare Part D service fees.
Turning to rebates, we earned a record $1.5 billion for the first quarter, an increase of 3.4% over the same period last year, even though we are dispensing fewer brand-name medication and more generics. This year-over-year growth is attributable to new client wins and continuous improvements with formulary contracting. Our first quarter 2011 rebate retention rate was 11.6% compared to 12.1% in the first quarter of 2010 as we continue to drive significant value to clients in a highly transparent manner. 
As Dave mentioned, mail-order volume remains strong as clients and members continue to choose this lower cost and clinically effective service. In first quarters 2011, our total mail-order prescription volume was $27.7 million. Within this, generic prescription volumes increased 9.3% to a record 17.7 million, while brand-name prescription volume decreased 9.1% to 10 million prescriptions. Our generic dispensing rate has now increased a very substantial 450 basis points since first quarter 2010 to a new record of 63.8%. Based upon our current forecast, we are raising our 2011 mail-order volume guidance range to 108 million to 110 million, up from the previous 107 million to 109 million scripts. 
Our strong generic mail-order prescription volumes and our fee service gross margin, meaningfully drove our first quarter consolidated gross margin, which increased 7.8% over first quarter 2010 to $1.07 billion. Our consolidated gross margin percentage of 6.3% for the quarter increased 20 basis points from the 6.1% in the first quarter 2010, including the strong first quarter 2011 generic mail-order prescription volume and growth in service margin. 
Selling, general and administrative expenses of $387.1 million for the first quarter increased over first quarter of 2010 by $36.5 million or 10.4%, including increased expenses associated with the addition of UBC, as well as higher professional fees and other expenses associated with strategic initiatives. Our total EBITDA for first quarter of 2011 reached $734.2 million, representing growth of 6.9%. EBITDA for adjusted prescription for the quarter increased 4.9% to $3.01. Our intangible amortization of $73.2 million in the first quarter 2011 increased 3.8% from $70.5 million in first quarter 2010, primarily reflecting the UBC intangible assets. The final purchase accounting valuation for the UBC acquisition resulted in a lower identified intangible asset value that we included in our previous GAAP EPS guidance. And therefore, overall intangible amortization expense for full year 2011 will be lower than originally guided by approximately $20 million.
Total amortization of intangibles for 2011 is now expected to be in the range of $280 million to $300 million compared to the previous guidance of $300 million to $320 million. The $20 million reduction in the range equates to the $0.03 improvement in our revised full year 2011 GAAP diluted EPS guidance.
Total net interest and other expense of $54.2 million for the first quarter of 2011 increased $14.9 million from the $39.3 million in first quarter 2010, primarily reflecting the new debt we added to finance the UBC acquisition last September. 
First quarter of 2011 effective tax rate was 40.1% compared to 39.8% in the first quarter 2010. We still expect the full year of 2011 effective tax rate to be approximately 39%. Net income for the quarter increased 3.9% to $333.1 million from the $320.5 million reported for the first quarter of 2010.
Moving on to share repurchases. During the first quarter of 2011, we repurchased 13.5 million shares for $836.6 million at an average per share cost of $60.20, through our pre-authorized trading plan. Of these repurchases, a total 6.4 million shares, cost of $400 million, have been repurchased under the new $3 billion plan authorized by Medco's Board of Directors on February 2. We expect to begin repurchasing shares again next week and anticipate repurchasing approximately $2 billion in shares during 2011, consistent with the detailed guidance we provided last November. 
As a result of our share repurchases and normal climate component, we closed the first quarter with a cash balance of $127 million. We expect our quarterly cash balances to increase over the course of this year. Our total debt for the first quarter remained consistent with fourth quarter 2010 of $5.0 billion.
Turning to our Specialty segment, as Dave already mentioned, Accredo achieved revenues of $3.1 billion and record operating income of $120.6 million for first quarter 2011. Accredo's gross margin percentage for the quarter was 6.6% compared to 7.1% first quarter 2010, reflecting the product, channel and new client mix effects to be experienced as 2010 progressed, which includes meaningful growth across the vast majority of Accredo's products. Sequentially, Accredo's gross margin percentage increased 10 basis points from the 6.5% reported in the fourth quarter 2010.
Moving on to Medicare. We continue to experience growth in our highly rated Medicare PDP. First quarter 2011, Medco's PDP revenues increased over 16% to nearly $440 million. As Dave explained, we are raising the midpoint of our 2011 EPS guidance for both GAAP and pure cash EPS measures, narrowing the range for the high-end to a $0.10 range from the previous $0.13 range, and additionally, increasing our full year GAAP diluted EPS by $0.03. The raising of the midpoint reflects strengthened fundamental operating earnings expectations for the year, while the $0.03 raise to full year GAAP diluted EPS is the function of the lower intangible amortization expense I mentioned earlier. 
Table 9 of our earnings release lays out the math very clearly. To briefly repeat our improved 2011 guidance, diluted GAAP EPS is now expected to grow 14% to 17% over 2010 in the range of $3.59 to $3.69. Pure cash EPS is now expected in the guidance range of $4.02 to $4.12, representing growth of 13% to 16% over the 2010 full year equivalent of $3.55.
Now I would like to take you through the detailed component of our 2011 guidance beginning with renewals. We continue to expect to renew approximately $15 billion of business in 2011, including schedule and early elective renewals, representing less than 1/4 of our business. As Dave mentioned, we now have over 90% of our 2011 renewals completed, up from the over 80% we recorded last quarter. As previously disclosed, approximately 75% of the 2011 renewal pricing already took effect in the first quarter of 2011, with the remainder expected primarily in the third quarter. At this point, we continue to expect 2012 renewals to be in the range of $16 billion to $17 billion, approximately 25% of our book. 
As you can see from our slides on the web, the majority of our detailed 2011 guidance component remains consistent with those we provided on our fourth quarter call. 2011, we continue to expect a $0.09 incremental contribution from new generics, $0.01 expected in the second quarter, $0.02 expected in the third quarter and $0.06 expected in the fourth quarter, $0.03 of which relates to Lipitor for the five-week month of December.  We continue to expect stability or year-over-year expansion in our gross margin percentage and EBITDA for adjusted script performance in 2011. 
Now I would like to walk you through some of the changes to our 2011 guidance components. As I briefly mentioned earlier, our mail-order prescription volumes for 2011 are now expected to be in the range of $108 million to $110 million, up from the previous range of $107 million to $109 million. SG&A expenses for 2011 are now expected to be approximately $1.7 billion, an improvement from the previously narrowed range of $1.7 billion to $1.75 billion. 
Now to give you some insights into the quarterly flow of earnings for 2011, we now expect EPS to improve progressively quarter-to-quarter, with the largest sequential improvement from third quarter to fourth quarter 2011. Our second quarter 2011 pure cash EPS is now expected to increase slightly over the first quarter 2011 EPS amount of $0.91. The percentage split in EPS between the first half and the second half of 2011 is now expected to be consistent with that experienced in 2010. 
In conclusion, we delivered a strong quarter of operating results and EPS, representing a solid start to 2011. We remain confident in our prospects for the quarters ahead and for our continued growth well into the future. Now Dave and I would like to open the lines for questions. Andrea?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Lisa Gill with JPMorgan",14,"[Operator Instructions] Your first question comes from the line of Lisa Gill with JPMorgan"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter, which includes the onetime benefit, is that correct?",37,"Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter, which includes the onetime benefit, is that correct?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That is correct. We expect it to be higher than the $0.91 we reported this quarter.",16,"That is correct. We expect it to be higher than the $0.91 we reported this quarter."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, great. And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offering, can you talk at all if -- what's happened recently with CalPERS? Does that come up in t",91,"Okay, great. And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offering, can you talk at all if -- what's happened recently with CalPERS? Does that come up in the conversation? Are people just looking beyond that and saying, ""Medco's got a great offering, and it's not having any impact on your selling season for 2012""? Any comments would be helpful. And then just lastly, if you can help us to understand the timing of FEP?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure. I'll answer a couple of pieces, and then I'll ask the guys who are out there everyday with the clients to answer another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty",271,"Sure. I'll answer a couple of pieces, and then I'll ask the guys who are out there everyday with the clients to answer another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty side of the business. And they're looking for new innovation and solutions there because it's -- the small molecule goes from brand -- generic, they're getting great relief. But they see where specialty is heading. That's where all the new brand innovation is occurring, and we're working with them on some, I think, exciting solutions for the future. And that's where a lot of the conversation goes when you talk about renewals and retention. When you look at FEPO, I will just tell you that we actually went back and look at what this timing was for announcement last time they went out the full RFP. And they're on schedule actually. When we looked at it last time, which is I think 5 years ago now, they didn't actually announced till late in the second quarter. And we didn't have invest -- we weren't able to tell investors where we - where that went until our second quarter call. So they may or may not be ahead of that schedule, but relative to previous years, they're on schedule, and we still feel as though we have a very competitive offering there. Relative to your final question, Lisa, I'm going to ask Tim Wentworth and then Glenn Taylor to reflect their markets and the CalPERS situation. So, guys, why don't you go ahead."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We feel, in a nutshell, it's not been a significant topic of conversation. Once we got passed the first week and were able to file the points of the 8-K. It's not been a significant distraction. I don't think it's an issue to putting together a fabulous",165,"We feel, in a nutshell, it's not been a significant topic of conversation. Once we got passed the first week and were able to file the points of the 8-K. It's not been a significant distraction. I don't think it's an issue to putting together a fabulous  sales and retention year for us. When you look in the marketplace I am in, which include the states, where we you may have expected some sensitivity, plans, their consultants have significant challenges. They recognize the quality of our programs. They recognize the long standing integrity of our company. And most importantly, we've consistently delivered. When you take a look at the most recent awards that we're very pleased to get and the information that's out publicly, there exact quote was they believe Medco provides high value cost-management programs, and they have a strong critical underpinning that sits under that. So we have had no issue. And in fact, I'm extraordinarily excited about what I see this year."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Lisa, this is Glenn Taylor. Tim's right since the 8-K and we were able to give a little bit more explanation. We've had about a 10-day news cycle, if you will, from the middle to the end of March. And that was it. I haven't had a single conversation since",100,"Lisa, this is Glenn Taylor. Tim's right since the 8-K and we were able to give a little bit more explanation. We've had about a 10-day news cycle, if you will, from the middle to the end of March. And that was it. I haven't had a single conversation since March 31. In that time, we've had 2 significant renewals, which we don't talk about and disclose individual contracts. We've had 2 fairly significant wins. So we're thinking we're in very good shape to have a very good selling season this year, and this issue is just not an issue."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Larry Marsh from Barclays Capital.",13,"Your next question comes from the line of Larry Marsh from Barclays Capital."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a follow up to Lisa's question, maybe another add-on, which is around timing. Dave, obviously, when you're at healthcare conference, the Steptoe[ph] report came out which, I thought, was very inflammatory, and you did disclose in the 8-K that clearly",104,"Just a follow up to Lisa's question, maybe another add-on, which is around timing. Dave, obviously, when you're at healthcare conference, the Steptoe[ph] report came out which, I thought, was very inflammatory, and you did disclose in the 8-K that clearly you see there's nothing that you've done wrong. You're not alleged to do anything wrong. But as you talked about, there's still a little bit of this air of uncertainty. Are you in a position at all to talk about when you like to be able to be clear about the position you have in the marketplace and the resolution of this?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I'm going to ask Tom Moriarty, our General Counsel. This is a legal matter and I'm going to have to [indiscernible] some thoughts, okay, Larry?",26,"Well, I'm going to ask Tom Moriarty, our General Counsel. This is a legal matter and I'm going to have to [indiscernible] some thoughts, okay, Larry?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure, Larry. I mean, as we said before, we're working with both the SEC and the California AG. We have been and will continue to voluntarily provide information. We very clearly are working to put this behind us, but I cannot predict with any real certain",92,"Sure, Larry. I mean, as we said before, we're working with both the SEC and the California AG. We have been and will continue to voluntarily provide information. We very clearly are working to put this behind us, but I cannot predict with any real certainty of the timing of that or the outcome. But as we've seen in this quarter and as we go forward, we're going to remain very focused on our business and continue to drive value for our clients, and continue to work to put this behind us."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your for next question comes from the line of Ross Muken with Deutsche Bank.",14,"Your for next question comes from the line of Ross Muken with Deutsche Bank."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So in talking to the consultants, one of the things that consistently comes up this season, and it's come up in prior seasons, is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of a regu",113,"So in talking to the consultants, one of the things that consistently comes up this season, and it's come up in prior seasons, is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of a regular basis. As you think about sort of the key messaging in the upcoming season and where you really feel like you're kind of driving the biggest delta versus your peers, what for you is kind of the key focal points that's new and different versus the prior year? And what do you have, kind of, that you sort of talked about more recently on the pharmacogenomic front?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Let me talk about the things that I'm excited about and the things that have resonated in my conversations with clients. And then again I'll ask the Group Presidents to add anything that I don't cover. But for me, continuing to extend the consumer-driven",412,"Let me talk about the things that I'm excited about and the things that have resonated in my conversations with clients. And then again I'll ask the Group Presidents to add anything that I don't cover. But for me, continuing to extend the consumer-driven capabilities down to the individual consumers -- so, for example, expressing gaps in care and evidence-based protocols through our website in the layperson language, so the consumer can understand how to manage their care better and where their gap exists and how they're following their treatment protocol has been hugely powerful. And in fact, the gap in care closures we're getting on the self-help basis has been dramatic and growing, and I'm excited about that, both because it improves outcomes at lower cost, but also it's the least expensive way to close gaps in care because I don't need to do the labor-intensive pharmacist coaching each and every time. I'm also thrilled that we just recently launched the Medco's smart phone app with Verizon, available both in Android and BlackBerry version. These are really exciting apps and that again get us to the next levels of influencing consumers in powerful ways that are clinically oriented, but also give them enormous financial information at the point of care with their doctor. And I think that that's something that is going to continue to propel better outcomes at lower costs through real clinical care and in complete communication among the parties involved for that care. And I like that. The other thing that isn't getting a lot of air time, and we've talked to all of you 2 times at 2 Analyst Day's, and I don't think people fully appreciate the power of it yet, but I guarantee you they will, if our investments and our efforts around what we call Medco 2.0 and the agile enterprise. The benefit that will bring to the competitive marketplace in go-forward years is incredible to me. It will unleash our ability to innovate in a quantum way. And I think we're going to take another attempt next Analyst Day to further explain how powerful this is, but that to me is what is really going to make a difference in how we take care of patients in a way and how we service our customers in a way no one else can. And I'm going to leave it there. I'll ask you guys, Tim and Glen, if you have anything to add."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think the only thing that I would really point to besides the app, we launched, we actually developed in concert with our client advisory group, and we launched it recently to them. And everyone of them is going to heavily promote the app to their membe",286,"I think the only thing that I would really point to besides the app, we launched, we actually developed in concert with our client advisory group, and we launched it recently to them. And everyone of them is going to heavily promote the app to their members, particularly once we get an iPhone application as well, which will be before the end of the second quarter. Huge in terms of the response to them, what that's going to enable in terms of the way we engage with our patients. But beyond that, I think the other big thing, Dave, are 2 things. One is our extended enterprise. We are continually being the leader at vendor summits that clients have to sit down with multiple points of care inside of their constellation, and being able to enable a greater level of connectivity than they can get by virtue of the way it goes in an unmanaged setting. So that's very powerful. And the fact that we can enabled that and bring to the table our open architecture, our patient health action plan and we can work that bidirectionally with these other caregivers is compelling. The third piece I would say is our EGWP strategy has been hugely successful. We have modeled over 50 clients in terms of looking at the value that list. We are installing a whole lot of them for '12 or '13. And we think that we brought a level of value there that is unparalleled in terms of both the number care that these clients want to continue to care for the members and at the same time bring in significant financial change to what it looks like in terms of providing that."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I would agree and say that every plan, health plan that I'm selling is looking for a 360 degree view of the patient, a true 360 degree view. While we can provide that that on the pharmacy side, we need to integrate that in with what they're doing on",74,"Yes, I would agree and say that every plan, health plan that I'm selling is looking for a 360 degree view of the patient, a true 360 degree view. While we can provide that that on the pharmacy side, we need to integrate that in with what they're doing on the medical, the lab et cetera. And that with the extended enterprise that Tim mentioned is really paying off, big dividends in our conversation."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So obviously, Ross, we love that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going ask Dr. Epstein to talk about his world, both research, UBC and the things we're d",127,"So obviously, Ross, we love that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going ask Dr. Epstein to talk about his world, both research, UBC and the things we're doing that are resonating with clients there. I'm also going to ask Kenny if you could perhaps talk about some of the innovations we're working on relative to physicians stakeholders as we prepare for accountable care because I think that healthcare reform initiative is important. I think it again drives better clinical outcomes, and we think we can be a major enabler in that space. Maybe a brief comment on that related to 2.0 might be helpful. So, Rob?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","On the pharmacogenomics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer, and they are selling very briskly. We now have over 300 clients enrolled in multiple pharmacogenomics programs, representing about 12 m",455,"On the pharmacogenomics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer, and they are selling very briskly. We now have over 300 clients enrolled in multiple pharmacogenomics programs, representing about 12 million of our lives. So it's really exciting, and they're really excited to take on new pharmacogenomics tests which are new. These are trickier to do than the prior ones, they're not cheap [indiscernible] or blood tests. So it's a real positive for us to be able to figure out how to get that done. Also, we've launched our new service which is kind of like a 1-800 number to call certified genetic counselor to get advice when you're newly diagnosed with any sort of problem like cancer. And that's actually gotten a little traction even when we just started subscribing that new service. We've added a number of hospitals to our genomic medical institute network, including one in Canada, which is pretty exciting, where we are arming hospitals around the country with genomic information to make them certified genomic centers. And then in another area in genomic which is new for us is to take the intelligence around  [ph] that DNA Direct has and offer those as the policy service health plan, who don't have their own technology equipment. And we've actually had a number of sales in that area since the beginning which has been a real uplift for us. So all areas are inspiring. They're all new. On the research front, we have a dozen large multi  [indiscernible] patient ongoing studies, several of which we'll complete this year. But you'll be hearing in the back half of the year some of the results that are very large prospective studies that has taken us into new areas including neuropsychiatry, where we have not been before. So it's pretty exciting. Actually, the neuroscientific community has been really excited about the work we're doing since no one else is really doing it.On the UBC front, the synergy has just been simply awesome. Since we announced the acquisition at the end of September, we also launched the Medco Research Consortium, which is any client interested in participating in the research, including UBC. We now have well over 100 clients representing 40 million of our lives in the consortium. And we now actually have clients participating in  [indiscernible] studies or safety studies or both. And the early feedback has been really exciting. People love it. The members love it. They like the having the added protection of the safety in the particular type study. And so everything has been a real exciting first quarter for us, and we're just really looking forward to ongoing advances this year."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Just to add to what's been said is we view the area of health Information Technology as a really exciting space for us. One of the things that we're very excited about when you think in terms of extended enterprise and the broad portfolio of clinical capa",210,"Just to add to what's been said is we view the area of health Information Technology as a really exciting space for us. One of the things that we're very excited about when you think in terms of extended enterprise and the broad portfolio of clinical capability is -- the real game changer is to help get the healthcare system wired in the country. And 1 of the most powerful features of that is being able to help support the point of care where the patient and the physician interaction is at its most important. To be able to provide this 360 degree insights to that point of care. We believe it improves the ability of the physician to make decisions and prescribing course of treatment and also allows us to place a set of evidence-based protocol that allows us to put a benchmark to the type of activities that are happening. So I think you will see over the not too distant future an expanding portfolio of cloud computing-based solutions at point of care, and it's also the mechanism we're going to be using to enable both the medical home and Campbell Care Organization  [ph as well. So the wiring aspect, we think, has a lot of potential."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of George Hill with Citigroup.",12,"Your next question comes from the line of George Hill with Citigroup."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave and Rich, the increase in generic volumes in mail is pretty impressive this quarter given the lack of generic introductions. Can you talk about what drove that?",28,"Dave and Rich, the increase in generic volumes in mail is pretty impressive this quarter given the lack of generic introductions. Can you talk about what drove that?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes I'll mention a few things, and then, Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an incredible cost-effective channel, and that mail is outstanding at driving generic e",215,"Yes I'll mention a few things, and then, Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an incredible cost-effective channel, and that mail is outstanding at driving generic expensing rates. So we've had great benefit design support on the part of our clients to drive this outcome. And I would also tell you the economy continues to aid the choice of generics because clearly when people are financially strapped, they say, ""Hey, I'd rather have less out of pocket expense,"" and they're moving from brands to generic. And the interchange that's going on between brand and generic voluntarily on the part of consumers is simply that I need to save some money has been incredibly strong. The final thing I've mentioned is that we have a team that always is working with clients to drive better generic expensing results across the channel, both mail and retail, and we've come up with a few new innovations that I don't choose to describe in great detail, but they've been very effective in improving mail choice and generic choices at mail. So we're actually feeling as though this is a momentum thing that we can sustain for a while."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll just add to that. Now when you look into the significant products that went generic last year, Flomax, Cozaar, Hyzaar, Effexor XR, those all had very high mail-order penetration rates in our book of business. You might recall that at Analyst Day, I p",138,"I'll just add to that. Now when you look into the significant products that went generic last year, Flomax, Cozaar, Hyzaar, Effexor XR, those all had very high mail-order penetration rates in our book of business. You might recall that at Analyst Day, I pointed to them on average being about 45% mail-order penetration, which is probably 10 points higher book of business average. In addition, we continue to see significant share gains as volume increases for simvastatin. That continues to be the case. Of course, we pointed to that in the past as well. Lastly, I'll say that plan designs have been established recently perhaps more than ever before in support of step therapy programs. We're ultimately -- we are driving very material savings for clients and patients by starting them on the lower cost alternatives."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard",14,"[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess, what confuse some people with sort of sequential ramp earlier this year. And now it seems it's a little bit more than we might have expected with some progre",100,"My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess, what confuse some people with sort of sequential ramp earlier this year. And now it seems it's a little bit more than we might have expected with some progress from Q1 into Q2. And you're sort of flattening, I guess, a little bit the steepness of the ramp throughout the year. So can you tell us what changed in the last couple of months that gives you a little bit more weight towards the first half as opposed to the second half?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I can tell you probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter. And obviously as we get deeper into the year, we have a clearer line of sight. And now obviously the second quart",155,"Well, I can tell you probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter. And obviously as we get deeper into the year, we have a clearer line of sight. And now obviously the second quarter is upon us, and I'm confident, at that this point, with my current line of sight, that it will be stronger than the first quarter. So the way I look at my -- you really have to take advantage of the most current information in projecting the year on this company because it's not that easy to look out for 2, 3, 4 quarters. I'm very confident in the second quarter. What I'm seeing is a continuation of what we've seen in the first. Strong mail, strong generic, continued competitiveness with regards to our ability to achieve competitive purchasing discounts, significant level of business efficiency across the board."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to add a couple of secondary players. Rich is right in terms of one of the big player. But I would also add that we were very pleased with incrementally enrollment we got in our Medicare PDP. And I think that's heavily related to the 5-star rati",167,"I'm going to add a couple of secondary players. Rich is right in terms of one of the big player. But I would also add that we were very pleased with incrementally enrollment we got in our Medicare PDP. And I think that's heavily related to the 5-star rating we got as a national PDP because many of the patients who are 65 plus who picked these PDPs go to the government website to make their choice, and they look at the star rating as an important metric for making choice. So we had a nice surprise there relative to enrollment, which will sustain itself. The key members will stay members through the year. I would also say I'm extremely pleased in the rate of growth we're seeing at UBC. It's, and at this point, outperforming my original expectations, and I think it's sustainable. So there's some other players out there that are actually at an operating level contributing to our growing optimism for the year."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, great. And maybe just as a follow there. You're talking about, Rich, mail generics being one of the bigger drivers. I guess, can you tell us what you sort of get factored in as you look at the second of the year relative to what we've seen in the fi",96,"Okay, great. And maybe just as a follow there. You're talking about, Rich, mail generics being one of the bigger drivers. I guess, can you tell us what you sort of get factored in as you look at the second of the year relative to what we've seen in the first quarter? Is there a chance that if these trends sustain themselves and your line of sight continues to improve with times that you could do a little bit better or have you, sort of, got a little higher expectations already factored into the second half?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see how the year progresses as we get closer to the middle of the year. So obviously, I'll give you further insight in our next quar",79,"Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see how the year progresses as we get closer to the middle of the year. So obviously, I'll give you further insight in our next quarter call, but right now, we're delighted with where we are. Obviously, we're pleased to lop off the $0.03 in the bottom end of guidance. And just stay tuned."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line Randall Stanicky with Goldman Sachs.",12,"Your next question comes from the line Randall Stanicky with Goldman Sachs."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","On the Lipitor, Dave, I'm sure you're aware of  [ph] pressing pretty hard from the litigation perspective to get a generic in earlier. And we're going to get an update on that today. Question is, if that was the case and we saw generics come earlier, shou",66,"On the Lipitor, Dave, I'm sure you're aware of  [ph] pressing pretty hard from the litigation perspective to get a generic in earlier. And we're going to get an update on that today. Question is, if that was the case and we saw generics come earlier, should we be thinking about your $0.03 per month contribution in any different way? And then I have one follow-up."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay,Randall, I'll ask Rich to take that, and then Tom, who's obviously the one who put together all our pharma deals. If you have anything to add, Tom, please feel free to...",33,"Okay,Randall, I'll ask Rich to take that, and then Tom, who's obviously the one who put together all our pharma deals. If you have anything to add, Tom, please feel free to..."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would just say that at this point, the probability level there is probably, I would think, quite low. Tom, would you agree with that?",25,"I would just say that at this point, the probability level there is probably, I would think, quite low. Tom, would you agree with that?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree with that.",5,"I would agree with that."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So ultimately, from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before then, but, Tom, why don't you try to...",41,"So ultimately, from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before then, but, Tom, why don't you try to..."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree with that. I think if you look at the scenario, it's looking more likely towards November date as a  [indiscernible] day.",24,"I would agree with that. I think if you look at the scenario, it's looking more likely towards November date as a  [indiscernible] day."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?",27,"The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Randall, as a matter of policy, we don't get into different sources and get pushed into probability therewith. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you",47,"Randall, as a matter of policy, we don't get into different sources and get pushed into probability therewith. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Amanda Murphy with William Blair.",13,"Your next question comes from the line of Amanda Murphy with William Blair."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I had a question on Accredo. The revenue growth there seems to be inline with sort of what you've guided to but has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind of",75,"I had a question on Accredo. The revenue growth there seems to be inline with sort of what you've guided to but has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind of longer term? And have we seen the gross margin line kind of normalize? It was a little but of an improvement over last quarter."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay, I'll ask Steve Fitzpatrick to give you some help on that question.",13,"Okay, I'll ask Steve Fitzpatrick to give you some help on that question."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's maybe come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lot of opportunity as this proportion of the specialties spin is on the medical sid",124,"It's maybe come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lot of opportunity as this proportion of the specialties spin is on the medical side of the business, which we had historically been fairly effective in pulling over, and we'll continue to drive that. Particularly as we package our infusion capabilities, which are really unmatched in the market, and move forward to be a little more aggressive in the packaging [indiscernible]. We should continue to drive, not only our core specialty, which has driven a lot of our growth recently, but in the future the infusion capability which is some of the higher margin benefits."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I'd add to what Steve just said. I think the infusion capabilities are real competitive assets that Medco uniquely has. But I would also say more broadly in the specialty space, there's an enormous opportunity on the medical side of the specialty spe",146,"Yes, I'd add to what Steve just said. I think the infusion capabilities are real competitive assets that Medco uniquely has. But I would also say more broadly in the specialty space, there's an enormous opportunity on the medical side of the specialty spend benefit. And we're making great inroads there. I expect that to grow over time as we continue to build the products that make that whole over from medical to drug management on the PBM side more scalable. So we technically could double the size of Accredo if we could get the biotech spend that's on the medical side of the business over to the PBM side of the business. On top of that, there are 611 drugs in the pipeline clinical Phase II and III on their way to FDA approval, which will create its own source of growth for our business."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would just add. From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but not massive variability.",42,"I would just add. From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but not massive variability."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, thanks. And then just one more on utilization. Some of the other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that just from an underlying prescri",43,"Okay, thanks. And then just one more on utilization. Some of the other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that just from an underlying prescription consumption standpoint?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I would say that we'll be issuing our drug term report soon. And for last year, certainly, we did see utilization increases, as I recall, of about 2-plus percent. That trend is not changing, so we are starting to see signs of that carrying into this",62,"Yes, I would say that we'll be issuing our drug term report soon. And for last year, certainly, we did see utilization increases, as I recall, of about 2-plus percent. That trend is not changing, so we are starting to see signs of that carrying into this year as well a little early. But we certainly aren't seeing any declines in utilization."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Helene Wolk with Stanford Bernstein.",13,"Your next question comes from the line of Helene Wolk with Stanford Bernstein."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a question around cost trends and understanding what you're seeing from a generic sourcing and a retail network fee perspective, both currently and what you expect for the year.",31,"Just a question around cost trends and understanding what you're seeing from a generic sourcing and a retail network fee perspective, both currently and what you expect for the year."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay, Tom, you want to take that?",7,"Okay, Tom, you want to take that?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I think, as we've commented before, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]",26,"Well, I think, as we've commented before, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's the same from a retail contracting perspective as well. We have a line of sight into the continued improvement on the broader procurement front across channel.",28,"It's the same from a retail contracting perspective as well. We have a line of sight into the continued improvement on the broader procurement front across channel."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And any sense of or help that you can provide in terms of the timing of the share repos? How we should think about the rest of the year unfolding?",30,"And any sense of or help that you can provide in terms of the timing of the share repos? How we should think about the rest of the year unfolding?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Obviously, we're still at the $2 billion level. So the strongest quarter for repurchases is first quarter, but we expect it to come down a little bit in the second quarter from a dollar-value perspective. And then it should flatten off in the back half of",84,"Obviously, we're still at the $2 billion level. So the strongest quarter for repurchases is first quarter, but we expect it to come down a little bit in the second quarter from a dollar-value perspective. And then it should flatten off in the back half of the year. So you'll see us going down from the $836 million the first quarter to some level probably north of $500 million in the second quarter and then evens off in the back half of the year."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your final question comes from the line of Ricky Goldwasser with Morgan Stanley.",14,"And your final question comes from the line of Ricky Goldwasser with Morgan Stanley."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3 manufacturers in December?",33,"I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3 manufacturers in December?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in the $0.03 as we were when we brought up the $0.03 several months ago.",46,"Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in the $0.03 as we were when we brought up the $0.03 several months ago."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then, Dave, any update on the timing of United? Do still expect to hear any resolution at around the fall time?",22,"And then, Dave, any update on the timing of United? Do still expect to hear any resolution at around the fall time?"
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to echo the comment of Steve Hensley  [ph] that he made on his earnings call. And that this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I c",98,"I'm going to echo the comment of Steve Hensley  [ph] that he made on his earnings call. And that this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I can't speculate about what the outcome will be, but we are anticipating a process just as we've talked about before. There's nothing really new to add at this point. But my view is, there's always a strong possibility of future relationships when your current relationship is so fundamentally strong."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And I would now turn it back over to our presentors for closing remarks.",14,"And I would now turn it back over to our presentors for closing remarks."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day.",31,"Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day."
1541811,129808770,119224,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect.",14,"Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning. My name is Andrea, And I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions First Quarter 2011 Earnings Call. [Operator Instructions] I would like to now turn the call over to",54,"Good morning. My name is Andrea, And I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions First Quarter 2011 Earnings Call. [Operator Instructions] I would like to now turn the call over to Ms. Valerie Haertel. Ms. Haertel, you may begin your conference."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Andrea. Good morning, and thank you for joining us on Medco's first quarter 2011 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us",329,"Thank you, Andrea. Good morning, and thank you for joining us on Medco's first quarter 2011 earnings conference call. With me today as speakers are Dave Snow, Chairman and Chief Executive Officer; and Rich Rubino, Chief Financial Officer. Also joining us for our question-and-answer session are: Kenny Klepper, President and Chief Operating Officer; Tom Moriarty, General Counsel, Secretary and President of Global Pharmaceutical Strategies; Steve Fitzpatrick, President of Accredo Health Group; Dr. Rob Epstein, President of Advanced Clinical Science and Research; Tim Wentworth, Group President of the Employer and Key Accounts; Glenn Taylor, Group President of Health Plans; and Mary Daschner, Group President of Government PBM. 
During the course of this call, we will make forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in our SEC filings. 
Copies of Medco's filings are available from the SEC, the Medco Investor Relations Department or the Medco website. Medco intends to use the Investor Relations section of its website as a means for disclosing material non-public information and for complying with these disclosure obligations under Regulation FC. The copyrights for the contents of this discussion and the written materials used on this earning call are owned by MedcoHealth Solutions, Inc. 2011. 
Slides to accompany our presentation, which detail our financial and operating results and the guidance discussed on this call, are currently available in the Events section of the Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-Q after the close of the market today. 
At this time, I would like to turn the call over to Dave Snow. Dave?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valerie, and thanks to all of you for joining us this morning. Today we're reporting strong first quarter 2011 earnings reflecting continuous success across our strategic growth drivers. Additionally, we are raising the midpoint of our full yea",813,"Thank you, Valerie, and thanks to all of you for joining us this morning. Today we're reporting strong first quarter 2011 earnings reflecting continuous success across our strategic growth drivers. Additionally, we are raising the midpoint of our full year 2011 EPS guidance range of -- for the first quarter, GAAP diluted earnings per share reached $0.80 representing 19.4% growth over first quarter 2010. Diluted earnings split per share, excluding all intangible amortization, our new pure cash EPS measure, reached $0.91, a 19.7% increase over first quarter 2010 equivalent. 
Even with ever growing volumes at the lower-priced generic drugs in our revenue mix, first quarter 2011 net revenues increased to a record of more than $17 billion representing 4.3% growth over the same period last year. Within our net revenues, service revenues grew 57.5% to a record $357.8 million fueled by our United BioSource acquisition and service revenue growth across the company. With the respect to the operating metrics that contributed to our strong financial results. 
Total prescription volumes for first quarter 2011 adjusted to the difference in dates applied between retail and mail grew 2.1% to 244.3 million prescription. Importantly, mail-order prescriptions totaled 27.7 million, with generic mail-order volumes increasing a substantial 9.3% to a record 17.7 million prescription, even in a quarter where there were no contributions from new generics. Our first quarter 2011 overall generic dispensing rate rose 3.4 percentage point to a record 73.1%. And within that, our mail-order generic dispensing rate component increased 4.5 percentage points to a record 53.8%.
The year-over-year improvement in our overall generic dispensing rate drove record incremental savings to our clients and members of $1.1 billion for the quarter, as a growing number of members took advantage of this high-quality, more affordable alternative.
Moving on to our Specialty business, Accredo's performance remains strong, with record first quarter 2011 revenues of $3.1 billion, up 14.9%. Accredo's operating income rose 13.2% to a record $120.6 million. 
As an aside, Keith Fitzpatrick, who has served as President of Accredo since 2008, recently announced his retirement effective July 1. We all thank Steve for his years of excellent service and wish him a very happy retirement. We have named Frank Sheehy, a 13-year Medco veteran, to succeed Steve on July 1 as Accredo's President. Frank also joins Medco's Executive Committee. Frank has an outstanding track record of business success and has earned some of the highest client and employee satisfaction ratings ever recorded in our company. Frank's deep understanding of our customers and their needs in the specialty drug space make him well suited to lead the Accredo  business as we continue to expand Accredo's capabilities through new innovations. 
On the 2012 sales front, while it is still too early in the 2012 selling season for the majority of our prospects who have finalized their decisions, we are very pleased with several significant early season wins. We remain confident in our well differentiated services and our strategic positioning in the marketplace. A good example of our differentiated service offerings is our Medicare business. For the quarter, our Medicare PDP grew 16% over first quarter 2010, driven by the national 5-star rating of excellence that was awarded to Medco. This 5-star rating was the first and only one to be awarded to any national PDP by CMS. 
For 2011 year-to-date, our annualized new-named sales remain at approximately $1.7 billion, and our net-new sales remain approximately $1.5 billion. We have now completed over 90% of our 2011 scheduled and early elective client renewals, up from the over 80% we reported on our fourth quarter call, and our 2011 year-to-date client retention rate remains at over 99%.
Turning to guidance. It is with confidence that we raise the midpoint of both our GAAP diluted EPS and our diluted EPS excluding all intangible amortization, reflecting the strength we are seeing, thus far, in our 2011 results. In addition, we are raising our GAAP diluted EPS range by $0.03 due to a lower-than-expected intangible amortization expense associated with our UBC asset, which Rich will discuss further. Our full year 2011 GAAP diluted EPS guidance increased to a range of $3.59 to $3.69, up from the previous range of $3.53 to $3.56, now reflecting a growth rate of 14% to 17% over 2010. Diluted earnings per share, excluding all intangible amortization is now expected to be in the range of $4.02
 to $4.12, up from $3.99 to $4.12, now reflecting 13% to 16% growth over 2010 earnings per share. 
In summary, we remain focused on the fundamentals of our business, and are enthusiastic about our prospects for continued strong growth. Our ability to narrow guidance this early in the year serves to further fuel that enthusiasm. With that, I'll turn the call over to Rich Rubino, who will take you through the details of our first quarter 2011 financial and 2011 guidance. Rich?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. As Dave mentioned come first quarter EPS results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representing 19",1595,"Thank you, Dave. Good morning. As Dave mentioned come first quarter EPS results were strong with GAAP diluted EPS of $0.80 representing 19.4% growth over first quarter 2010 and diluted EPS excluding all of intangible amortization of $0.91, representing 19.7% growth over the first quarter equivalent of $0.76. 
As we previously guided, first quarter 2011 EPS results include a planned $0.04 benefit associated with changes to the employee post-retirement health care benefit plan. Approximately 3/4 of which flowed to cost of sales and 1/4 to SG&A expense. 
Even when excluding net benefit, the GAAP EPS growth rate was 13.4% and the pure cash EPS growth rate was 14.5%. Our gross margin and EBITDA per adjusted script both grew with this onetime benefit is excluded. Total first quarter 2011 net revenues reached a record $17 billion, representing growth of 4.3% over first quarter 2010. Our product revenue grew 3.6%, reflecting our new business wins, as well as higher prices charged by brand name, pharmaceutical manufacturers, partially offset by a higher representation of lower-priced generics. 
Service revenue continues to be a very meaningful growth driver, increasing 57.5% over first quarter 2010. This strong performance reflects the service revenue contribution from UBC, which closed on September 16, 2010, as well as the expansion of our overall client base and our Medicare Part D service fees.
Turning to rebates, we earned a record $1.5 billion for the first quarter, an increase of 3.4% over the same period last year, even though we are dispensing fewer brand-name medication and more generics. This year-over-year growth is attributable to new client wins and continuous improvements with formulary contracting. Our first quarter 2011 rebate retention rate was 11.6% compared to 12.1% in the first quarter of 2010 as we continue to drive significant value to clients in a highly transparent manner. 
As Dave mentioned, mail-order volume remains strong as clients and members continue to choose this lower cost and clinically effective service. In first quarters 2011, our total mail-order prescription volume was 27.7 million. Within this, generic prescription volumes increased 9.3% to a record 17.7 million, while brand-name prescription volume decreased 9.1% to 10 million prescriptions. Our generic dispensing rate has now increased a very substantial 450 basis points since first quarter 2010 to a new record of 63.8%. Based upon our current forecast, we are raising our 2011 mail-order volume guidance range to 108 million to 110 million, up from the previous 107 million to 109 million scripts. 
Our strong generic mail-order prescription volumes and our fee service gross margin, meaningfully drove our first quarter consolidated gross margin, which increased 7.8% over first quarter 2010 to $1.07 billion. Our consolidated gross margin percentage of 6.3% for the quarter increased 20 basis points from the 6.1% in the first quarter 2010, including the strong first quarter 2011 generic mail-order prescription volume and growth in service margin. 
Selling, general and administrative expenses of $387.1 million for the first quarter increased over first quarter of 2010 by $36.5 million or 10.4%, including increased expenses associated with the addition of UBC, as well as higher professional fees and other expenses associated with strategic initiatives. Our total EBITDA for first quarter of 2011 reached $734.2 million, representing growth of 6.9%. EBITDA for adjusted prescription for the quarter increased 4.9% to $3.01. 
Our intangible amortization of $73.2 million in the first quarter 2011 increased 3.8% from $70.5 million in first quarter 2010, primarily reflecting the UBC intangible assets. The final purchase accounting valuation for the UBC acquisition resulted in a lower identified intangible asset value that we included in our previous GAAP EPS guidance. And therefore, overall intangible amortization expense for full year 2011 will be lower than originally guided by approximately $20 million.
Total amortization of intangibles for 2011 is now expected to be in the range of $280 million to $300 million compared to the previous guidance of $300 million to $320 million. The $20 million reduction in the range equates to the $0.03 improvement in our revised full year 2011 GAAP diluted EPS guidance.
Total net interest and other expense of $54.2 million for the first quarter of 2011 increased $14.9 million from the $39.3 million in first quarter 2010, primarily reflecting the new debt we added to finance the UBC acquisition last September. 
First quarter of 2011 effective tax rate was 40.1% compared to 39.8% in the first quarter 2010. We still expect the full year of 2011 effective tax rate to be approximately 39%. Net income for the quarter increased 3.9% to $333.1 million from the $320.5 million reported for the first quarter of 2010.
Moving on to share repurchases. During the first quarter of 2011, we repurchased 13.5 million shares for $836.6 million at an average per share cost of $60.20, through our pre-authorized trading plan. Of these repurchases, a total 6.4 million shares, cost of $400 million, have been repurchased under the new $3 billion plan authorized by Medco's Board of Directors on February 2. We expect to begin repurchasing shares again next week and anticipate repurchasing approximately $2 billion in shares during 2011, consistent with the detailed guidance we provided last November. 
As a result of our share repurchases and normal climate component, we closed the first quarter with a cash balance of $127 million. We expect our quarterly cash balances to increase over the course of this year. Our total debt for the first quarter remained consistent with fourth quarter 2010 of $5.0 billion.
Turning to our Specialty segment, as Dave already mentioned, Accredo achieved revenues of $3.1 billion and record operating income of $120.6 million for first quarter 2011. Accredo's gross margin percentage for the quarter was 6.6% compared to 7.1% first quarter 2010, reflecting the product, channel and new client mix effects to be experienced as 2010 progressed, which includes meaningful growth across the vast majority of Accredo's products. Sequentially, Accredo's gross margin percentage increased 10 basis points from the 6.5% reported in the fourth quarter 2010.
Moving on to Medicare. We continue to experience growth in our highly rated Medicare PDP. First quarter 2011, Medco's PDP revenues increased over 16% to nearly $440 million. As Dave explained, we are raising the midpoint of our 2011 EPS guidance for both GAAP and pure cash EPS measures, narrowing the range for the high-end to a $0.10 range from the previous $0.13 range, and additionally, increasing our full year GAAP diluted EPS by $0.03. The raising of the midpoint reflects strengthened fundamental operating earnings expectations for the year, while the $0.03 raise to full year GAAP diluted EPS is the function of the lower intangible amortization expense I mentioned earlier. 
Table 9 of our earnings release lays out the math very clearly. To briefly repeat our improved 2011 guidance, diluted GAAP EPS is now expected to grow 14% to 17% over 2010 in the range of $3.59 to $3.69. Pure cash EPS is now expected in the guidance range of $4.02 to $4.12, representing growth of 13% to 16% over the 2010 full year equivalent of $3.55.
Now I would like to take you through the detailed component of our 2011 guidance beginning with renewals. We continue to expect to renew approximately $15 billion of business in 2011, including schedule and early elective renewals, representing less than 1/4 of our business. As Dave mentioned, we now have over 90% of our 2011 renewals completed, up from the over 80% we recorded last quarter. As previously disclosed, approximately 75% of the 2011 renewal pricing already took effect in the first quarter of 2011, with the remainder expected primarily in the third quarter. At this point, we continue to expect 2012 renewals to be in the range of $16 billion to $17 billion, approximately 25% of our book. 
As you can see from our slides on the web, the majority of our detailed 2011 guidance component remains consistent with those we provided on our fourth quarter call. 2011, we continue to expect a $0.09 incremental contribution from new generics, $0.01 expected in the second quarter, $0.02 expected in the third quarter and $0.06 expected in the fourth quarter, $0.03 of which relates to Lipitor for the five-week month of December.  We continue to expect stability or year-over-year expansion in our gross margin percentage and EBITDA for adjusted script performance in 2011. 
Now I would like to walk you through some of the changes to our 2011 guidance components. As I briefly mentioned earlier, our mail-order prescription volumes for 2011 are now expected to be in the range of $108 million to $110 million, up from the previous range of $107 million to $109 million. SG&A expenses for 2011 are now expected to be approximately $1.7 billion, an improvement from the previously narrowed range of $1.7 billion to $1.75 billion. 
Now to give you some insights into the quarterly flow of earnings for 2011, we now expect EPS to improve progressively quarter-to-quarter, with the largest sequential improvement from third quarter to fourth quarter 2011. Our second quarter 2011 pure cash EPS is now expected to increase slightly over the first quarter 2011 EPS amount of $0.91. The percentage split in EPS between the first half and the second half of 2011 is now expected to be consistent with that experienced in 2010. 
In conclusion, we delivered a strong quarter of operating results and EPS, representing a solid start to 2011. We remain confident in our prospects for the quarters ahead and for our continued growth well into the future. Now Dave and I would like to open the lines for questions. Andrea?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Lisa Gill with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Lisa Gill with JPMorgan."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter, which includes the onetime benefit, is that correct?",37,"Rich, just first a clarification. When you talk about the second quarter being up from the first quarter, you're talking about the actual number that you reported this quarter, which includes the onetime benefit, is that correct?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That is correct. We expect it to be higher than the $0.91 we reported this quarter.",16,"That is correct. We expect it to be higher than the $0.91 we reported this quarter."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, great. And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offering, can you talk at all if -- what's happened recently with CalPERS? Does that come up in t",91,"Okay, great. And then just secondly, as you think about 2012, Dave, and you think about what customers are looking for, you talked about your  differentiated offering, can you talk at all if -- what's happened recently with CalPERS? Does that come up in the conversation? Are people just looking beyond that and saying, ""Medco's got a great offering, and it's not having any impact on your selling season for 2012""? Any comments would be helpful. And then just lastly, if you can help us to understand the timing of FEP?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure. I'll answer a couple of pieces, and then I'll ask the guys who are out there every day with the clients to answer another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty",272,"Sure. I'll answer a couple of pieces, and then I'll ask the guys who are out there every day with the clients to answer another piece. But what our clients are most focused on in 2012 and beyond that is really the rate of increase in cost on the specialty side of the business. And they're looking for new innovation and solutions there because it's -- the small molecule goes from brand -- generic, they're getting great relief. But they see where specialty is heading. That's where all the new brand innovation is occurring, and we're working with them on some, I think, exciting solutions for the future. And that's where a lot of the conversation goes when you talk about renewals and retention. When you look at FEPO, I will just tell you that we actually went back and look at what this timing was for announcement last time they went out the full RFP. And they're on schedule actually. When we looked at it last time, which is I think 5 years ago now, they didn't actually announced till late in the second quarter. And we didn't have invest -- we weren't able to tell investors where we - where that went until our second quarter call. So they may or may not be ahead of that schedule, but relative to previous years, they're on schedule, and we still feel as though we have a very competitive offering there. Relative to your final question, Lisa, I'm going to ask Tim Wentworth and then Glenn Taylor to reflect their markets and the CalPERS situation. So, guys, why don't you go ahead."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We feel, in a nutshell, it's not been a significant topic of conversation. Once we got passed the first week and were able to file the points of the 8-K. It's not been a significant distraction. I don't think it's an issue to putting together a fabulous",165,"We feel, in a nutshell, it's not been a significant topic of conversation. Once we got passed the first week and were able to file the points of the 8-K. It's not been a significant distraction. I don't think it's an issue to putting together a fabulous  sales and retention year for us. When you look in the marketplace I am in, which include the states, where we you may have expected some sensitivity, plans, their consultants have significant challenges. They recognize the quality of our programs. They recognize the long standing integrity of our company. And most importantly, we've consistently delivered. When you take a look at the most recent awards that we're very pleased to get and the information that's out publicly, there exact quote was they believe Medco provides high value cost-management programs, and they have a strong critical underpinning that sits under that. So we have had no issue. And in fact, I'm extraordinarily excited about what I see this year."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Lisa, this is Glenn Taylor. Tim's right since the 8-K and we were able to give a little bit more explanation. We've had about a 10-day news cycle, if you will, from the middle to the end of March. And that was it. I haven't had a single conversation since",100,"Lisa, this is Glenn Taylor. Tim's right since the 8-K and we were able to give a little bit more explanation. We've had about a 10-day news cycle, if you will, from the middle to the end of March. And that was it. I haven't had a single conversation since March 31. In that time, we've had 2 significant renewals, which we don't talk about and disclose individual contracts. We've had 2 fairly significant wins. So we're thinking we're in very good shape to have a very good selling season this year, and this issue is just not an issue."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Larry Marsh from Barclays Capital.",13,"Your next question comes from the line of Larry Marsh from Barclays Capital."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a follow up to Lisa's question, maybe another add-on, which is around timing. Dave, obviously, when you're at healthcare conference, the Steptoe[ph] report came out which, I thought, was very inflammatory, and you did disclose in the 8-K that clearly",104,"Just a follow up to Lisa's question, maybe another add-on, which is around timing. Dave, obviously, when you're at healthcare conference, the Steptoe[ph] report came out which, I thought, was very inflammatory, and you did disclose in the 8-K that clearly you see there's nothing that you've done wrong. You're not alleged to do anything wrong. But as you talked about, there's still a little bit of this air of uncertainty. Are you in a position at all to talk about when you like to be able to be clear about the position you have in the marketplace and the resolution of this?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I'm going to ask Tom Moriarty, our General Counsel. This is a legal matter and I'm going to have to [indiscernible] some thoughts, okay, Larry?",26,"Well, I'm going to ask Tom Moriarty, our General Counsel. This is a legal matter and I'm going to have to [indiscernible] some thoughts, okay, Larry?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure, Larry. I mean, as we said before, we're working with both the SEC and the California AG. We have been and will continue to voluntarily provide information. We very clearly are working to put this behind us, but I cannot predict with any real certain",92,"Sure, Larry. I mean, as we said before, we're working with both the SEC and the California AG. We have been and will continue to voluntarily provide information. We very clearly are working to put this behind us, but I cannot predict with any real certainty of the timing of that or the outcome. But as we've seen in this quarter and as we go forward, we're going to remain very focused on our business and continue to drive value for our clients, and continue to work to put this behind us."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your for next question comes from the line of Ross Muken with Deutsche Bank.",14,"Your for next question comes from the line of Ross Muken with Deutsche Bank."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So in talking to the consultants, one of the things that consistently comes up this season, and it's come up in prior seasons, is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of a regu",113,"So in talking to the consultants, one of the things that consistently comes up this season, and it's come up in prior seasons, is sort of your differentiated clinical offering and sort of the distance you put versus the competition there on sort of a regular basis. As you think about sort of the key messaging in the upcoming season and where you really feel like you're kind of driving the biggest delta versus your peers, what for you is kind of the key focal points that's new and different versus the prior year? And what do you have, kind of, that you sort of talked about more recently on the pharmacogenomic front?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Let me talk about the things that I'm excited about and the things that have resonated in my conversations with clients. And then again I'll ask the Group Presidents to add anything that I don't cover. But for me, continuing to extend the consumer-driven",412,"Let me talk about the things that I'm excited about and the things that have resonated in my conversations with clients. And then again I'll ask the Group Presidents to add anything that I don't cover. But for me, continuing to extend the consumer-driven capabilities down to the individual consumers -- so, for example, expressing gaps in care and evidence-based protocols through our website in the layperson language, so the consumer can understand how to manage their care better and where their gap exists and how they're following their treatment protocol has been hugely powerful. And in fact, the gap in care closures we're getting on the self-help basis has been dramatic and growing, and I'm excited about that, both because it improves outcomes at lower cost, but also it's the least expensive way to close gaps in care because I don't need to do the labor-intensive pharmacist coaching each and every time. I'm also thrilled that we just recently launched the Medco's smart phone app with Verizon, available both in Android and BlackBerry version. These are really exciting apps and that again get us to the next levels of influencing consumers in powerful ways that are clinically oriented, but also give them enormous financial information at the point of care with their doctor. And I think that that's something that is going to continue to propel better outcomes at lower costs through real clinical care and in complete communication among the parties involved for that care. And I like that. The other thing that isn't getting a lot of air time, and we've talked to all of you 2 times at 2 Analyst Day's, and I don't think people fully appreciate the power of it yet, but I guarantee you they will, if our investments and our efforts around what we call Medco 2.0 and the agile enterprise. The benefit that will bring to the competitive marketplace in go-forward years is incredible to me. It will unleash our ability to innovate in a quantum way. And I think we're going to take another attempt next Analyst Day to further explain how powerful this is, but that to me is what is really going to make a difference in how we take care of patients in a way and how we service our customers in a way no one else can. And I'm going to leave it there. I'll ask you guys, Tim and Glen, if you have anything to add."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think the only thing that I would really point to besides the app, we launched, we actually developed in concert with our client advisory group, and we launched it recently to them. And everyone of them is going to heavily promote the app to their membe",286,"I think the only thing that I would really point to besides the app, we launched, we actually developed in concert with our client advisory group, and we launched it recently to them. And everyone of them is going to heavily promote the app to their members, particularly once we get an iPhone application as well, which will be before the end of the second quarter. Huge in terms of the response to them, what that's going to enable in terms of the way we engage with our patients. But beyond that, I think the other big thing, Dave, are 2 things. One is our extended enterprise. We are continually being the leader at vendor summits that clients have to sit down with multiple points of care inside of their constellation, and being able to enable a greater level of connectivity than they can get by virtue of the way it goes in an unmanaged setting. So that's very powerful. And the fact that we can enabled that and bring to the table our open architecture, our patient health action plan and we can work that bidirectionally with these other caregivers is compelling. The third piece I would say is our EGWP strategy has been hugely successful. We have modeled over 50 clients in terms of looking at the value that list. We are installing a whole lot of them for '12 or '13. And we think that we brought a level of value there that is unparalleled in terms of both the number care that these clients want to continue to care for the members and at the same time bring in significant financial change to what it looks like in terms of providing that."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I would agree and say that every plan, health plan that I'm selling is looking for a 360 degree view of the patient, a true 360 degree view. While we can provide that that on the pharmacy side, we need to integrate that in with what they're doing on",74,"Yes, I would agree and say that every plan, health plan that I'm selling is looking for a 360 degree view of the patient, a true 360 degree view. While we can provide that that on the pharmacy side, we need to integrate that in with what they're doing on the medical, the lab et cetera. And that with the extended enterprise that Tim mentioned is really paying off, big dividends in our conversation."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So obviously, Ross, we love that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going ask Dr. Epstein to talk about his world, both research, UBC and the things we're d",127,"So obviously, Ross, we love that question because we have so much going on. I have to ask a couple of more executives to chime in simply because it's exciting. So I'm going ask Dr. Epstein to talk about his world, both research, UBC and the things we're doing that are resonating with clients there. I'm also going to ask Kenny if you could perhaps talk about some of the innovations we're working on relative to physicians stakeholders as we prepare for accountable care because I think that healthcare reform initiative is important. I think it again drives better clinical outcomes, and we think we can be a major enabler in that space. Maybe a brief comment on that related to 2.0 might be helpful. So, Rob?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","On the pharmacogenomics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer, and they are selling very briskly. We now have over 300 clients enrolled in multiple pharmacogenomics programs, representing about 12 m",456,"On the pharmacogenomics front, we have launched 4 new clinical programs this year in the areas of neurology and cancer, and they are selling very briskly. We now have over 300 clients enrolled in multiple pharmacogenomics programs, representing about 12 million of our lives. So it's really exciting, and they're really excited to take on new pharmacogenomics tests which are new. These are trickier to do than the prior ones, they're not cheap [indiscernible] or blood tests. So it's a real positive for us to be able to figure out how to get that done. Also, we've launched our new service which is kind of like a 1-800 number to call certified genetic counselor to get advice when you're newly diagnosed with any sort of problem like cancer. And that's actually gotten a little traction even when we just started subscribing that new service. We've added a number of hospitals to our genomic medical institute network, including one in Canada, which is pretty exciting, where we are arming hospitals around the country with genomic information to make them certified genomic centers. And then in another area in genomic which is new for us is to take the intelligence around [ph] that DNA Direct has and offer those as the policy service health plan, who don't have their own technology equipment. And we've actually had a number of sales in that area since the beginning which has been a real uplift for us. So all areas are inspiring. They're all new. On the research front, we have a dozen large multi  [indiscernible] patient ongoing studies, several of which we'll complete this year. But you'll be hearing in the back half of the year some of the results that are very large prospective studies that has taken us into new areas including neuropsychiatry, where we have not been before. So it's pretty exciting. Actually, the neuroscientific community has been really excited about the work we're doing since no one else is really doing it. On the UBC front, the synergy has just been simply awesome. Since we announced the acquisition at the end of September, we also launched the Medco Research Consortium, which is any client interested in participating in the research, including UBC. We now have well over 100 clients representing 40 million of our lives in the consortium. And we now actually have clients participating in [indiscernible] studies or safety studies or both. And the early feedback has been really exciting. People love it. The members love it. They like the having the added protection of the safety in the particular type study. And so everything has been a real exciting first quarter for us, and we're just really looking forward to ongoing advances this year."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Just to add to what's been said is we view the area of health Information Technology as a really exciting space for us. One of the things that we're very excited about when you think in terms of extended enterprise and the broad portfolio of clinical capa",210,"Just to add to what's been said is we view the area of health Information Technology as a really exciting space for us. One of the things that we're very excited about when you think in terms of extended enterprise and the broad portfolio of clinical capability is -- the real game changer is to help get the healthcare system wired in the country. And 1 of the most powerful features of that is being able to help support the point of care where the patient and the physician interaction is at its most important. To be able to provide this 360 degree insights to that point of care. We believe it improves the ability of the physician to make decisions and prescribing course of treatment and also allows us to place a set of evidence-based protocol that allows us to put a benchmark to the type of activities that are happening. So I think you will see over the not too distant future an expanding portfolio of cloud computing-based solutions at point of care, and it's also the mechanism we're going to be using to enable both the medical home and Campbell Care Organization  [ph as well. So the wiring aspect, we think, has a lot of potential."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of George Hill with Citigroup.",12,"Your next question comes from the line of George Hill with Citigroup."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave and Rich, the increase in generic volumes in mail is pretty impressive this quarter given the lack of generic introductions. Can you talk about what drove that?",28,"Dave and Rich, the increase in generic volumes in mail is pretty impressive this quarter given the lack of generic introductions. Can you talk about what drove that?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes I'll mention a few things, and then, Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an incredible cost-effective channel, and that mail is outstanding at driving generic e",215,"Yes I'll mention a few things, and then, Rich, feel free to add on. I think a couple of things. First of all, clients are at a point where they understand that mail is an incredible cost-effective channel, and that mail is outstanding at driving generic expensing rates. So we've had great benefit design support on the part of our clients to drive this outcome. And I would also tell you the economy continues to aid the choice of generics because clearly when people are financially strapped, they say, ""Hey, I'd rather have less out of pocket expense,"" and they're moving from brands to generic. And the interchange that's going on between brand and generic voluntarily on the part of consumers is simply that I need to save some money has been incredibly strong. The final thing I've mentioned is that we have a team that always is working with clients to drive better generic expensing results across the channel, both mail and retail, and we've come up with a few new innovations that I don't choose to describe in great detail, but they've been very effective in improving mail choice and generic choices at mail. So we're actually feeling as though this is a momentum thing that we can sustain for a while."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll just add to that. Now when you look into the significant products that went generic last year, Flomax, Cozaar, Hyzaar, Effexor XR, those all had very high mail-order penetration rates in our book of business. You might recall that at Analyst Day, I p",138,"I'll just add to that. Now when you look into the significant products that went generic last year, Flomax, Cozaar, Hyzaar, Effexor XR, those all had very high mail-order penetration rates in our book of business. You might recall that at Analyst Day, I pointed to them on average being about 45% mail-order penetration, which is probably 10 points higher book of business average. In addition, we continue to see significant share gains as volume increases for simvastatin. That continues to be the case. Of course, we pointed to that in the past as well. Lastly, I'll say that plan designs have been established recently perhaps more than ever before in support of step therapy programs. We're ultimately -- we are driving very material savings for clients and patients by starting them on the lower cost alternatives."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard.",14,"[Operator Instructions]  Your next question comes from the line of Tom Gallucci with Lazard."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess, what confuse some people with sort of sequential ramp earlier this year. And now it seems it's a little bit more than we might have expected with some progre",100,"My question is for Rich, I think, primarily. Just curious, Rich, coming off the Q4 call, I guess, what confuse some people with sort of sequential ramp earlier this year. And now it seems it's a little bit more than we might have expected with some progress from Q1 into Q2. And you're sort of flattening, I guess, a little bit the steepness of the ramp throughout the year. So can you tell us what changed in the last couple of months that gives you a little bit more weight towards the first half as opposed to the second half?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I can tell you probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter. And obviously as we get deeper into the year, we have a clearer line of sight. And now obviously the second quart",155,"Well, I can tell you probably the primary driver there is the strength we have in generic mail volumes. That clearly drove the first quarter. And obviously as we get deeper into the year, we have a clearer line of sight. And now obviously the second quarter is upon us, and I'm confident, at that this point, with my current line of sight, that it will be stronger than the first quarter. So the way I look at my -- you really have to take advantage of the most current information in projecting the year on this company because it's not that easy to look out for 2, 3, 4 quarters. I'm very confident in the second quarter. What I'm seeing is a continuation of what we've seen in the first. Strong mail, strong generic, continued competitiveness with regards to our ability to achieve competitive purchasing discounts, significant level of business efficiency across the board."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to add a couple of secondary players. Rich is right in terms of one of the big player. But I would also add that we were very pleased with incrementally enrollment we got in our Medicare PDP. And I think that's heavily related to the 5-star rati",167,"I'm going to add a couple of secondary players. Rich is right in terms of one of the big player. But I would also add that we were very pleased with incrementally enrollment we got in our Medicare PDP. And I think that's heavily related to the 5-star rating we got as a national PDP because many of the patients who are 65 plus who picked these PDPs go to the government website to make their choice, and they look at the star rating as an important metric for making choice. So we had a nice surprise there relative to enrollment, which will sustain itself. The key members will stay members through the year. I would also say I'm extremely pleased in the rate of growth we're seeing at UBC. It's, and at this point, outperforming my original expectations, and I think it's sustainable. So there's some other players out there that are actually at an operating level contributing to our growing optimism for the year."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, great. And maybe just as a follow there. You're talking about, Rich, mail generics being one of the bigger drivers. I guess, can you tell us what you sort of get factored in as you look at the second of the year relative to what we've seen in the fi",96,"Okay, great. And maybe just as a follow there. You're talking about, Rich, mail generics being one of the bigger drivers. I guess, can you tell us what you sort of get factored in as you look at the second of the year relative to what we've seen in the first quarter? Is there a chance that if these trends sustain themselves and your line of sight continues to improve with times that you could do a little bit better or have you, sort of, got a little higher expectations already factored into the second half?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see how the year progresses as we get closer to the middle of the year. So obviously, I'll give you further insight in our next quar",79,"Well, I'm not going to change the guidance we just gave as a result of that question. I think we'll have to stay tuned and see how the year progresses as we get closer to the middle of the year. So obviously, I'll give you further insight in our next quarter call, but right now, we're delighted with where we are. Obviously, we're pleased to lop off the $0.03 in the bottom end of guidance. And just stay tuned."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line Randall Stanicky with Goldman Sachs.",12,"Your next question comes from the line Randall Stanicky with Goldman Sachs."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","On the Lipitor, Dave, I'm sure you're aware of  [ph] pressing pretty hard from the litigation perspective to get a generic in earlier. And we're going to get an update on that today. Question is, if that was the case and we saw generics come earlier, shou",66,"On the Lipitor, Dave, I'm sure you're aware of  [ph] pressing pretty hard from the litigation perspective to get a generic in earlier. And we're going to get an update on that today. Question is, if that was the case and we saw generics come earlier, should we be thinking about your $0.03 per month contribution in any different way? And then I have one follow-up."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay, Randall, I'll ask Rich to take that, and then Tom, who's obviously the one who put together all our pharma deals. If you have anything to add, Tom, please feel free to...",33,"Okay, Randall, I'll ask Rich to take that, and then Tom, who's obviously the one who put together all our pharma deals. If you have anything to add, Tom, please feel free to..."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would just say that at this point, the probability level there is probably, I would think, quite low. Tom, would you agree with that?",25,"I would just say that at this point, the probability level there is probably, I would think, quite low. Tom, would you agree with that?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree with that.",5,"I would agree with that."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So ultimately, from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before then, but, Tom, why don't you try to...",41,"So ultimately, from a probability perspective, we're assuming that we're going to stick with our $0.03 benefit from Lipitor in the fourth quarter. We're not expecting any news that would alter that before then, but, Tom, why don't you try to..."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would agree with that. I think if you look at the scenario, it's looking more likely towards November date as a  [indiscernible] day.",24,"I would agree with that. I think if you look at the scenario, it's looking more likely towards November date as a  [indiscernible] day."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?",27,"The economics that you've got contracted, would that still be a similar type of opportunity or would that be potentially changed if it did come early?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Randall, as a matter of policy, we don't get into different sources and get pushed into probability therewith. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you",47,"Randall, as a matter of policy, we don't get into different sources and get pushed into probability therewith. So we're not going to discuss that. I think from a probability point of view, you should, as I always guide, to use the numbers that we gave you."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Amanda Murphy with William Blair.",13,"Your next question comes from the line of Amanda Murphy with William Blair."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I had a question on Accredo. The revenue growth there seems to be in line with sort of what you've guided to but has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind of",76,"I had a question on Accredo. The revenue growth there seems to be in line with sort of what you've guided to but has sort of come down a little bit from what we've seen over the past few years. I'm just curious, how do you think about that segment kind of longer term? And have we seen the gross margin line kind of normalize? It was a little bit of an improvement over last quarter."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay, I'll ask Steve Fitzpatrick to give you some help on that question.",13,"Okay, I'll ask Steve Fitzpatrick to give you some help on that question."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's maybe come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lot of opportunity as this proportion of the specialties spin is on the medical sid",124,"It's maybe come down a little bit as we've been very effective in penetrating the Medco book of business and capitalizing from clients there. Moving forward, there's still lot of opportunity as this proportion of the specialties spin is on the medical side of the business, which we had historically been fairly effective in pulling over, and we'll continue to drive that. Particularly as we package our infusion capabilities, which are really unmatched in the market, and move forward to be a little more aggressive in the packaging [indiscernible]. We should continue to drive, not only our core specialty, which has driven a lot of our growth recently, but in the future the infusion capability which is some of the higher margin benefits."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I'd add to what Steve just said. I think the infusion capabilities are real competitive assets that Medco uniquely has. But I would also say more broadly in the specialty space, there's an enormous opportunity on the medical side of the specialty spe",146,"Yes, I'd add to what Steve just said. I think the infusion capabilities are real competitive assets that Medco uniquely has. But I would also say more broadly in the specialty space, there's an enormous opportunity on the medical side of the specialty spend benefit. And we're making great inroads there. I expect that to grow over time as we continue to build the products that make that whole over from medical to drug management on the PBM side more scalable. So we technically could double the size of Accredo if we could get the biotech spend that's on the medical side of the business over to the PBM side of the business. On top of that, there are 611 drugs in the pipeline clinical Phase II and III on their way to FDA approval, which will create its own source of growth for our business."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I would just add. From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but not massive variability.",42,"I would just add. From a gross margin percentage perspective, we're going to be pretty much in the zone that we've seen in the first quarter for the rest of year. You may see some ups and downs, but not massive variability."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, thanks. And then just one more on utilization. Some of the other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that just from an underlying prescri",43,"Okay, thanks. And then just one more on utilization. Some of the other companies on our list have reported stronger utilization growth over medium improving utilization growth in the first quarter. Would you agree with that just from an underlying prescription consumption standpoint?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I would say that we'll be issuing our drug term report soon. And for last year, certainly, we did see utilization increases, as I recall, of about 2-plus percent. That trend is not changing, so we are starting to see signs of that carrying into this",62,"Yes, I would say that we'll be issuing our drug term report soon. And for last year, certainly, we did see utilization increases, as I recall, of about 2-plus percent. That trend is not changing, so we are starting to see signs of that carrying into this year as well a little early. But we certainly aren't seeing any declines in utilization."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Helene Wolk with Stanford Bernstein.",13,"Your next question comes from the line of Helene Wolk with Stanford Bernstein."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a question around cost trends and understanding what you're seeing from a generic sourcing and a retail network fee perspective, both currently and what you expect for the year.",31,"Just a question around cost trends and understanding what you're seeing from a generic sourcing and a retail network fee perspective, both currently and what you expect for the year."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay, Tom, you want to take that?",7,"Okay, Tom, you want to take that?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I think, as we've commented before, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]",26,"Well, I think, as we've commented before, we have a multi-sourcing strategy. And in terms of our ability to continue to generate value going forward [indiscernible]"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's the same from a retail contracting perspective as well. We have a line of sight into the continued improvement on the broader procurement front across channel.",28,"It's the same from a retail contracting perspective as well. We have a line of sight into the continued improvement on the broader procurement front across channel."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And any sense of or help that you can provide in terms of the timing of the share repos? How we should think about the rest of the year unfolding?",30,"And any sense of or help that you can provide in terms of the timing of the share repos? How we should think about the rest of the year unfolding?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Obviously, we're still at the $2 billion level. So the strongest quarter for repurchases is first quarter, but we expect it to come down a little bit in the second quarter from a dollar-value perspective. And then it should flatten off in the back half of",84,"Obviously, we're still at the $2 billion level. So the strongest quarter for repurchases is first quarter, but we expect it to come down a little bit in the second quarter from a dollar-value perspective. And then it should flatten off in the back half of the year. So you'll see us going down from the $836 million the first quarter to some level probably north of $500 million in the second quarter and then evens off in the back half of the year."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your final question comes from the line of Ricky Goldwasser with Morgan Stanley.",14,"And your final question comes from the line of Ricky Goldwasser with Morgan Stanley."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3 manufacturers in December?",33,"I have a couple of follow up questions. Rich, just following up on the Lipitor question, is this $0.03 from Lipitor dependent on whether we will have 2 versus 3 manufacturers in December?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in the $0.03 as we were when we brought up the $0.03 several months ago.",46,"Consistent with my previous comment, I'm not going to get into any details with regard to who and how many. I just want you to know that we are as confident in the $0.03 as we were when we brought up the $0.03 several months ago."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then, Dave, any update on the timing of United? Do still expect to hear any resolution at around the fall time?",22,"And then, Dave, any update on the timing of United? Do still expect to hear any resolution at around the fall time?"
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm going to echo the comment of Steve Hensley  [ph] that he made on his earnings call. And that this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I c",98,"I'm going to echo the comment of Steve Hensley  [ph] that he made on his earnings call. And that this we have a great relationship with United. We have been great partners. We are clearly looking to the end of this our current contract for 1/1/13, and I can't speculate about what the outcome will be, but we are anticipating a process just as we've talked about before. There's nothing really new to add at this point. But my view is, there's always a strong possibility of future relationships when your current relationship is so fundamentally strong."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And I would now turn it back over to our presentors for closing remarks.",14,"And I would now turn it back over to our presentors for closing remarks."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day.",31,"Thank you very much all of you for joining us today. And we look forward to talking to you at future conferences and our next quarterly call. Have a great day."
1541811,129808770,119527,"MedcoHealth Solutions Inc., Q1 2011 Earnings Call, Apr 28, 2011",2011-04-28,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect.",14,"Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Welcome to Express Scripts and Medco Health Solutions Definitive Merger Agreement Conference Call and webcast. Today's call is being recorded and will be available for replay beginning 11:30 a.m. Eastern time. The conference call replay can be accessed by",83,"Welcome to Express Scripts and Medco Health Solutions Definitive Merger Agreement Conference Call and webcast. Today's call is being recorded and will be available for replay beginning 11:30 a.m. Eastern time. The conference call replay can be accessed by dialing (855) 859-2056 or (404) 537-3406 and entering access code 84888352. At this time [Operator Instructions] It is now my pleasure to turn the floor over to Mr. David Myers, Express Scripts Vice President of Investor Relations for opening remarks. Sir, you may begin."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, and welcome everyone to our conference call to discuss this morning's announcement of the proposed measure of Express Scripts and Medco. With me today are George Paz, Chairman and CEO; and Jeff Hall, CEO from ExpressScripts, joining us Dave Sno",179,"Thank you, and welcome everyone to our conference call to discuss this morning's announcement of the proposed measure of Express Scripts and Medco. With me today are George Paz, Chairman and CEO; and Jeff Hall, CEO from ExpressScripts, joining us Dave Snow, Chairman and CEO of Medco. Before we begin, I need to read the following Safe Harbor statement.
Slide statements are comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors which are discussed in detail in the company's filings with the Securities and Exchange Commission. In addition, you should refer to the various information and legends included at the end of this presentation for additional information regarding the matters discussed.
Now I'm going to turn the call over to George who will discuss this morning's announcement."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, David. Before I get started, let me take a minute to welcome Dave Snow to St. Louis. I've a lot of respect for what David and his team have accomplished over the years. They have strong fundamentals and proven people with strengths are compleme",67,"Thank you, David. Before I get started, let me take a minute to welcome Dave Snow to St. Louis. I've a lot of respect for what David and his team have accomplished over the years. They have strong fundamentals and proven people with strengths are complementary to ours. We look forward to this combination which will accelerate our efforts to lower healthcare costs while improving health outcomes."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thanks, George, we're also excited because our 2 organizations in their own ways represent 2 great success stories in American business. We have each been successful in creating shareholder value because we are both passionate about driving value to our c",78,"Thanks, George, we're also excited because our 2 organizations in their own ways represent 2 great success stories in American business. We have each been successful in creating shareholder value because we are both passionate about driving value to our customers through service, innovation and the focus on cost and quality. Organizations have a shared desire to improve the way healthcare is delivered in this country and I believe this creates a strong foundation for a successful future."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Since our inception 25 years ago, we've had an unwavering focus on making the user prescription drugs safe and more affordable. Over the years, we identified and tackled inefficiencies in a healthcare and succeeded through innovation, exe",357,"Thank you, Dave. Since our inception 25 years ago, we've had an unwavering focus on making the user prescription drugs safe and more affordable. Over the years, we identified and tackled inefficiencies in a healthcare and succeeded through innovation, execution and a commitment to our business model of alignment. This unique foundation of alignment has enabled us to grow, become stronger and enhance our ability to provide dynamic services designed to drive out ways that improved healthcare outcomes. We have never been better positioned to take advantage of a long-term growth opportunities inherent in the PBMs in the marketplace. Our behavior-centric approach continues to gain traction in the marketplace and the lead our sector in earnings growth in return on invested capital. We have complemented our strong organic growth over the years through successful strategic mergers and acquisitions which created opportunities to new business segments, offer new services and increase the scope of our business. We have always been opportunistic in looking for ways to enhance value, and today's announcement of our combination with Medco is a perfect example.
This is a transaction the nation needs now. Massive changes around the horizon for our industry, including healthcare reform and the upcoming wave of brand-name drugs losing patent protection. Meanwhile, healthcare costs continued to rise. In this environment, we have to be nimble and we have to be supported off to influence events and forward thinking enough to interpret events before they occur. Combined, we can build on our legacy of advancing healthcare, do innovation and an unwavering commitment to our clients.
Both Express Scripts and Medco have different strengths in clinical, Specialty Pharmacy Services, research, the behavioral sciences, pharmacy technology and overall patient care. The combination of these complementary strengths will accelerate our clinical offerings which will reduce costs and improve health outcomes. Our breadth of services across traditional PBM management, specialty management and Medicare Part D will be unparalleled in history. The combined company will also be well-positioned to help clients and members navigate the landscape in the wake of healthcare reform.
At this point, I'll invite Dave to talk about the transaction from Medco's perspective."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thanks, George. Since we took Medco public in 2003, we doubled the size of our business and delivered average annual earnings per share growth of 22%. We've done that by driving clinical innovation focused on addressing the 50% of patients with chronic an",209,"Thanks, George. Since we took Medco public in 2003, we doubled the size of our business and delivered average annual earnings per share growth of 22%. We've done that by driving clinical innovation focused on addressing the 50% of patients with chronic and complex disease will account for 96% of all drug spending and more than 75% of healthcare costs. We launched Therapeutic Resource Centers, built a world-class Accredo Specialty Pharmacy business, generated breakthrough science in research in the area of personalized medicine, and created a Medicare business that receives CMS's first and only national 5-star rating. We are a trailblazer in pharmacogenomics and have extended our footprint internationally. Clinical excellence in service innovation is where the catalyst for our growth, and over the last 8 years, we've quintupled our market cap.
With that history, why this combination? Over the past year, we at Medco have been very focused on the changing healthcare environment in this country, which is demanding better, faster and less expensive capabilities for all who participate in the healthcare system. This strategic combination delivers on these important value propositions to the benefit of our clients, patients and shareholders. We look forward to working with you, George and the Express Scripts team in completing this merger."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Our successful track record of strategic combinations is based in a philosophy of taking a best-in-class of both organizations and combining them for the benefit of our clients, patients and stockholders. We will unite the expertise of 2",256,"Thank you, Dave. Our successful track record of strategic combinations is based in a philosophy of taking a best-in-class of both organizations and combining them for the benefit of our clients, patients and stockholders. We will unite the expertise of 2 complementary PBMs to make the delivery of prescription drugs safer and less expensive for millions of Americans. By burning the combined clinical skills with the behavioral sciences, we'll be able to accelerate efforts from our greater efficiencies in the healthcare system and better protect American families from the rising costs of prescription medications. Our shared vision is to increase therapy adherence, lower costs and drive to better health outcomes.
This combination will truly build on our legacy of innovation, alignment with our clients and patients, and our commitment to making drugs safer and more affordable. And because we are aligned, as we delivered increased value to our clients and patients, our shareholder performance improves. This transaction continues our commitment to strong growth, both organically and through strategic combinations. The merger with Medco will provide the opportunity to accelerate our ability to achieve cost savings for our patients and clients while improving health outcomes.
One of the keys to our history of building shareholder value has come through successful strategic mergers and acquisitions. Our focus all the years on execution and innovation has enabled us to successfully integrate these businesses, and we we'll use the same discipline in approaching this transaction. at this point, I will ask Jeff to discuss the financial aspects of this transaction."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, George. Let me start off by saying that we have observed Medco over the years and I've worked closely with them on this transaction. It's clear they share a passion for driving out ways in healthcare and providing world-class patient care. This",427,"Thank you, George. Let me start off by saying that we have observed Medco over the years and I've worked closely with them on this transaction. It's clear they share a passion for driving out ways in healthcare and providing world-class patient care. This merger is consistent with our philosophy on capital deployment. First, to fund internal investments, and second, to look for strategic mergers and acquisitions. We have funded our internal needs and so I'm pleased to take you through some of the details of our combination, which is expected to generate strong returns on the capital invested. The name of the combined companies will be Express Scripts Holding, Inc., it will be headquartered in St. Louis, Missouri. George Pause will be the Chairman and CEO, and the board will consist of Express Scripts existing board, plus members from Medco's board.
We will exchange $28.80 in cash and 0.81 shares of Express Scripts stock for each share of Medco stock. This results in a purchase price of approximately $29 billion or $71.36 per share, which represents a 28% premium over yesterday's closing price. We have committed financing in place for the cash component and anticipate raising permanent capital in the form of bank debt and bonds. We are committed to maintaining our investment grade rating and we have structured this transaction to do so. At the close of this transaction, Express Scripts shareholders will own approximately 59% of the combined company, and Medco shareholders will own about 41%. We expect the transaction to close in the first half of 2012, subject to regulatory approval.
The merger is expected to be slightly accretive in the first full year after closing, and moderately accreting, accretive after the integration is completed. Based on our due diligence today, we have identified $1 billion of synergy. In addition, we expect to deliver more than $4 billion of annual cash from operations once fully integrated. For modeling purposes, we have excluded the UnitedHealthcare contract beyond the end of 2012. We have a strong track record of the completing acquisitions, integrating them seamlessly and meeting or exceeding our synergy expectations.
In addition to this track record, we have also demonstrated our ability to reduce leverage rapidly, and our expectations for this transaction are no different. At the time of closing, we expect to be at the debt level of 2.9x EBITDA. We expect to return back to our targeted range of 1x to 2x with an 18 months of closing. And now I'll turn the call back to George for some final remarks."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Jeff. We are excited about this outstanding opportunity. This is the seventh major transaction we have made since I joined the company in 1998, and the third one that is doubling the size of our company. We believe that this transaction is proc",303,"Thank you, Jeff. We are excited about this outstanding opportunity. This is the seventh major transaction we have made since I joined the company in 1998, and the third one that is doubling the size of our company. We believe that this transaction is procompetition, will reduce healthcare costs and very much in the public interest. Everyone agrees that our country needs to get a handle on and control its healthcare costs, and our priority on behalf of our clients and patients is to help drive the way set of the healthcare industry. Reducing costs and improving health outcomes is our primary goal. This goal is reflected on our business model of aligning those at our clients and our patients. That is, we make money when they saved money. This transaction allows us to accelerate cost savings and improve health outcomes. Given the level of competition at the PBM business, the sophistication of our customers and their desire to keep their healthcare costs down, and the real benefits arising out of this very exciting transaction, we believe we will work our way successfully through the regulatory approval process. Being disciplined on our approach to acquisition is a key to our success. Our industry-leading ROIC is proof of our ability to acquire and integrate major acquisition. The combination with Medco is a continuum of our disciplined approach.
Our roadmap to completion involves completing all required SEC filings, holding special meetings for both sets of stockholders and working through the regulatory approval process. We believe this transaction can be completed in the first half of 2012. I want to again share my enthusiasm for this transaction, which validates our differentiated business model and provides a platform for continued strong growth in the future.
At this point, we would be happy to answer any questions. Operator?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Our first question is coming from Robert Willoughby of Bank of America Merrill Lynch.",16,"[Operator Instructions] Our first question is coming from Robert Willoughby of Bank of America Merrill Lynch."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","George and David, one long question for you. The synergy number of $1 billion seems lower relative to what Express generated on the Well Point deal. Can you give us anything anecdotally what that $1 billion is comprised of? And secondarily, George, Medco'",81,"George and David, one long question for you. The synergy number of $1 billion seems lower relative to what Express generated on the Well Point deal. Can you give us anything anecdotally what that $1 billion is comprised of? And secondarily, George, Medco's in a number of businesses that you have had less interest that in the past, whether it's a Medicare, PDP or infusion therapy or the international arena. Any preliminary views on your plans for some of those relationships?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Robert, I think we've always been very open and always tried to be innovative. I look forward to spending the next couple of months or next 6 months or so or more with David and understanding the opportunities that exist in Europe. And his vision on the d",130,"Robert, I think we've always been very open and always tried to be innovative. I look forward to spending the next couple of months or next 6 months or so or more with David and understanding the opportunities that exist in Europe. And his vision on the different businesses they've entered into over the years, I think what I would tell you at this stage is, we're very early on and we will complete a thorough analysis and determine what's in the best interest of our shareholders and figure out how to enhance value across all lines of our business. From a synergy perspective, I'll let Jeff talked to that. But again, we're very preliminary in this process and we look forward to getting more details as the merger involves."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, Bob, what we said this morning is based on the due diligence we've identified $1 billion of synergy, but I'd caveat that by saying the deal is, at the end of the day, not about cutting costs, it's about putting 2 great companies together to accelerat",88,"Yes, Bob, what we said this morning is based on the due diligence we've identified $1 billion of synergy, but I'd caveat that by saying the deal is, at the end of the day, not about cutting costs, it's about putting 2 great companies together to accelerate cost reductions for our clients and their members in healthcare while improving the healthcare outcomes for everybody. So that's really the primary focus here. And we are excited about the combined capabilities of the 2 companies to execute on exactly that."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And just to pile on real quick, Bob, as you know our business alignment as we take down those costs for our patients and our clients, we create value for our shareholders. So we believe there's tremendous opportunity here as evidenced in $1 billion.",44,"And just to pile on real quick, Bob, as you know our business alignment as we take down those costs for our patients and our clients, we create value for our shareholders. So we believe there's tremendous opportunity here as evidenced in $1 billion."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Larry Marsh of Barclays Capital.",10,"The next question comes from Larry Marsh of Barclays Capital."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Several things. One, just George and Dave, could you elaborate a little bit how long you guys have been in any sort of conversation with any confidentiality issues? And then I guess also, as you think about arguably, the $1 billion synergies seems modest,",130,"Several things. One, just George and Dave, could you elaborate a little bit how long you guys have been in any sort of conversation with any confidentiality issues? And then I guess also, as you think about arguably, the $1 billion synergies seems modest, but I guess a bigger picture view is, when I think about with Medicare, with United, I guess you're pulling that out of your numbers but when they mentioned to you that they were terminating their service agreements, did they confirm that they are bringing that in-house or do they not suggested this? and I guess along with that, if they are bringing in this in-house, would that be an important argument as you make the FEC to show valid and strong competition in the marketplace?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll let Dave speak to The United situation. Do you want to?",13,"I'll let Dave speak to The United situation. Do you want to?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, sure. Let me take that first. So as you might imagine, the conversations with Express Scripts and the conversations with our client, United, we are on independent, completely independent track and came to their own independent conclusion. So the anno",99,"Yes, sure. Let me take that first. So as you might imagine, the conversations with Express Scripts and the conversations with our client, United, we are on independent, completely independent track and came to their own independent conclusion. So the announcement relative to United is tied to last week's conversations with them directly, and our decision that, in fact, what was left on the table was did not meet the needs of our shareholders. So that was an independent decision that we arrived at and that was very recent. And it is announced when now our decision is made."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I see. But you don't know what they're going to be doing with that business?",15,"I see. But you don't know what they're going to be doing with that business?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I mean Larry, what I would say is there is plenty of paper trail that's public that indicates what the alternative is they've been thinking about. So without putting words in Steve have these not, I have to assume that he will go with that other alt",60,"Well, I mean Larry, what I would say is there is plenty of paper trail that's public that indicates what the alternative is they've been thinking about. So without putting words in Steve have these not, I have to assume that he will go with that other alternative that he's publicly talked about so often, which is take it in-house."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And just for the timing of the talks and discussion?",10,"And just for the timing of the talks and discussion?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Dave and I have been friends for a lot of years. We sit on our trade association board together and we have numerous opportunities to talk in the past. The beauty of our 2 companies is we share a common passion for taking costs out of the system and impro",105,"Dave and I have been friends for a lot of years. We sit on our trade association board together and we have numerous opportunities to talk in the past. The beauty of our 2 companies is we share a common passion for taking costs out of the system and improving health outcomes, optimally go out at slightly different or quite a bit differently, but at the end of the day, by combining those 2 differences, we create a tremendous synergistic opportunity to take even more cost out, create better value for our patients and clients, and drive better outcomes. So we're very excited about this."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And I guess, George, just finally, when you mentioned your argument to the FEC is being able to drive costs down and share those to your customers. That seems to be an important message here today. What would you respond to any pushback around concentrati",49,"And I guess, George, just finally, when you mentioned your argument to the FEC is being able to drive costs down and share those to your customers. That seems to be an important message here today. What would you respond to any pushback around concentration of males script volume?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I don't want to deliberate the FTC issues. We are obviously going to work very closely. If you take a step back and say what is America need today more than anything else, we, the healthcare costs that are under control and driving quality, you ough",174,"Well, I don't want to deliberate the FTC issues. We are obviously going to work very closely. If you take a step back and say what is America need today more than anything else, we, the healthcare costs that are under control and driving quality, you ought to hear David speak from a public podium about quality and how important it is and how important it is to take costs out of the system. Again, we share that common goal. The FTC is part of the administration, which is part of the government, which is also is very focused on healthcare costs. We're going to work very hard to show the government the value that this brings to patients and members as we drive those costs out of the system. And we wouldn't be doing this if we didn't think we didn't have a very good chance of getting this through. It's a lot of work and we don't need a lot of work to do nothing. So we are excited about moving forward."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Lisa Gill of JPMorgan.",9,"The next question comes from Lisa Gill of JPMorgan."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Obviously, congratulations. David, it's been great working with you since 2003. And George, I'll be honest, I mean, I was thinking an acquisition maybe in 2014 so obviously I think all of us were a little surprised. Just a few questions I guess around the",128,"Obviously, congratulations. David, it's been great working with you since 2003. And George, I'll be honest, I mean, I was thinking an acquisition maybe in 2014 so obviously I think all of us were a little surprised. Just a few questions I guess around the selling season. Can we maybe just talk about, is the 2012 selling season wrapped up, number 1? And number 2, if someone has is in the decision-making process of I've awarded the business to either Medco or Express, does this open it up for them to come back and perhaps change their decision based on this combined entity? So that would be my first question. And then secondly, is there hope to wrap this up before we get into the 2013 selling season?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, the answer to the last question first is yes. As far as the selling season is concerned, I prefer to wait till the third quarter. There are still on awful lot of decisions that are out there. We're in the middle of renewing clients and selling busin",114,"Well, the answer to the last question first is yes. As far as the selling season is concerned, I prefer to wait till the third quarter. There are still on awful lot of decisions that are out there. We're in the middle of renewing clients and selling business. And obviously, our companies will remain stand-alone and compete vigorously in the marketplace until this transaction closes. And I prefer just to hold off on that selling season. As far as clients, our clients have always asked for more, and the question is, the more value we can deliver or cost contractions they need and hopefully we can deliver more value and that satisfies their need."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then, just lastly, George, obviously, there's a public dispute between yourself and Walgreens around this. Do you believe that this potential combination brings them back to the table? I mean, this is an awful lot of business for them should the trans",45,"And then, just lastly, George, obviously, there's a public dispute between yourself and Walgreens around this. Do you believe that this potential combination brings them back to the table? I mean, this is an awful lot of business for them should the transaction go through."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I did call Greg this morning, gave him a heads-up as to what was going on. I think with each other once it became public, of course, and just let him know that this was coming down. And Greg and I talked and it's I'm hopeful that we will come to a c",64,"Well, I did call Greg this morning, gave him a heads-up as to what was going on. I think with each other once it became public, of course, and just let him know that this was coming down. And Greg and I talked and it's I'm hopeful that we will come to a conclusion on this. We'll have to see how that plays out."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Ross Muken of Deutsche Bank.",10,"The next question comes from Ross Muken of Deutsche Bank."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So obviously, this changes the theoretically assuming a successful or hopeful close, and this changes the competitive landscape in the context of the positioning of the other entities that now exist post the sort of United business going in house. How do",96,"So obviously, this changes the theoretically assuming a successful or hopeful close, and this changes the competitive landscape in the context of the positioning of the other entities that now exist post the sort of United business going in house. How do you view, on a pro forma basis, kind of the strategic positioning of the pro forma asset that you've created with the unique capabilities of each of the 2 businesses as it sort of has to compete in this change, but still highly competitive landscape of players that look a bit dissimilar to yourself?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","To be quite frankly, this is a great world. There's many, many players out there that offer different approach to solve healthcare costs that are increasing. One of the problems I've had over the years is David, my pitch and David's pitch were pretty simi",178,"To be quite frankly, this is a great world. There's many, many players out there that offer different approach to solve healthcare costs that are increasing. One of the problems I've had over the years is David, my pitch and David's pitch were pretty similar. We both went after the same thing. We both thought that from pharmacogenomics and personalized medicine and attacking member, decision-making were the right answers. we were fairly close. Obviously, one of my competitors likes to use the retail drugstore chain as an avenue and another one of my competitors, so quite a few of my competitors are in-house. PBMs for managed care companies, so there is all types, there's tons of competition out there. And the beauty of the world today is, they are fairly unique in our offering, but that gives the chooser of our services many, many different options on how to choose which PBM and which process to go with that are trying to get to lower their costs. So I think we are very well defined in the industry."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And Ross, let me add something. It's Dave. I think if you think about this strategically at 30,000 feet and I'm talking broader than PBM, I'm talking the healthcare system, I believe you are going to see all sorts of combinations across the spectrum of he",136,"And Ross, let me add something. It's Dave. I think if you think about this strategically at 30,000 feet and I'm talking broader than PBM, I'm talking the healthcare system, I believe you are going to see all sorts of combinations across the spectrum of healthcare as everyone realigned to the new imperatives related to healthcare reform and the demand the government is making relative to lowering costs of the healthcare system. And I think this combination puts us squarely on the side of a solution to what the government is going to be pushing for over the next decade. So I think you'll be surprised that the other healthcare combinations that are encouraged by the incentives in healthcare reform and this is trust an alignment that makes enormous sense as you look to the future."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And maybe just one quick follow-up. In terms of the synergies related to the transaction, how should we think about sort of the pacing assuming that mid-year or first half of 2011 closed in terms of what synergies that were named, were sort of easier to c",73,"And maybe just one quick follow-up. In terms of the synergies related to the transaction, how should we think about sort of the pacing assuming that mid-year or first half of 2011 closed in terms of what synergies that were named, were sort of easier to capture and some flow through kind of in the only part of the transaction and which would kind of take a slightly longer piece of time?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","As we said earlier, we expect the deal to close in the first half of 2012 and we're sitting here in the second half of 2011. what I would prefer to do is defer your question until we get closer to the closing and see where we are at, and obviously, at tha",65,"As we said earlier, we expect the deal to close in the first half of 2012 and we're sitting here in the second half of 2011. what I would prefer to do is defer your question until we get closer to the closing and see where we are at, and obviously, at that time, we will build out the guidance and the model for you."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Steven Valiquette of UBS.",9,"The next question comes from Steven Valiquette of UBS."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just trying to get a little more color on the process with the FTC. Just kind of thinking ahead and being borderline case. What are the scenarios? Do they come down to potentially giving up a certain percent of customers, is it just sort of yes or no with",68,"Just trying to get a little more color on the process with the FTC. Just kind of thinking ahead and being borderline case. What are the scenarios? Do they come down to potentially giving up a certain percent of customers, is it just sort of yes or no with the existing books of business? How does that sort of play out the way you think about the FTC?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, first of all, I don't share your opinion on a borderline case. I think everything Dave just talked about in healthcare is being delivered in this model or this merger. And I believe it's what America needs, that's what the patient's needs, it what t",85,"Well, first of all, I don't share your opinion on a borderline case. I think everything Dave just talked about in healthcare is being delivered in this model or this merger. And I believe it's what America needs, that's what the patient's needs, it what the client needs, and our job is just to provide the information and help the FTC work through this process. And we feel as I said earlier, we wouldn't do this if we didn't think we couldn't get it done."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. So the way it stands right now, you're not too worried from FTC point of view that's what it boils down to?",23,"Okay. So the way it stands right now, you're not too worried from FTC point of view that's what it boils down to?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, that's correct.",3,"Yes, that's correct."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from John Kreger of William Blair.",10,"The next question comes from John Kreger of William Blair."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a follow-up question on the synergies and where you think they might come from. George, from your perspective, is there still room as you're going to gain a lot more scale with this deal? Do you still see room to drive additional purchasing opportuni",61,"Just a follow-up question on the synergies and where you think they might come from. George, from your perspective, is there still room as you're going to gain a lot more scale with this deal? Do you still see room to drive additional purchasing opportunities in the channel? And if so, where do you think the biggest opportunities still are?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","If I take the total cost of goods sold, SG&A and DPC we're talking about $100 billion of spend. I feel very comfortable there's a lot of opportunities to take costs out of the equation.",35,"If I take the total cost of goods sold, SG&A and DPC we're talking about $100 billion of spend. I feel very comfortable there's a lot of opportunities to take costs out of the equation."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Have you gotten far enough to know what you're going to do on the systems side or the facility side?",21,"Have you gotten far enough to know what you're going to do on the systems side or the facility side?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No, we haven't. We just announced today, John. Without obviously coming. We've got to go through that process. Medco, we compete with them everyday. They've got incredible people, incredible systems and incredible approaches. I'm a little biased, but I th",142,"No, we haven't. We just announced today, John. Without obviously coming. We've got to go through that process. Medco, we compete with them everyday. They've got incredible people, incredible systems and incredible approaches. I'm a little biased, but I think I've got pretty good ones too, and now the question is, how do I put them both together and get the best of the best? And I'm confident. And if you look back at DPS, we kept their systems. If you look at value RX, they brought us unique capabilities in mail order. As I go down this list, everyone of our acquisitions have been strategic. This one is incredibly strategic to us and they will bring us incredible tools and incredible people. And we are just so excited to be uniting these 2 entities together to pick up that excess cost."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Ricky Goldwasser of Morgan Stanley.",10,"The next question comes from Ricky Goldwasser of Morgan Stanley."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a follow-up on the synergies. Does the $1 billion in synergies that you identified from back early on assumes consolidating their relationship with your respective distributors?",28,"Just a follow-up on the synergies. Does the $1 billion in synergies that you identified from back early on assumes consolidating their relationship with your respective distributors?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Again, I'm not going to get into where everything situated now. We are way too early on. We got a lot of work to do. We feel very comfortable with the numbers we've presented and I'm just going to leave it at that.",43,"Again, I'm not going to get into where everything situated now. We are way too early on. We got a lot of work to do. We feel very comfortable with the numbers we've presented and I'm just going to leave it at that."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. and then just in terms of market share of the combined entity, it's kind of like 30% are we in the ballpark once we factor in kind of like take out United out of kind of Medco equation? Is 30% market share a reasonable number to think about it?",50,"Okay. and then just in terms of market share of the combined entity, it's kind of like 30% are we in the ballpark once we factor in kind of like take out United out of kind of Medco equation? Is 30% market share a reasonable number to think about it?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","What's the purpose of your question? I'm trying to?",10,"What's the purpose of your question? I'm trying to?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","In terms of kind of like your market share in terms of combined companies would cover?",16,"In terms of kind of like your market share in terms of combined companies would cover?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","There's a lot whole lot of things going on right now, Ricky. We are in the middle of selling season. There's a lot of pieces. Why we give you that color as we build towards completion of the merger.",40,"There's a lot whole lot of things going on right now, Ricky. We are in the middle of selling season. There's a lot of pieces. Why we give you that color as we build towards completion of the merger."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Kemp Dolliver of Avondale Partners.",10,"The next question comes from Kemp Dolliver of Avondale Partners."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I'm trying, as a customer, I'm trying to determine -- is the cost savings story here is pretty straightforward at as it's been with other deals. But beyond that, given, George, talked about very similar philosophies, but yes, there are things that you all",106,"I'm trying, as a customer, I'm trying to determine -- is the cost savings story here is pretty straightforward at as it's been with other deals. But beyond that, given, George, talked about very similar philosophies, but yes, there are things that you all have both companies have done that have been very different in approach and I think essentially when the rubber meets the road, have had different come across differently to the member. So can you talk just a little bit about what the combined entity is going to do, 1 or 2 things that you wouldn't have done, George, on your own?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, yes, that's actually pretty easy. David's built one tremendously good model of a disease-centric focused TRCs. And what he's been able to accomplish to that focus and improving people's health outcomes is quite incredible. And we went in different p",127,"Well, yes, that's actually pretty easy. David's built one tremendously good model of a disease-centric focused TRCs. And what he's been able to accomplish to that focus and improving people's health outcomes is quite incredible. And we went in different paths. We went around with the consumer side. And if I cannot take that disease-centric focus and couple it with understanding that behavioral aspects of the human being and put those 2 together, I think we've got a powerhouse for keeping people adherent, for tracking their needs, delivering incredible value for that patient. At the end of the day, when we deliver value to each and every one of our patients, that rolls up to an incredible savings for our clients, which is what it's all about."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Our next question comes from Tom Gallucci of Lazard Capital Markets.",11,"Our next question comes from Tom Gallucci of Lazard Capital Markets."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","George, you mentioned the long history there of Express ad doing consolidations, having doubled the company 3x in the last 12 or 13 years. Just as you head into the a deal like this, can you maybe highlight for us some of the things in terms of integratio",75,"George, you mentioned the long history there of Express ad doing consolidations, having doubled the company 3x in the last 12 or 13 years. Just as you head into the a deal like this, can you maybe highlight for us some of the things in terms of integration that you think is similar to the types of things you've done in the past, and maybe how this deal or Medco maybe a little bit different?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I think this one actually is big, it's complex, but Dave and his team have done an incredible job of keeping on 1 platform and keeping it disciplined and we look at some of our deals, especially if you go back to the value RX deal, I think we bought a com",153,"I think this one actually is big, it's complex, but Dave and his team have done an incredible job of keeping on 1 platform and keeping it disciplined and we look at some of our deals, especially if you go back to the value RX deal, I think we bought a company 9 stand-alone entities running 11 platforms, and many of them, they didn't have great processes and that was a challenge, to say the least. And we've learned a lot as we've rolled those together. So there is always similarities, there's always differences. At the end of the day, the only thing that matters is patient satisfaction and client savings. And we'll make every move and every step with those 2 goals in mind. And we are confident we'll be able to deliver a combined company in a reasonable short order.
Well, thank you, everyone, for joining us. David, any last remarks?"
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. Thanks for joining us everybody and stay tuned because I believe this is going to be very exciting.",19,"No. Thanks for joining us everybody and stay tuned because I believe this is going to be very exciting."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I thank you all for questions, comments, and we look forward to talking to you again in the near future. Thank you.",22,"I thank you all for questions, comments, and we look forward to talking to you again in the near future. Thank you."
1541811,136705591,144418,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you. This concludes today's teleconference. Please disconnect your lines at this time and have a wonderful day.",18,"Thank you. This concludes today's teleconference. Please disconnect your lines at this time and have a wonderful day."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Welcome to Express Scripts and Medco Health Solutions Definitive Merger Agreement Conference Call and Webcast. Today's call is being recorded and will be available for replay beginning 11:30 a.m. Eastern time. The conference call replay can be accessed by",80,"Welcome to Express Scripts and Medco Health Solutions Definitive Merger Agreement Conference Call and Webcast. Today's call is being recorded and will be available for replay beginning 11:30 a.m. Eastern time. The conference call replay can be accessed by dialing (855) 859-2056 or (404) 537-3406 and entering access code 84888352. [Operator Instructions] It is now my pleasure to turn the floor over to Mr. David Myers, Express Scripts Vice President of Investor Relations for opening remarks. Sir, you may begin."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, and welcome everyone to our conference call to discuss this morning's announcement of the proposed merger of Express Scripts and Medco. With me today are George Paz, Chairman and CEO; and Jeff Hall, CFO from ExpressScripts. Joining us is Dave S",179,"Thank you, and welcome everyone to our conference call to discuss this morning's announcement of the proposed merger of Express Scripts and Medco. With me today are George Paz, Chairman and CEO; and Jeff Hall, CFO from ExpressScripts. Joining us is Dave Snow, Chairman and CEO of Medco.
Before we begin, I need to read the following Safe Harbor statement.
Slide statements are comments made on this conference call may be forward-looking statements and may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions. These matters involve certain risks and uncertainties. The company's actual results may differ significantly from those projected or suggested in any forward-looking statement due to a variety of factors which are discussed in detail in the company's filings with the Securities and Exchange Commission. In addition, you should refer to the various informational legends included at the end of this presentation for additional information regarding the matters discussed.
Now I'm going to turn the call over to George, who will discuss this morning's announcement."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, David. Before I get started, let me take a minute to welcome Dave Snow to St. Louis. I've a lot of respect for what David and his team have accomplished over the years. They have strong fundamentals and proven people with strengths that are com",68,"Thank you, David. Before I get started, let me take a minute to welcome Dave Snow to St. Louis. I've a lot of respect for what David and his team have accomplished over the years. They have strong fundamentals and proven people with strengths that are complementary to ours. We look forward to this combination which will accelerate our efforts to lower healthcare costs while improving health outcomes."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thanks, George. We're also excited because our 2 organizations in our own ways represent 2 great success stories in American business. We have each been successful in creating shareholder value because we are both passionate about driving value to our cus",78,"Thanks, George. We're also excited because our 2 organizations in our own ways represent 2 great success stories in American business. We have each been successful in creating shareholder value because we are both passionate about driving value to our customers through service, innovation and the focus on cost and quality. Organizations have a shared desire to improve the way healthcare is delivered in this country, and I believe this creates a strong foundation for a successful future."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Since our inception 25 years ago, we've had an unwavering focus on making the user prescription drugs safe and more affordable. Over the years, we identified and tackled inefficiencies in the healthcare and succeeded through innovation, e",357,"Thank you, Dave. Since our inception 25 years ago, we've had an unwavering focus on making the user prescription drugs safe and more affordable. Over the years, we identified and tackled inefficiencies in the healthcare and succeeded through innovation, execution and a commitment to our business model of alignment. This unique foundation of alignment has enabled us to grow, become stronger and enhance our ability to provide dynamic services designed to drive out ways that improve health outcomes.
We have never been better positioned to take advantage of the long-term growth opportunities inherent in the PBMs with marketplace. Our behavior-centric approach continues to gain traction in the marketplace and we lead our sector in earnings growth and return on invested capital.
We have complemented our strong organic growth over the years through successful strategic mergers and acquisitions, which create opportunities to our new business segments, offer new services and increase the scope of our business. We have always been opportunistic in looking for ways to enhance value, and today's announcement of our combination with Medco is a perfect example.
This is a transaction the nation needs now. Massive changes around the horizon for our industry, including healthcare reform and the upcoming wave of brand-name drugs losing patent protection. Meanwhile, healthcare costs continue to rise. In this environment, we have to be nimble and we have to be smart enough to influence events and forward thinking enough to interpret events before they occur. Combined, we can build on our legacy of advancing healthcare, do innovation and an unwavering commitment to our clients.
Both Express Scripts and Medco have different strengths in clinical, specialty pharmacy services, research, the behavioral sciences, pharmacy technology and overall patient care. The combination of these complementary strengths will accelerate our clinical offerings, which will reduce costs and improve health outcomes. Our breadth of services across traditional PBM management, specialty management and Medicare Part D will be unparalleled in history. The combined company will also be well-positioned to help clients and members navigate the landscape in the wake of healthcare reform.
At this point, I'll invite Dave to talk about the transaction from Medco's perspective."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thanks, George. Since we took Medco public in 2003, we doubled the size of our business and delivered average annual earnings per share growth of 22%. We've done that by driving clinical innovation focused on addressing the 50% of patients with chronic an",209,"Thanks, George. Since we took Medco public in 2003, we doubled the size of our business and delivered average annual earnings per share growth of 22%. We've done that by driving clinical innovation focused on addressing the 50% of patients with chronic and complex disease, who account for 96% of all drug spending and more than 75% of healthcare costs.
We launched Therapeutic Resource Centers, built a world-class Accredo Specialty Pharmacy business, generated breakthrough science in research in the area of personalized medicine, and created a Medicare business that receives CMS' first and only national 5-star rating. We are a trailblazer in pharmacogenomics and have extended our footprint internationally. Clinical excellence in service innovations were the catalyst for our growth, and over the last 8 years, we've quintupled our market cap.
With that history, why this combination? Over the past year, we at Medco have been very, very focused on the changing healthcare environment in this country, which is demanding better, faster and less expensive capabilities for all who participate in the healthcare system. This strategic combination delivers on these important value propositions to the benefit of our clients, patients and shareholders. We look forward to working with you, George and the Express Scripts team, in completing this merger."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Our successful track record of strategic combinations is based in a philosophy of taking a best-in-class of both organizations and combining them for the benefit of our clients, patients and stockholders. We will unite the expertise of 2",254,"Thank you, Dave. Our successful track record of strategic combinations is based in a philosophy of taking a best-in-class of both organizations and combining them for the benefit of our clients, patients and stockholders. We will unite the expertise of 2 complementary PBMs to make the delivery of prescription drugs safer and less expensive for millions of Americans. By boning the combined clinical skills with the behavioral sciences, we'll be able to accelerate efforts from our greater efficiencies in the healthcare system and better protect American families from the rising costs of prescription medications.
Our shared vision is to increase therapy adherence, lower costs and drive to better health outcomes. This combination will truly build on our legacy of innovation, alignment with our clients and patients, and our commitment to making drugs safer, more affordable. And because we are aligned, as we deliver increased value to our clients and patients, our shareholder performance improves. This transaction continues our commitment to strong growth, both organically and through strategic combinations. The merger with Medco will provide the opportunity to accelerate our ability to achieve cost savings for our patients and clients while improving health outcomes.
One of the keys to our history of building shareholder value has come through successful strategic mergers and acquisitions. Our focus of the years on execution and innovation has enabled us to successfully integrate these businesses, and we use the same discipline in approaching this transaction. 
At this point, I will ask Jeff to discuss the financial aspects of this transaction."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, George. Let me start off by saying that we have observed Medco over the years and have worked closely with them on this transaction. It's clear they share our passion for driving out ways in healthcare and providing world-class patient care. Th",429,"Thank you, George. Let me start off by saying that we have observed Medco over the years and have worked closely with them on this transaction. It's clear they share our passion for driving out ways in healthcare and providing world-class patient care. This merger is consistent with our philosophy on capital deployment. First, to fund internal investments, and second, to look for strategic mergers and acquisitions.
We have funded our internal needs, and so I'm pleased to take you through some of the details of our combination, which is expected to generate strong returns on the capital invested. The name of the combined companies will be Express Scripts Holding, Inc. It will be headquartered in St. Louis, Missouri. George Paz will be the Chairman and CEO, and the board will consist of Express Scripts existing board, plus 2 members from Medco's board.
We will exchange $28.80 in cash and 0.81 shares of Express Scripts stock for each share of Medco stock. This results in a purchase price of approximately $29 billion or $71.36 per share, which represents a 28% premium over yesterday's closing price. We have committed financing in place for the cash component and anticipate raising permanent capital in the form of bank debt and bonds. We are committed to maintaining our investment grade rating and we have structured this transaction to do so. At the close of this transaction, Express Scripts shareholders will own approximately 59% of the combined company, and Medco shareholders will own about 41%. We expect the transaction to close in the first half of 2012, subject to regulatory approval.
The merger is expected to be slightly accretive in the first full year after closing, and moderately accreting -- accretive after the integration is completed. Based on our due diligence today, we have identified $1 billion of synergy. In addition, we expect to deliver more than $4 billion of annual cash from operations once fully integrated.
For modeling purposes, we have excluded the UnitedHealthcare contract beyond the end of 2012. We have a strong track record of the completing acquisitions, integrating them seamlessly and meeting or exceeding our synergy expectations.
In addition to this track record, we have also demonstrated our ability to reduce leverage rapidly, and our expectations for this transaction are no different. At the time of closing, we expect to be at the debt level of 2.9x EBITDA. We expect to return back to our targeted range of 1 to 2x with an 18 months of closing.
And now I'll turn the call back to George for some final remarks."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Jeff. We are excited about this outstanding opportunity. This is the seventh major transaction we have made since I joined the company in 1998, and the third one that is doubling the size of our company. We believe that this transaction is pro-",306,"Thank you, Jeff. We are excited about this outstanding opportunity. This is the seventh major transaction we have made since I joined the company in 1998, and the third one that is doubling the size of our company. We believe that this transaction is pro-competition, will reduce healthcare costs and very much in the public interest.
Everyone agrees that our country needs to get a handle on and control its healthcare costs, and our priority on behalf of our clients and patients is to help drive the way set of the healthcare industry. Reducing costs and improving health outcomes is our primary goal. This goal is reflected on our business model of aligning our interests to those of our clients and our patients. That is, we make money when they save money. This transaction allows us to accelerate cost savings and improve health outcomes. Given the level of competition at the PBM business, the sophistication of our customers and their desire to keep their healthcare costs down and the real benefits arising out of this very exciting transaction, we believe we will work our way successfully through the regulatory approval process. Being disciplined on our approach to acquisition is a key to our success. Our industry-leading ROIC is proof of our ability to acquire and integrate major acquisition. The combination with Medco is a continuum of our disciplined approach.
Our roadmap to completion involves completing all required SEC filings, holding special meetings for both sets of stockholders and working through the regulatory approval process. We believe this transaction can be completed in the first half of 2012. I want to again, share my enthusiasm for this transaction, which validates our differentiated business model and provides a platform of continued strong growth in the future.
At this point, we would be happy to answer any questions. Operator?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Our first question is coming from Robert Willoughby of Bank of America Merrill Lynch.",16,"[Operator Instructions] Our first question is coming from Robert Willoughby of Bank of America Merrill Lynch."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","One long question for you. The synergy number of $1 billion seems low relative to what Express generated on the WellPoint deal. Can you give us anything anecdotally what that $1 billion is comprised of? And secondarily, George, Medco's in a number of busi",77,"One long question for you. The synergy number of $1 billion seems low relative to what Express generated on the WellPoint deal. Can you give us anything anecdotally what that $1 billion is comprised of? And secondarily, George, Medco's in a number of businesses that you have had less interest in, in the past, whether it's a Medicare, PDP or infusion therapy or the international arena. Any preliminary views on your plans for some of those relationships?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, Robert, I think we've always been very open and always tried to be innovative. I look forward to spending the next couple of months or the next 6 months or so or more with David and understanding the opportunities that exist in Europe. And his visio",132,"Well, Robert, I think we've always been very open and always tried to be innovative. I look forward to spending the next couple of months or the next 6 months or so or more with David and understanding the opportunities that exist in Europe. And his vision on the different businesses they've entered into over the years. I think what I would tell you at this stage is, we're very early on and we will complete a thorough analysis and determine what's in the best interest of our shareholders and figure out how to enhance value across all lines of our business. From a synergy perspective, I'll let Jeff talk to that. But again, we're very preliminary in this process and we look forward to getting more details as the merger evolves."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, Bob, so, what we said this morning is based on the due diligence we've identified $1 billion of synergy. But I'd caveat that by saying the deal is, at the end of the day, not about cutting costs, it's about putting 2 great companies together to accel",88,"Yes, Bob, so, what we said this morning is based on the due diligence we've identified $1 billion of synergy. But I'd caveat that by saying the deal is, at the end of the day, not about cutting costs, it's about putting 2 great companies together to accelerate cost reductions for our clients and their members in healthcare, while improving the healthcare outcomes for everybody. So that's really the primary focus here. And we're excited about the combined capabilities of the 2 companies to execute on exactly that."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And just to pile on real quick, Bob, as you know our business follow an alignment, as we take down those costs for our patients and our clients, we create value for our shareholders. So we believe there's tremendous opportunity here as evidenced in $1 bil",46,"And just to pile on real quick, Bob, as you know our business follow an alignment, as we take down those costs for our patients and our clients, we create value for our shareholders. So we believe there's tremendous opportunity here as evidenced in $1 billion."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Larry Marsh of Barclays Capital.",10,"The next question comes from Larry Marsh of Barclays Capital."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Several things. One, just George and Dave, could you elaborate a little bit how long you guys have been in any sort of conversation without any confidentiality issues? And then I guess also, as you think about -- I agree, I think the $1 billion synergies",135,"Several things. One, just George and Dave, could you elaborate a little bit how long you guys have been in any sort of conversation without any confidentiality issues? And then I guess also, as you think about -- I agree, I think the $1 billion synergies seems modest, but I guess a bigger picture view is, when I think about with Medicare, with United, I guess, you're pulling that out of your numbers. But when they mentioned to you that they were terminating their service agreement, did they confirm that they're bringing that in-house or have they not suggested this? And I guess along with that, if they are bringing it in this house, would that be an important argument that you make to the FTC to show valid and strong competition in the marketplace?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll let Dave speak to the United situation. Do you want to?",13,"I'll let Dave speak to the United situation. Do you want to?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, sure. Let me take that first. So as you might imagine, the conversations with Express Scripts and the conversations with our client, United, we're on independent, completely independent tracks and came to their own independent conclusion. So the anno",98,"Yes, sure. Let me take that first. So as you might imagine, the conversations with Express Scripts and the conversations with our client, United, we're on independent, completely independent tracks and came to their own independent conclusion. So the announcement relative to United is tied to last week's conversations with them directly, and our decision that, in fact, what was left on the table was did not meet the needs of our shareholders. So that was an independent decision that we arrived at and that was very recent. And here, it is announced when our decision is made."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I see. But you don't know what they're going to be doing with that business?",15,"I see. But you don't know what they're going to be doing with that business?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I mean Larry, what I would say is there is plenty of paper trail that's public that indicates what the alternative is they've been thinking about. So without putting words in Steve Hemsley's mouth, I have to assume that he will go with that other al",59,"Well, I mean Larry, what I would say is there is plenty of paper trail that's public that indicates what the alternative is they've been thinking about. So without putting words in Steve Hemsley's mouth, I have to assume that he will go with that other alternative that he's publicly talked about so often, which is take it in-house."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Very good. And then just the timing of the talks and discussion?",12,"Very good. And then just the timing of the talks and discussion?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Dave and I have been friends for a lot of years. We sit on our trade association board together and we've had numerous opportunities to talk in the past. The beauty of our 2 companies is we share a common passion for taking costs out of the system and imp",106,"Dave and I have been friends for a lot of years. We sit on our trade association board together and we've had numerous opportunities to talk in the past. The beauty of our 2 companies is we share a common passion for taking costs out of the system and improving health outcomes, optimally go out at a slightly different or quite a bit differently, but at the end of the day, by combining those 2 differences, we create a tremendous synergistic opportunity to take even more cost out, create better value for our patients and clients, and drive better outcomes. So we're very excited about this."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Right, that's very good. And again I guess, George, just finally, when you mentioned your argument to the FTC, is being able to drive cost down and share those to your customers, that seems to be the important message here today. What would you respond to",54,"Right, that's very good. And again I guess, George, just finally, when you mentioned your argument to the FTC, is being able to drive cost down and share those to your customers, that seems to be the important message here today. What would you respond to any pushback around concentration of mail script volume?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, mails -- I don't want to deliberate the FTC issues. We're obviously going to work very closely. If you take a step back and say what does America need today more than anything else, we -- healthcare costs that are under control and driving quality.",174,"Well, mails -- I don't want to deliberate the FTC issues. We're obviously going to work very closely. If you take a step back and say what does America need today more than anything else, we -- healthcare costs that are under control and driving quality. You ought to hear David speak from a public podium about quality and how important it is and how important it is to take costs out of the system. Again, we share that common goal. The FTC is part of the administration, which is part of government, which is also is very focused on healthcare costs. We're going to work very hard to show the government the value that this brings to patients and members as we drive those costs out of the system. And we wouldn't be doing this if we didn't think we didn't have a very good chance of getting this through. It's a lot of work and we don't need a lot of work to do nothing. So we're excited about it moving forward."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Next question comes from Lisa Gill of JPMorgan.",8,"Next question comes from Lisa Gill of JPMorgan."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And George, I'll be honest, I mean, I was thinking an acquisition maybe in 2014, so obviously, I think all of us were a little surprised today. Just a few questions I guess around the selling season. Can we maybe just talk about, if the 2012 selling seaso",118,"And George, I'll be honest, I mean, I was thinking an acquisition maybe in 2014, so obviously, I think all of us were a little surprised today. Just a few questions I guess around the selling season. Can we maybe just talk about, if the 2012 selling season wrapped up, number one? And number two, if someone has is in the decision-making process of, ""I've awarded the business to either Medco or Express,"" does this open it up for them to come back and perhaps change their decision based on this combined entity? So that would be my first question. And then secondly, is there hope to wrap this up before we get into the 2013 selling season?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, the answer to the last question first is yes. As far as the selling season is concerned -- I prefer to wait till the third quarter. There's still an awful lot of decisions that are out there. We're in the middle of renewing clients and selling busin",116,"Well, the answer to the last question first is yes. As far as the selling season is concerned -- I prefer to wait till the third quarter. There's still an awful lot of decisions that are out there. We're in the middle of renewing clients and selling business. And obviously, our companies will remain standalone and compete vigorously in the marketplace until this transaction closes. And I prefer just to hold off on that selling season. As far as clients -- our clients have always asked for more. And the question is, is the more value we can deliver or cost contractions they need? And hopefully, we can deliver more value and that satisfies their needs."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then, just lastly, George. Obviously, there's a very public dispute between yourself and Walgreens around this. Do you believe that this potential combination brings them back to the table? I mean, this is an awful lot of business for them should the",46,"And then, just lastly, George. Obviously, there's a very public dispute between yourself and Walgreens around this. Do you believe that this potential combination brings them back to the table? I mean, this is an awful lot of business for them should the transaction go through."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I did call Greg this morning, gave him a heads-up as to what was going on. I think CEOs do that with each other once it became public, of course. And just let him know that this was coming down. And Greg and I talked and it's I'm hopeful that we wil",69,"Well, I did call Greg this morning, gave him a heads-up as to what was going on. I think CEOs do that with each other once it became public, of course. And just let him know that this was coming down. And Greg and I talked and it's I'm hopeful that we will come to a conclusion on this. We'll have to look to see how that plays out."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Ross Muken of Deutsche Bank.",10,"The next question comes from Ross Muken of Deutsche Bank."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So obviously, this changes the theoretically assuming successful or hopeful close, and this changes the competitive landscape in the context of the positioning of the other entities that now exist post the sort of United business going in house. How do yo",95,"So obviously, this changes the theoretically assuming successful or hopeful close, and this changes the competitive landscape in the context of the positioning of the other entities that now exist post the sort of United business going in house. How do you view, on a pro forma basis, kind of the strategic positioning of the pro forma asset that you've created with the unique capabilities of each of the 2 businesses as it sort of has to compete in this change, but still highly competitive landscape of players that look a bit dissimilar to yourself?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","To be quite frankly, this is a great world. There's many, many players out there that offer different approach to solve healthcare costs that are increasing. One of the problems I've had over the years is David, my pitch and David's pitch were pretty simi",175,"To be quite frankly, this is a great world. There's many, many players out there that offer different approach to solve healthcare costs that are increasing. One of the problems I've had over the years is David, my pitch and David's pitch were pretty similar. We both went after the same thing. We both thought that pharmacogenomics and personalized medicine and attacking member decision-making were the right answers. We were fairly close. Obviously, he's one of my competitors. Likes to use the retail drugstore chain as an avenue, another one of my competitors. So quite a few of my competitors are in-house. PBMs for managed care companies, so there's all types, there's tons of competition out there. And the beauty of the world today is, we're fairly unique in our offering. But that gives the chooser of our services many, many different options on how to choose which PBM and which process to go with, that are trying to get to lower their costs. So I think we are very well defined in the industry."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And Ross, let me add something. It's Dave. I think if you think about this strategically at 30,000 feet and I'm talking broader than PBM, I'm talking the healthcare system, I believe you are going to see all sorts of combinations across the spectrum of he",137,"And Ross, let me add something. It's Dave. I think if you think about this strategically at 30,000 feet and I'm talking broader than PBM, I'm talking the healthcare system, I believe you are going to see all sorts of combinations across the spectrum of healthcare as everyone realigned to the new imperatives related to healthcare reform and the demands the government is making relative to lowering costs of the healthcare system. And I think this combination puts us squarely on the side of a solution to what the government is hopefully going to be pushing for over the next decade. So I think you'll be surprised that the other healthcare combinations that are encouraged by the incentives in healthcare reform, and this is just an alignment that makes enormous sense as you look to the future."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Great. And maybe just one quick follow-up. In terms of the synergies related to the transaction, how should we think about sort of the pacing assuming that mid-year or first half 2011 close, in terms of what synergies that were named were sort of easier t",72,"Great. And maybe just one quick follow-up. In terms of the synergies related to the transaction, how should we think about sort of the pacing assuming that mid-year or first half 2011 close, in terms of what synergies that were named were sort of easier to capture and some flow through kind of in the only part of the transaction? And which would kind of take a slightly longer piece of time?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","As we said earlier, we expect the deal to close in the first half of 2012 and we're sitting here in the second half of 2011. What I would prefer to do is defer your question until we get closer to the closing and see where we are at. And obviously, on tha",65,"As we said earlier, we expect the deal to close in the first half of 2012 and we're sitting here in the second half of 2011. What I would prefer to do is defer your question until we get closer to the closing and see where we are at. And obviously, on that time, we will build out the guidance and the model for you."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Steven Valiquette of UBS.",9,"The next question comes from Steven Valiquette of UBS."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just trying to get a little more color on the process with the FTC. Just kind of thinking ahead and being the borderline case. What are the scenarios? Do they come down to potentially giving up a certain percent of customers? Is it just sort of a yes or n",70,"Just trying to get a little more color on the process with the FTC. Just kind of thinking ahead and being the borderline case. What are the scenarios? Do they come down to potentially giving up a certain percent of customers? Is it just sort of a yes or no with the existing books of business? How does that sort of play out the way you think about the FTC?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, first of all, I don't share your opinion about a borderline case. I think everything Dave just talked about in healthcare is being delivered in this model of this merger. And I believe it's what America needs, it's what the patients need, it's what",87,"Well, first of all, I don't share your opinion about a borderline case. I think everything Dave just talked about in healthcare is being delivered in this model of this merger. And I believe it's what America needs, it's what the patients need, it's what the clients need, and our job is to just to provide the information and help the FTC work through this process. And we feel -- as I said earlier, we wouldn't do this if we didn't think we couldn't get it done."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. So the way it stands right now, you're not too worried from FTC point of view that's what it boils down to?",23,"Okay. So the way it stands right now, you're not too worried from FTC point of view that's what it boils down to?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, that's correct.",3,"Yes, that's correct."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from John Kreger of William Blair.",10,"The next question comes from John Kreger of William Blair."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a follow-up question on the synergies and where you think they might come from. George, from your perspective, is there still room as you're going to gain a lot more scale with this deal? Do you still see room to drive additional purchasing opportuni",61,"Just a follow-up question on the synergies and where you think they might come from. George, from your perspective, is there still room as you're going to gain a lot more scale with this deal? Do you still see room to drive additional purchasing opportunities in the channel? And if so, where do you think the biggest opportunities still are?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","If I take the total cost of goods sold, SG&A and DPC we're talking about $100 billion of spend. I feel very comfortable there's a lot of opportunities to take costs out of the equation.",35,"If I take the total cost of goods sold, SG&A and DPC we're talking about $100 billion of spend. I feel very comfortable there's a lot of opportunities to take costs out of the equation."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Have you gotten far enough to know what you're going to do on the systems side or the facility side?",21,"Have you gotten far enough to know what you're going to do on the systems side or the facility side?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No, we haven't. We just announced today, John. Without obviously coming. We've got to go through that process. Medco, we compete with them everyday. They've got incredible people, incredible systems and incredible approaches. I'm a little biased, but I th",143,"No, we haven't. We just announced today, John. Without obviously coming. We've got to go through that process. Medco, we compete with them everyday. They've got incredible people, incredible systems and incredible approaches. I'm a little biased, but I think I've got pretty good ones, too. And now the question is, how do I put them both together and get the best of the best? And I'm confident. And if you look back at DPS, we kept their systems. If you look at Value Rx, they brought us the unique capabilities in mail order. As I go down this list, everyone of our acquisitions have been strategic. This one is incredibly strategic to us and they will bring us incredible tools and incredible people. And we are just so excited to be uniting these 2 entities together to pick up that excess cost."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Ricky Goldwasser of Morgan Stanley.",10,"The next question comes from Ricky Goldwasser of Morgan Stanley."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a follow-up on the synergies. Does the $1 billion in synergies that you identified from back early on assumes consolidating their relationship with your respective distributors?",28,"Just a follow-up on the synergies. Does the $1 billion in synergies that you identified from back early on assumes consolidating their relationship with your respective distributors?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Again, I'm not going to get into where everything situated now. We're way too early on. We got a lot of work to do. We feel very comfortable with the numbers we have presented, and I'm just going to leave it at that.",43,"Again, I'm not going to get into where everything situated now. We're way too early on. We got a lot of work to do. We feel very comfortable with the numbers we have presented, and I'm just going to leave it at that."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. and then just in terms of market share of the combined entity, it's kind of like 30% are we in the ballpark once we factor in kind of like take out United out of kind of Medco equation? Is 30% market share a reasonable number to think about it?",50,"Okay. and then just in terms of market share of the combined entity, it's kind of like 30% are we in the ballpark once we factor in kind of like take out United out of kind of Medco equation? Is 30% market share a reasonable number to think about it?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","What's the purpose of your question? I'm trying to?",10,"What's the purpose of your question? I'm trying to?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","In terms of kind of like your market share in terms of scripts that the combined companies would cover?",19,"In terms of kind of like your market share in terms of scripts that the combined companies would cover?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","There's a lot whole lot of things going on right now, Ricky. We're in the middle of selling season. There's a lot of pieces. Why don't we give you that color as we build towards completion of the merger.",40,"There's a lot whole lot of things going on right now, Ricky. We're in the middle of selling season. There's a lot of pieces. Why don't we give you that color as we build towards completion of the merger."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","The next question comes from Kemp Dolliver of Avondale Partners.",10,"The next question comes from Kemp Dolliver of Avondale Partners."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I'm trying, as a customer, I'm trying to determine -- is the cost savings story here is pretty straightforward as it's been with other deals. But beyond that, given, George, you talked about very similar philosophies, but yes -- but yet, there are things",113,"I'm trying, as a customer, I'm trying to determine -- is the cost savings story here is pretty straightforward as it's been with other deals. But beyond that, given, George, you talked about very similar philosophies, but yes -- but yet, there are things that you all have both companies have done that have been very different in approach and I think at the -- essentially when the rubber meets the road, have had different -- come across differently to the member. So can you talk just a little bit about what the combined entity is going to do, 1 or 2 things that you wouldn't have done, George, on your own?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, yes, that's actually pretty easy. David's built one tremendously good model of a disease-centric focused TRCs. And what he's been able to accomplish to that focus and improving people's health outcomes is quite incredible. And we went in different p",127,"Well, yes, that's actually pretty easy. David's built one tremendously good model of a disease-centric focused TRCs. And what he's been able to accomplish to that focus and improving people's health outcomes is quite incredible. And we went in different paths. We went around with the consumer side. And if I cannot take that disease-centric focus and couple it with understanding that behavioral aspects of the human being and put those 2 together, I think we've got a powerhouse for keeping people adherent, for tracking their needs, delivering incredible value for that patient. At the end of the day, when we deliver value to each and every one of our patients, that rolls up to an incredible savings for our clients, which is what it's all about."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Our next question comes from Tom Gallucci of Lazard Capital Markets.",11,"Our next question comes from Tom Gallucci of Lazard Capital Markets."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","George, you mentioned the long history there of Express in doing consolidation, having doubled the company 3x in the last 12 or 13 years. Just as you head into the a deal like this, can you maybe highlight for us some of the things in terms of integration",75,"George, you mentioned the long history there of Express in doing consolidation, having doubled the company 3x in the last 12 or 13 years. Just as you head into the a deal like this, can you maybe highlight for us some of the things in terms of integration that you think is similar to the types of things you've done in the past, and maybe how this deal or Medco maybe a little bit different?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, we're going to cancel everyone's vacation to start with. So we know, they're going over the summer now, everybody's got a challenge. I think this one actually is big, it's complex, but Dave and his team have done an incredible job of keeping on 1 pla",177,"Yes, we're going to cancel everyone's vacation to start with. So we know, they're going over the summer now, everybody's got a challenge. I think this one actually is big, it's complex, but Dave and his team have done an incredible job of keeping on 1 platform and keeping it disciplined. And we look at some of our deals, especially if you go back to the Value Rx deal, I think we bought a company that was 9 standalone entities, running 11 platforms, and many of them, they didn't have great processes and that was a challenge, to say the least. And we've learned a lot as we've rolled those together. So there's always similarities, there's always differences. At the end of the day, the only thing that matters is patient satisfaction and client savings. And we'll make every move and every step with those 2 goals in mind. And we are confident we'll be able to deliver a combined company in a reasonable short order.
Well, thank you, everyone, for joining us. David, any last remarks?"
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. Thanks for joining us everybody, and stay tuned because I believe this is going to be very exciting.",19,"No. Thanks for joining us everybody, and stay tuned because I believe this is going to be very exciting."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I thank you all for questions, comments, and we look forward to talking to you again in the near future. Thank you.",22,"I thank you all for questions, comments, and we look forward to talking to you again in the near future. Thank you."
1541811,136705591,144527,"MedcoHealth Solutions Inc., Q2 2011 Earnings Call, Jul 21, 2011",2011-07-21,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you. This concludes today's teleconference. Please disconnect your lines at this time and have a wonderful day.",18,"Thank you. This concludes today's teleconference. Please disconnect your lines at this time and have a wonderful day."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions Third Quarter 2011 Earnings Call. [Operator Instructions] I would now like to turn the call over to",55,"Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the MedcoHealth Solutions Third Quarter 2011 Earnings Call. [Operator Instructions] I would now like to turn the call over to Vice President of Investor Relations, Ms. Valerie Haertel. You may begin."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Andrea. Good morning, everyone, and thank you for joining us on Medco's Third Quarter 2011 Earnings Conference Call. With me today as speakers are Chairman and Chief Executive Officer, Dave Snow; and Rich Rubino, Chief Financial Officer. Also j",315,"Thank you, Andrea. Good morning, everyone, and thank you for joining us on Medco's Third Quarter 2011 Earnings Conference Call. With me today as speakers are Chairman and Chief Executive Officer, Dave Snow; and Rich Rubino, Chief Financial Officer. Also joining us for our question-and-answer session are: Kenny Klepper, President and Chief Operating Officer; Tom Moriarty, General Counsel, Secretary and President of Global Pharmaceutical Strategies;, President of Accredo Health Group; Dr. Rob Epstein, President of Advanced Clinical Science and Research; Tim Wentworth, Group President of the Employer and Key Accounts; Glenn Taylor. During the course of this call, we will make forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in our SEC filings.  Copies of Medco's filings are available from the SEC, the Medco Investor Relations Department or the Medco website. Medco intends to use the Investor Relations section of its website as a means for disclosing material non-public information and for complying with these disclosure obligations under Regulation FC. The copyrights for the contents of this discussion and the written materials used on this earning call are owned by MedcoHealth Solutions, Inc. 2011. Slides to accompany our presentation, which detail our financial and operating results, and the guidance discussed on this call, are currently available in the Events section of the Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-Q after the close of the market today. At this time, I would like to turn the call over to Dave Snow. Dave?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valerie, and thanks, to all of you for joining us this morning. Today, we are reporting strong third quarter 2011 earnings and narrowing the range of our full year 2011 earnings per share guidance for the high end of previous guidance. GAAP dil",1419,"Thank you, Valerie, and thanks, to all of you for joining us this morning. Today, we are reporting strong third quarter 2011 earnings and narrowing the range of our full year 2011 earnings per share guidance for the high end of previous guidance. GAAP diluted earnings per share for third quarter 2011 reached $0.90 or $0.96, excluding merger-related expenses incurred in the quarter, representing solid 12.9% growth over third quarter 2010. Even when including the merger-related expenses, our GAAP EPS is a record. Our diluted earnings per share, excluding all intangible amortization and the merger-related expenses, reached a record $1.07, reflecting a 12.6% growth rate over third quarter 2010. Importantly, our gross margin percentage was consistent with third quarter 2010 at 6.9%, up meaningfully from the 6.5% in second quarter 2011. And our EBITDA per script, excluding the merger-related expenses, also reached a record level at $3.43. Our mail volumes continued to be strong at this stage of the year. We are now confident that we will meaningfully surpass the high-end of our previous mail volume guidance range of 108 to 110 million script. 
Our Accredo business also delivered strong results with revenue growth of 16.7% and operating income growth of 33%, all at a 6.8% gross margin, consistent with third quarter 2010. The company is performing well across the board and we now at our a 2007 diluted earnings per share guidance excluding merger-related expenses and all intangible amortization to a range of $4.08 to $4.12, which represents 15% to 16% growth over 2010. Our previous guidance of $4.02 to $4.12 reflect the growth of 13% to 16% over 2010. 
For the 2011 selling season, our annualized new name sales totaled $3.2 billion, up from the $3 billion we previously reported. We have completed 98% of our 2011 renewals amounting to $16 billion client drove spent. Our 2012 annualized new name sales currently stand at approximately $1.6 billion, double the $800 million reported last quarter as our clinically focused model continues to have strong appeal in the marketplace. 
Now, I would like to share some thoughts on the pending merger with Express Scripts. As you saw in the recently filed S4, after an extensive review of numerous strategic alternatives through an exhaustive planning process, we determined that combining with Express Scripts was the best strategy to maximize value for our clients, members and shareholders. The merger is the solution to control escalating healthcare costs in America, the costs that are undermining U.S. competitiveness in the global economy. In 2010 alone, U.S. spending for prescription drugs reached $307.4 billion. Our aging population and an increased prevalence of chronic diseases are projected to drive a 50% increase in prescription drug spending to well over $450 billion by 2019. At Medco, we have lowered the cost of prescription medications for our clients by enabling greater use of generics, driving savings of $3.7 billion to Medco's clients in full year 2010, and $2.7 billion year-to-date in 2011. We have expertly managed the challenges associated with the rising costs of care, including specialty medications, that we have improved efficiencies my enabling clients to make effective use of the highest value channels of distribution, including mail-order delivery for chronic medication. The combined organization is well positioned to advance the quality and cost set forth in America's healthcare reform legislation by combining 2 innovative approaches, Medco advanced clinical services that utilize the evidence-based protocols and Express Script Services which focus on behavioral science to increase medication adherence. As you can see from this year's performance and our projections included in the S4, we are planning to merge from a position of strength. Combining forces with Express Scripts positions us to deliver what our nation needs now, high-quality care at even lower cost to our patients and clients, and we can do this much more effectively together. Many of you have asked where we are in the regulatory review process and what will be the likely outcome. As I have said previously, and most recently at a hearing in Washington DC, we would not have announced this combination if we were not confident in our ability to obtain the necessary regulatory approvals. As we stated when the deal was announced, we anticipated the transaction will close in the first half of 2012 and we remain confident in that projection for a number of reasons. First, the opponents of this proposed mergers are not customers. Our proposed merger is receiving very positive reaction from our customers who understand that the combination of Medco and Express Scripts can mean to them and their members. This combination includes over $1 billion in savings as it's expected to be delivered to customers after closing. Second, the PBM marketplace is highly competitive and will remain highly competitive after the deal closes. There are at least 10 PBMs serving the largest employers in the Fortune 50 and over 15 serving the Fortune 500 alone. In addition, these and and many other PBMs also serve large government account and health plan. In fact, today, our competitors include over 40 PBMs with household names like Etna, CIGNA, CVS Caremark and others who may not be as well known, but continues to make major investments such as prime therapeutic, Cialis and XC. Additionally, in specialty drugs, hundreds of different firms compete including PBMs, pharmacy chains and independents, wholesalers, managed-care organizations, as well as standalone specialty pharmacy. Also and very importantly, United Health Group has announced its plans to bring in house 40 million live previously served by Medco and combine that business with a substantial Medicare and other national employer lives that are already directly service through its own PBM known as Optimal RX. With this, United Health Group will be one of the nation's largest PBMs. The merger with Express Scripts provides us with the opportunity to reduce our acquisition costs for medication and pass on additional savings for our clients and agents. The SEC is concerned as protecting consumer, not competitors. That means ensuring competition remains healthy in the marketplace and consumers are not harmed by price increases resulting from tier competitors. We firmly believe that this combination will benefit consumers. To conclude my remarks on this topic, the proposed merger, in our view, embodies the spirit of the new healthcare reform legislation that promotes innovation to solve America's healthcare burden. As I have said previously, we are confident that this merger will receive SEC approval in the first half of 2012. We are an important part of the solution and we remain dedicated to providing our clients with quality care at the lowest possible cost. Not only does this merger promises to serve our clients well, it will create substantial value for our shareholders. 
Before I turn the call over to Rich who will cover the 2012 guidance more thoroughly, I would like to highlight a few observations for next year. First, as you saw in the S4 and in our earnings release, revenue is expected to decrease to approximately $58.9 billion in 2012, equating to a $10 billion or 14.5% decline. This decline contains many moving parts, including clients that are transitioning from Medco due to acquisitions by competitors and other regions, also contributing to the decline in revenues is the generic wave in 2012, which is projected to have reduced our net revenues next year by approximately $6.5 billion. If you look at this from the other side of the ledger, this is value that accrues to clients and patients, a massive winds to consumer. The last point I will make on guidance is regarding our EBITDA, which at the high-end is expected to grow by as much as 9.5% in 2012 as a function of the generic wave and continuously improving business efficiencies. And looking at EBITDA as a percentage of revenue, what is known as EBITDA margin, we expect this measure to increase from approximately 4.5% in 2011 to as much as 5.8% at the high-end in 2012, which would represent a Medco record. We expect meaningful increases in our gross margin percentage and EBITDA per script for 2012 as well, resulting not only from the generic wave and business efficiencies I just mentioned, but also from the fact that the large retail clients that will be transitioning in 2012 carry extraordinarily low profit margins. With that, I'll turn the call over to our CFO, Rich Rubino, who will discuss additional third quarter 2011 financial performance details and provide you with additional color regarding our 2012 guidance. Rich?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. As Dave mentioned, our third quarter EPS results were strong, with record GAAP diluted EPS of $0.90. The record gets even more impressive when you exclude the $0.06 in merger-related expenses, bringing that number to an equi",2217,"Thank you, Dave. Good morning. As Dave mentioned, our third quarter EPS results were strong, with record GAAP diluted EPS of $0.90. The record gets even more impressive when you exclude the $0.06 in merger-related expenses, bringing that number to an equivalent of $0.96, a growth of 12.9% over third quarter last year. Diluted EPS, excluding all intangibles and merger-related expenses, of $1.07 for this quarter is also a record, representing a 12.6% increase. This $1.07 is a meaningful $0.08 higher than our previous EPS record of $0.99 set in the fourth quarter of 2010. The merger-related expenses, which primarily include bankruptcies, legal fees and employee retention related expenses, totaled $36.6 million or $0.06 per share. And that of course, was for the third quarter of 2011, with $35.6 million flowing to SG&A expense and the remaining $1 million flowing to cost of sales. We currently expect the fourth quarter 2011 amount to merger-related expenses to be slightly less than the third quarter at $0.05 per share, bringing full the year 2011 estimated merger-related expenses to $0.11 per share. 
Total third quarter 2011 net revenues reached $17.0 billion, representing growth 4.1% over third quarter 2010. Our product revenues grew at 3.4% over third quarter 2010 to $16.6 billion, reflecting our new business wins, as well as higher prices charged by brand-name pharmaceutical manufacturers, partially offset by a higher mix of lower-priced generics. On that generics point, our clients and members saved approximately $700 million this quarter compared to third quarter 2010 from increased utilization of generic. For 2011, we expect these savings to total approximately $3.7 billion. If you look at how much Medco clients and members have saved from generic drug utilization since 2006 when the first blockbuster drug started losing their patent, it is a very substantial number, $16.7 billion, add to that the expected record 2012 year for generic savings that Dave already mentioned, contributing another expected $6.5 billion in savings and the cumulative savings since 2006 rose to over $23 billion. 
Service revenue continued to be a significant growth driver, increasing 26.9% over third quarter 2010 to a record $379 million. This strong performance reflects the service revenue contribution from UBC, as well as growth to our client service offerings across the company. 
Turning to rebates, we earned $1.5 billion for the third quarter, an increase of 5.6% over the same period last year even though we are dispensing fewer brand-name medications and more generics. This year-over-year growth is attributable to continuous improvements in formulary contracts. Our third quarter 2011 rebate retention rate was 13.0%, consistent with the 12.8% in the third quarter 2010 as we continue to drive significant value to clients in a highly transparent manner. 
As Dave mentioned, mail-order volume remains strong with clients and members continuing to the lower cost and clinically effective channel. In third quarter 2011, our toll mail-order prescription volume was 27.4 million. Within this, generic prescription mail-order volumes increased 3.5% to 17.7 million. Just 100,000 scripts shy of our record experienced last few quarter. Brand name prescription volumes decreased 4.9% to 9.7 million prescriptions. Mail-order volumes are on their way to exceeding the high end of the previous guidance we provided of 110 million scripts. We now expect 2011 mail-order volumes of approximately 112 million prescriptions. Our generic dispensing rate at mail increased 2 full percentage points from third quarter 2010 to a new record of 64.8%. The strong generic mail-order prescription volume and our increased service gross margin drove our third quarter gross margin to a new record of $1.17 billion, a 4.3% increase over the third quarter of 2010. The total gross margin percentage of 6.9% is consistent with third quarter 2010, which you may recall was an important quarter for 2010, the reflected a significant gross margin percent recovery from where we were earlier in that year. 
Selling, general and administrative expenses for third quarter 2011 totaled $255.6 million. When we do the $35.6 million in merger-related expenses I explained earlier, SG&A expenses declined to $420 million. When adjusted further for the effective UVC, which was acquired on September 16, 2010, our SG&A increased only 1.7%. This reflects efficiencies across the enterprise while we continued to invest in our clinical and strategic programs and new technologies to drive even higher levels of service to our clients and members. 
The EBITDA and EBITDA per script performance I'm about to explain excludes the merger-related expense. Our total EBITDA for the third quarter 2011 marks yet another record at $800.9 million, representing growth of 3.9% over third quarter 2010. EBITDA per adjusted prescription for the third quarter 2011 also represents a record, increasing 4.6% to $3.43 from the $3.28 in the third quarter of 10 '10 which was our previous record. Our intangibles amortization as $73.2 million in third quarter 2011 increased 2.8% from $71.2 million in third quarter 2010 primarily reflecting the UVC intangible assets. Total net interest and other expense of $49.6 million for third quarter 2011 increased $8.8 million from the $40.8 million in third quarter 2010, reflecting the new debt we added to finance the UBC acquisition last September. Third quarter 2011 effective tax rate was 39.6% compared to 39.3% in the third quarter 2010. 
Net income in the third quarter 2011 of $355.4 million includes $22.0 million in merger-related expenses. This essentially being the tax effective equivalent of the $36.6 million pretax number I described earlier. Excluding these expenses the results of net income of $377.4 million represents a 1.6% increase in the third quarter 2010. 
Moving onto share repurchases. During the third quarter of 2011, we repurchased 6.3 million shares for $350 million at an average per share cost of $55.89 to our preauthorized trading plan. This third quarter repurchase allotment under the preauthorized plan was completed on July 15. Since the repurchase, this has since been suspended as a result of the pending merger with Express Scripts. We have always huge viewed share repurchases as an effective tool in enhancing value to shareholders. On an inception to date basis since we started our first share repurchase program in 2005, we have repurchased 285.5 million shares at a cost of $12.85 billion at an average per share cost of $45 even. 
Our year-to-date cash flow from operations is $1.086 billion compared to $1.365 billion for the same period in 2010, with the largest driver being the approximately $200 million payment from the IRS in 2010 related to its tax receivable in prior years. Our inventories reached a record low of $788 million. You may recall that in June 2008, our inventory balance closed at nearly $2.1 billion. We have since then reduced inventory by over 60% to the lowest it has been since 1999. and the Mail volume was about 60 million Scripps. All of that impacting patient service levels. We closed the third quarter with a cash balance of $161.5 million. We expect our quarterly cash balances to build for the remainder of 2011 and into 2012 due to the suspension of our share repurchase program. 
Our total debt for the third quarter has remained consistent since third quarter of 2010 at $5.0 billion. 
Turning to our specialty segment. Accredo achieved record revenues and operating income with growth of 16.7% and 33.0%, respectively, and sustained a strong margin of 6.8%. This strong performance our clients preference to the Accredo service model, as well as, more generally, to grow the utilization of specialty drugs. To be more specific, the product categories driving the growth in specialty include rheumatoid arthritis, multiple sclerosis, immune disorders and oncology, with new drug introductions also driving growth in the hepatitis class. 
As Dave mentioned, we are narrowing our 2011 EPS guidance to the high end of the previous range. Our 2011 for your gapp diluted EPS, including the merger-related expenses suspected in the range of $3.54 to $3.58. Including the merger-related expenses, 2011 guidance is $0.11 stronger as I discussed earlier the $0.11, this guidance represents a range of $3.65 to $3.69 for a growth rate of 16% to 17% over 2010. Our full year 2011 diluted EPS guidance excluding all intangible and amortization merger-related expenses is now in the range of $4.08 to $4.12, reflecting growth of 15% to 16% over 2010. We essentially updated what was previously at $0.10 guidance range and narrowed it to the high end with a much tighter $0.04 spread, reflecting confidence in our strength for the remainder of the year. 
I'm not going to walk you line by line through 2011 guidance since our current expectations are consistent with what we have previously communicated. 
Our fourth quarter is expected to be the strongest quarter in 2011 as I have guided in the past. Included in the fourth quarter is an expected lift in the incremental EPS effect in new generics led by Lipitor with an approximate $0.03 contribution. We also expect our fourth quarter tax rate to be lower, bringing in the full year effective tax rate with lower end of the previous guidance range for approximately 38.5%. You may recall that when I first gave guidance for 2011 on our third quarter 2010 earnings call, I pointed to an expectation for stability or possible expansion in gross margin percentage and EBITDA per script. Looking back to October 2011 year-to-date, excluding this year's merger-related expenses, gross margin is consistent at 6.5% through '11 and '10, and our EBITDA per adjusted script has, in fact, expanded to $3.16 in 2011 compared to $3.07 in 2010. Again, these are all year-to-date specifics. Additionally, one measure that is very important to this company, return on invested capital was projected to exceed 30% this year even if fully including the invested capital associated with the UBC acquisition in September 2010. 
Now this leads me to a discussion of our expected 2012 performance. This is an unusual year and that the S-4 recently filed by Express Scripts under the name Aristotle Holding Inc. on October 6 includes Medco forecast for 2011 through 2014 for net revenues, EBITDA and net income. You can find these forecasts on Page 123 of that document. The S-4 forecast do not exclude merger-related expenses or any one-time costs that may be incurred, they are meant to reflect Medco's expected operating performance in a stand-alone basis. For those of you who don't have the S-4 handy, the 2011 forecast presented includes revenues of $68.951 billion, EBITDA of $3.113 billion, and net income of $1.473 billion. This 2011 forecast should be viewed as a reflection of the midpoint of our recently narrowed guidance range or about $4.10 in diluted EPS, excluded all amortization and merger-related expenses. The amounts included in the S-4 for 2012 include revenues of $58.931 billion, EBITDA of $3.408 billion and net income of $1.626 billion. These 2012 amounts represent our internal operating plan. You should consider these forecasts as reflecting the high end of the 2012 guidance range with the 4% reduction representing the low end of the range. And since those ranges provided the previous years. 
Revenue for 2012 is expected to decline by $10 billion or 14.5% from 2011. This decline includes the effect of clients that were required by competitors when transition in the normal course of competitive activity, all as previously announced. It also includes the $6.5 billion generic affect discussed earlier, which decreases our revenues, and very importantly, increase the savings to clients and patients. The EBITDA growth from 2011 to 2012 using the forecast presented in the S-4 amounts to 9.5%. Our EBITDA growth from 2010 to 2011 amounts to 4.7%. As you can see, our 2012 EBITDA growth rate is expected to more than double by 2011 EBITDA growth rate. The 2012 growth rate reflects improved profitability, largely because 2012 is the peak year of the generic wave. In addition, we expect to yields efficiencies commensurate with what our business will now require. We have various alternative plans in place to yield these business efficiencies. And you must realize that the large majority of our cost and expense base is, in fact, variable and manageable. 
The 2012 net income growth of 10.4% follows the growth I explained for EBITDA. One statistic that becomes critical with these forecasted amounts being presented is the relationship with EBITDA over revenue which for the S-4 will be 5% in 2011 and 5.8% in 2012, recognizing from earlier comments of 5.8% reflects the high end of the range, we may end up with a record EBITDA margin year in 2012. With EBITDA margin expansion, gross margin percentage and EBITDA per adjusted script expansion are also expected to follow. You will note that the S-4 disclosures do not include any EPS projections for Medco as our share count is uncertain to the suspension of repurchases while the merger is pending. 
At this point, I do not expect to give any further guidance detail for 2012 beyond what I just provided. In conclusion, we delivered another strong quarter of operating results and EPS. We remain confident in our future prospects for continued growth well into the future and I do believe the value we can drive to clients and members will be even greater with a combined Medco and Express Scripts. Now, Dave and I will like to open up the lines for questions. Andrea?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Larry Marsh with Barclays Capital.",15,"[Operator Instructions] Our first question comes from the line of Larry Marsh with Barclays Capital."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","In your S-4, which you addressed this morning, you talked about the 2012 and you showed the numbers through 2014. I'm assuming that disclosure doesn't include the loss of UnitedHealth beginning in 2013. And then you talked about net new business being neg",63,"In your S-4, which you addressed this morning, you talked about the 2012 and you showed the numbers through 2014. I'm assuming that disclosure doesn't include the loss of UnitedHealth beginning in 2013. And then you talked about net new business being negative because acquisitions and such, do you have a net new number, business number for 2012 that you can share?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I would say that to answer your second question first, the net new number for 2012 pretty much equates to the net change in revenues that you see for the year because we have many puts and takes in that revenue dynamics. You have the effect of the l",92,"Well, I would say that to answer your second question first, the net new number for 2012 pretty much equates to the net change in revenues that you see for the year because we have many puts and takes in that revenue dynamics. You have the effect of the lost clients. You have the effect of the generic wave but you have offsetting effects also from expected AWC inflation, et cetera. But when you look at the net new number, it's coincidentally ties to the reduction in the net revenue, the S-4."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Right. And just to for Rich, I mean you say all of this has been previously disclosed, because when I add up all the previously disclosed information, I don't quite get there but maybe I'm underestimating something.",37,"Right. And just to for Rich, I mean you say all of this has been previously disclosed, because when I add up all the previously disclosed information, I don't quite get there but maybe I'm underestimating something."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, well, we never gave varying new amounts for clients. Of course, we have never disclosed the amounts to Universal America and the, large accounts we, of course, closed the SEP because of its profit contributions but not the others. So the reason why y",169,"Yes, well, we never gave varying new amounts for clients. Of course, we have never disclosed the amounts to Universal America and the, large accounts we, of course, closed the SEP because of its profit contributions but not the others. So the reason why you're getting there is probably because you don't have the proper estimates for some of those other accounts which is completely understandable. Regarding 2013, while many have assumed that UnitedHealth is in actually in our 2013 numbers, it is not. One point you have to understand in this business is living and breathing and healthy, and we'd expect to continue to win business and don't take 1 year as a trend. We have a long history of winning clients and we don't plan on stopping at any time soon. And that revenue number that you see is not a guess, we have underlying assumptions that are actually quite detailed, and that's all I can say for obvious reasons but it does in fact, exclude UnitedHealthcare."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So just to confirm, the 2013 and '14 numbers exclude UnitedHealth both in revenues and, obviously, in your assumed EBITDA, so it's obviously reflecting some offsets to your cost structure that you allude to in your prepared remarks?",38,"So just to confirm, the 2013 and '14 numbers exclude UnitedHealth both in revenues and, obviously, in your assumed EBITDA, so it's obviously reflecting some offsets to your cost structure that you allude to in your prepared remarks?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's exactly right, Larry. I mentioned the high proportion of variable expenses and our total cost-based just to give you some color on that, it's over 60% in some cost categories, it's over 70% in certain expense categories. So there was quite a bit of",62,"That's exactly right, Larry. I mentioned the high proportion of variable expenses and our total cost-based just to give you some color on that, it's over 60% in some cost categories, it's over 70% in certain expense categories. So there was quite a bit of variable expense in the base unlike some reports have indicated, and by definition therefore, quite manageable."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So you might be assuming about $8 billion incremental increase in net new business for 2013? Is that about right?",20,"So you might be assuming about $8 billion incremental increase in net new business for 2013? Is that about right?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, you should be thankful that you got the 2000 numbers out there from a revenue perspective. I'm not going to go in to the puts and takes and what's net new versus how much is inflation and the rollover of generic affect, and so forth. But ultimately,",66,"Well, you should be thankful that you got the 2000 numbers out there from a revenue perspective. I'm not going to go in to the puts and takes and what's net new versus how much is inflation and the rollover of generic affect, and so forth. But ultimately, you can assume that there is certain net new growth in 2013. That's all I'm going to say."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Tom Gallucci with Lazard Capital Markets.",14,"Your next question comes from the line of Tom Gallucci with Lazard Capital Markets."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I guess 2 quick questions. One, your Lipitor expectations have remained very consistent. From the outside, looking in, it seems to be sort of a fluid situation so I was wondering if you can give us any color on why you've got that visibility at this point",95,"I guess 2 quick questions. One, your Lipitor expectations have remained very consistent. From the outside, looking in, it seems to be sort of a fluid situation so I was wondering if you can give us any color on why you've got that visibility at this point? And then number 2, just wondering if you got any commentary or anecdotally that you can offer from your clients on the Walgreens Express situation or their view toward narrower retail networks in general given the potential implications for your business depending on how the merger turns out?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay. I'll answer the first question and Dave will take the second. Interestingly, we had visibility to Lipitor a year ago at $0.03, and a year later, it's $0.03. And as I've said many times in the past, we are not going to disclose our sources or the bas",95,"Okay. I'll answer the first question and Dave will take the second. Interestingly, we had visibility to Lipitor a year ago at $0.03, and a year later, it's $0.03. And as I've said many times in the past, we are not going to disclose our sources or the basis for our confidence other than, as you would imagine, we are more confident again than ever before in that $0.03 and I know that there are various press reports and I know it is fluid, but from a Medco perspective, again, very confident in the $0.03."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. And Tom, regarding client questions about lag, we get many of them. We actually have a reasonable drug trend symposium that we conduct each and every year, one in the West Coast, one on the East Coast, so total, of I'd say, 400, 500 customers between",211,"Yes. And Tom, regarding client questions about lag, we get many of them. We actually have a reasonable drug trend symposium that we conduct each and every year, one in the West Coast, one on the East Coast, so total, of I'd say, 400, 500 customers between the 2. And that was the universal question, asking us what was behind the activity between ESN remain clear to them we don't really have insight into the details of the arguments between Wag and ESI. But independent of that, I can tell you that many of our clients are looking at restructured networks to get optimal value and pricing. And they also understand, when you look at a network across the country of 65,000 retail pharmacies and when you do geo-access for many, many, many of our customers and see that there's literally no disruption in terms of travel distance to exclude parts of that network to get significant changes in pricing, they're all looking at it, and that's an independent activity that's been going on at Medco for quite some time. And as the pressures mount to this economy, I would tell you they are looking harder at that option now than they ever have before, and I expect that to continue."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your next question comes from the line of Ricky Goldwasser with Morgan Stanley.",14,"And your next question comes from the line of Ricky Goldwasser with Morgan Stanley."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I have a couple of questions here. So first of all, on the 2012 selling season, at this point, what percent of off the season is completed in terms of renewals in your business?",34,"I have a couple of questions here. So first of all, on the 2012 selling season, at this point, what percent of off the season is completed in terms of renewals in your business?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So I can say regarding 2012 renewals, we've made very good progress. And the renewal number for 2012 is quite consistent with the renewal number for 2011. And we're over 2/3 completed with the renewals for 2012.",37,"So I can say regarding 2012 renewals, we've made very good progress. And the renewal number for 2012 is quite consistent with the renewal number for 2011. And we're over 2/3 completed with the renewals for 2012."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And should we assume that the remaining business is more skewed to the lower, mid to small accounts?",19,"Okay. And should we assume that the remaining business is more skewed to the lower, mid to small accounts?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes.",1,"Yes."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then you talked about rebates and how you continued to see improvement in kind like in your management and what the branded manufacturers are willing to pay. When you think ahead to 2012, with all the patent expirations, do you think that we're going",62,"And then you talked about rebates and how you continued to see improvement in kind like in your management and what the branded manufacturers are willing to pay. When you think ahead to 2012, with all the patent expirations, do you think that we're going to continue to see kind of like that same kind of like strategy from the pharma companies?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Let me turn it over to Tom Moriarty.",8,"Let me turn it over to Tom Moriarty."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure. So I view and I think you will see. We obviously have a multipronged approach that deals at a client level that match their needs. And as we look to different formulary strategies, those formulary strategies drive value for the clients. And then ult",61,"Sure. So I view and I think you will see. We obviously have a multipronged approach that deals at a client level that match their needs. And as we look to different formulary strategies, those formulary strategies drive value for the clients. And then ultimately, The Pharma companies want to stay in that, and the way to participate is to agree."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And do you anticipate, because you talked about the assumptions for AWP pricing that's factored into your 2012 revenues, do you anticipate manufacturers like Pfizer and Lipitor will continue to raise prices post the patent expiration?",37,"Okay. And do you anticipate, because you talked about the assumptions for AWP pricing that's factored into your 2012 revenues, do you anticipate manufacturers like Pfizer and Lipitor will continue to raise prices post the patent expiration?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm not going to talk about specific drugs or specific manufacturers. I can tell you, in 2011, we experienced a brand inflation rate that's well over 10% for the highest inflation rates we've seen in recent years. Our assumptions actually assume that, tha",57,"I'm not going to talk about specific drugs or specific manufacturers. I can tell you, in 2011, we experienced a brand inflation rate that's well over 10% for the highest inflation rates we've seen in recent years. Our assumptions actually assume that, that gets down a bit to between the 5% and 10% range in 2012."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And Ricky, just to make sure everybody understands why this is predictable. When you look at the tax that pharma needs to be pay tied to healthcare reform, you knew that was a pass for you, you knew that it comes from somewhere and that's what exactly wha",110,"And Ricky, just to make sure everybody understands why this is predictable. When you look at the tax that pharma needs to be pay tied to healthcare reform, you knew that was a pass for you, you knew that it comes from somewhere and that's what exactly what's going on. And you also have the additional pressure tied to this generic wave that these brand manufacturers are dealing with. So I think it's reasonable to think that you will continue to see inflation. Although, you're going to see a lot of people fighting to prevent that rate of inflation, I think there's a real tug-of-war going on that will continue."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your next question comes from the line of Steven Valiquette with UBS.",13,"And your next question comes from the line of Steven Valiquette with UBS."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So the generic launches for 2012 are obviously positive, but I'm just kind of curious, that $6.5 billion number and it's close to 10% of 2012 revs, it kind of seems like a fairly large numbers, so I guess I'm just curious, is there anything unique about m",99,"So the generic launches for 2012 are obviously positive, but I'm just kind of curious, that $6.5 billion number and it's close to 10% of 2012 revs, it kind of seems like a fairly large numbers, so I guess I'm just curious, is there anything unique about maybe your mail versus retail mix or some other internal factor? And maybe read that to have a larger impact on Medco than maybe other Pharma services companies or would you kind of assume that maybe everybody in this industry would kind of have a similar 10% drag on the top line?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay. So let me give you some statistics, Steve. You look at our book of business mail penetration rate for this quarter, it's 34.8%. When you look at the big drugs that are going to affect that generic affect we mentioned earlier, you have Lipitor, which",138,"Okay. So let me give you some statistics, Steve. You look at our book of business mail penetration rate for this quarter, it's 34.8%. When you look at the big drugs that are going to affect that generic affect we mentioned earlier, you have Lipitor, which is at, the last time I checked, about 60% mail-order penetration rate. You have Lexapro, that's a 35%; Plavix is 50%, Singulair at 45%, at 50% at 50%. Those are all numbers that I gave at last year's Analyst Meeting on Page 16 of my presentation. Even though there've been some client puts and takes, those numbers are still good reference points. You can see that the majority of the drugs, and these are very high drugs spend molecules here are way beyond our book of business out of mail penetration rates."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. And just to make clear. It all fits in our line of sight and all within our 5 and more recent 10-year plan. This has been well known.",29,"Yes. And just to make clear. It all fits in our line of sight and all within our 5 and more recent 10-year plan. This has been well known."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then just a quick follow-up on specialty, getting a lot of questions on that. I'm wondering the size of the markets kind of why of wide open to interpretation but do you have an approximate number for how you guys define the size of the specialt",86,"Okay. And then just a quick follow-up on specialty, getting a lot of questions on that. I'm wondering the size of the markets kind of why of wide open to interpretation but do you have an approximate number for how you guys define the size of the specialty markets, I mean you roughly $13 billion of revenues this year mainly to Accredo. But where do you give your approximate market share within specialty in terms of how the discussion might be going with FTC, et cetera?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We don't have a number going. We focus with our actual performance. I think the market is very, very broad, as Dave mentioned in his prepared remarks, and there are many, many providers. And the specialty market is very likely a much greater than what you",66,"We don't have a number going. We focus with our actual performance. I think the market is very, very broad, as Dave mentioned in his prepared remarks, and there are many, many providers. And the specialty market is very likely a much greater than what you would be see in disclosures of the respective PBMs which is just a small piece of the broader market."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then just real quick, 2 follow-up on that UNA, is that spread across 2013 and 2014? Was just that 2013 that you're assuming the loss of UNH within that 5-year, 4 or 5-year projection?",36,"Okay. And then just real quick, 2 follow-up on that UNA, is that spread across 2013 and 2014? Was just that 2013 that you're assuming the loss of UNH within that 5-year, 4 or 5-year projection?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's assumed out all on '13.",7,"It's assumed out all on '13."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your next question comes from the line of Ross Muken with Deutsche Bank.",14,"And your next question comes from the line of Ross Muken with Deutsche Bank."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","It's actually Mike in for Ross. So just quickly, on the closing of the 2 JVs with Celesio and the United Drug, can you talk about the cash flow impact there if there has any changes to your outlook and any financial terms you can provide above beyond what",53,"It's actually Mike in for Ross. So just quickly, on the closing of the 2 JVs with Celesio and the United Drug, can you talk about the cash flow impact there if there has any changes to your outlook and any financial terms you can provide above beyond what was already discussed?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No, it's all quite immaterial so it's really -- nothing to worry about, nothing that will meaningfully change models going forward.",21,"No, it's all quite immaterial so it's really -- nothing to worry about, nothing that will meaningfully change models going forward."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And then you mentioned in terms of the rationale for the deal, Dave, talking about customer response so far and how they are excited about the savings that can be provided to them, I guess as you went to the later stage at the selling season and talking a",121,"And then you mentioned in terms of the rationale for the deal, Dave, talking about customer response so far and how they are excited about the savings that can be provided to them, I guess as you went to the later stage at the selling season and talking about the fiscal '12 selling season as well, can you talk about, I guess kind of reaction from that perspective in terms of both going out and winning new deals, what the thought process was on how you're going to change the approach once the merger with Express Script was completed and kind of what kind of service levels and other added benefits they'd beginning in terms of planned design post the merger?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, sure. First of all, I'd love to point out the fact that just in our system ed group alone, they closed over 70 deals post merger announcement and they are still extremely busy right now. From the point of view of a client, they understand how the com",290,"Yes, sure. First of all, I'd love to point out the fact that just in our system ed group alone, they closed over 70 deals post merger announcement and they are still extremely busy right now. From the point of view of a client, they understand how the combination create better financials for them and which is critically important. So that beyond the financials, the questions they are asking is, what will the combined company look like? How will it operate? Will we still get the same services that we got from Medco as a stand-alone company? As George and I talked about what this combined company will look like, we have this concept of best-of-breed in best of both worlds. So my feeling is, there are clients that are likely to experience continued innovation, combinations of best-of-breed assets to get even better service and better options. So, and obviously, part of that is in execution and we're still in integration planning process we have a lot of work to do still. But conceptually, we do know where we want to end up. I think both companies know where they want to end up and I think it's safe to say both companies have the client and the client need squarely in their focus is the number 1 priority. At the end of the day, these we still want to delight and retain customers and we new customers. So I'm there he comfortable that as we look at the capabilities of both companies, I we will get to something we call best be between the 2. I think that makes clients comfortable. I think that the what they're looking for and I'll be there going to watch that over time."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of John CAGR with John Kreger with William Blair.",16,"Your next question comes from the line of John CAGR with John Kreger with William Blair."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave, you mentioned a few minutes ago that clients are showing greater interest in some of these narrower networks. What sort of savings are you able to offer to them and are you finding that the savings is there going to have to sort of assume the hassle",49,"Dave, you mentioned a few minutes ago that clients are showing greater interest in some of these narrower networks. What sort of savings are you able to offer to them and are you finding that the savings is there going to have to sort of assume the hassle factor?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It varies by client. It ties with the geographic dispersion of their people. But I can tell you in a range, it is very meaningful and very worthwhile considering, especially when you're a jumble account, which Medco has a lot of. It's extremely meaningful",53,"It varies by client. It ties with the geographic dispersion of their people. But I can tell you in a range, it is very meaningful and very worthwhile considering, especially when you're a jumble account, which Medco has a lot of. It's extremely meaningful. You can see 2 points easily and sometimes more."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And Rich, you made the comment that your cost structure is flexible. Can we infer from that, that your starting down the path of cutting some costs as you've had some losses or should we assume that, that's a process that's going to potentially be held up",50,"And Rich, you made the comment that your cost structure is flexible. Can we infer from that, that your starting down the path of cutting some costs as you've had some losses or should we assume that, that's a process that's going to potentially be held up by the merger?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, if you look at our SG&A numbers, given this quarter, you can see that inherent growth rate is quite low so we've been, I think, doing a great job in managing our expenses. Just all the course of business, but ultimately, the efficiencies need to be",67,"Well, if you look at our SG&A numbers, given this quarter, you can see that inherent growth rate is quite low so we've been, I think, doing a great job in managing our expenses. Just all the course of business, but ultimately, the efficiencies need to be yielded on a stand-alone basis or in a merged scenario. So we have to do what we have to do."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Bob Willoughby with Bank of America Merrill Lynch.",16,"Your next question comes from the line of Bob Willoughby with Bank of America Merrill Lynch."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a quick one, the European joint ventures, you guys have bought back, I guess a couple of them. These were growth drivers for you for 2014 and beyond. And what's the plan there? Are you bringing them off-line or are you porting the economics? What's t",49,"Just a quick one, the European joint ventures, you guys have bought back, I guess a couple of them. These were growth drivers for you for 2014 and beyond. And what's the plan there? Are you bringing them off-line or are you porting the economics? What's the strategy there?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's more the latter than the former, Bob. We are still very committed to Europe. We like the opportunity opportunities as we find tune what Europe needs and wants, we feel we're incredibly well prepared to deliver it without a joint venture partner. And",130,"It's more the latter than the former, Bob. We are still very committed to Europe. We like the opportunity opportunities as we find tune what Europe needs and wants, we feel we're incredibly well prepared to deliver it without a joint venture partner. And so now we've learned a lot in these seeds we planted. And as we refine and focus on what we want to do and how we want to approach it, taking it all in-house made sense for us. And if Brian Griffin, who's running our international operations were here today, he would tell you that this is something that he is excited about now that he has full control and he is able to focus upon the market without the distractions of managing a JV."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And how do we think about the profit profile and the future investment needed for them?",16,"And how do we think about the profit profile and the future investment needed for them?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I would say, over the next few years, the investments will be relative to the broader company, nominal immaterial. The growth profile remains the same. We never expected it to be material in '12, 13. But certainly, when you get to the back half of t",63,"Well, I would say, over the next few years, the investments will be relative to the broader company, nominal immaterial. The growth profile remains the same. We never expected it to be material in '12, 13. But certainly, when you get to the back half of this decade, our thinking is consistent that the loan start to become meaningful contribution to our profitability."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And I'll just add, Brian Griffin and his team have had some nice wins recently and we're very encouraged that the trajectory is going to be something like what we originally envisioned. So we're feeling very good about this progress there.",42,"And I'll just add, Brian Griffin and his team have had some nice wins recently and we're very encouraged that the trajectory is going to be something like what we originally envisioned. So we're feeling very good about this progress there."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Charles Rhyee with Cowen.",12,"Your next question comes from the line of Charles Rhyee with Cowen."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just 1 more question on Celesio. If I recall at the beginning of this year, you made an adjustment for the JV, and a bunch of the mail volume when it was part of the JV, so it wasn't counted in your mail volume. How should we think about treating that, I",72,"Just 1 more question on Celesio. If I recall at the beginning of this year, you made an adjustment for the JV, and a bunch of the mail volume when it was part of the JV, so it wasn't counted in your mail volume. How should we think about treating that, I think it was almost like 10 million mail scripts, should we think that's coming back onto the income statement again?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, the mail scripts are you're a weigh off by  a multiple factor with regards to the volumes, it's actually more like a fraction of that. The mail volumes came from Europe and. in has been in our volumes because joint venture in the first place. So tha",65,"Well, the mail scripts are you're a weigh off by  a multiple factor with regards to the volumes, it's actually more like a fraction of that. The mail volumes came from Europe and. in has been in our volumes because joint venture in the first place. So that just continues in our run rate and will continue as it grows through the next several years."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. So there's really no then change to how we should be looking at the go forward mail volumes other than some of the announced contracts?",26,"Okay. So there's really no then change to how we should be looking at the go forward mail volumes other than some of the announced contracts?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's correct.",3,"That's correct."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then a quick question on maybe on FEP, we're obviously looking, when you look at the '12 numbers, does the change that we're seeing also include any sort of purchasing leverage you might be losing because, clearly, your mail revenues drop and a",62,"Okay. And then a quick question on maybe on FEP, we're obviously looking, when you look at the '12 numbers, does the change that we're seeing also include any sort of purchasing leverage you might be losing because, clearly, your mail revenues drop and a chunk definitely does come from branded. Now how should we think about that part of the contribution?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll let Rich answer that. But I think I just want to remind you because we extended before, that the loss of has literally no impact on our leverage and our ability to contract at competitive prices. This change in volume, on our side, has literally no i",52,"I'll let Rich answer that. But I think I just want to remind you because we extended before, that the loss of has literally no impact on our leverage and our ability to contract at competitive prices. This change in volume, on our side, has literally no impact on our leverage."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. And there is no leverage effect in sort of today's point and we have a very clear line of sight into our purchasing leverage for 2012. And of course, that's baked into what you see in the S-4.",39,"Yes. And there is no leverage effect in sort of today's point and we have a very clear line of sight into our purchasing leverage for 2012. And of course, that's baked into what you see in the S-4."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay, that's helpful. And then just one last question on Accredo. obviously, I think a couple of years ago, we saw some margin pressure on the margin line, it's clearly stabilized here. What has really changed here now and should we think about the margin",56,"Okay, that's helpful. And then just one last question on Accredo. obviously, I think a couple of years ago, we saw some margin pressure on the margin line, it's clearly stabilized here. What has really changed here now and should we think about the margins being pretty stable at this a high 6.8% rate going forward?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll start with that and then I'll ask Frank Sheehy to add anything that he wishes to. The thing I will add is that what's changed, he's gone in there. He has looked at the operations. He's done a very, very good job working with our clients and also work",137,"I'll start with that and then I'll ask Frank Sheehy to add anything that he wishes to. The thing I will add is that what's changed, he's gone in there. He has looked at the operations. He's done a very, very good job working with our clients and also working with the operations to get the cost in line and to make us more efficient. And what's great about Frank is he came from the customer side of our business in the core, knows these customers, know what they're looking for, and he's made some great changes, to I think be better aligns with what our client needs and serve them better and more cost-effectively and I do know if you want to point anything specific at this point, Frank, but I'm giving you the opportunity."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. Thanks, very much, Dave. I think to Dave's point, working aggressively with and their team including programs that are aligned with our clients interest are definitely resonating combined with the differentiating service model that we've bought there",45,"Yes. Thanks, very much, Dave. I think to Dave's point, working aggressively with and their team including programs that are aligned with our clients interest are definitely resonating combined with the differentiating service model that we've bought there's a create a opportunity for Accredo clients."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Eugene Goldenberg with BB&T.",13,"Your next question comes from the line of Eugene Goldenberg with BB&T."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Can you just provide any additional commentary around some of the chatter that we're hearing off of Pfizer getting a little bit or actually a lot more aggressive in the rebate strategy when it comes to Lipitor? I think they recently raised the rebate on L",64,"Can you just provide any additional commentary around some of the chatter that we're hearing off of Pfizer getting a little bit or actually a lot more aggressive in the rebate strategy when it comes to Lipitor? I think they recently raised the rebate on Lipitor about 50% and happen off some PBMs, can you provide a little bit more color on that?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, obviously, they have a multipronged strategy on Lipitor about the marketplace. We've obviously chosen our strategy and are quite comfortable with that. So that's all I can to it.",30,"Well, obviously, they have a multipronged strategy on Lipitor about the marketplace. We've obviously chosen our strategy and are quite comfortable with that. So that's all I can to it."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your last question comes from the line of David Larsen with Leerink Swann.",14,"And your last question comes from the line of David Larsen with Leerink Swann."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Has the 2013 selling season started off for large Health Plans?",11,"Has the 2013 selling season started off for large Health Plans?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll ask Glenn Taylor who runs our health plan group to indicate what's going on there's.",17,"I'll ask Glenn Taylor who runs our health plan group to indicate what's going on there's."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, I would say, yes, there is activity related to business. But we haven't had any announcements, haven't gone through this whole process yet. As little bit early.",28,"Yes, I would say, yes, there is activity related to business. But we haven't had any announcements, haven't gone through this whole process yet. As little bit early."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","On sale cycle for that type of account though",9,"On sale cycle for that type of account though"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So that sort of process is not necessarily have an impact on that 2013 revenue on the S-4 statement, right? It's not like you have great clarity on '13?  And then also in terms of the EBITDA growth rate for 2014 in the S-4, it looked pretty good to me be",68,"So that sort of process is not necessarily have an impact on that 2013 revenue on the S-4 statement, right? It's not like you have great clarity on '13?  And then also in terms of the EBITDA growth rate for 2014 in the S-4, it looked pretty good to me be and like maybe 14% year-over-year. Is there anything in '14 in particular that would drive that?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, you might recall again from Analyst Day last year that we show that famous generic EPS contribution slide. It had a wave going through. You might recall at 2014 and 2018, we were both strong years. Actually our 2014 was the strongest after 2012 and",96,"Well, you might recall again from Analyst Day last year that we show that famous generic EPS contribution slide. It had a wave going through. You might recall at 2014 and 2018, we were both strong years. Actually our 2014 was the strongest after 2012 and that includes some pretty large drugs going generic. And for our book, at the time at least, they averaged about 45% mail order penetration rate. The include in order expected introduction,, Nexium, which is of course, I is a very large drug, and Actonel. So those important drivers for '14."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then for new members coming on through the exchanges in '14, that's not a big driver of that growth rate, is that correct? It's more the generics?",29,"Okay. And then for new members coming on through the exchanges in '14, that's not a big driver of that growth rate, is that correct? It's more the generics?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That is correct.",3,"That is correct."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes, you're going to be seeing the exchange growth come through health plan partners given the way the rates are written right now.",23,"Yes, you're going to be seeing the exchange growth come through health plan partners given the way the rates are written right now."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And just my last question, Dave, assuming this merger does go through, do we get any clarity on sort of what your role is going to be or what your plans are?",33,"Okay. And just my last question, Dave, assuming this merger does go through, do we get any clarity on sort of what your role is going to be or what your plans are?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We don't have complete clarity now. But remember, we are the company being acquired, so I think you can think about it from that point of view.",28,"We don't have complete clarity now. But remember, we are the company being acquired, so I think you can think about it from that point of view."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And thank you, ladies and gentlemen. Are there any closing remarks, sir?",12,"And thank you, ladies and gentlemen. Are there any closing remarks, sir?"
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No, I think we're done, and I just want to thank everyone for dialing into our call and joining us. And we look forward to continuing, updating you as we make progress with the FTC. Thanks.",36,"No, I think we're done, and I just want to thank everyone for dialing into our call and joining us. And we look forward to continuing, updating you as we make progress with the FTC. Thanks."
1541811,141271840,177962,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect.",14,"Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Medco Health Solutions Third Quarter 2011 Earnings Call. [Operator Instructions] I would now like to turn the call over to",56,"Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Medco Health Solutions Third Quarter 2011 Earnings Call. [Operator Instructions] I would now like to turn the call over to Vice President of Investor Relations, Ms. Valerie Haertel. You may begin."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Andrea. Good morning, everyone, and thank you for joining us on Medco's Third Quarter 2011 Earnings Conference Call. With me today as speakers are Chairman and Chief Executive Officer, Dave Snow; and Chief Financial Officer, Rich Rubino. Also j",314,"Thank you, Andrea. Good morning, everyone, and thank you for joining us on Medco's Third Quarter 2011 Earnings Conference Call. With me today as speakers are Chairman and Chief Executive Officer, Dave Snow; and Chief Financial Officer, Rich Rubino. Also joining us for our question-and-answer session are: Kenny Klepper, President and Chief Operating Officer; Tom Moriarty, General Counsel, Secretary and President of Global Pharmaceutical Strategies; Frank Sheehy, President of Accredo Health Group; Tim Wentworth, Group President of the Employer and Key Accounts; and Glenn Taylor, Group President of Health Plans. 
During the course of this call, we will make forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in our SEC filings.  Copies of Medco's filings are available from the SEC, the Medco Investor Relations Department or the Medco website. Medco intends to use the Investor Relations section of its website as a means of disclosing material non-public information and for complying with these disclosure obligations under Regulation FD. The copyrights for the contents of this discussion and the written materials used on this earning call are owned by Medco Health Solutions, Inc. 2011. 
Slides to accompany our presentation, which detail our financial and operating results and the guidance discussed on this call, are currently available in the Events section of the Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-Q after the close of the market today. At this time, I would like to turn the call over to Dave Snow. Dave?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valerie, and thanks to all of you for joining us this morning. Today, we are reporting strong third quarter 2011 earnings and narrowing the range of our full year 2011 earnings per share guidance to the high-end of previous guidance. GAAP dilut",1416,"Thank you, Valerie, and thanks to all of you for joining us this morning. Today, we are reporting strong third quarter 2011 earnings and narrowing the range of our full year 2011 earnings per share guidance to the high-end of previous guidance. GAAP diluted earnings per share for third quarter 2011 reached $0.90 or $0.96, excluding merger-related expenses incurred in the quarter, representing solid 12.9% growth over third quarter 2010. Even when including the merger-related expenses, our GAAP EPS is a record. Our diluted earnings per share, excluding all intangible amortization and the merger-related expenses, reached a record $1.07, reflecting a 12.6% growth rate over third quarter 2010. Importantly, our gross margin percentage was consistent with third quarter 2010 at 6.9%, up meaningfully from the 6.5% in second quarter 2011. And our EBITDA per script, excluding the merger-related expenses, also reached a record level at $3.43. Our mail volumes continue to be strong at this stage of the year. We are now confident that we will meaningfully surpass the high-end of our previous mail volume guidance range of 108 million to 110 million script. 
Our Accredo business also delivered strong results with revenue growth of 16.7% and operating income growth of 33%, all at a 6.8% gross margin, consistent with third quarter 2010. The company is performing well across the board and we narrowed our a 2011 diluted earnings per share guidance excluding merger-related expenses and all intangible amortization to a range of $4.08 to $4.12, which represents 15% to 16% growth over 2010. Our previous guidance of $4.02 to $4.12 reflect the growth of 13% to 16% over 2010. 
For the 2011 selling season, our annualized new-named sales totaled $3.2 billion, up from the $3 billion we previously reported. We have completed 98% of our 2011 renewals amounting to $16 billion client-drove spend. Our 2012 annualized new-named sales currently stand at approximately $1.6 billion, double the $800 million reported last quarter as our clinically focused model continues to have strong appeal in the marketplace. 
Now, I would like to share some thoughts on the pending merger with Express Scripts. As you saw in the recently filed S-4, after an extensive review of numerous strategic alternatives through an exhaustive planning process, we determined that combining with Express Scripts was the best strategy to maximize value for our clients, members and shareholders. The merger is a solution to control escalating healthcare costs in America, costs that are undermining the U.S. competitiveness in the global economy. In 2010 alone, U.S. spending for prescription drugs reached $307.4 billion. Our aging population and an increased prevalence of chronic disease are projected to drive a 50% increase in prescription drug spending to well over $450 billion by 2019. 
At Medco, we have lowered the cost of prescription medications for our clients by enabling greater use of generics, driving savings of $3.7 billion to Medco's clients in full year 2010, and $2.7 billion year-to-date in 2011. We have expertly managed the challenges associated with the rising costs of care, including specialty medications, and we have improved efficiencies my enabling clients to make effective use of the highest value channels of distribution, including mail-order delivery for chronic medication. The combined organization is well positioned to advance the quality and cost goal set forth in America's healthcare reform legislation by combining 2 innovative approaches, Medco's advanced clinical services that utilize an evidence-based protocols and Express Script Services which focus on behavioral science to increase medication adherence. As you can see from this year's performance and our projections included in the S-4, we are planning to merge from a position of strength. Combining forces with Express Scripts positions us to deliver what our nation needs now, high-quality care at even lower cost to our patients and clients. And we can do this much more effectively together. 
Many of you have asked where we are in the regulatory review process and what will be the likely outcome. As I have said previously, and most recently at a hearing in Washington DC, we would not have announced this combination if we were not confident in our ability to obtain the necessary regulatory approvals. As we stated when the deal was announced, we anticipated that the transaction will close in the first half of 2012, and we remain confident in that projection for a number of reasons. First, the opponents of this proposed mergers are not customers. Our proposed merger is receiving very positive reaction from our customers who understand that the combination of Medco and Express Scripts can mean to them and their members. This combination includes over $1 billion in savings as it's expected to be delivered to customers after closing. 
Second, the PBM marketplace is highly competitive and will remain highly competitive after the deal closes. There are at least 10 PBMs serving the largest employers in the Fortune 50 and over 15 serving the Fortune 500 alone. In addition, these and many other PBMs also serve large government account and health plan. In fact, today, our competitors include over 40 PBMs with household names like Aetna, CIGNA, CVS Caremark and others who may not be as well known, but continues to make major investments such as prime therapeutic, catalysts and FXP [ph]. Additionally, in specialty drugs, hundreds of different firms compete including PBMs, pharmacy chains and independents, wholesalers, managed-care organizations, as well as stand-alone specialty pharmacy. Also, and very importantly, UnitedHealth Group has announced its plans to bring in-house the 40 million lives previously served by Medco and combine that business with a substantial Medicare and other national employer lives that already directly services through its own PBM known as Optim RX [ph]. With this, United Health Group will be one of the nation's largest PBMs. 
The merger with Express Scripts provides us with the opportunity to reduce our acquisition costs for medication and pass on additional savings for our clients and patients. The SEC is concerned at protecting consumer, not competitors. That means ensuring competition remains healthy in the marketplace and consumers are not harmed by price increases resulting from tier competitors. We firmly believe that this combination will benefit consumers. 
To conclude my remarks on this topic, the proposed merger, in our view, embodies the spirit of the new healthcare reform legislation that promotes innovation to solve America's healthcare burden. As I have said previously, we are confident that this merger will receive SEC approval in the first half of 2012. We are an important part of the solution and we remain dedicated to providing our clients with quality care at the lowest possible cost. Not only does this merger promise to serve our clients well, it will create substantial value for our shareholders. 
Before I turn the call over to Rich, who will cover the 2012 guidance more thoroughly, I would like to highlight a few observations for next year. First, as you saw in the S-4 and in our earnings release, revenue is expected to decrease to approximately $58.9 billion in 2012, equating to a $10 billion or 14.5% decline. This decline contains many moving parts, including clients that are transitioning from Medco due to acquisitions by competitors and other reasons. Also, contributing to the decline in revenues is the generic wave in 2012, which is projected to reduce our net revenues next year by approximately $6.5 billion. If you look at this from the other side of the ledger, this is value that accrues to clients and patients, a massive win to the consumer. 
The last point I will make on guidance is regarding our EBITDA, which at the high-end is expected to grow by as much as 9.5% in 2012 as a function of the generic wave and continuously improving business efficiencies. And looking at EBITDA as a percentage of revenue, what is known as EBITDA margin, we expect this measure to increase from approximately 4.5% in 2011 to as much as 5.8% at the high-end in 2012, which would represent a Medco record. We expect meaningful increases in our gross margin percentage and EBITDA per script for 2012 as well. Resulting not only from the generic wave and business efficiencies I just mentioned, but also from the fact that the large retail clients that will be transitioning in 2012 carries extraordinarily low profit margins. 
With that, I'll turn the call over to our CFO, Rich Rubino, who will discuss additional third quarter 2011 financial performance details, and provide you with additional color regarding our 2012 guidance. Rich?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. As Dave mentioned, our third quarter EPS results were strong, with record GAAP diluted EPS of $0.90. The record gets even more impressive when you exclude the $0.06 of merger-related expenses, bringing that number to an equi",2225,"Thank you, Dave. Good morning. As Dave mentioned, our third quarter EPS results were strong, with record GAAP diluted EPS of $0.90. The record gets even more impressive when you exclude the $0.06 of merger-related expenses, bringing that number to an equivalent of $0.96, a growth of 12.9% over third quarter last year. Diluted EPS, excluding all intangibles and merger-related expenses of $1.07 for this quarter is also a record, representing a 12.6% increase. This $1.07 is a meaningful $0.08 higher than our previous EPS record of $0.99 set in the fourth quarter of 2010. The merger-related expenses, which primarily include bankruptcies, legal fees and employee retention-related expenses, totaled $36.6 million or $0.06 per share. And that of course, was for the third quarter of 2011, with $35.6 million flowing to SG&A expense and the remaining $1 million flowing to cost of sales. We currently expect the fourth quarter 2011 amount of merger-related expenses to be slightly less than the third quarter at $0.05 per share, bringing full year 2011 estimated merger-related expenses to $0.11 per share. 
Total third quarter 2011 net revenues reached $17.0 billion, representing growth of 4.1% over  third quarter 2010. Our product revenues grew at 3.4% over third quarter 2010 to $16.6 billion, reflecting our new business wins, as well as higher prices charged by brand-name pharmaceutical manufacturers, partially offset by a higher mix of lower-priced generics. On that generics point, our clients and members saved approximately $700 million this quarter compared to third quarter 2010 from increased utilization of generic. For 2011, we expect these savings to total approximately $3.7 billion. If you look at how much Medco clients and members have saved from generic drug utilization since 2006, when the first blockbuster drug started losing their patent, it is a very substantial number, $16.7 billion. Add to that the expected record 2012 year for generic savings that Dave already mentioned, contributing another expected $6.5 billion in savings, and the cumulative savings since 2006 rose to over $23 billion. 
Service revenue continue to be a significant growth driver, increasing 26.9% over the third quarter 2010 to a record $379 million. This strong performance reflects the service revenue contribution from UBC, as well as growth to our client service offerings across the company. 
Turning to rebates, we earned $1.5 billion for the third quarter, an increase of 5.6% over the same period last year, even though we are dispensing fewer brand-name medications and more generics. This year-over-year growth is attributable to continuous improvements in formulary contract. Our third quarter 2011 rebate retention rate was 13.0%, consistent with the 12.8% in the third quarter 2010 as we continue to drive significant value to clients in a highly transparent manner. 
As Dave mentioned, mail-order volume remains strong as clients and members continue to choose this lower cost and clinically effective channel. In third quarter 2011, our total mail-order prescription volume is 27.4 million. Within this, generic prescription mail-order volumes increased 3.5% to 17.7 million. Just 100,000 scripts shy of our record experienced last few quarter. Brand name prescription volumes decreased 4.9% to 9.7 million prescriptions. Mail-order volumes are on their way to exceeding the high end of the previous guidance we provided of 110 million scripts. We now expect 2011 mail-order volumes of approximately 112 million prescriptions. 
Our generic dispensing rate at mail increased 2 full percentage points from third quarter 2010 to a new record of 64.8%. The strong generic mail-order prescription volumes and our increased service gross margin drove our third quarter gross margin to a new record of $1.17 billion, a 4.3% increase over third quarter 2010. The total gross margin percentage of 6.9% is consistent with third quarter 2010, which you may recall was an important quarter for 2010, it reflected a significant gross margin percent recovery from where we were earlier in that year. 
Selling, general and administrative expenses for third quarter 2011 totaled $455.6 million. When reduce by the $35.6 million in merger-related expenses I explained earlier, SG&A expenses declined to $420 million. When adjusted further for the effective UBC, which was acquired on September 16, 2010, our SG&A increased only 1.7%. This reflects efficiencies across the enterprise while we continued to invest in our clinical and strategic programs and new technologies to drive even higher levels of service to our clients and members. 
The EBITDA and EBITDA per script performance I'm about to explain excludes the merger-related expenses. Our total EBITDA for the third quarter 2011 marks yet another record at $800.9 million, representing growth of 3.9% over third quarter 2010. EBITDA per adjusted prescription for the third quarter 2011 also represents a record, increasing 4.6% to $3.43 from the $3.28 in the third quarter of 2010, which was our previous record. Our intangible amortization as $73.2 million in third quarter 2011 increased 2.8% from $71.2 million in third quarter of 2010, primarily reflecting the UBC intangible assets. Total net interest and other expense of $49.6 million for third quarter of 2011 increased $8.8 million from the $40.8 million in third quarter 2010, reflecting the new debt we added to finance the UBC acquisition last September. Third quarter 2011 effective tax rate was 39.6% compared to 39.3% in the third quarter 2010. 
Net income in the third quarter of 2011 of $355.4 million includes $22.0 million in merger-related expenses. This essentially being the tax effective equivalent of the $36.6 million pretax number I described earlier. Excluding these expenses the results of net income of $377.4 million represents a 1.6% increase in the third quarter 2010. 
Moving on to share repurchases. During the third quarter of 2011, we repurchased 6.3 million shares for $350 million at an average per share cost of $55.89 to our pre-authorized trading plan. This third quarter repurchase allotment under the pre-authorized plan was completed on July 15. Future repurchases have since been suspended as a result of the pending merger with Express Scripts. We have always viewed share repurchases as an effective tool in enhancing value to shareholders. On an inception-to-date basis, since we started our first share repurchase program in 2005, we have repurchased 285.5 million shares at a cost of $12.85 billion in an average per share cost of $45 even. 
Our year-to-date cash flow from operations is $1.086 billion compared to $1.365 billion for the same period in 2010, with the largest driver being the approximately $200 million payment from the IRS in 2010 related to its tax receivable in prior years. Our inventories reached a record low of $788 million. You may recall that in June 2008, our inventory balance closed at nearly $2.1 billion. We have since then reduced inventory by over 60% to the lowest it has been since 1999, the year when our mail volume was about 60 million prescription. All of that impacting patient service level. 
We closed the third quarter with a cash balance of $161.5 million, and we expect our quarterly cash balances to build for the remainder of 2011 and into 2012 due to the suspension of our share repurchase program. Our total debt for the third quarter has remained consistent since third quarter of 2010 at $5.0 billion. 
Turning to our specialty segment. Accredo achieved record revenues and operating income with growth of 16.7% and 33.0%, respectively, and sustained a strong margin of 6.8%. This strong performance reflects our clients preference to the Accredo service model, as well as, more generally, to grow the utilization of specialty drugs. To be more specific, the product categories driving the growth in specialty include rheumatoid arthritis, multiple sclerosis, immune disorders and oncology. With new drug introductions also driving growth in the hepatitis class. 
As Dave mentioned, we are narrowing our 2011 EPS guidance to the high end of the previous range. Our 2011 full year GAAP diluted EPS, including the merger-related expenses is expected in the range of $3.54 to $3.58. Excluding the merger-related expenses, 2011 guidance is $0.11 stronger as I discussed earlier. When adding back the $0.11, this guidance represents a range of $3.65 to $3.69 for a growth rate of 16% to 17% over 2010. Our full year 2011 diluted EPS guidance excluding all intangible and amortization and merger-related expenses is now in the range of $4.08 to $4.12, reflecting growth of 15% to 16% over 2010. We essentially updated what was previously at $0.10 guidance range and narrowed it to the high end with a much tighter $0.04 spread, reflecting confidence in our strength for the remainder of the year. I'm not going to walk you line by line through 2011 guidance since our current expectations are consistent with what we have previously communicated. 
Our fourth quarter is expected to be the strongest quarter of 2011, as I have guided in the past. Included in the fourth quarter is an expected lift in the incremental EPS effect in new generics led by Lipitor, with an approximate $0.03 contribution. We also expect our fourth quarter tax rate to be lower, bringing the full year effective tax rate to the lower end of the previous guidance range or approximately 38.5%. 
You may recall that when I first gave guidance for 2011 on our third quarter 2010 earnings call, I pointed to an expectation for stability or possible expansion in gross margin percentage and EBITDA per script. Looking back to September 2011 year-to-date, excluding this year's merger-related expenses, gross margin is consistent at 6.5% through '11 and '10, and our EBITDA per adjusted script has, in fact, expanded to $3.16 in 2011 compared to $3.07 in 2010. Again, these are all year-to-date specific. Additionally, one measure that is very important to this company, return on invested capital was projected to exceed 30% this year, even when fully including the invested capital associated with the UBC acquisition in September 2010. 
Now this leads me to a discussion of our expected 2012 performance. This is an unusual year and that the Form S-4 recently filed by Express Scripts under the name Aristotle Holding Inc. on October 6, includes Medco forecast for 2011 through 2014 for net revenues, EBITDA and net income. You can find these forecasts on Page 123 of that document. The S-4 forecast do not include merger-related expenses or any other onetime costs that may be incurred. They are meant to reflect Medco's expected operating performance in a stand-alone basis. For those of you who don't have the S-4 handy, the 2011 forecast presented includes revenues of $68.951 billion, EBITDA of $3.113 billion and net income of $1.473 billion. This 2011 forecast should be viewed as a reflection of the midpoint of our recently narrowed guidance range or about $4.10 in diluted EPS, excluding all amortization and merger-related expenses. The amounts included in the S-4 for 2012 include revenues of $58.931 billion, EBITDA of $3.408 billion and net income of $1.626 billion. These 2012 amounts represent our internal operating plan. You should consider these forecasts as reflecting the high end of the 2012 guidance range with the 4% reduction representing the low end of the range, consistent with ranges provided the previous years. 
Revenue for 2012 is expected to decline by $10 billion or 14.5% from 2011. This decline includes the effect of clients that were required by competitors, were transitioned in the normal course of competitive activity, all as previously announced. It also includes the $6.5 billion generic affect discussed earlier, which decreases our revenues, and very importantly, increase the savings to clients and patients. 
The EBITDA growth from 2011 to 2012 using the forecast presented in the S-4, amounts to 9.5%. Our EBITDA growth from 2010 to 2011 amounts to 4.7%. As you can see, our 2012 EBITDA growth rate is expected to more than double by 2011 EBITDA growth rate. The 2012 growth rate reflects improved profitability, largely because 2012 is the peak year of the generic wave. In addition, we expect to yield efficiencies commensurate with what our business will now require. We have various alternative plans in place to yield these business efficiencies. And you must realize that the large majority of our cost and expense base is, in fact, variable and manageable. 
The 2012 net income growth of 10.4% follows the growth I explained for EBITDA. One statistic that becomes critical with these forecasted amounts being presented is the relationship with EBITDA to revenue, which for the S-4 would be 5% in 2011 and 5.8% in 2012. Recognizing from earlier comment, the 5.8% reflects the high end of the range, we may end up with a record EBITDA margin year in 2012. With EBITDA margin expansion, gross margin percentage and EBITDA per adjusted script expansion are also expected to follow. You will note that the S-4 disclosures do not include any EPS projections for Medco as our share count is uncertain due to the suspension of repurchases while the merger is pending. At this point, I do not expect to give any further guidance detail for 2012 beyond what I just provided. 
In conclusion, we delivered another strong quarter of operating results and EPS. We remain confident in our future prospects for continued growth well into the future and I do believe the value we can drive to clients and members will be even greater with a combined Medco and Express Scripts. Now Dave and I will like to open up the lines for questions. Andrea?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Larry Marsh with Barclays Capital.",15,"[Operator Instructions] Your first question comes from the line of Larry Marsh with Barclays Capital."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","In your S-4, which you addressed this morning, you talked about the 2012 and you showed numbers through 2014. I'm assuming that disclosure doesn't include the loss of United beginning in 2013. And then you talked about net new business being negative beca",63,"In your S-4, which you addressed this morning, you talked about the 2012 and you showed numbers through 2014. I'm assuming that disclosure doesn't include the loss of United beginning in 2013. And then you talked about net new business being negative because acquisitions and such, do you have a net new number, a business number for 2012 that you can share?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I would say that -- to answer your second question first, the net new number for 2012 pretty much equates to the net change in revenues that you see for the year, because we have many puts and takes in that revenue dynamic. You have the effect of th",94,"Well, I would say that -- to answer your second question first, the net new number for 2012 pretty much equates to the net change in revenues that you see for the year, because we have many puts and takes in that revenue dynamic. You have the effect of the lost clients. You have the effect of the generic wave, but you have offsetting effects, also, from expected AWP inflation, et cetera. But when you look at the net new number, it's coincidentally ties to the reduction in the net revenue in the S-4."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Right. And just for Rich, I mean you say all of this has been previously disclosed. Because when I add up all the previously disclosed information, I don't quite get there but maybe I'm underestimating something.",36,"Right. And just for Rich, I mean you say all of this has been previously disclosed. Because when I add up all the previously disclosed information, I don't quite get there but maybe I'm underestimating something."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. You won't -- well, we never gave that new amounts for clients. Of course, we've never disclosed the amounts to Universal American nor for Bravo, as example, which are large accounts. So we of course disclosed the FEP because of its profit contributio",177,"Yes. You won't -- well, we never gave that new amounts for clients. Of course, we've never disclosed the amounts to Universal American nor for Bravo, as example, which are large accounts. So we of course disclosed the FEP because of its profit contributions but not the others. So the reason why you're not getting there is probably because you don't have the proper estimates for some of those other accounts, which is completely understandable. Regarding 2013, while many have assumed that United is actually in our 2013 numbers, it is not. One point you have to understand in this business is living and breathing and healthy, and we expect to continue to win business and don't take one year as a trend. We have a long history of winning clients and we don't plan on stopping at any time soon. And that revenue number that you see is not a guess, we have underlying assumptions that are actually quite detailed, and that's all I can say for obvious reasons. But it does, in fact, exclude United."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So just to confirm, the 2013 and '14 numbers exclude United both in revenues and obviously -- and you assumed EBITDA, so it's obviously reflecting some offsets to your cost structure that you allude to in your prepared remarks?",39,"So just to confirm, the 2013 and '14 numbers exclude United both in revenues and obviously -- and you assumed EBITDA, so it's obviously reflecting some offsets to your cost structure that you allude to in your prepared remarks?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's exactly right, Larry. I mentioned the high proportion of variable expenses and our total cost base, just to give you some color on that. It's over 60% in some cost categories. It's over 70% in certain expense categories. So there is quite a bit of",63,"That's exactly right, Larry. I mentioned the high proportion of variable expenses and our total cost base, just to give you some color on that. It's over 60% in some cost categories. It's over 70% in certain expense categories. So there is quite a bit of variable expense in the base unlike some reports have indicated. And by definition, therefore, quite manageable."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So you must be assuming about an $8 billion incremental increase in net new business for 2013? Is that about right?",21,"So you must be assuming about an $8 billion incremental increase in net new business for 2013? Is that about right?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, you should be thankful that you got the 2000 numbers out there from a revenue perspective. I'm not going to get into the puts and takes on what's net new versus how much is inflation and the rollover of generic effect, and so forth. But ultimately,",65,"Well, you should be thankful that you got the 2000 numbers out there from a revenue perspective. I'm not going to get into the puts and takes on what's net new versus how much is inflation and the rollover of generic effect, and so forth. But ultimately, you can assume that there is certain net new growth in 2013. That's all I'm going to say."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Tom Gallucci with Lazard Capital Markets.",14,"Your next question comes from the line of Tom Gallucci with Lazard Capital Markets."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I guess 2 quick questions. One, your Lipitor expectations have remained very consistent. From the outside looking in, it seems to be sort of a fluid situation. So I was wondering if you can give us any color on why you've got that visibility at this point",94,"I guess 2 quick questions. One, your Lipitor expectations have remained very consistent. From the outside looking in, it seems to be sort of a fluid situation. So I was wondering if you can give us any color on why you've got that visibility at this point? And then number 2, just wondering if you got any commentary or anecdotally that you can offer from your clients on the Walgreens-Express situation or their view toward narrower retail networks in general, given the potential implications for your business depending on how the merger turns out?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay. I'll answer the first question and Dave will take the second. Interestingly, we had visibility to Lipitor a year ago at $0.03. And a year later, it's still $0.03. And as I've said many times in the past, we are not going to disclose our sources or t",96,"Okay. I'll answer the first question and Dave will take the second. Interestingly, we had visibility to Lipitor a year ago at $0.03. And a year later, it's still $0.03. And as I've said many times in the past, we are not going to disclose our sources or the basis for our confidence other than, as you would imagine, we are more confident again than ever before in that $0.03. And I know that there are various press report and I know it is fluid, but from a Medco perspective, again, very confident in the $0.03."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. And Tom, regarding clients questions about WAG, we get many of them. We actually have a regional Drug Trend Symposium that we conduct each and every year, one in the West Coast, one on the East Coast. So a total of, I'd say, 400 or 500 customers betw",219,"Yes. And Tom, regarding clients questions about WAG, we get many of them. We actually have a regional Drug Trend Symposium that we conduct each and every year, one in the West Coast, one on the East Coast. So a total of, I'd say, 400 or 500 customers between the 2. And that was a universal question, asking us what was behind the activity between WAG and ESI. And we've made it clear to them we don't really have insight into the details of the arguments between WAG and ESI. But independent of that, I can tell you that many of our clients are looking at restructured networks to get optimal value and pricing. And they also understand, when you look at a network across the country of 65,000 retail pharmacies and when you do geo-access for many, many, many of our customers and see that there's literally no disruption in terms of travel distance to exclude parts of that network to get significant changes in pricing, they're all looking at it. And that's an independent activity that's been going on at Medco for quite some time. And as the pressures mount tied to this economy, I would tell you they are looking harder at that option now than they ever have before, and I expect that to continue."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your next question comes from the line of Ricky Goldwasser with Morgan Stanley.",14,"And your next question comes from the line of Ricky Goldwasser with Morgan Stanley."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I have a couple of thought questions here. So first of all, on the 2012 selling season, at this point, what percent of the season is completed in terms of renewals in your business?",34,"I have a couple of thought questions here. So first of all, on the 2012 selling season, at this point, what percent of the season is completed in terms of renewals in your business?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So I can say regarding 2012 renewals, we've made very good progress. And the renewal number for 2012 is quite consistent with the renewal number for 2011. And we're over 2/3 completed with the renewals for 2012.",37,"So I can say regarding 2012 renewals, we've made very good progress. And the renewal number for 2012 is quite consistent with the renewal number for 2011. And we're over 2/3 completed with the renewals for 2012."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And should we assume that the remaining business is more skewed to the lower, mid to small accounts?",19,"Okay. And should we assume that the remaining business is more skewed to the lower, mid to small accounts?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes.",1,"Yes."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. Great. And then you talked about rebates and how you continue to see improvement in kind of like from your management and would the branded manufacturers are willing to pay. When you think ahead to 2012, with all the patent expirations, do you think",65,"Okay. Great. And then you talked about rebates and how you continue to see improvement in kind of like from your management and would the branded manufacturers are willing to pay. When you think ahead to 2012, with all the patent expirations, do you think that we're going to continue to see kind of like that same kind of like strategy from the pharma companies?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Let me turn it over to Tom Moriarty.",8,"Let me turn it over to Tom Moriarty."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure. So I view, and I think you will see. We obviously have a multipronged approach that deals at a client level that match their needs. And as we look to different formulary strategies, those formulary strategies thought drive value for the clients. And",62,"Sure. So I view, and I think you will see. We obviously have a multipronged approach that deals at a client level that match their needs. And as we look to different formulary strategies, those formulary strategies thought drive value for the clients. And then ultimately, the pharma companies want to stay in that, and the way they participate is through [indiscernible]."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And do you anticipate -- because you talked about kind of like some of the assumptions for AWP pricing that's factored into your 2012 revenues. Do you anticipate manufacturers like Pfizer and Lipitor will continue to raise prices post the patent exp",43,"Okay. And do you anticipate -- because you talked about kind of like some of the assumptions for AWP pricing that's factored into your 2012 revenues. Do you anticipate manufacturers like Pfizer and Lipitor will continue to raise prices post the patent expiration?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm not going to talk about specific drugs or specific manufacturers. I can tell you, in 2011, we experienced a brand inflation rate that's well over 10% for the highest inflation rates we've seen in recent years. Our assumptions actually assume that, tha",57,"I'm not going to talk about specific drugs or specific manufacturers. I can tell you, in 2011, we experienced a brand inflation rate that's well over 10% for the highest inflation rates we've seen in recent years. Our assumptions actually assume that, that gets down a bit to between the 5% and 10% range in 2012."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And Ricky, just to make sure everybody understands why, I mean this is predictable. When you look at the tax that pharma needs to be pay tied to healthcare reform, you knew that was a pass for you. You knew that was going to come from somewhere and that's",113,"And Ricky, just to make sure everybody understands why, I mean this is predictable. When you look at the tax that pharma needs to be pay tied to healthcare reform, you knew that was a pass for you. You knew that was going to come from somewhere and that's exactly what's going on. And you also have the additional pressure tied to this generic wave that these brand manufacturers are dealing with. So I think it's reasonable to think that you will continue to see inflation. Although, you're going to see a lot of people fighting to prevent that rate of inflation, I think there's a real tug-of-war going on that will continue."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your next question comes from the line of Steven Valiquette with UBS.",13,"And your next question comes from the line of Steven Valiquette with UBS."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So the generic launches for 2012 are obviously positive. But I'm just kind of curious, that $6.5 billion number and it's close to 10% of 2012 revs, it kind of seems like a fairly large numbers. So I guess I'm just curious, is there anything unique about m",100,"So the generic launches for 2012 are obviously positive. But I'm just kind of curious, that $6.5 billion number and it's close to 10% of 2012 revs, it kind of seems like a fairly large numbers. So I guess I'm just curious, is there anything unique about maybe your mail versus retail mix or some other internal factor? And maybe read that to have a larger impact on Medco than maybe other pharma services companies? Or would you just kind of assume that maybe everybody in this industry would kind of have a similar 10% drag on the top line?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay. So let me give you some statistics, Steve. If you look at our book of business mail penetration rate for this quarter, it's 34.8%. When you look at the big drugs that are going to affect that generic effect we mentioned earlier, you have Lipitor whi",140,"Okay. So let me give you some statistics, Steve. If you look at our book of business mail penetration rate for this quarter, it's 34.8%. When you look at the big drugs that are going to affect that generic effect we mentioned earlier, you have Lipitor which is at, the last time I checked, about 60% mail-order penetration rate. You have Lexapro that's at 35%, Plavix at 50%, Singulair at 45%, Actos at 50%, Diovan at 50%. Those are all numbers that I gave at last year's Analyst Meeting on Page 16 of my presentation. Even though there've been some client puts and takes, those numbers are still good reference points. You can see that the majority of the drugs, and these are very high drug spend molecules here, are way beyond our book of business average mail penetration rate."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And just to make it clear. This is always in our line of sight and always been limited within our 5 and more recent 10-year plan. And this has been well known.",32,"And just to make it clear. This is always in our line of sight and always been limited within our 5 and more recent 10-year plan. And this has been well known."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. That's helpful. And then just a quick follow-up on specialty, hitting a lot of questions on that. I'm wondering the size of the market is kind of wide open to interpretation, but do you have an approximate number for how you guys define the size of",89,"Okay. That's helpful. And then just a quick follow-up on specialty, hitting a lot of questions on that. I'm wondering the size of the market is kind of wide open to interpretation, but do you have an approximate number for how you guys define the size of the specialty markets, I mean, you have roughly $13 billion of revenues this year mainly to Accredo. But where do you give your approximate market share within specialty in terms of how the discussion might be going with the FTC, et cetera?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We don't have a number going. We focus on what our actual performance. I think, the market is very, very broad, as Dave mentioned in his prepared remark, and there are many, many providers. And the specialty market is very likely much greater than what yo",65,"We don't have a number going. We focus on what our actual performance. I think, the market is very, very broad, as Dave mentioned in his prepared remark, and there are many, many providers. And the specialty market is very likely much greater than what you would see in disclosures of the respective PBMs, which is just a small piece of the broader market."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then just real quick, 2 second follow-up on that UNH, is that spread across 2013 and 2014? Or was just that 2013 that you're assuming the loss of UNH within that 5-year, or 4- or 5-year projection?",39,"Okay. And then just real quick, 2 second follow-up on that UNH, is that spread across 2013 and 2014? Or was just that 2013 that you're assuming the loss of UNH within that 5-year, or 4- or 5-year projection?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's assumed out '13.",5,"It's assumed out '13."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your next question comes from the line of Ross Muken with Deutsche Bank.",14,"And your next question comes from the line of Ross Muken with Deutsche Bank."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","It's actually Mike Cherny in for Ross. So just quickly, on the closing of the 2 JVs with Celesio and the United Drug, can you talk about the cash flow impact there if there has any changes to your outlook and any financial terms you can provide above and",55,"It's actually Mike Cherny in for Ross. So just quickly, on the closing of the 2 JVs with Celesio and the United Drug, can you talk about the cash flow impact there if there has any changes to your outlook and any financial terms you can provide above and beyond what was already discussed?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. It's all quite immaterial so it's really -- nothing to worry about, nothing that will meaningfully change models going forward.",21,"No. It's all quite immaterial so it's really -- nothing to worry about, nothing that will meaningfully change models going forward."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Perfect. And then you mentioned in terms of the rationale for the deal, Dave, talking about customer response so far and how they are excited about the savings that can be provided to them. I guess, as you went to the later stage of the selling season and",122,"Perfect. And then you mentioned in terms of the rationale for the deal, Dave, talking about customer response so far and how they are excited about the savings that can be provided to them. I guess, as you went to the later stage of the selling season and talking about the fiscal '12 selling season as well, can you talk about, I guess, kind of reaction from that perspective in terms of both going out and winning new deals, what the thought process was on how you're going to change the approach once the merger with Express Script was completed and kind of what kind of service levels and other added benefits they'd beginning in terms of planned design post the merger?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. Sure. First of all, I'd love to point out the fact that just in our Systemed Group alone, they closed over 70 deals post-merger announcement and they're still extremely busy right now. From the point of view of a client, they understand how the combi",281,"Yes. Sure. First of all, I'd love to point out the fact that just in our Systemed Group alone, they closed over 70 deals post-merger announcement and they're still extremely busy right now. From the point of view of a client, they understand how the combination create better financials for them and it was just critically important. So that beyond the financials, the questions they're asking is, what will the combined company look like? How will it operate? Will we still get the same services that we got from Medco as a stand-alone company? As George and I talked about what this combined company will look like, we have this concept of best-of-breed and best of both worlds. So my feeling is, our clients are likely to experience continued innovation, combinations of best-of-breed assets to get even better service and better options. And obviously, part of that is in execution, and we're still in integration planning process so we have a lot of work to do still, but conceptually, we do know where we want to end up. I think both companies know where they want to end up and I think it's safe to say both companies have the client and the clients' need squarely in their focus is the #1 priority. Because at the end of the day, we still want to delight and retain customers and win new customers. So I'm very comfortable that as we look at the capabilities of both companies, we will get to something we call best-of-breed between the 2. And I think that make a client comfortable. I think that's what they're looking for and obviously, they're going to watch that over time."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of John Kreger with William Blair.",13,"Your next question comes from the line of John Kreger with William Blair."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave, you mentioned a few minutes ago that clients are showing a greater interest in some of these narrow networks. What sort of savings are you able to offer to them and are you finding that the savings is big enough to sort of assume the hassle factor?",48,"Dave, you mentioned a few minutes ago that clients are showing a greater interest in some of these narrow networks. What sort of savings are you able to offer to them and are you finding that the savings is big enough to sort of assume the hassle factor?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It varies by client because it ties with the geographic dispersion of their people. But I can tell you in a range, it's very meaningful and very worthwhile considering, especially when you're a jumbo account, which Medco has a lot of. It's extremely meani",53,"It varies by client because it ties with the geographic dispersion of their people. But I can tell you in a range, it's very meaningful and very worthwhile considering, especially when you're a jumbo account, which Medco has a lot of. It's extremely meaningful. You can see 2 points easily and sometimes more."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Great. And Rich, you made the comment that your cost structure is flexible. Can we infer from that, that your starting down the path of cutting some costs as you've had some losses or should we assume that, that's a process that's going to potentially be",51,"Great. And Rich, you made the comment that your cost structure is flexible. Can we infer from that, that your starting down the path of cutting some costs as you've had some losses or should we assume that, that's a process that's going to potentially be held up by the merger?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, if you look at our SG&A numbers, given this quarter, you can see that the inherent growth rate is quite low so we've been, I think, doing a great job in managing our expenses and just all the course of business. But ultimately, the efficiencies need",69,"Well, if you look at our SG&A numbers, given this quarter, you can see that the inherent growth rate is quite low so we've been, I think, doing a great job in managing our expenses and just all the course of business. But ultimately, the efficiencies need to be yielded on a stand-alone basis or in a merged scenario. So we have to do what we have to do."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch.",16,"Your next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a quick one, the European joint ventures, you guys have bought back, I guess a couple of them. These were growth drivers for you for 2014 and beyond. And what's the plan there? Are you bringing them off-line or are you hoarding the economics? What's",49,"Just a quick one, the European joint ventures, you guys have bought back, I guess a couple of them. These were growth drivers for you for 2014 and beyond. And what's the plan there? Are you bringing them off-line or are you hoarding the economics? What's the strategy there?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's more the latter than the former, Bob. We are still very committed to Europe. We like the opportunities as we find tune what Europe needs and want. We feel we're incredibly well prepared to deliver it without a joint venture partner. And so now we've",129,"It's more the latter than the former, Bob. We are still very committed to Europe. We like the opportunities as we find tune what Europe needs and want. We feel we're incredibly well prepared to deliver it without a joint venture partner. And so now we've learned a lot in these seeds we planted. And as we refine and focus on what we want to do and how we want to approach it, taking it all in-house made sense for us. And if Brian Griffin, who's running our international operations were here today, he would tell you that this is something that he is excited about now that he has full control and he is able to focus upon the market without the distractions of managing a JV."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And how do we think about the profit profile and the future investment needed for them?",16,"And how do we think about the profit profile and the future investment needed for them?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I would say, over the next few years, the investments will be relative to the broader company, nominal immaterial. The growth profile remains the same. We never expected it to be material in '12, 13. But certainly, when you get to the back half of t",66,"Well, I would say, over the next few years, the investments will be relative to the broader company, nominal immaterial. The growth profile remains the same. We never expected it to be material in '12, 13. But certainly, when you get to the back half of this decade, our thinking is consistent that the it will in fact start to become meaningful contribution to our profitability."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And I'll just add, Brian Griffin and his team have had some nice wins recently and we're very encouraged that the trajectory is going to be something like what we originally envisioned. So we're feeling very good about his progress there.",42,"And I'll just add, Brian Griffin and his team have had some nice wins recently and we're very encouraged that the trajectory is going to be something like what we originally envisioned. So we're feeling very good about his progress there."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Charles Rhyee with Cowen.",12,"Your next question comes from the line of Charles Rhyee with Cowen."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just one more question on Celesio. If I recall at the beginning of this year, you made an adjustment for the JV and a bunch of the mail volume went -- it was part of the JV, so it wasn't counted in your mail volume. How should we think about treating that",74,"Just one more question on Celesio. If I recall at the beginning of this year, you made an adjustment for the JV and a bunch of the mail volume went -- it was part of the JV, so it wasn't counted in your mail volume. How should we think about treating that, I think it was almost like 10 million mail scripts. Should we think that's coming back on to the income statement again?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, the mail scripts are -- you're a weigh off by  a multiple factor with regards to the volumes. It's actually more like a fraction of that. The mail volumes came from Europa Apotheek Venlo. And Europa Apotheek Venlo has been in our volumes because it",76,"Well, the mail scripts are -- you're a weigh off by  a multiple factor with regards to the volumes. It's actually more like a fraction of that. The mail volumes came from Europa Apotheek Venlo. And Europa Apotheek Venlo has been in our volumes because it was never contributed for the joint venture in the first place. So that just continues in our run rate and will continue as it grows through the next several years."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. So there's really no then change to how we should be looking at the go forward mail volumes other than some of the announced contracts?",26,"Okay. So there's really no then change to how we should be looking at the go forward mail volumes other than some of the announced contracts?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's correct.",3,"That's correct."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then a quick question maybe on FEP, we're obviously looking at -- when you look at the '12 numbers, does the change that we're seeing also include any sort of purchasing leverage you might be losing because, clearly, your mail revenues drop and",63,"Okay. And then a quick question maybe on FEP, we're obviously looking at -- when you look at the '12 numbers, does the change that we're seeing also include any sort of purchasing leverage you might be losing because, clearly, your mail revenues drop and a chunk definitely does come from branded. Now how should we think about that part of the contribution?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll let Rich answer that. But I think -- I just want to remind you because we've said this before, that the loss of FEP has literally no impact on our leverage and our ability to contract at competitive prices. This change in volume on our side has liter",55,"I'll let Rich answer that. But I think -- I just want to remind you because we've said this before, that the loss of FEP has literally no impact on our leverage and our ability to contract at competitive prices. This change in volume on our side has literally no impact on our leverage."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. There is no leverage effect in sort of today's point. And we have a very clear line of sight into our purchasing leverage for 2012 and of course, that's baked into what you see in the S-4.",38,"Yes. There is no leverage effect in sort of today's point. And we have a very clear line of sight into our purchasing leverage for 2012 and of course, that's baked into what you see in the S-4."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. That's helpful. And then just one last question on Accredo. Obviously -- I think a couple of years ago, we saw some margin pressure on the gross margin line, it's clearly stabilized here. What has really changed here now and then shall we think abou",60,"Okay. That's helpful. And then just one last question on Accredo. Obviously -- I think a couple of years ago, we saw some margin pressure on the gross margin line, it's clearly stabilized here. What has really changed here now and then shall we think about the margins being pretty stable at this -- a high 6.8% range going forward?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll start with that and then I'll ask Frank Sheehy to add anything that he wishes to. The thing I will add is that, what's changed is Frank Sheehy. He's gone in there. He's looked at the operations. He's done a very, very good job working with our client",139,"I'll start with that and then I'll ask Frank Sheehy to add anything that he wishes to. The thing I will add is that, what's changed is Frank Sheehy. He's gone in there. He's looked at the operations. He's done a very, very good job working with our clients and also working with the operations to get the cost in line and to make us more efficient. And what's great about Frank is he came from the customer side of our business in the core, knows these customers, knows what they're looking for, and he's made some great changes to, I think, be better aligned with what our client need and serve them better and more cost-effectively. And I don't know if you want to point anything specific at this point, Frank, but I'm giving you the opportunity."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. I think to Dave's point, working aggressively with Tim Wentworth and Glenn Taylor and their team and putting programs out there that are aligned with our clients interest are definitely resonating, combined with the differentiating service model that",52,"Yes. I think to Dave's point, working aggressively with Tim Wentworth and Glenn Taylor and their team and putting programs out there that are aligned with our clients interest are definitely resonating, combined with the differentiating service model that we've bought there have create a great opportunity for Accredo and our clients."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Eugene Goldenberg with BB&T.",13,"Your next question comes from the line of Eugene Goldenberg with BB&T."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Can you just provide any additional commentary around some of the chatter that we're hearing of Pfizer getting a little bit or actually a lot more aggressive on the rebate strategy when it comes to Lipitor? I think they recently raised the rebate on Lipit",67,"Can you just provide any additional commentary around some of the chatter that we're hearing of Pfizer getting a little bit or actually a lot more aggressive on the rebate strategy when it comes to Lipitor? I think they recently raised the rebate on Lipitor to about 50% and have been offering it to some PBMs. Can you provide a little bit of color on that?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll ask Tom if he has any insight into that?",11,"I'll ask Tom if he has any insight into that?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, obviously, they have a multipronged strategy for the market around Lipitor and what you cited obviously about the marketplace. We've obviously chosen our strategy and are quite comfortable with that. So that's all I can add to it.",39,"Well, obviously, they have a multipronged strategy for the market around Lipitor and what you cited obviously about the marketplace. We've obviously chosen our strategy and are quite comfortable with that. So that's all I can add to it."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your last question comes from the line of David Larsen with Leerink Swann.",14,"And your last question comes from the line of David Larsen with Leerink Swann."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Has the 2013 selling season started off for large health plans?",11,"Has the 2013 selling season started off for large health plans?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll ask Glenn Taylor, who runs our Health Plan Group to indicate what's going on there.",17,"I'll ask Glenn Taylor, who runs our Health Plan Group to indicate what's going on there."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. I would say, yes, there's RFP activity related to '11, '13 business. But we haven't had any finals and haven't gone through the full process yet. It's a little bit early.",32,"Yes. I would say, yes, there's RFP activity related to '11, '13 business. But we haven't had any finals and haven't gone through the full process yet. It's a little bit early."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It is in the sale cycle for that type of account though.",12,"It is in the sale cycle for that type of account though."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. So that sort of process is not necessarily having an impact on that 2013 revenue on the S-4 statement, right? It's not like you have great clarity on '13. Okay. And then also in terms of the EBITDA growth rate for 2014 in the S-4, it looked pretty g",69,"Okay. So that sort of process is not necessarily having an impact on that 2013 revenue on the S-4 statement, right? It's not like you have great clarity on '13. Okay. And then also in terms of the EBITDA growth rate for 2014 in the S-4, it looked pretty good to me be and like maybe 14% year-over-year. Is there anything in '14 in particular that would drive that?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, you might recall again from Analyst Day last year that we show that famous generic EPS contribution slide. It had a wave going through it. And you might recall that 2014 and 2018, were both strong years. Actually 2014 was the strongest after 2012 an",97,"Well, you might recall again from Analyst Day last year that we show that famous generic EPS contribution slide. It had a wave going through it. And you might recall that 2014 and 2018, were both strong years. Actually 2014 was the strongest after 2012 and that includes some pretty large drugs going generic. And for our book, at the time at least, they averaged about 45% mail-order penetration rate. The include, in order expected introduction, Asacol; Evista; Nexium, which of course is a very large drug; Telebrix and Actonel. So those were important drivers for '14."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then for new members coming on through the exchanges in '14, that's not a big driver of that growth rate. Is that correct? It's more the generics?",29,"Okay. And then for new members coming on through the exchanges in '14, that's not a big driver of that growth rate. Is that correct? It's more the generics?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That is correct.",3,"That is correct."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. You're going to be seeing the exchange growth come through health plan partners given the way the rates are written right now.",23,"Yes. You're going to be seeing the exchange growth come through health plan partners given the way the rates are written right now."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then just my last question, Dave, assuming this merger does go through, do we get any clarity on sort of what your role is going to be or what your plans are?",34,"Okay. And then just my last question, Dave, assuming this merger does go through, do we get any clarity on sort of what your role is going to be or what your plans are?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We don't have complete clarity now. But remember, we are the company being acquired. So I think you can think about it from that point of view.",28,"We don't have complete clarity now. But remember, we are the company being acquired. So I think you can think about it from that point of view."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Are there any closing remarks, sir?",6,"Are there any closing remarks, sir?"
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. I think we're done. And I just want to thank everyone for dialing in to our call and joining us. And we look forward to continuing, updating you as we make progress with the FTC. Thanks.",37,"No. I think we're done. And I just want to thank everyone for dialing in to our call and joining us. And we look forward to continuing, updating you as we make progress with the FTC. Thanks."
1541811,141271840,178180,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect.",14,"Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Medco Health Solutions Third Quarter 2011 Earnings Call. [Operator Instructions] I would now like to turn the call over to",56,"Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Medco Health Solutions Third Quarter 2011 Earnings Call. [Operator Instructions] I would now like to turn the call over to Vice President of Investor Relations, Ms. Valerie Haertel. You may begin."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Andrea. Good morning, everyone, and thank you for joining us on Medco's Third Quarter 2011 Earnings Conference Call. With me today as speakers are Chairman and Chief Executive Officer, Dave Snow; and Chief Financial Officer, Rich Rubino. Also j",314,"Thank you, Andrea. Good morning, everyone, and thank you for joining us on Medco's Third Quarter 2011 Earnings Conference Call. With me today as speakers are Chairman and Chief Executive Officer, Dave Snow; and Chief Financial Officer, Rich Rubino. Also joining us for our question-and-answer session are: Kenny Klepper, President and Chief Operating Officer; Tom Moriarty, General Counsel, Secretary and President of Global Pharmaceutical Strategies; Frank Sheehy, President of Accredo Health Group; Tim Wentworth, Group President of the Employer and Key Accounts; and Glenn Taylor, Group President of Health Plans. 
During the course of this call, we will make forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements made on this call should be evaluated together with the risks and uncertainties that affect our business, particularly those disclosed in our SEC filings.  Copies of Medco's filings are available from the SEC, the Medco Investor Relations Department or the Medco website. Medco intends to use the Investor Relations section of its website as a means of disclosing material non-public information and for complying with these disclosure obligations under Regulation FD. The copyrights for the contents of this discussion and the written materials used on this earning call are owned by Medco Health Solutions, Inc. 2011. 
Slides to accompany our presentation, which detail our financial and operating results and the guidance discussed on this call, are currently available in the Events section of the Investor Relations site on medcohealth.com. Additionally, please note that we expect to file our 10-Q after the close of the market today. At this time, I would like to turn the call over to Dave Snow. Dave?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Valerie, and thanks to all of you for joining us this morning. Today, we are reporting strong third quarter 2011 earnings and narrowing the range of our full year 2011 earnings per share guidance to the high-end of previous guidance. GAAP dilut",1413,"Thank you, Valerie, and thanks to all of you for joining us this morning. Today, we are reporting strong third quarter 2011 earnings and narrowing the range of our full year 2011 earnings per share guidance to the high-end of previous guidance. GAAP diluted earnings per share for third quarter 2011 reached $0.90 or $0.96, excluding merger-related expenses incurred in the quarter, representing solid 12.9% growth over third quarter 2010. Even when including the merger-related expenses, our GAAP EPS is a record. Our diluted earnings per share, excluding all intangible amortization and the merger-related expenses, reached a record $1.07, reflecting a 12.6% growth rate over third quarter 2010. Importantly, our gross margin percentage was consistent with third quarter 2010 at 6.9%, up meaningfully from the 6.5% in second quarter 2011. And our EBITDA per script, excluding the merger-related expenses, also reached a record level at $3.43. Our mail volumes continue to be strong at this stage of the year. We are now confident that we will meaningfully surpass the high-end of our previous mail volume guidance range of 108 million to 110 million script. 
Our Accredo business also delivered strong results with revenue growth of 16.7% and operating income growth of 33%, all at a 6.8% gross margin, consistent with third quarter 2010. The company is performing well across the board and we narrowed our a 2011 diluted earnings per share guidance excluding merger-related expenses and all intangible amortization to a range of $4.08 to $4.12, which represents 15% to 16% growth over 2010. Our previous guidance of $4.02 to $4.12 reflect the growth of 13% to 16% over 2010. 
For the 2011 selling season, our annualized new-named sales totaled $3.2 billion, up from the $3 billion we previously reported. We have completed 98% of our 2011 renewals amounting to $16 billion client-drove spend. Our 2012 annualized new-named sales currently stand at approximately $1.6 billion, double the $800 million reported last quarter as our clinically focused model continues to have strong appeal in the marketplace. 
Now, I would like to share some thoughts on the pending merger with Express Scripts. As you saw in the recently filed S-4, after an extensive review of numerous strategic alternatives through an exhaustive planning process, we determined that combining with Express Scripts was the best strategy to maximize value for our clients, members and shareholders. The merger is a solution to control escalating healthcare costs in America, costs that are undermining the U.S. competitiveness in the global economy. In 2010 alone, U.S. spending for prescription drugs reached $307.4 billion. Our aging population and an increased prevalence of chronic disease are projected to drive a 50% increase in prescription drug spending to well over $450 billion by 2019. 
At Medco, we have lowered the cost of prescription medications for our clients by enabling greater use of generics, driving a savings of $3.7 billion to Medco's clients in full year 2010, and $2.7 billion year-to-date in 2011. We have expertly managed the challenges associated with the rising costs of care, including specialty medications, and we have improved efficiencies my enabling clients to make effective use of the highest value channels of distribution, including mail-order delivery for chronic medication. The combined organization is well positioned to advance the quality and cost goals set forth in America's healthcare reform legislation by combining 2 innovative approaches, Medco's advanced clinical services that utilize an evidence-based protocols and Express Script Services which focus on behavioral science to increase medication adherence. As you can see from this year's performance and our projections included in the S-4, we are planning to merge from a position of strength. Combining forces with Express Scripts positions us to deliver what our nation needs now, high-quality care at even lower cost to our patients and clients. And we can do this much more effectively together. 
Many of you have asked where we are in the regulatory review process and what will be the likely outcome. As I have said previously, and most recently at a hearing in Washington DC, we would not have announced this combination if we were not confident in our ability to obtain the necessary regulatory approvals. As we stated when the deal was announced, we anticipated that the transaction will close in the first half of 2012, and we remain confident in that projection for a number of reasons. First, the opponents of this proposed mergers are not customers. Our proposed merger is receiving very positive reaction from our customers who understand that the combination of Medco and Express Scripts can mean to them and their members. This combination includes over $1 billion in savings as it's expected to be delivered to customers after closing. 
Second, the PBM marketplace is highly competitive and will remain highly competitive after the deal closes. There are at least 10 PBMs serving the largest employers in the Fortune 50 and over 15 serving the Fortune 500 alone. In addition, these and many other PBMs also serve large government accounts and health plan. In fact, today, our competitors include over 40 PBMs with household names like Aetna, CIGNA, CVS Caremark and others who may not be as well known, but continues to make major investments such as Prime Therapeutics, Catalyst and FXP. Additionally, in specialty drugs, hundreds of different firms compete including PBMs, pharmacy chains and independents, wholesalers, managed-care organizations, as well as stand-alone specialty pharmacies.  Also, and very importantly, UnitedHealth Group has announced its plans to bring in-house the 40 million lives previously served by Medco and combine that business with a substantial Medicare and other national employer lives it already directly services through its own PBM known as OptimRx. With this, United Health Group will be one of the nation's largest PBMs. 
The merger with Express Scripts provides us with the opportunity to reduce our acquisition costs for medications and pass on additional savings for our clients and patients. The SEC's concern is protecting consumers, not competitors. That means ensuring competition remains healthy in the marketplace and consumers are not harmed by price increases resulting from fewer competitors. We firmly believe that this combination will benefit consumers. 
To conclude my remarks on this topic, the proposed merger, in our view, embodies the spirit of the new healthcare reform legislation that promotes innovation to solve America's healthcare burden. As I have said previously, we are confident that this merger will receive SEC approval in the first half of 2012. We are an important part of the solution and we remain dedicated to providing our clients with quality care at the lowest possible cost. Not only does this merger promise to serve our clients well, it will create substantial value for our shareholders. 
Before I turn the call over to Rich, who will cover the 2012 guidance more thoroughly, I would like to highlight a few observations for next year. First, as you saw in the S-4 and in our earnings release, revenue is expected to decrease to approximately $58.9 billion in 2012, equating to a $10 billion or 14.5% decline. This decline contains many moving parts, including clients that are transitioning from Medco due to acquisitions by competitors and other reasons. Also, contributing to the decline in revenues is the generic wave in 2012, which is projected to reduce our net revenues next year by approximately $6.5 billion. If you look at this from the other side of the ledger, this is value that accrues to clients and patients, a massive win to the consumer. 
The last point I will make on guidance is regarding our EBITDA, which at the high-end is expected to grow by as much as 9.5% in 2012 as a function of the generic wave and continuously improving business efficiencies. And looking at EBITDA as a percentage of revenue, what is known as EBITDA margin, we expect this measure to increase from approximately 4.5% in 2011 to as much as 5.8% at the high-end in 2012, which would represent a Medco record. We expect meaningful increases in our gross margin percentage and EBITDA per script for 2012 as well. Resulting not only from the generic wave and business efficiencies I just mentioned, but also from the fact that the large retail clients that will be transitioning in 2012 carries extraordinarily low profit margins. 
With that, I'll turn the call over to our CFO, Rich Rubino, who will discuss additional third quarter 2011 financial performance details, and provide you with additional color regarding our 2012 guidance. Rich?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Thank you, Dave. Good morning. As Dave mentioned, our third quarter EPS results were strong, with record GAAP diluted EPS of $0.90. The record gets even more impressive when you exclude the $0.06 of merger-related expenses, bringing that number to an equi",2223,"Thank you, Dave. Good morning. As Dave mentioned, our third quarter EPS results were strong, with record GAAP diluted EPS of $0.90. The record gets even more impressive when you exclude the $0.06 of merger-related expenses, bringing that number to an equivalent of $0.96, a growth of 12.9% over third quarter last year. Diluted EPS, excluding all intangibles and merger-related expenses of $1.07 for this quarter is also a record, representing a 12.6% increase. This $1.07 is a meaningful $0.08 higher than our previous EPS record of $0.99 set in the fourth quarter of 2010. The merger-related expenses, which primarily include bankruptcies, legal fees and employee retention-related expenses, totaled $36.6 million or $0.06 per share. And that of course, was for the third quarter of 2011, with $35.6 million flowing to SG&A expense and the remaining $1 million flowing to cost of sales. We currently expect the fourth quarter 2011 amount of merger-related expenses to be slightly less than the third quarter at $0.05 per share, bringing full year 2011 estimated merger-related expenses to $0.11 per share. 
Total third quarter 2011 net revenues reached $17.0 billion, representing growth of 4.1% over  third quarter 2010. Our product revenues grew 3.4% over third quarter 2010 to $16.6 billion, reflecting our new business wins, as well as higher prices charged by brand-name pharmaceutical manufacturers, partially offset by a higher mix of lower-priced generics. On that generics point, our clients and members saved approximately $700 million this quarter compared to third quarter 2010 from increased utilization of generics.  For 2011, we expect these savings to total approximately $3.7 billion. If you look at how much Medco clients and members have saved from generic drug utilization since 2006, when the first blockbuster drug started losing their patents, it is a very substantial number, $16.7 billion. Add to that the expected record 2012 year for generic savings that Dave already mentioned, contributing another expected $6.5 billion in savings, and the cumulative savings since 2006 rose to over $23 billion. 
Service revenue continue to be a significant growth driver, increasing 46.9% over the third quarter 2010 to a record $379 million. This strong performance reflects the service revenue contribution from UBC, as well as growth in our client service offerings across the company. 
Turning to rebates, we earned $1.5 billion for the third quarter, an increase of 5.6% over the same period last year, even though we are dispensing fewer brand-name medications and more generics. This year-over-year growth is attributable to continuous improvements in formulary contract. Our third quarter 2011 rebate retention rate was 13.0%, consistent with the 12.8% in the third quarter 2010 as we continue to drive significant value to clients in a highly transparent manner. 
As Dave mentioned, mail-order volume remains strong as clients and members continue to choose this lower cost and clinically effective channel. In third quarter 2011, our total mail-order prescription volume is 27.4 million. Within this, generic prescription mail-order volumes increased 3.5% to 17.7 million, just 100,000 scripts shy of our record experienced last few quarter. Brand name prescription volumes decreased 4.9% to 9.7 million prescriptions. Mail-order volumes are on their way to exceeding the high end of the previous guidance we provided of 110 million scripts. We now expect 2011 mail-order volumes of approximately 112 million prescriptions. 
Our generic dispensing rate at mail increased 2 full percentage points from third quarter 2010 to a new record of 64.8%. The strong generic mail-order prescription volumes and our increased service gross margin drove our third quarter gross margin to a new record of $1.17 billion, a 4.3% increase over third quarter 2010. The total gross margin percentage of 6.9% is consistent with third quarter 2010, which you may recall was an important quarter for 2010, it reflected a significant gross margin percent recovery from where we were earlier in that year. 
Selling, general and administrative expenses for third quarter 2011 totaled $455.6 million. When reduced by the $35.6 million in merger-related expenses I explained earlier, SG&A expenses declined to $420 million. When adjusted further for the effective UBC, which was acquired on September 16, 2010, our SG&A increased only 1.7%. This reflects efficiencies across the enterprise while we continued to invest in our clinical and strategic programs and new technologies to drive even higher levels of service to our clients and members. 
The EBITDA and EBITDA per script performance I'm about to explain excludes the merger-related expenses. Our total EBITDA for the third quarter 2011 marks yet another record at $800.9 million, representing growth of 3.9% over third quarter 2010. EBITDA per adjusted prescription for the third quarter 2011 also represents a record, increasing 4.6% to $3.43 from the $3.28 in the third quarter of 2010, which was our previous record. Our intangible amortization of $73.2 million in third quarter 2011 increased 2.8% from $71.2 million in third quarter of 2010, primarily reflecting the UBC intangible assets. Total net interest and other expense of $49.6 million for third quarter of 2011 increased $8.8 million from the $40.8 million in third quarter 2010, reflecting the new debt we added to finance the UBC acquisition last September. Third quarter 2011 effective tax rate was 39.6% compared to 39.3% in the third quarter 2010. 
Net income in the third quarter of 2011 of $355.4 million included $22.0 million in merger-related expenses. This essentially being the tax effective equivalent of the $36.6 million pretax number I described earlier. Excluding these expenses the results of net income of $377.4 million represents a 1.6% increase in the third quarter 2010. 
Moving on to share repurchases. During the third quarter of 2011, we repurchased 6.3 million shares for $350 million at an average per share cost of $55.89 through our pre-authorized trading plan. This third quarter repurchase allotment under the pre-authorized plan was completed on July 15. Future repurchases have since been suspended as a result of the pending merger with Express Scripts. We have always viewed share repurchases as an effective tool in enhancing value to shareholders. On an inception-to-date basis, since we started our first share repurchase program in 2005, we have repurchased 285.5 million shares at a cost of $12.85 billion and an average per share cost of $45 even. 
Our year-to-date cash flow from operations is $1.086 billion compared to $1.365 billion for the same period in 2010, with the largest driver being the approximately $200 million payment from the IRS in 2010 related to its tax receivable in prior years. Our inventories reached a record low of $788 million. You may recall that in June 2008, our inventory balance closed at nearly $2.1 billion. We have since then reduced inventory by over 60% to the lowest it has been since 1999, the year when our mail volume was about 60 million prescriptions.  All of that impacting patient service level. 
We closed the third quarter with a cash balance of $161.5 million, and we expect our quarterly cash balances to build for the remainder of 2011 and into 2012 due to the suspension of our share repurchase program. Our total debt for the third quarter has remained consistent since third quarter of 2010 at $5.0 billion. 
Turning to our specialty segment. Accredo achieved record revenues and operating income with growth of 16.7% and 33.0%, respectively, and sustained a strong margin of 6.8%. This strong performance reflects our clients preference to the Accredo service model, as well as, more generally, to grow the utilization of specialty drugs. To be more specific, the product categories driving the growth in specialty include rheumatoid arthritis, multiple sclerosis, immune disorders and oncology. With new drug introductions also driving growth in the hepatitis class. 
As Dave mentioned, we are narrowing our 2011 EPS guidance to the high end of the previous range. Our 2011 full year GAAP diluted EPS, including the merger-related expenses is expected in the range of $3.54 to $3.58. Excluding the merger-related expenses, 2011 guidance is $0.11 stronger as I discussed earlier. When adding back the $0.11, this guidance represents a range of $3.65 to $3.69 for a growth rate of 16% to 17% over 2010. Our full year 2011 diluted EPS guidance excluding all intangible amortization and merger-related expenses is now in the range of $4.08 to $4.12, reflecting growth of 15% to 16% over 2010. We essentially updated what was previously at $0.10 guidance range and narrowed it to the high end with a much tighter $0.04 spread, reflecting confidence in our strength for the remainder of the year. I'm not going to walk you line by line through 2011 guidance since our current expectations are consistent with what we have previously communicated. 
Our fourth quarter is expected to be the strongest quarter of 2011, as I have guided in the past. Included in the fourth quarter is an expected lift in the incremental EPS effect in new generics led by Lipitor, with an approximate $0.03 contribution. We also expect our fourth quarter tax rate to be lower, bringing the full year effective tax rate to the lower end of the previous guidance range or approximately 38.5%. 
You may recall that when I first gave guidance for 2011 on our third quarter 2010 earnings call, I pointed to an expectation for stability or possible expansion in gross margin percentage and EBITDA per script. Looking back to September 2011 year-to-date, excluding this year's merger-related expenses, gross margin is consistent at 6.5% through '11 and '10, and our EBITDA per adjusted script has, in fact, expanded to $3.16 in 2011 compared to $3.07 in 2010. Again, these are all year-to-date specific. Additionally, one measure that is very important to this company, return on invested capital was projected to exceed 30% this year, even when fully including the invested capital associated with the UBC acquisition in September 2010. 
Now this leads me to a discussion of our expected 2012 performance. This is an unusual year in that the Form S-4 recently filed by Express Scripts under the name Aristotle Holding Inc. on October 6, includes Medco forecast for 2011 through 2014 for net revenues, EBITDA and net income. You can find these forecasts on Page 123 of that document. The S-4 forecasts do not include merger-related expenses or any other onetime costs that may be incurred. They are meant to reflect Medco's expected operating performance on a stand-alone basis. For those of you who don't have the S-4 handy, the 2011 forecast presented includes revenues of $68.951 billion, EBITDA of $3.113 billion and net income of $1.473 billion. These 2011 forecasts should be viewed as a reflection of the midpoint of our recently narrowed guidance range or about $4.10 in diluted EPS, excluding all amortization and merger-related expenses. The amounts included in the S-4 for 2012 include revenues of $58.931 billion, EBITDA of $3.408 billion and net income of $1.626 billion. These 2012 amounts represent our internal operating plan. You should consider these forecasts as reflecting the high end of the 2012 guidance range with the 4% reduction representing the low end of the range, consistent with ranges provided the previous years. 
Revenue for 2012 is expected to decline by $10 billion or 14.5% from 2011. This decline includes the effect of clients that were required by competitors or transitioned in the normal course of competitive activity, all as previously announced. It also includes the $6.5 billion generic affect discussed earlier, which decreases our revenues, and very importantly, increase the savings to clients and patients. 
The EBITDA growth from 2011 to 2012 using the forecast presented in the S-4, amounts to 9.5%. Our EBITDA growth from 2010 to 2011 amounts to 4.7%. As you can see, our 2012 EBITDA growth rate is expected to more than double by 2011 EBITDA growth rate. The 2012 growth rate reflects improved profitability, largely because 2012 is the peak year of the generic wave. In addition, we expect to yield efficiencies commensurate with what our business will now require. We have various alternative plans in place to yield these business efficiencies. And you must realize that the large majority of our cost and expense base is, in fact, variable and manageable. 
The 2012 net income growth of 10.4% follows the growth I explained for EBITDA. One statistic that becomes critical with these forecasted amounts being presented is the relationship with EBITDA to revenue, which for the S-4, would be 5% in 2011 and 5.8% in 2012. Recognizing from earlier comments, the 5.8% reflects the high end of the range, we may end up with a record EBITDA margin year in 2012. With EBITDA margin expansion, gross margin percentage and EBITDA per adjusted script expansion are also expected to follow. You will note that the S-4 disclosures do not include any EPS projections for Medco as our share count is uncertain due to the suspension of repurchases while the merger is pending. At this point, I do not expect to give any further guidance detail for 2012 beyond what I just provided. 
In conclusion, we delivered another strong quarter of operating results and EPS. We remain confident in our future prospects for continued growth well into the future and I do believe the value we can drive to clients and members will be even greater with a combined Medco and Express Scripts. Now Dave and I will like to open up the lines for questions. Andrea?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","[Operator Instructions] Your first question comes from the line of Larry Marsh with Barclays Capital.",15,"[Operator Instructions] Your first question comes from the line of Larry Marsh with Barclays Capital."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","In your S-4, which you addressed this morning, you talked about the 2012 and you showed numbers through 2014. I'm assuming that disclosure doesn't include the loss of United beginning in 2013. And then you talked about net new business being negative beca",64,"In your S-4, which you addressed this morning, you talked about the 2012 and you showed numbers through 2014. I'm assuming that disclosure doesn't include the loss of United beginning in 2013. And then you talked about net new business being negative because of acquisitions and such, do you have a net new number, a business number for 2012 that you can share?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I would say that -- to answer your second question first, the net new number for 2012 pretty much equates to the net change in revenues that you see for the year, because we have many puts and takes in that revenue dynamic. You have the effect of th",95,"Well, I would say that -- to answer your second question first, the net new number for 2012 pretty much equates to the net change in revenues that you see for the year, because we have many puts and takes in that revenue dynamic. You have the effect of the lost clients. You have the effect of the generic wave, but you have offsetting effects, also, from expected AWP inflation, et cetera. But when you look at the net new number, it's -- coincidentally ties to the reduction in the net revenue in the S-4."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Right. And just for Rich, I mean you say all of this has been previously disclosed. Because when I add up all the previously disclosed information, I don't quite get there but maybe I'm underestimating something.",36,"Right. And just for Rich, I mean you say all of this has been previously disclosed. Because when I add up all the previously disclosed information, I don't quite get there but maybe I'm underestimating something."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. You won't -- well, we never gave revenue amounts for clients. Of course, we've never disclosed the amounts to Universal American nor for Bravo, as example, which are large accounts. So we of course disclosed the FEP because of its profit contribution",176,"Yes. You won't -- well, we never gave revenue amounts for clients. Of course, we've never disclosed the amounts to Universal American nor for Bravo, as example, which are large accounts. So we of course disclosed the FEP because of its profit contributions but not the others. So the reason why you're not getting there is probably because you don't have the proper estimates for some of those other accounts, which is completely understandable. Regarding 2013, while many have assumed that United is actually in our 2013 numbers, it is not. One point you have to understand is this business is living and breathing and healthy, and we expect to continue to win business and don't take one year as a trend. We have a long history of winning clients and we don't plan on stopping at any time soon. And that revenue number that you see is not a guess, we have underlying assumptions that are actually quite detailed, and that's all I can say for obvious reasons. But it does, in fact, exclude United."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So just to confirm, the 2013 and '14 numbers exclude United both in revenues and obviously in your assumed EBITDA, so it's obviously reflecting some offsets to your cost structure that you allude to in your prepared remarks?",38,"So just to confirm, the 2013 and '14 numbers exclude United both in revenues and obviously in your assumed EBITDA, so it's obviously reflecting some offsets to your cost structure that you allude to in your prepared remarks?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's exactly right, Larry. I mentioned the high proportion of variable expenses and our total cost base, just to give you some color on that. It's over 60% in some cost categories. It's over 70% in certain expense categories. So there is quite a bit of",63,"That's exactly right, Larry. I mentioned the high proportion of variable expenses and our total cost base, just to give you some color on that. It's over 60% in some cost categories. It's over 70% in certain expense categories. So there is quite a bit of variable expense in the base unlike some reports have indicated. And by definition, therefore, quite manageable."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So you must be assuming about an $8 billion incremental increase in net new business for 2013? Is that about right?",21,"So you must be assuming about an $8 billion incremental increase in net new business for 2013? Is that about right?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, you should be thankful that you got the 2000 numbers out there from a revenue perspective. I'm not going to get into the puts and takes on what's net new versus how much is inflation and the rollover of generic effect, and so forth. But ultimately,",65,"Well, you should be thankful that you got the 2000 numbers out there from a revenue perspective. I'm not going to get into the puts and takes on what's net new versus how much is inflation and the rollover of generic effect, and so forth. But ultimately, you can assume that there is certain net new growth in 2013. That's all I'm going to say."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Tom Gallucci with Lazard Capital Markets.",14,"Your next question comes from the line of Tom Gallucci with Lazard Capital Markets."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I guess 2 quick questions. One, your Lipitor expectations have remained very consistent. From the outside looking in, it seems to be sort of a fluid situation. So I was wondering if you can give us any color on why you've got that visibility at this point",94,"I guess 2 quick questions. One, your Lipitor expectations have remained very consistent. From the outside looking in, it seems to be sort of a fluid situation. So I was wondering if you can give us any color on why you've got that visibility at this point? And then number 2, just wondering if you got any commentary or anecdotally that you can offer from your clients on the Walgreens-Express situation or their view toward narrower retail networks in general, given the potential implications for your business depending on how the merger turns out?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay. I'll answer the first question and Dave will take the second. Interestingly, we had visibility to Lipitor a year ago at $0.03. And a year later, it's still $0.03. And as I've said many times in the past, we are not going to disclose our sources or t",96,"Okay. I'll answer the first question and Dave will take the second. Interestingly, we had visibility to Lipitor a year ago at $0.03. And a year later, it's still $0.03. And as I've said many times in the past, we are not going to disclose our sources or the basis for our confidence other than, as you would imagine, we are more confident again than ever before in that $0.03. And I know that there are various press reports and I know it is fluid, but from a Medco perspective, again, very confident in the $0.03."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. And Tom, regarding clients questions about WAG, we get many of them. We actually have a regional Drug Trend Symposium that we conduct each and every year, one in the West Coast, one on the East Coast. So a total of, I'd say, 400 or 500 customers betw",219,"Yes. And Tom, regarding clients questions about WAG, we get many of them. We actually have a regional Drug Trend Symposium that we conduct each and every year, one in the West Coast, one on the East Coast. So a total of, I'd say, 400 or 500 customers between the 2. And that was a universal question, asking us what was behind the activity between WAG and ESI. And we've made it clear to them we don't really have insight into the details of the arguments between WAG and ESI. But independent of that, I can tell you that many of our clients are looking at restructured networks to get optimal value and pricing. And they also understand, when you look at a network across the country of 65,000 retail pharmacies and when you do geo-access for many, many, many of our customers and see that there's literally no disruption in terms of travel distance to exclude parts of that network to get significant changes in pricing, they're all looking at it. And that's an independent activity that's been going on at Medco for quite some time. And as the pressures mount tied to this economy, I would tell you they are looking harder at that option now than they ever have before, and I expect that to continue."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your next question comes from the line of Ricky Goldwasser with Morgan Stanley.",14,"And your next question comes from the line of Ricky Goldwasser with Morgan Stanley."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","I have a couple of thought questions here. So first of all, on the 2012 selling season, at this point, what percent of the season is completed in terms of renewals in your business?",34,"I have a couple of thought questions here. So first of all, on the 2012 selling season, at this point, what percent of the season is completed in terms of renewals in your business?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","So I can say regarding 2012 renewals, we've made very good progress. And the renewal number for 2012 is quite consistent with the renewal number for 2011. And we're over 2/3 completed with the renewals for 2012.",37,"So I can say regarding 2012 renewals, we've made very good progress. And the renewal number for 2012 is quite consistent with the renewal number for 2011. And we're over 2/3 completed with the renewals for 2012."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And should we assume that the remaining business is more skewed to the lower, mid to small accounts?",19,"Okay. And should we assume that the remaining business is more skewed to the lower, mid to small accounts?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes.",1,"Yes."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. Great. And then you talked about rebates and how you continue to see improvement in kind of like from your management and what the branded manufacturers are willing to pay. When you think ahead to 2012, with all the patent expirations, do you think",65,"Okay. Great. And then you talked about rebates and how you continue to see improvement in kind of like from your management and what the branded manufacturers are willing to pay. When you think ahead to 2012, with all the patent expirations, do you think that we're going to continue to see kind of like that same kind of like strategy from the pharma companies?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Let me turn it over to Tom Moriarty.",8,"Let me turn it over to Tom Moriarty."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Sure. So I do and I think you will see it. We obviously have a multipronged approach that deals at a client level that match their needs. And as we look to different formulary strategies, those formulary strategies thought drive value for the clients. And",63,"Sure. So I do and I think you will see it. We obviously have a multipronged approach that deals at a client level that match their needs. And as we look to different formulary strategies, those formulary strategies thought drive value for the clients. And then ultimately, the pharma companies want to stay in that, and the way they participate is through [indiscernible]."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And do you anticipate -- because you talked about kind of like some of the assumptions for AWP pricing that's factored into your 2012 revenues. Do you anticipate manufacturers like Pfizer and Lipitor will continue to raise prices post the patent exp",43,"Okay. And do you anticipate -- because you talked about kind of like some of the assumptions for AWP pricing that's factored into your 2012 revenues. Do you anticipate manufacturers like Pfizer and Lipitor will continue to raise prices post the patent expiration?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'm not going to talk about specific drugs or specific manufacturers. I can tell you, in 2011, we experienced a brand inflation rate that's well over 10%, one of the highest inflation rates we've seen in recent years. Our assumptions actually assume that,",58,"I'm not going to talk about specific drugs or specific manufacturers. I can tell you, in 2011, we experienced a brand inflation rate that's well over 10%, one of the highest inflation rates we've seen in recent years. Our assumptions actually assume that, that gets down a bit to between the 5% and 10% range in 2012."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And Ricky, just to be sure everybody understands why, I mean this is predictable. When you look at the tax that pharma needs to be pay tied to healthcare reform, you knew that was a pass for you. You knew that was going to come from somewhere and that's e",113,"And Ricky, just to be sure everybody understands why, I mean this is predictable. When you look at the tax that pharma needs to be pay tied to healthcare reform, you knew that was a pass for you. You knew that was going to come from somewhere and that's exactly what's going on. And you also have the additional pressure tied to this generic wave that these brand manufacturers are dealing with. So I think it's reasonable to think that you will continue to see inflation. Although, you're going to see a lot of people fighting to prevent that rate of inflation, I think there's a real tug-of-war going on that will continue."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your next question comes from the line of Steven Valiquette with UBS.",13,"And your next question comes from the line of Steven Valiquette with UBS."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","So the generic launches for 2012 are obviously positive. But I'm just kind of curious, that $6.5 billion number and it's close to 10% of 2012 revs, it kind of seems like a fairly large number. So I guess I'm just curious, is there anything unique about ma",100,"So the generic launches for 2012 are obviously positive. But I'm just kind of curious, that $6.5 billion number and it's close to 10% of 2012 revs, it kind of seems like a fairly large number. So I guess I'm just curious, is there anything unique about maybe your mail versus retail mix or some other internal factor? And maybe read that to have a larger impact on Medco than maybe other pharma services companies? Or would you just kind of assume that maybe everybody in this industry would kind of have a similar 10% drag on the top line?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Okay. So let me give you some statistics, Steve. If you look at our book of business mail penetration rate for this quarter, it's 34.8%. When you look at the big drugs that are going to affect that generic effect we mentioned earlier, you have Lipitor whi",140,"Okay. So let me give you some statistics, Steve. If you look at our book of business mail penetration rate for this quarter, it's 34.8%. When you look at the big drugs that are going to affect that generic effect we mentioned earlier, you have Lipitor which is at, the last time I checked, about 60% mail-order penetration rate. You have Lexapro that's at 35%, Plavix at 50%, Singulair at 45%, Actos at 50%, Diovan at 50%. Those are all numbers that I gave at last year's Analyst Meeting on Page 16 of my presentation. Even though there've been some client puts and takes, those numbers are still good reference points. You can see that the majority of the drugs, and these are very high drug spend molecules here, are way beyond our book of business average mail penetration rate."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And just to make it clear. This is always been in our line of sight and always been limited within our 5 and more recent 10-year plan. And this has been well known.",33,"And just to make it clear. This is always been in our line of sight and always been limited within our 5 and more recent 10-year plan. And this has been well known."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. That's helpful. And then just a quick follow-up on specialty, hitting a lot of questions on that. I'm wondering the size of the market is kind of wide open to interpretation, but do you have an approximate number for how you guys define the size of",89,"Okay. That's helpful. And then just a quick follow-up on specialty, hitting a lot of questions on that. I'm wondering the size of the market is kind of wide open to interpretation, but do you have an approximate number for how you guys define the size of the specialty markets, I mean, you have roughly $13 billion of revenues this year mainly to Accredo. But where do you give your approximate market share within specialty in terms of how the discussion might be going with the FTC, et cetera?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We don't have a number going. We focus on what our actual performance. I think, the market is very, very broad, as Dave mentioned in his prepared remark, and there are many, many providers. And the specialty market is very likely much greater than what yo",66,"We don't have a number going. We focus on what our actual performance. I think, the market is very, very broad, as Dave mentioned in his prepared remark, and there are many, many providers. And the specialty market is very likely much greater than what you would see in the disclosures of the respective PBMs, which is just a small piece of the broader market."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then just real quick, 2 second follow-up on that UNH, is that spread across 2013 and 2014? Or was just that 2013 that you're assuming the loss of UNH within that 5-year, or 4- or 5-year projection?",39,"Okay. And then just real quick, 2 second follow-up on that UNH, is that spread across 2013 and 2014? Or was just that 2013 that you're assuming the loss of UNH within that 5-year, or 4- or 5-year projection?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's assumed out 1/1/13.",5,"It's assumed out 1/1/13."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your next question comes from the line of Ross Muken with Deutsche Bank.",14,"And your next question comes from the line of Ross Muken with Deutsche Bank."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","It's actually Mike Cherny in for Ross. So just quickly, on the closing of the 2 JVs with Celesio and the United Drug, can you talk about the cash flow impact there if there has any changes to your outlook and any financial terms you can provide above and",55,"It's actually Mike Cherny in for Ross. So just quickly, on the closing of the 2 JVs with Celesio and the United Drug, can you talk about the cash flow impact there if there has any changes to your outlook and any financial terms you can provide above and beyond what was already discussed?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. It's all quite immaterial so it's really -- nothing to worry about, nothing that will meaningfully change models going forward.",21,"No. It's all quite immaterial so it's really -- nothing to worry about, nothing that will meaningfully change models going forward."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Perfect. And then you mentioned in terms of the rationale for the deal, Dave, talking about customer response so far and how they are excited about the savings that can be provided to them. I guess, as you went to the later stage of the selling season and",121,"Perfect. And then you mentioned in terms of the rationale for the deal, Dave, talking about customer response so far and how they are excited about the savings that can be provided to them. I guess, as you went to the later stage of the selling season and talking about the fiscal '12 selling season as well, can you talk about, I guess, client reaction from that perspective in terms of both going out and winning new deals, what the thought process was on how you're going to change the approach once the merger with Express Script was completed and kind of what kind of service levels and other added benefits they'd beginning in terms of planned design post the merger?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. Sure. First of all, I'd love to point out the fact that just in our Systemed Group alone, they closed over 70 deals post-merger announcement and they're still extremely busy right now. From the point of view of a client, they understand how the combi",280,"Yes. Sure. First of all, I'd love to point out the fact that just in our Systemed Group alone, they closed over 70 deals post-merger announcement and they're still extremely busy right now. From the point of view of a client, they understand how the combination creates better financials for them and it was just critically important. So that beyond the financials, the questions they're asking is, what will the combined company look like? How will it operate? Will we still get the same services that we got from Medco as a stand-alone company? As George and I talked about what this combined company will look like, we have this concept of best-of-breed and best of both worlds. So my feeling is, our clients are likely to experience continued innovation, combinations of best-of-breed assets to get even better service and better options. And obviously, part of that is in execution, and we're still in integration planning process so we have a lot of work to do still, but conceptually, we do know where we want to end up. I think both companies know where they want to end up and I think it's safe to say both companies have the client and the clients' need squarely in their focus is the #1 priority. Because at the end of the day, we still want to delight and retain customers and win new customers. So I'm very comfortable that as we look at the capabilities of both companies, we will get to something we call best-of-breed between the 2. And I think that makes clients comfortable. I think that's what they're looking for and obviously, they're going to watch that over time."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of John Kreger with William Blair.",13,"Your next question comes from the line of John Kreger with William Blair."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Dave, you mentioned a few minutes ago that clients are showing a greater interest in some of these narrow networks. What sort of savings are you able to offer to them and are you finding that the savings is big enough to sort of assume the hassle factor?",48,"Dave, you mentioned a few minutes ago that clients are showing a greater interest in some of these narrow networks. What sort of savings are you able to offer to them and are you finding that the savings is big enough to sort of assume the hassle factor?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It varies by client because it ties with the geographic dispersion of their people. But I can tell you in a range, it's very meaningful and very worthwhile considering, especially when you're a jumbo account, which Medco has a lot of. It's extremely meani",53,"It varies by client because it ties with the geographic dispersion of their people. But I can tell you in a range, it's very meaningful and very worthwhile considering, especially when you're a jumbo account, which Medco has a lot of. It's extremely meaningful. You can see 2 points easily and sometimes more."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Great.  And Rich, you made the comment that your cost structure is flexible. Can we infer from that, that your starting down the path of cutting some costs as you've had some losses or should we assume that, that's a process that's going to potentially be",51,"Great.  And Rich, you made the comment that your cost structure is flexible. Can we infer from that, that your starting down the path of cutting some costs as you've had some losses or should we assume that, that's a process that's going to potentially be held up by the merger?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, if you look at our SG&A numbers, given this quarter, you can see that the inherent growth rate is quite low so we've been, I think, doing a great job in managing our expenses and just all the course of business. But ultimately, the efficiencies need",69,"Well, if you look at our SG&A numbers, given this quarter, you can see that the inherent growth rate is quite low so we've been, I think, doing a great job in managing our expenses and just all the course of business. But ultimately, the efficiencies need to be yielded on a stand-alone basis or in a merged scenario. So we have to do what we have to do."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch.",16,"Your next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just a quick one, the European joint ventures, you guys have bought back, I guess a couple of them. These were growth drivers for you for 2014 and beyond. And what's the plan there? Are you bringing them off-line or are you hoarding the economics? What's",49,"Just a quick one, the European joint ventures, you guys have bought back, I guess a couple of them. These were growth drivers for you for 2014 and beyond. And what's the plan there? Are you bringing them off-line or are you hoarding the economics? What's the strategy there?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It's more the latter than the former, Bob. We are still very committed to Europe. We like the opportunities.  As we fine tune what Europe needs and want, we feel we're incredibly well prepared to deliver it without a joint venture partner. And so now we'v",129,"It's more the latter than the former, Bob. We are still very committed to Europe. We like the opportunities.  As we fine tune what Europe needs and want, we feel we're incredibly well prepared to deliver it without a joint venture partner. And so now we've learned a lot in these seeds we planted. And as we refine and focus on what we want to do and how we want to approach it, taking it all in-house made sense for us. And if Brian Griffin, who's running our international operations were here today, he would tell you that this is something that he is excited about now that he has full control and he is able to focus upon the market without the distractions of managing a JV."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","And how do we think about the profit profile and the future investment needed for them?",16,"And how do we think about the profit profile and the future investment needed for them?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, I would say, over the next few years, the investments will be relative to the broader company, nominally material. The growth profile remains the same. We never expected it to be material in '12, 13. But certainly, when you get to the back half of t",66,"Well, I would say, over the next few years, the investments will be relative to the broader company, nominally material. The growth profile remains the same. We never expected it to be material in '12, 13. But certainly, when you get to the back half of this decade, our thinking is consistent that the it will in fact start to become meaningful contribution to our profitability."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","And I'll just add, Brian Griffin and his team have had some nice wins recently and we're very encouraged that the trajectory is going to be something like what we originally envisioned. So we're feeling very good about his progress there.",42,"And I'll just add, Brian Griffin and his team have had some nice wins recently and we're very encouraged that the trajectory is going to be something like what we originally envisioned. So we're feeling very good about his progress there."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Charles Rhyee with Cowen.",12,"Your next question comes from the line of Charles Rhyee with Cowen."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Just one more question on Celesio. If I recall at the beginning of this year, you made an adjustment for the JV and a bunch of the mail volume went -- it was part of the JV, so it wasn't counted in your mail volume. How should we think about treating that",74,"Just one more question on Celesio. If I recall at the beginning of this year, you made an adjustment for the JV and a bunch of the mail volume went -- it was part of the JV, so it wasn't counted in your mail volume. How should we think about treating that, I think it was almost like 10 million mail scripts. Should we think that's coming back on to the income statement again?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, the mail scripts are -- you're way off by  a multiple factor with regards to the volumes. It's actually more like a fraction of that. The mail volumes came from Europa Apotheek Venlo. And Europa Apotheek Venlo has been in our volumes because it was",75,"Well, the mail scripts are -- you're way off by  a multiple factor with regards to the volumes. It's actually more like a fraction of that. The mail volumes came from Europa Apotheek Venlo. And Europa Apotheek Venlo has been in our volumes because it was never contributed for the joint venture in the first place. So that just continues in our run rate and will continue as it grows through the next several years."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. So there's really no then change to how we should be looking at the go forward mail volumes other than some of the announced contracts?",26,"Okay. So there's really no then change to how we should be looking at the go forward mail volumes other than some of the announced contracts?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That's correct.",3,"That's correct."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then a quick question maybe on FEP, we're obviously looking at -- when you look at the '12 numbers, does the change that we're seeing also include any sort of purchasing leverage you might be losing because, clearly, your mail revenues drop and",63,"Okay. And then a quick question maybe on FEP, we're obviously looking at -- when you look at the '12 numbers, does the change that we're seeing also include any sort of purchasing leverage you might be losing because, clearly, your mail revenues drop and a chunk definitely does come from branded. Now how should we think about that part of the contribution?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll let Rich answer that. But I think -- I just want to remind you because we've said this before, that the loss of FEP has literally no impact on our leverage and our ability to contract at competitive prices. This change in volume on our side has liter",55,"I'll let Rich answer that. But I think -- I just want to remind you because we've said this before, that the loss of FEP has literally no impact on our leverage and our ability to contract at competitive prices. This change in volume on our side has literally no impact on our leverage."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. There is no leverage effect in today's point. And we have a very clear line of sight into our purchasing leverage for 2012 and of course, that's baked into what you see in the S-4.",36,"Yes. There is no leverage effect in today's point. And we have a very clear line of sight into our purchasing leverage for 2012 and of course, that's baked into what you see in the S-4."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. That's helpful. And then just one last question on Accredo. Obviously -- I think a couple of years ago, we saw some margin pressure on the gross margin line, it's clearly stabilized here. What has really changed here now and then shall we think abou",60,"Okay. That's helpful. And then just one last question on Accredo. Obviously -- I think a couple of years ago, we saw some margin pressure on the gross margin line, it's clearly stabilized here. What has really changed here now and then shall we think about the margins being pretty stable at this -- a high 6.8% range going forward?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll start with that and then I'll ask Frank Sheehy to add anything that he wishes to. The thing I will add is that, what's changed is Frank Sheehy. He's gone in there. He's looked at the operations. He's done a very, very, very good job working with our",140,"I'll start with that and then I'll ask Frank Sheehy to add anything that he wishes to. The thing I will add is that, what's changed is Frank Sheehy. He's gone in there. He's looked at the operations. He's done a very, very, very good job working with our clients and also working with the operations to get the costs in line and to make us more efficient. And what's great about Frank is he came from the customer side of our business in the core, knows these customers, knows what they're looking for, and he's made some great changes to, I think, be better aligned with what our clients need and serve them better and more cost-effectively. And I don't know if you want to point anything specific at this point, Frank, but I'm giving you the opportunity."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. I think to Dave's point, working aggressively with Tim Wentworth and Glenn Taylor and their team and putting programs out there that are aligned with our clients interest are definitely resonating, combined with the differentiating service model that",52,"Yes. I think to Dave's point, working aggressively with Tim Wentworth and Glenn Taylor and their team and putting programs out there that are aligned with our clients interest are definitely resonating, combined with the differentiating service model that we've bought there have create a great opportunity for Accredo and our clients."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Your next question comes from the line of Eugene Goldenberg with BB&T.",13,"Your next question comes from the line of Eugene Goldenberg with BB&T."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Can you just provide any additional commentary around some of the chatter that we're hearing of Pfizer getting a little bit or actually a lot more aggressive on the rebate strategy when it comes to Lipitor? I think they recently raised the rebate on Lipit",67,"Can you just provide any additional commentary around some of the chatter that we're hearing of Pfizer getting a little bit or actually a lot more aggressive on the rebate strategy when it comes to Lipitor? I think they recently raised the rebate on Lipitor to about 50% and have been offering it to some PBMs. Can you provide a little bit of color on that?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll ask Tom if he has any insight into that?",11,"I'll ask Tom if he has any insight into that?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, obviously, they have a multipronged strategy for the market around Lipitor and what you cited obviously about the marketplace. We've obviously chosen our strategy and are quite comfortable with that. So that's all I can add to it.",39,"Well, obviously, they have a multipronged strategy for the market around Lipitor and what you cited obviously about the marketplace. We've obviously chosen our strategy and are quite comfortable with that. So that's all I can add to it."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","And your last question comes from the line of David Larsen with Leerink Swann.",14,"And your last question comes from the line of David Larsen with Leerink Swann."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Has the 2013 selling season started off for large health plans?",11,"Has the 2013 selling season started off for large health plans?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","I'll ask Glenn Taylor, who runs our Health Plan Group to indicate what's going on there.",17,"I'll ask Glenn Taylor, who runs our Health Plan Group to indicate what's going on there."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. I would say, yes, there's RFP activity related to 1/1/13 business. But we haven't had any finals and haven't gone through the full process yet. It's a little bit early.",31,"Yes. I would say, yes, there's RFP activity related to 1/1/13 business. But we haven't had any finals and haven't gone through the full process yet. It's a little bit early."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","It is in the sale cycle for that type of account though.",12,"It is in the sale cycle for that type of account though."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. So that sort of process is not necessarily having an impact on that 2013 revenue on the S-4 statement, right? It's not like you have great clarity on '13. Okay. And then also in terms of the EBITDA growth rate for 2014 in the S-4, it looked pretty g",69,"Okay. So that sort of process is not necessarily having an impact on that 2013 revenue on the S-4 statement, right? It's not like you have great clarity on '13. Okay. And then also in terms of the EBITDA growth rate for 2014 in the S-4, it looked pretty good to me be and like maybe 14% year-over-year. Is there anything in '14 in particular that would drive that?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Well, you might recall again from Analyst Day last year that we show that famous generic EPS contribution slide. It had a wave going through it. And you might recall that 2014 and 2018, were both strong years. Actually 2014 was the strongest after 2012 an",97,"Well, you might recall again from Analyst Day last year that we show that famous generic EPS contribution slide. It had a wave going through it. And you might recall that 2014 and 2018, were both strong years. Actually 2014 was the strongest after 2012 and that includes some pretty large drugs going generic. And for our book, at the time at least, they averaged about 45% mail-order penetration rate. They include, in order expected introduction, Asacol; Evista; Nexium, which of course is a very large drug; Telebrix and Actonel. So those were important drivers for '14."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then for new members coming on through the exchanges in '14, that's not a big driver of that growth rate. Is that correct? It's more the generics?",29,"Okay. And then for new members coming on through the exchanges in '14, that's not a big driver of that growth rate. Is that correct? It's more the generics?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","That is correct.",3,"That is correct."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","Yes. You're going to be seeing the exchange growth come through health plan partners given the way the rates are written right now.",23,"Yes. You're going to be seeing the exchange growth come through health plan partners given the way the rates are written right now."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Analysts","Okay. And then just my last question, Dave, assuming this merger does go through, do we get any clarity on sort of what your role is going to be or what your plans are?",34,"Okay. And then just my last question, Dave, assuming this merger does go through, do we get any clarity on sort of what your role is going to be or what your plans are?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","We don't have complete clarity now. But remember, we are the company being acquired. So I think you can think about it from that point of view.",28,"We don't have complete clarity now. But remember, we are the company being acquired. So I think you can think about it from that point of view."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Are there any closing remarks, sir?",6,"Are there any closing remarks, sir?"
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Executives","No. I think we're done. And I just want to thank everyone for dialing into our call and joining us. And we look forward to continuing, updating you as we make progress with the FTC. Thanks.",36,"No. I think we're done. And I just want to thank everyone for dialing into our call and joining us. And we look forward to continuing, updating you as we make progress with the FTC. Thanks."
1541811,141271840,178430,"Medco Health Solutions, Inc., Q3 2011 Earnings Call, Oct 26, 2011",2011-10-26,"Earnings Calls","Medco Health Solutions, Inc.","Operator","Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect.",14,"Thank you, ladies and gentlemen. This concludes today's conference call. You may now disconnect."
